RAPAMYCIN (MTOR INHIBITION)

/ SCIENCE, SOLUTIONS / By
  1. Mechanism of action of the immunosuppressant Rapamycin
  2. Rapamycin in transplantation: a review of the evidence
  3. Rapamycin: Clinical Results and Future Opportunities1
  4. Targets for cell cycle arrest by the immunosuppressant Rapamycin in yeast
  5. The target of Rapamycin (TOR) proteins
  6. Solubilization of Rapamycin
  7. Rapamune (Sirolimus, Rapamycin): an overview and mechanism of action.
  8. Total synthesis of Rapamycin
  9. Activity of Rapamycin (AY-22, 989) against transplanted tumors
  10. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
  11. SDZ RAD, a new Rapamycin derivative: pharmacological properties in vitro and in vivo
  12. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase
  13. Regulation of cellular growth by the Drosophila target of Rapamycin dTOR
  14. Bench to bedside: the development of Rapamycin and its application to stent restenosis
  15. Rapamycin (AY-22, 989), a new antifungal antibiotic II. Fermentation, isolation and characterization
  16. Two TOR complexes, only one of which is Rapamycin sensitive, have distinct roles in cell growth control
  17. Rapamycin (AY-22, 989), a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle
  18. The Rapamycin-sensitive signal transduction pathway as a target for cancer therapy
  19. A mammalian protein targeted by G1-arresting Rapamycin–receptor complex
  20. Rapamycin inhibits vascular smooth muscle cell migration.
  21. TOR mutations confer Rapamycin resistance by preventing interaction with FKBP12-Rapamycin
  22. Isolation of a protein target of the FKBP12-Rapamycin complex in mammalian cells
  23. Rapamycin selectively represses translation of the” polypyrimidine tract” mRNA family
  24. Phosphorylation of the translational repressor PHAS-I by the mammalian target of Rapamycin
  25. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update.
  26. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
  27. Elucidating TOR signaling and Rapamycin action: lessons from Saccharomyces cerevisiae
  28. Biosynthesis of erythromycin and Rapamycin
  29. Blood distribution of Rapamycin.
  30. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of Rapamycin
  31. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of Rapamycin
  32. Studies on the mechanism of resistance to Rapamycin in human cancer cells
  33. A Rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus
  34. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations.
  35. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1
  36. Structure of the FKBP12-Rapamycin complex interacting with binding domain of human FRAP
  37. Expression and disruption of the Arabidopsis TOR (target of Rapamycin) gene
  38. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro
  39. The biosynthetic gene cluster for the polyketide immunosuppressant Rapamycin
  40. Mammalian target of Rapamycin (mTOR): pro-and anti-apoptotic
  41. SDZ RAD, a new Rapamycin derivative: synergism with cyclosporine
  42. Rapamycin (AY-22, 989), A NEW ANTIFUNGAL ANTIBIOTIC III. IN VITRO AND IN VIVO EVALUATION
  43. RAFT1: a mammalian protein that binds to FKBP12 in a Rapamycin-dependent fashion and is homologous to yeast TORs
  44. p53/p21CIP1 cooperate in enforcing Rapamycin-induced G1 arrest and determine the cellular response to Rapamycin
  45. Raptor, a binding partner of target of Rapamycin (TOR), mediates TOR action
  46. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase
  47. The principal target of Rapamycin‐induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain.
  48. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases
  49. The immunosuppressant Rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation
  50. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
  51. TOR kinase domains are required for two distinct functions, only one of which is inhibited by Rapamycin
  52. inhibition of cell cycle progression by Rapamycin induces T cell clonal anergy even in the presence of costimulation
  53. Revised NMR assignments for Rapamycin
  54. Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation.
  55. Absorption and intestinal metabolism of SDZ-RAD and Rapamycin in rats
  56. Rapamycin resistance tied to defective regulation of p27Kip1.
  57. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/Rapamycin complex
  58. Targeted disruption of p70s6k defines its role in protein synthesis and Rapamycin sensitivity
  59. Target of Rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression
  60. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus
  61. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins
  62. SIROLIMUS (Rapamycin)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATION: Similar Efficacy and Different Toxicity Compared with Cyclosporine: 1, 2
  63. Inhibitors of mammalian target of Rapamycin as novel antitumor agents: from bench to clinic
  64. Cytoplasmic–nuclear shuttling of FKBP12-Rapamycin-associated protein is involved in Rapamycin-sensitive signaling and translation initiation
  65. A protein kinase B-dependent and Rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification
  66. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability
  67. A chemical genomics approach toward understanding the global functions of the target of Rapamycin protein (TOR)
  68. Mechanism of metabolic control: target of Rapamycin signaling links nitrogen quality to the activity of the Rtg1 and Rtg3 transcription factors
  69. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a Rapamycin-sensitive pathway
  70. inhibition of human B lymphocyte cell cycle progression and differentiation by Rapamycin
  71. Mammalian target of Rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on …
  72. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or Rapamycin.
  73. Cyclosporin A, FK506 and Rapamycin: more than just immunosuppression
  74. Rapamycin inhibits human adipocyte differentiation in primary culture
  75. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells
  76. inhibition of T and B lymphocyte proliferation by Rapamycin.
  77. Target of Rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation
  78. Partitioning the transcriptional program induced by Rapamycin among the effectors of the Tor proteins
  79. Rapamycin (AY-22, 989), A NEW ANTIFUNGAL ANTIBIOTIC IV. MECHANISM OF ACTION
  80. Control of translation by the target of Rapamycin proteins
  81. Control of Ser2448 phosphorylation in the mammalian target of Rapamycin by insulin and skeletal muscle load
  82. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of Rapamycin mediated by a protein kinase B signaling pathway
  83. Serum‐stimulated, Rapamycin‐sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI
  84. Rapamune®(RAPA, Rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle …
  85. Regulation of Ribosome Biogenesis by the Rapamycin-sensitive TOR-signaling Pathway in Saccharomyces cerevisiae
  86. Enhancement of human platelet aggregation and secretion induced by Rapamycin.
  87. A Rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1
  88. Biochemical correlates of mTOR inhibition by the Rapamycin ester CCI-779 and tumor growth inhibition
  89. The mammalian target of Rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism
  90. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via Rapamycin (mTOR)‐dependent signaling
  91. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites
  92. Immunopurified mammalian target of Rapamycin phosphorylates and activates p70 S6 kinase α in vitro
  93. The principal Rapamycin-sensitive p70 (s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by Rapamycin-insensitive kinase kinases.
  94. Direct inhibition of the signaling functions of the mammalian target of Rapamycin by the phosphoinositide 3‐kinase inhibitors, wortmannin and LY294002.
  95. The Rapamycin-binding domain governs substrate selectivity by the mammalian target of Rapamycin
  96. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells
  97. Interaction of RAFT1 with gephyrin required for Rapamycin-sensitive signaling
  98. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
  99. Suppression of B cell activation by cyclosporin A, FK506 and Rapamycin
  100. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins
  101. Rapamycin and FK506 binding proteins (immunophilins)
  102. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
  103. On the chemistry and high field nuclear magnetic resonance spectroscopy of Rapamycin
  104. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and Rapamycin
  105. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, Rapamycin and cyclosporin A
  106. Activated mammalian target of Rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors
  107. inhibition of the mammalian target of Rapamycin sensitizes U87 xenografts to fractionated radiation therapy
  108. Atomic structure of the Rapamycin human immunophilin FKBP-12 complex
  109. The FKBP12-Rapamycin-binding domain is required for FKBP12-Rapamycin-associated protein kinase activity and G1 progression
  110. A novel pathway regulating the mammalian target of Rapamycin (mTOR) signaling
  111. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the Rapamycin target mTOR
  112. Mammalian target of Rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
  113. Rapamycin: a bone sparing immunosuppressant?
  114. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of Rapamycin
  115. Mechanism of action of Rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells
  116. Preclinical evaluation of a new potent immunosuppressive agent, Rapamycin.
  117. Early clinical experience with a novel Rapamycin derivative
  118. Antitumor activity of the Rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination …
  119. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of Rapamycin (mTOR) signaling
  120. Total synthesis of Rapamycin and demethoxyRapamycin
  121. Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway
  122. Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and Rapamycin in rat adipocytes
  123. Synergistic interactions of cyclosporine and Rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro.
  124. Interaction between FKBP12-Rapamycin and TOR involves a conserved serine residue.
  125. Comparison of acute Rapamycin nephrotoxicity with cyclosporine and FK506
  126. Refined structure of the FKBP12–Rapamycin–FRB ternary complex at 2.2 Å resolution
  127. Immunosuppressants FK506 and Rapamycin function as reversal agents of the multidrug resistance phenotype
  128. Regulation of the cell integrity pathway by Rapamycin-sensitive TOR function in budding yeast
  129. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells
  130. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease1
  131. Hyperlipidemia in renal transplant recipients treated with sirolimus (Rapamycin)
  132. Effects of Rapamycin on Ryanodine Receptor/Ca2+-Release Channels From Cardiac Muscle
  133. Conversion to Rapamycin immunosuppression in renal transplant recipients: report of an initial Experience1
  134. Global and specific translational control by Rapamycin in T cells uncovered by microarrays and proteomics
  135. Synergistic effects of cyclosporine and Rapamycin in a chronic nephrotoxicity model1
  136. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells
  137. Total synthesis of (-)-Rapamycin using an Evans-Tishchenko fragment coupling
  138. FKBP12-Rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions
  139. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein.
  140. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle
  141. FKBP12-Rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction
  142. Modulation of transcription of rRNA genes by Rapamycin
  143. The effect of Rapamycin on kidney function in the Sprague-Dawley rat.
  144. Organization of the biosynthetic gene cluster for Rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase
  145. Growth-dependent translation of IGF-II mRNA by a Rapamycin-sensitive pathway
  146. Effects of Rapamycin in experimental organ allografting.
  147. Metabolic and autocrine regulation of the mammalian target of Rapamycin by pancreatic β-cells
  148. Predominant nuclear localization of mammalian target of Rapamycin in normal and malignant cells in culture
  149. Effect of nitrogen source on biosynthesis of Rapamycin by Streptomyces hygroscopicus
  150. Rapamycin‐sensitive phase of 3T3‐L1 preadipocyte differentiation after clonal expansion
  151. The mammalian target of Rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus
  152. Rapamycin eluting stent: the onset of a new era in interventional cardiology
  153. Efficacy of sirolimus (Rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled …
  154. B cell receptor-associated protein α4 displays Rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A
  155. The immunosuppressant Rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites
  156. Regulation of translational effectors by amino acid and mammalian target of Rapamycin signaling pathways: possible involvement of autophagy in cultured …
  157. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and Rapamycin.
  158. … vascular smooth muscle cell DNA synthesis. inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of Rapamycin by …
  159. Mammalian target of Rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and …
  160. Influence of cyclosporin, tacrolimus and Rapamycin on renal function and arterial hypertension after renal transplantation
  161. Antifungal activities of Rapamycin and its derivatives, prolylRapamycin, 32-desmethylRapamycin, and 32-desmethoxyRapamycin
  162. Rapamycin inhibits macropinocytosis and mannose receptor–mediated endocytosis by bone marrow–derived dendritic cells
  163. Pharmacokinetics of Rapamycin.
  164. The immunosuppressant Rapamycin represses human immunodeficiency virus type 1 replication
  165. Treatment with Rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement.
  166. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured …
  167. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model
  168. Total synthesis of Rapamycin via a novel titanium-mediated aldol macrocyclization reaction
  169. Cyclosporin A, FK-506, and Rapamycin: pharmacologic probes of lymphocyte signal transduction
  170. Enhancement of the antifungal activity of Rapamycin by the coproduced elaiophylin and nigericin
  171. … X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and Rapamycin
  172. Mammalian target of Rapamycin-dependent phosphorylation of PHAS-I in four (S/T) P sites detected by phospho-specific antibodies
  173. Rapamycin induces apoptosis in monocyte-and CD34-derived dendritic cells but not in monocytes and macrophages
  174. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple Rapamycin-sensitive steps
  175. Clinical development of mammalian target of Rapamycin inhibitors
  176. Identification of an 11-kDa FKBP12-Rapamycin-binding domain within the 289-kDa FKBP12-Rapamycin-associated protein and characterization of a critical serine …
  177. COMBINED COSTIMULATION BLOCKADE PLUS Rapamycin BUT NOT CYCLOSPORINE PRODUCES PERMANENT ENGRAFTMENT1
  178. Effect of amino acids on Rapamycin biosynthesis by Streptomyces hygroscopicus
  179. Rapamycin antifungal action is mediated via conserved complexes with fkbp12 and tor kinase homologs incryptococcus neoformans
  180. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.
  181. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate Rapamycin cytotoxicity.
  182. … autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of Rapamycin-independent signaling pathway
  183. Control of PHAS-I by insulin in 3T3-L1 adipocytes: synthesis, degradation, and phosphorylation by a Rapamycin-sensitive and mitogen-activated protein …
  184. Stress-activated protein kinase-2/p38 and a Rapamycin-sensitive pathway are required for C2C12 myogenesis
  185. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR
  186. Rapamycin (sirolimus, rapamune).
  187. Organisation of the biosynthetic gene cluster for Rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase
  188. Rapamycin selectively inhibits angiotensin II–induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II …
  189. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of Rapamycin-dependent signaling pathway
  190. Resistance to Rapamycin: a novel anticancer drug
  191. Carbon source nutrition of Rapamycin biosynthesis in Streptomyces hygroscopicus
  192. Osteoblastic differentiation is enhanced by Rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells
  193. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of Rapamycin phosphorylation site
  194. The Rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats
  195. Regulation of translation elongation factor‐2 by insulin via a Rapamycin‐sensitive signalling pathway.
  196. The FKBP12‐Rapamycin‐associated protein (FRAP) is a CLIP‐170 kinase
  197. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor
  198. Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and Rapamycin
  199. Synergistic effect of Rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis.
  200. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver
  201. Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of Rapamycin (mTOR)-mediated downstream signaling
  202. Evidence that phosphorylation of human Upfl protein varies with intracellular location and is mediated by a wortmannin-sensitive and Rapamycin-sensitive PI 3-kinase …
  203. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of Rapamycin sensitive signaling
  204. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, Rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase …
  205. cAMP-and Rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells
  206. A Rapamycin-selective 25-kDa immunophilin
  207. FKBP12‐Rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol‐4 kinase activity.
  208. Pharmacokinetics and safety of single oral doses of sirolimus (Rapamycin) in healthy male volunteers
  209. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and Rapamycin in 3T3-L1 adipocytes: evidence for the involvement …
  210. The TOR (target of Rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae
  211. Heat capacity changes and hydrophobic interactions in the binding of FK506 and Rapamycin to the FK506 binding protein
  212. Attenuation of mammalian target of Rapamycin activity by increased cAMP in 3T3-L1 adipocytes
  213. Rapamycin specifically interferes with the developmental response of fission yeast to starvation.
  214. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant Rapamycin.
  215. Incorporation of acetate, propionate, and methionine into Rapamycin by Streptomyces hygroscopicus
  216. … Virus 1 Envelope Glycoprotein Complex-induced Apoptosis Involves Mammalian Target of Rapamycin/FKBP12-Rapamycin–associated Protein–mediated p53 …
  217. The efficacy and toxicity of Rapamycin in murine islet transplantation. In vitro and in vivo studies.
  218. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment
  219. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells
  220. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (Rapamycin), mycophenolate mofetil and leflunomide
  221. Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex
  222. Prolongation of renal allograft survival in a large animal model by oral Rapamycin monotherapy.
  223. The effect of a high‐fat meal on the oral bioavailability of the immunosuppressant sirolimus (Rapamycin)
  224. Intracellular sensing of amino acids in Xenopus laevis oocytes stimulates p70 S6 kinase in a target of Rapamycin-dependent manner
  225. SIROLIMUS (Rapamycin) HALTS AND REVERSES PROGRESSION OF ALLOGRAFT VASCULAR DISEASE IN NON-HUMAN PRIMATES1
  226. The isolation, synthesis and characterization of an isomeric form of Rapamycin
  227. Effects of cyclosporin, FK506, and Rapamycin on graft-vessel disease
  228. … translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin: role of mammalian target of Rapamycin, protein kinase b, and …
  229. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
  230. A Unified Total Synthesis of the Immunomodulators (−)-Rapamycin and (−)-27-DemethoxyRapamycin: Assembly of the Common C (1− 20) Perimeter and Final …
  231. Mechanism of the combination immunosuppressive effects of Rapamycin with either cyclosporine or tacrolimus
  232. The antimicrobial activities of cyclosporine, FK506, and Rapamycin
  233. Molecular cloning of a membrane-associated human FK506-and Rapamycin-binding protein, FKBP-13.
  234. Contrasting impacts of immunosuppressive agents (Rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during …
  235. … new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12: prevention by the immunosuppressant drugs FK506 and Rapamycin
  236. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and Rapamycin in man and rat.
  237. Rapamycin Inhibits α1-Adrenergic Receptor–Stimulated Cardiac Myocyte Hypertrophy but Not Activation of Hypertrophy-Associated Genes: Evidence for Involvement …
  238. FK506 and Rapamycin: novel pharmacological probes of the immune response
  239. Target of Rapamycin
  240. Mutagenesis of the Rapamycin producer Streptomyces hygroscopicus FC904
  241. The effect of Rapamycin on T cell development in mice
  242. The effects of Rapamycin in murine peripheral nerve isografts and allografts
  243. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to Rapamycin
  244. A putative sirolimus (Rapamycin) effector protein
  245. Rapamycin: In Vitro Profile of a New Immunosuppressive Macrolide.
  246. The Upregulation of p27Kip1 by Rapamycin Results in G1 Arrest in Exponentially Growing T-Cell Lines
  247. Generation of novel Rapamycin structures by microbial manipulations
  248. Consensus guidelines for therapeutic drug monitoring of Rapamycin: report of the consensus panel
  249. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and Rapamycin on coronary endothelial function
  250. Convergence of the target of Rapamycin and the Snf1 protein kinase pathways in the regulation of the subcellular localization of Msn2, a transcriptional …
  251. FKBP-Rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line.
  252. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral Rapamycin
  253. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by Rapamycin-insensitive pathways in skeletal muscle …
  254. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and Rapamycin
  255. Studies on the chemistry of Rapamycin: novel transformations under Lewis-acid catalysis
  256. Rapamycin on trial
  257. Effects of Rapamycin on cultured hepatocyte proliferation and gene expression
  258. Therapeutic monitoring of Rapamycin: a new immunosuppressive drug.
  259. Chlamydia trachomatis Mip‐like protein has peptidylprolyl cis/trans isomerase activity that is inhibited by FK506 and Rapamycin and is implicated in initiation of …
  260. MID1 and MID2 homo-and heterodimerise to tether the Rapamycin-sensitive PP2A regulatory subunit, alpha 4, to microtubules: implications for the clinical …
  261. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells.
  262. Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice
  263. Sensitive and specific quantification of sirolimus (Rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry
  264. … LYMPHOCYTES MAY DISTINGUISH CYCLOSPORINE EFFECT IN RENAL TRANSPLANT RECIPIENTS RECEIVING A CYCLOSPORINE+ Rapamycin REGIMEN1
  265. Rapamycin, a potential disease-modifying antiarthritic drug.
  266. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a Rapamycin-sensitive point immediately …
  267. Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of Rapamycin
  268. Treatment of autoimmune uveoretinitis in the rat with Rapamycin, an inhibitor of lymphocyte growth factor signal transduction
  269. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat.
  270. lnterleukin-2-mediated elimination of the p27 Kipl cyclin-dependent kinase inhibitor prevented by Rapamycin
  271. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and Rapamycin
  272. Ultraviolet-induced phosphorylation of p70S6K at Thr389 and Thr421/Ser424 involves hydrogen peroxide and mammalian target of Rapamycin but not Akt and atypical …
  273. Toxicity of Rapamycin–a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat.
  274. L-Asparaginase inhibits the Rapamycin-targeted signaling pathway
  275. The Rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity
  276. The Target of Rapamycin Signaling Pathway Regulates mRNA Turnover in the Yeast Saccharomyces cerevisiae
  277. Protein kinase activity and identification of a toxic effector domain of the target of Rapamycin TOR proteins in yeast
  278. inhibition of in vitro immunoglobulin production by Rapamycin.
  279. Rapamycin inhibits corneal allograft rejection and neovascularization
  280. Base catalyzed degradations of Rapamycin
  281. Rapamycin inhibits the generation of graft-versus-host disease-and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic …
  282. The immunosuppressive macrolides FK-506 and Rapamycin act as reciprocal antagonists in murine T cells.
  283. Rapamycin: FK506’s fraternal twin or distant cousin?
  284. Substrate specificity for the human rotamase FKBP: a view of FK506 and Rapamycin as leucine-(twisted amide)-proline mimics
  285. Structure-activity studies of Rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP …
  286. Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production
  287. A novel FK506-and Rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus.
  288. p70s6k integrates phosphatidylinositol 3-kinase and Rapamycin-regulated signals for E2F regulation in T lymphocytes
  289. DIFFERENTIAL EFFECTS OF CYCLOSPORINE A, METHYLPREDNISOLONE, MYCOPHENOLATE, AND Rapamycin ON CD154 INDUCTION AND REQUIREMENT …
  290. Target of Rapamycin proteins and their kinase activities are required for meiosis
  291. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line.
  292. inhibition by Rapamycin of PDGF-and bFGF-induced human tenon fibroblast proliferation in vitro.
  293. New process control strategy used in a Rapamycin fermentation
  294. Tacrolimus-Rapamycin combination therapy for experimental autoimmune uveoretinitis
  295. Serotonin Activates S6 Kinase in a Rapamycin-Sensitive Manner inAplysia Synaptosomes
  296. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of Rapamycin in mitogen-stimulated and transformed cells
  297. Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin-and Rapamycin-sensitive pathways
  298. Phosphate, ammonium, magnesium and iron nutrition of Streptomyces hygroscopicus with respect to Rapamycin biosynthesis
  299. Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and Rapamycin sensitivity domains.
  300. Growth of Streptomyces hygroscopicus in rotating-wall bioreactor under simulated microgravity inhibits Rapamycin production
  301. Structure of Rapamycin: an NMR and molecular‐dynamics investigation
  302. 40-O-(2-Hydroxyethyl)-Rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats
  303. The Drosophila p70s6k homolog exhibits conserved regulatory elements and Rapamycin sensitivity
  304. Structure-activity studies of nonmacrocyclic Rapamycin derivatives
  305. Gene disruption and replacement in the Rapamycin-producing Streptomyces hygroscopicus strain ATCC 29253
  306. Production of synergistic but nonidentical mechanisms of immunosuppression by Rapamycin and cyclosporine.
  307. A Unified Total Synthesis of the Immunomodulators (−)-Rapamycin and (−)-27-DemethoxyRapamycin: Construction of the C (21− 42) Perimeters
  308. Design and Synthesis of a Rapamycin-based high affinity binding FKBP12 ligand
  309. Synthetic investigations of Rapamycin. 2. Synthesis of a C (22)-C (42) fragment
  310. The immunosuppressant Rapamycin, alone or with transforming growth factor-b, enhances osteoclast differentiation of RAW264. 7 monocyte-macrophage cells in the …
  311. Origin and true nature of the starter unit for the Rapamycin polyketide synthase
  312. … , p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of Rapamycin (mTOR) pathway in the …
  313. Impaired phosphate handling of renal allografts is aggravated under Rapamycin‐based immunosuppression
  314. … in stereochemical communication: a strategy for the stereospecific synthesis and stabilization of the triene substructure of Rapamycin through sulfone substitution
  315. TACROLIMUS (FK506) AND SIROLIMUS (Rapamycin) IN COMBINATION ARE NOT ANTAGONISTIC BUT PRODUCE EXTENDED GRAFT SURVIVAL IN CARDIAC …
  316. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and Rapamycin.
  317. Raf/MAPK and Rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells
  318. Rapamycin INDUCES TRANSFORMING GROWTH FACTOR-β PRODUCTION BY LYMPHOCYTES1
  319. Insulin release and suppression by tacrolimus, Rapamycin and cyclosporin A are through regulation of the ATP‐sensitive potassium channel
  320. … kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by Rapamycin: evidence that wortmannin …
  321. The Pipecolate‐Incorporating Enzyme for the Biosynthesis of the Immunosuppressant Rapamycin—Nucleotide Sequence Analysis, Disruption and Heterologous …
  322. Graft-versus-host disease prevention by Rapamycin: cellular mechanisms
  323. Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and Rapamycin …
  324. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography–electrospray tandem mass spectrometry
  325. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and Rapamycin.
  326. Isolation of two immunosuppressive metabolites after in vitro metabolism of Rapamycin.
  327. p-Glycoprotein-mediated transport of a fluorescent Rapamycin derivative in renal proximal tubule
  328. Expression, enzyme activity, and subcellular localization of mammalian target of Rapamycin in insulin-responsive cells
  329. Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is Rapamycin-sensitive and requires phosphatidylinositol 3-kinase
  330. Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival
  331. Molecular cloning of a 25-kDa high affinity Rapamycin binding protein, FKBP25.
  332. The immediate precursor of the nitrogen-containing ring of Rapamycin is free pipecolic acid
  333. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin)
  334. A novel ring contraction of Rapamycin
  335. Prolongation of canine pancreatic islet allograft survival with combined Rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related.
  336. inhibition of liver, kidney, and intestine regeneration by Rapamycin
  337. Ig receptor binding protein 1 (α4) is associated with a Rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein …
  338. … of the International Society for Heart and Lung Transplantation working formulation for heart transplant biopsy specimens. Rapamycin Cardiac Rejection Treatment …
  339. Effect of Rapamycin on the cyclosporin A–resistant CD28-mediated costimulatory pathway
  340. Lack of change of cancellous bone volume with short-term use of the new immunosuppressant Rapamycin in rats
  341. Studies towards the total synthesis of Rapamycin: A convergent and stereoselective synthesis of the C22 C32 carbon framework
  342. Rapamycin and wortmannin enhance replication of a defective encephalomyocarditis virus
  343. … factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of Rapamycin
  344. … acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by Rapamycin, and is independent …
  345. Effect of p27 deficiency and Rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model
  346. The effect of dexamethasone, cyclosporine, and Rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and …
  347. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect
  348. Complete amino acid sequence of the FK506 and Rapamycin binding protein, FKBP, isolated from calf thymus
  349. Effects of Rapamycin, cyclosporin A, and dexamethasone on interleukin 5‐induced eosinophil degranulation and prolonged survival
  350. Microbial conversion of Rapamycin
  351. Therapeutic blood levels of sirolimus (Rapamycin) in the allografted rat
  352. Effect of Rapamycin on the expression of the IL‐2 receptor (CD25)
  353. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts.
  354. β-Agonists regulate Na, K-ATPase via novel MAPK/ERK and Rapamycin-sensitive pathways
  355. Assessment of cell‐signaling pathways in the regulation of mammalian target of Rapamycin (mTOR) by amino acids in rat adipocytes
  356. Beneficial effects of cyclosporine and Rapamycin in small bowel ischemic injury
  357. Routine clinical monitoring of sirolimus (Rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
  358. inhibition by Rapamycin of P‐glycoprotein 170‐mediated export from normal lymphocytes
  359. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood Rapamycin concentrations
  360. THE METABOLIC IMPACT OF Rapamycin (SIROLIMUS) IN CHRONIC CANINE ISLET GRAFT RECIPIENTS1
  361. Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes.
  362. Dominant mutations confer resistance to the immunosuppressant, Rapamycin, in variants of a T cell lymphoma
  363. Effects of cyclosporine and Rapamycin on immunoglobulin production by preactivated human B cells
  364. Facile synthesis of the “tricarbonyl” subunit in the immunosuppressant Rapamycin
  365. Effects of FK506 and Rapamycin on excitation‐contraction coupling in skeletal muscle fibres of the rat.
  366. Involvement of a Rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro
  367. Degradation of Rapamycin: synthesis of a Rapamycin derived fragment containing the tricarbonyl and triene sectors
  368. Calcineurin inhibitor‐induced chronic nephrotoxicity in liver transplant patients is reversible using Rapamycin as the primary immunosuppressive agent
  369. EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (Rapamycin) MONO-AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT …
  370. Efficacy of Rapamycin and FK 506 in prolonging rat hind limb allograft survival.
  371. Distinct repression of translation by wortmannin and Rapamycin
  372. Evidence that Rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes.
  373. Determination of Rapamycin in whole blood by HPLC
  374. Total synthesis of Rapamycin
  375. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition.
  376. Uncoupling p70s6 kinase activation and proliferation: Rapamycin-resistant proliferation of human CD8+ T lymphocytes
  377. Exogenous shikimic acid stimulates Rapamycin biosynthesis inStreptomyces hygroscopicus
  378. Ryanodine receptors from rabbit skeletal muscle are reversibly activated by Rapamycin
  379. Synthetic studies toward Rapamycin: a solution to a problem in chirality merger through use of the Ireland reaction
  380. The nature of the starter unit for the Rapamycin polyketide synthase
  381. Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (Rapamycin)
  382. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a Rapamycin derivative
  383. USE OF ANTI-CD25 MONOCLONAL ANTIBODY IN COMBINATION WITH Rapamycin TO ELIMINATE CYCLOSPORINE TREATMENT DURING THE INDUCTION …
  384. Loss of ypk1 function causes Rapamycin sensitivity, inhibition of translation initiation and synthetic lethality in 14-3-3-deficient yeast
  385. Acute effects of Rapamycin on glomerular dynamics: a micropuncture study in the rat
  386. Cyclosporine, FK506, and Rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells.
  387. The cyclohexane moiety of Rapamycin is derived from shikimic acid in Streptomyces hygroscopicus
  388. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of Rapamycin but develop an …
  389. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with Rapamycin
  390. Degradative studies on the tricarbonyl containing macrolide Rapamycin
  391. The potential role of Rapamycin in pediatric transplantation as observed from adult studies
  392. Comparison of the effects of FK-506, cyclosporin A and Rapamycin on IL-2 production.
  393. Insulin-stimulated kinase from rat fat cells that phosphorylates initiation factor 4E-binding protein 1 on the Rapamycin-insensitive site (serine-111)
  394. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and Rapamycin.
  395. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells
  396. Effect of Rapamycin on rat aortic ring vasomotion.
  397. … cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of Rapamycin
  398. Rapamycin blocks sexual development in fission yeast through inhibition of the cellular function of an FKBP12 homolog
  399. Simultaneous on-line extraction and analysis of sirolimus (Rapamycin) and ciclosporin in blood by liquid chromatography–electrospray mass spectrometry
  400. Both Rapamycin-sensitive and-insensitive pathways are involved in the phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in response to insulin in rat …
  401. Compared to mycophenolate mofetil, Rapamycin induces significant changes on growth factors and growth factor receptors in the early days postkidney …
  402. Mammalian RAFT1 kinase domain provides Rapamycin-sensitive TOR function in yeast.
  403. Conversion from liquid to solid Rapamycin formulations in stable renal allograft transplant recipients
  404. Secretion of FK506/FK520 and Rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans
  405. Side effects of Rapamycin in the rat
  406. The effect of Rapamycin on single ENaC channel activity and phosphorylation in A6 cells
  407. Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries …
  408. Measurement of Rapamycin in whole blood using reverse-phase high-performance liquid chromatography.
  409. Regulation of the Rapamycin and FKBP-target 1/mammalian target of Rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase
  410. Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection.
  411. Two discrete regions of interleukin-2 (IL2) receptor β independently mediate IL2 activation of a PD98059/Rapamycin/wortmannin-insensitive Stat5a/b serine …
  412. The tyrosine89 residue of yeast FKBP12 is required for Rapamycin binding
  413. Assignment of the human FKBP12-Rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization
  414. Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression
  415. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients.
  416. Rapamycin INHIBITS DEVELOPMENT OF OBLITERATIVE AIRWAY DISEASE IN A MURINE HETEROTOPIC AIRWAY TRANSPLANT MODEL1
  417. The immunosuppressant Rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo
  418. Estrogen and Rapamycin effects on cell cycle progression in T47D breast cancer cells
  419. The effects of the immunosuppressant Rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast
  420. Deletion of rapQONML from the Rapamycin gene cluster of Streptomyces hygroscopicus gives production of the 16-O-desmethyl-27-desmethoxy analog
  421. Rapamycin may prevent post-transplant lymphoma
  422. … π-face selectivity in anti aldol reactions of E-enol borinates from chiral alkoxymethyl ketones: stereocontrolled synthesis of a C24-C32 polyol subunit of Rapamycin
  423. … of MAP kinases, pp90rsk and pp70‐S6 kinases in mouse mast cells by signaling through the c‐kit receptor tyrosine kinase or FcϵRI: Rapamycin inhibits activation of …
  424. Intramolecular hydrogen transfer reactions of o-(bromophenyl) dialkylsilyl ethers. Preparation of Rapamycin-d1
  425. … 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of Rapamycin, Ly294002, and wortmannin on …
  426. Rapamycin dissociates p70S6K activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells
  427. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells
  428. Rapamycin: immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model.
  429. Effect of cyclosporine, mycophenolic acid, and Rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study
  430. Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and Rapamycin
  431. Use of Rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on …
  432. Failure of Rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase
  433. Rapamycin inhibits proteasome activator expression and proteasome activity
  434. ASSOCIATION OF GLUCOCORTICOIDS AND CYCLOSPORIN A OR Rapamycin PREVENTS E-SELECTIN AND IL-8 EXPRESSION DURING LPS-AND TNFα …
  435. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor Rapamycin
  436. Sirolimus (Rapamycin) in clinical transplantation
  437. Rapamycin inhibits didemnin B‐induced apoptosis in human HL‐60 cells: Evidence for the possible involvement of FK506‐binding protein 25
  438. Siloxanes: versatile templates for acyclic stereocontrol. Synthesis of the C27-C33 segment of Rapamycin
  439. Dose-dependent pharmacokinetics of Rapamycin-28-N,N-dimethylglycinate in the mouse
  440. Interstitial pneumonitis associated with sirolimus (Rapamycin) therapy after liver transplantation
  441. The relationship of blood concentrations of Rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model.
  442. … -severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and Rapamycin
  443. … hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and Rapamycin binding to FK506 …
  444. Selective epimerization of Rapamycin via a retroaldol/aldol mechanism mediated by titanium tetraisopropoxide
  445. inhibition of proliferation but not erythroid differentiation of J2E cells by Rapamycin
  446. The 14-3-3 proteins positively regulate Rapamycin-sensitive signaling
  447. Systemic toxicity following administration of sirolimus (formerly Rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes
  448. Oral administration of Rapamycin and cyclosporine differentially alter intestinal function in rabbits
  449. p70 S6 kinase sensitivity to Rapamycin is eliminated by amino acid substitution of Thr229.
  450. High‐Sensitivity sequencing of large proteins: Partial structure of the Rapamycin‐fkbp12 target
  451. Renal effects of Rapamycin in the spontaneously hypertensive rat
  452. Effects of immunosuppressants FK506 and Rapamycin on the heterooligomeric form of the progesterone receptor
  453. Sirolimus (Rapamycin, Rapamune®) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the …
  454. The effect of Rapamycin on renal function in the rat: a comparative study with cyclosporine
  455. Efficient Removal of Pipecolinate from Rapamycin and FK506 by Reaction with n-Bu4N+ CN−
  456. Rapamycin resistance in ataxia-telangiectasia.
  457. Regulation of ribosomal S6 kinase 2 by mammalian target of Rapamycin
  458. Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (Rapamycin and FK506) and calcium/calmodulin-dependent kinase …
  459. Lipophilic benzamide and anilide derivatives as high-performance liquid chromatography internal standards: application to sirolimus (Rapamycin) determination
  460. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with Rapamycin
  461. … by insulin and insulin-like growth factor-I: glycogen synthase activation is antagonized by wortmannin or LY294002 but not by Rapamycin or by inhibiting …
  462. Pharmacokinetics of Rapamycin: single-dose studies in the rabbit.
  463. Preferential production of Rapamycin vs prolylRapamycin by Streptomyces hygroscopicus
  464. Successful myoblast allotransplantation in mdx mice using Rapamycin
  465. A second type-I PKS gene cluster isolated from Streptomyces hygroscopicus ATCC 29253, a Rapamycin-producing strain
  466. Pediatric utilization of Rapamycin for severe cardiac allograft rejection
  467. An application of the suárez reaction to the regiospecific and stereospecific synthesis of the C28-C42 segment of Rapamycin
  468. Immunopharmacology of Rapamycin
  469. Manipulation of the Rapamycin effector domain. selective nucleophilic substitution of the C7 methoxy group
  470. High performance liquid chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two Rapamycin degradation products
  471. Antifungal Rapamycin analogues with reduced immunosuppressive activity
  472. … localization of the human α4/IGBP1 gene, the structure of which is closely related to the yeast TAP42 protein of the Rapamycin-sensitive signal transduction pathway
  473. Antagonistic roles for CTLA-4 and the mammalian target of Rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen …
  474. inhibition by Rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC‐6 cells in culture
  475. Insulin stimulation of muscle protein synthesis in obese Zucker rats is not via a Rapamycin-sensitive pathway
  476. Stability of sirolimus (Rapamycin) in whole blood
  477. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl)Rapamycin and cyclosporine in blood with electrospray-mass spectrometric …
  478. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with Rapamycin.
  479. FK506 and Rapamycin modulate the functional activities of human peripheral blood eosinophils
  480. Sirolimus (Rapamycin) potentiates cyclosporine in prevention of acute lung rejection
  481. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells
  482. FAP1, a homologue of human transcription factor NF‐X1, competes with Rapamycin for binding to FKBP12 in yeast
  483. Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3’untranslated region.
  484. Effect of Rapamycin on morphological and functional parameters in the kidney of the rabbit
  485. Synthetic investigations of Rapamycin. 1. Synthesis of a C10-C21 fragment
  486. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of Rapamycin derivative (SDZ RAD) used alone and …
  487. Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and Rapamycin binding protein
  488. Abrogation by Rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and …
  489. FK506 binding protein 12 mediates sensitivity to both FK506 and Rapamycin in murine mast cells
  490. Post-translational reduction of cell surface expression of insulin receptors by cyclosporin A, FK506 and Rapamycin in bovine adrenal chromaffin cells
  491. Antiproliferative effect of Rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of …
  492. Effects of the combination of Rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia
  493. Anisomycin and Rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction.
  494. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart …
  495. Studies towards the total synthesis of Rapamycin: Preparation of the C10 C17 carbon unit
  496. Effects of Rapamycin on apoptosis of rheumatoid synovial cells
  497. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under …
  498. Mean field analysis of FKBP12 complexes with FK506 and Rapamycin: Implications for a role of crystallographic water molecules in molecular recognition and …
  499. Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and Rapamycin, on hair growth initiation in …
  500. High performance liquid chromatographic isolation and spectroscopic characterization of three major metabolites from the plasma of rats receiving Rapamycin …
  501. Implication of alpha4 phosphoprotein and the Rapamycin-sensitive mammalian target-of-Rapamycin pathway in prolactin receptor signalling
  502. Effects of Rapamycin on human HLA-unrestricted cell killing
  503. cDNA Cloning of a human 5 kDa FK506 and Rapamycin binding protein
  504. Identification of a new metabolite of macrolide immunosuppressant, like Rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray …
  505. Evidence that Rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use.
  506. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides Rapamycin and FK506 inhibit progestin-and glucocorticosteroid receptor-mediated …
  507. CsA, FK506, corticosteroids and Rapamycin inhibit TNFα production by cultured PTEC
  508. Augmentation of SR Ca2+ release by Rapamycin and FK506 causes K+‐channel activation and membrane hyperpolarization in bladder smooth muscle
  509. Dihydroxylation of the triene subunit of Rapamycin
  510. Rituximab and Rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases
  511. Effect of single-dose Rapamycin-based immunosuppression on the development of cardiac allograft vasculopathy.
  512. Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression
  513. The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (Rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs …
  514. Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte: evidence for inhibition of CREB/ATF …
  515. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.
  516. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by Rapamycin.
  517. Glucocorticoid-induced insulin resistance of protein synthesis is independent of the Rapamycin-sensitive pathways in rat skeletal muscle
  518. Long-term in vivo effects of Rapamycin on humoral and cellular immune responses in the rat
  519. … signals that control cell proliferation in mammalian balance epithelia: key roles for phosphatidylinositol-3 kinase, mammalian target of Rapamycin, and S6 kinases in …
  520. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow [published erratum appears in …
  521. Immunosuppressant Rapamycin inhibits protein kinase C α and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis
  522. FK506 and Rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA.
  523. THE IMMUNOSUPPRESSIVE EFFECT OF Rapamycin ON MOUSE SMALL BOWEL TRANSPLANTATION1
  524. Studies on selective reductions of Rapamycin
  525. Rapamycin: biological and therapeutic effects, binding by immunophilins and molecular targets of action
  526. PHARMACOKINETICS AND TOLERABILITY OF 40–0-[2-HYDROXYETHYL] Rapamycin IN DE NOVO LIVER TRANSPLANT RECIPIENTS1
  527. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or Rapamycin alone and in triple combination.
  528. The future role of target of Rapamycin inhibitors in renal transplantation
  529. Rapamycin-induced long-term allograft survival depends on persistence of alloantigen.
  530. Effects of Rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin …
  531. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (Rapamycin) by electrospray-MS/MS after …
  532. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant Rapamycin.
  533. Comparison of the effect of Rapamycin and FK506 on release of prostacyclin and endothelin in vitro
  534. A nonimmunosuppressive triene-modified Rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans-isomerase
  535. Cleavage of the cyclohexyl-subunit of Rapamycin results in loss of immunosuppressive activity
  536. A high performance liquid chromatographic method for the determination of Rapamycin (sirolimus) in rat serum, plasma, and blood and in monkey serum
  537. Cyclosporin A, FK506, Rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions.
  538. Quantitative comparison of Rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction.
  539. Methionine Interference in Rapamycin Production Involves Repression of DemethylRapamycin Methyltransferase andS-Adenosylmethionine Synthetase
  540. A highly convergent strategy towards Rapamycin. Stereoselective construction of the C 8–C 18 fragment
  541. FK506 and Rapamycin binding to FKBP: Common elements in immunophilin-ligand complexation
  542. Cloning and sequence analysis of a Rapamycin-binding protein-encoding gene (RBP1) from Candida albicans
  543. Functional and histopathologic effects of Rapamycin on mouse kidney
  544. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent Rapamycin
  545. Structural basis for peptidomimicry by the effector element of Rapamycin
  546. Involvement of the Rapamycin-sensitive pathway in the insulin regulation of muscle protein synthesis in streptozotocin-diabetic rats
  547. COADMINISTRATION OF NEORAL AND THE NOVEL Rapamycin ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTS: Potentiation of …
  548. Efficacies of sirolimus (Rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of …
  549. ADJUNCTIVE Rapamycin AND CsA TREATMENT INHIBITS MONOCYTE/MACROPHAGE ASSOCIATED CYTOKINES/CHEMOKINES IN SENSITIZED CARDIAC …
  550. Rapamycin (sirolimus) inhibits heart cell growth in vitro
  551. Rapamycin‐resistant phosphorylation of the initiation factor‐4E‐binding protein (4E‐BP1) in v‐SRC‐transformed hamster fibroblasts
  552. Acid catalyzed functionalization of Rapamycin
  553. Discordant effects of Rapamycin on proliferation and p70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells
  554. Missense mutations at the FKBP12-Rapamycin-binding site of TOR1
  555. Nutritional and intestinal effects of the novel immunosuppressive agents: deoxyspergualin, Rapamycin, and mycophenolate mofetil
  556. Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells
  557. inhibition by Rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea‐pigs
  558. The RB/p107/p130 phosphorylation pathway is not inhibited in Rapamycin-induced G1-prolongation of NIH3T3 cells.
  559. The mechanism of unresponsiveness to allografts induced by Rapamycin and Rapamycin/cyclosporine treatment in rats.
  560. Calorimetric measurements of the complexation of cyclosporin A, ascomycin, fujimycin, and Rapamycin with lithium chloride and with an immunophilin
  561. ANALYSIS OF FUNCTIONAL RENAL ALLOGRAFT TOLERANCE WITH SINGLE-DOSE Rapamycin BASED INDUCTION IMMUNOSUPPRESSION1
  562. Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and Rapamycin
  563. Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma
  564. Rapamycin inhibits airway leukocyte infiltration and hyperreactivity in guinea pigs
  565. Synthetic approaches to Rapamycin
  566. Synthesis of the Tricarbonyl Subunit (C8−C19) of Rapamycin via Tandem Chan Rearrangement−Oxidation
  567. Rapamycin synthetic studies. 2. Elaboration of the C (10)-C (26) perimeter
  568. Use of Rapamycin in a transplant patient who developed cyclosporin neurotoxicity
  569. Prolactin and insulin synergize to regulate the translation modulator PHAS-I via mitogen-activated protein kinase-independent but wortmannin-and Rapamycin …
  570. Manipulation of the C (22)-C (27) region of Rapamycin: stability issues and biological implications
  571. Opposing effects of Rapamycin and cyclosporin A on activation-induced Ca2+ release
  572. Detection of noncovalent FKBP-FK506 and FKBP-Rapamycin complexes by capillary electrophoresis-mass spectrometry and capillary electrophoresis-tandem mass …
  573. Comparative effects of Rapamycin FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat
  574. Rapamycin insensitivity in Schistosoma mansoni is not due to FKBP12 functionality
  575. Lipase mediated hydrolysis of Rapamycin 42-hemisuccinate benzyl and methyl esters
  576. The effect of the immunophilin ligands Rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines.
  577. Rapamycin: A new and highly active immunosuppressive macrolide with an efficacy superior to cyclosporine
  578. Effect of a short course of Rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival.
  579. Cyclosporin A, FK506 and Rapamycin produce multiple, temporally distinct, effects on memory following single-trial, passive avoidance training in the chick
  580. Effect of Rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine.
  581. Synthesis of I‐125 labeled photoaffinity Rapamycin analogs
  582. Interleukin 4-inducible phosphorylation of HMG-I (Y) is inhibited by Rapamycin
  583. inhibition of CTL induction by Rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity.
  584. Effects of cyclosporin A, Rapamycin, and FK520 on peripheral T-cell deletion and anergy
  585. The effect of cyclosporin A, FK506 and Rapamycin on the murine contact sensitivity reaction
  586. Structure of FKBP12. 6 in complex with Rapamycin
  587. SUPERIORITY OF SIROLIMUS (Rapamycin) OVER CYCLOSPORINE IN AUGMENTING ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE TREATED WITH …
  588. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors
  589. inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by Rapamycin.
  590. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
  591. DETERMINATION OF AN IMPROVED SIROLIMUS (Rapamycin)-BASED REGIMEN FOR INDUCTION OF ALLOGRAFT TOLERANCE IN MICE TREATED WITH …
  592. Structure of the human 25 kDa FK506 binding protein complexed with Rapamycin
  593. The effects of Rapamycin on humoral immunity in vivo. Suppression of primary responses but not of ongoing alloantibody synthesis or memory responses.
  594. Hypersensitivity to Rapamycin of BJAB B lymphoblastoid cells.
  595. … IMMUNOMODULATION LEADS TO ENHANCED ALLOGRAFT SURVIVAL IN COMBINATION WITH CYCLOSPORINE A AND Rapamycin, BUT NOT FK5061
  596. The effect of Rapamycin on c-jun expression in human lymphocytes
  597. Tritium labelling of RAD001—a new Rapamycin derivative
  598. Relationship between multiple biologic effects of Rapamycin and the inhibition of pp70S6 protein kinase activity. Analysis in mutant clones of a T cell lymphoma.
  599. In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by Rapamycin leads to a clinical-pathological syndrome discrete from that …
  600. Rapamycin Prolongs Survival of Murine Recipients of Fully Allogeneic Donor Grafts When Administered during the Graft‐versus‐Host Disease Process a
  601. Isolation and identification of new Rapamycin dihydrodiol metabolites from dexamethasoneinduced rat liver microsomes
  602. Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca2+ signaling mechanism in rat hippocampal CA1 neurons
  603. … triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, Rapamycin and their analogues …
  604. … C/EBP homologous protein (CHOP) by amino acid deprivation requires insulin-like growth factor I, phosphatidylinositol 3-kinase, and mammalian target of Rapamycin …
  605. Insulin regulation of insulin-like growth factor-binding protein-1 gene expression is dependent on the mammalian target of Rapamycin, but independent of …
  606. Conformational changes of Rapamycin and analogs upon complexing with FKBP associated with activity: an application of second derivative CD spectroscopy
  607. inhibition of S6 Kinase by Rapamycin Blocks Maturation ofRana dybowskiiOocytes
  608. Reversible isomerization of Rapamycin demonstrated by liquid chromatography
  609. The human gene encoding FKBP-Rapamycin associated protein (FRAP) maps to chromosomal band 1p36. 2
  610. Studies towards the total synthesis of Rapamycin: Preparation of the cyclohexyl C33 C42 fragment and further coupling to afford the C22 C42 carbon unit
  611. The effect of anti‐IL‐4 monoclonal antibody, Rapamycin and interferon‐γ on airway hyperreactivity to acetylcholine in mice
  612. IL-2 induces beta2-integrin adhesion via a wortmannin/LY294002-sensitive, Rapamycin-resistant pathway. Phosphorylation of a 125-kilodalton protein correlates with …
  613. Biochemical and structural studies of the FK506-and Rapamycin-binding proteins (FKBPs).
  614. Rapamycin-sensitive phosphorylation of ribosomal protein S17 by p70 S6 kinase
  615. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and Rapamycin
  616. Cyclosporine and Rapamycin affect protein kinase C induction of the intracellular activation signal, activator of DNA replication.
  617. The effect of cyclosporin A, FK506, and Rapamycin on the murine chronic graft‐versus‐host response—an in vivo model of Th2‐like activity
  618. Efficacy of Rapamycin, RS-61443 and cyclophosphamide in the prolongation of survival of discordant pig to rabbit cardiac xenografts.
  619. Rapamycin graft pretreatment in small bowel and kidney transplantation in the rat.
  620. Left main Rapamycin-coated stent: Invasive versus noninvasive angiographic follow-up
  621. Investigation of Rapamycin transport and uptake across absorptive human intestinal cell monolayers
  622. Effects of wortmannin and Rapamycin on CSF-1-mediated responses in macrophages
  623. Cyclosporin A, Rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture
  624. Sirolimus: mammalian target of Rapamycin inhibitor to prevent kidney rejection
  625. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and Rapamycin
  626. Up-regulation of cell surface sodium channels by cyclosporin A, FK506, and Rapamycin in adrenal chromaffin cells
  627. Synergistic effect of Rapamycin and cyclosporine in prevention of acute kidney allograft rejection in the mouse
  628. Isolation of a human cDNA encoding a 25 kDa FK-506 and Rapamycin binding protein
  629. Suppression of allograft responses by combining alloantigen-specific iv pre-sensitization with suboptimal doses of Rapamycin
  630. Rapamycin
  631. Comparison of binding characteristics of four Rapamycin metabolites to the 14 and 52 kDa immunophilins with their pharmacologic activity measured by the mixed …
  632. Hemolytic uremic syndrome after renal transplantation: immunosuppressive therapy with Rapamycin
  633. Immunosuppressants FK506 and Rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation
  634. Inducible membrane recruitment of small GTP-binding proteins by Rapamycin-based system in living cells
  635. Intragraft cytokine expressionf in tolerant rat renal allografts with Rapamycin and cyclosporin immunosuppression
  636. Evidence that Rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats.
  637. Ethanol potentiates the stimulatory effects of insulin and phosphocholine on mitogenesis by a zinc-dependent and Rapamycin-sensitive mechanism in fibroblasts and …
  638. … CD8+ T cells tolerized in vivo: employing a model of Ld-specific TCR transgenic mice transplanted with allogenic hearts under the cover of a short-term Rapamycin …
  639. Insulin regulation of hepatic insulin-like growth factor-binding protein-1 (IGFBP-1) gene expression and mammalian target of Rapamycin (mTOR) signalling is impaired …
  640. Saccharomyces cerevisiae contains a homolog of human fkbp‐13, a membrane‐associated fk506/Rapamycin binding protein
  641. An unexpected inhibitory effect of Rapamycin against germination of spores of Bacillus brevis strain Nagano
  642. Identification of a 14 kDa FK-506/Rapamycin binding immunophilin from calf thymus
  643. … –electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl) Rapamycin
  644. Rapamycin inhibits activation of ryanodine receptors from skeletal muscle by the fatty acyl CoA–acyl CoA binding protein complex
  645. Exclusion of the 13-kDa Rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1
  646. Towards the synthesis of the C37-C42 fragment of Rapamycin: intramolecular reactions of allyl silanes with oxonium ions generated from α-alkoxy sulfones.
  647. Quantitative and temporal analysis of the cellular interaction of FK-506 and Rapamycin in T-lymphocytes.
  648. … ARE NOT REQUIRED FOR INDUCTION OF ALLOGRAFT TOLERANCE IN MICE TREATED WITH ANTILYMPHOCYTE SERUM, Rapamycin, AND DONOR BONE …
  649. A comparison of the effects of Rapamycin and cyclosporine on kidney and heart morphology in a rabbit heterotopic heart transplant model
  650. Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by Rapamycin, cyclosporin A, and inhibitors of …
  651. Cyclosporine, FK-506, Rapamycin, and other immunomodulators
  652. Rapamycin INDUCES TGF-β PRODUCTION IN LYMPOCYTES
  653. Marked prolongation of rat skin xenografts induced by intrathymic injection of xenogeneic splenocytes and a short course of Rapamycin in antilymphocyte serum …
  654. inhibition of cellular transfer of experimental autoimmune uveoretinitis by Rapamycin
  655. Rapamycin: a future in cancer treatment?
  656. Reduction of Sephadex-induced lung inflammation and bronchial hyperreactivity by Rapamycin.
  657. K+ currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and Rapamycin
  658. 14-3-3τ associates with a translational control factor FKBP12-Rapamycin-associated protein in T-cells after stimulation by pervanadate
  659. IL-2-dependent induction of G1 cyclins in primary T cells is not blocked by Rapamycin or cyclosporin A
  660. Evidence that FK506 and Rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and …
  661. Partial characterization of a 52 kDa CsA/FK506/Rapamycin binding protein
  662. Rapamycin: Therapeutic range investigations
  663. Brief treatment with Rapamycin in vivo increases responsiveness to alloantigens measured by the mixed lymphocyte response
  664. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or Rapamycin to induce tolerance.
  665. Up-regulation of insulin-like growth factor binding protein-5 is independent of muscle cell differentiation, sensitive to Rapamycin, but insensitive to wortmannin and …
  666. The effect of cyclosporine, Rapamycin and FK 506 the survival following allogeneic bone marrow transplantation
  667. Treatment of normal skeletal muscle with FK506 or Rapamycin results in halothane-induced muscle contracture
  668. EFFECT OF IN VIVO Rapamycin TREATMENT ON DE NOVO T-CELL DEVELOPMENT IN RELATION TO INDUCTION OF AUTOIMMUNE-LIKE …
  669. Swinging the vote for Rapamycin
  670. Activation of 70‐kDa S6 kinase, induced by the cytokines interleukin‐3 and erythropoietin and inhibited by Rapamycin, is not an absolute requirement for cell …
  671. Rapamycin increases transforming growth factor-β mRNA expression in immortalized rat proximal renal tubular cells
  672. Divergent effects of Rapamycin on mouse and rat cells following mitogenic stimulation
  673. Differential effects of the immunosuppressive macrolides FK-506 and Rapamycin on activation-induced T-cell apoptosis
  674. Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental Rapamycin.
  675. Isolation and identification of a C39 demethylated metabolite of Rapamycin from pig liver microsomes and evaluation of its immunosuppressive activity
  676. … from pig liver microsomes, identification by electrospray tandem mass spectrometry and in vitro immunosuppressive activity of a Rapamycin tris‐epoxide metabolite
  677. Ionization of the c7 methoxy group in Rapamycin by 5 M lithium perchlorate-diethyl ether
  678. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and Rapamycin
  679. Mammalian target of Rapamycin: Immunosuppressive drugs offer new insights into cell growth regulation
  680. Rapamycin-induced apoptosis is p53-independent in human prostate carcinoma PC-3 cells
  681. Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and Rapamycin
  682. Stereoselective construction of the C 21–C 42 fragment of Rapamycin
  683. Rapamycin FOR REFRACTORY RENAL ALLOGRAFT REJECTION.
  684. C‐14 labelling of NVP RAD001—a new Rapamycin derivative
  685. The immunosuppressive macrolides FK-506 and Rapamycin
  686. Inhibitors of mammalian target of Rapamycin
  687. inhibition of the Mr 70,000 S6 kinase pathway by Rapamycin results in chromosome malsegregation in yeast and mammalian cells
  688. Possible involvement of Rapamycin-sensitive pathway in Bcl-2 expression in human neuroblastoma SH-SY5Y cells
  689. Ionizing radiation enhances double-strand-break repair in Rapamycin-treated ataxia telangiectasia lymphoblasts
  690. Effect of Rapamycin on prolactin-stimulated S6 kinase activity and milk product formation in mouse mammary explants
  691. Differential effect of Rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2
  692. A short-term combination therapy with cyclosporine and Rapamycin or leflunomide induces long-term heart allograft survival in a strongly immunogenic strain …
  693. FK-506 and Rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells
  694. FK506 and Rapamycin: Differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes
  695. Late adjunctive therapy with single doses of Rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells
  696. Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70 (S6K)) in human astrocytoma cells
  697. … peptide corresponding to residues 65–79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug Rapamycin
  698. Synthesis and bioactivity of photolabile sirolimus (Rapamycin) analogs
  699. Rapamycin for GVHD prophylaxis-potential for severe myelotoxicity
  700. Provocative effects of the immunosuppressants Rapamycin, tacrolimus, and dexamethasone on Pneumocystis carinii pneumonitis in contrast to the anti-Pneumocystis …
  701. Comparative effects of FK-506, Rapamycin and cyclosporin A, on the in vitro differentiation of dorsal root ganglia explants and septal cholinergic neurons
  702. Anti‐CD28 antibody‐and IL‐4‐induced human T cell proliferation is sensitive to Rapamycin
  703. Rapamycin inhibits aldolase A expression during human lymphocyte activation
  704. The effects of FK 506, cyclosporine, and Rapamycin on liver growth in vitro and in vivo
  705. Analogous conformations of both binding and effector regions in cyclosporin A, FK506 and Rapamycin
  706. X-ray Crystal Structure of 28-O-MethylRapamycin complexed with FKBP12:  Is the Cyclohexyl Moiety Part of the Effector Domain of Rapamycin?
  707. Rapamycin, cyclosporine, and perioperative donor-specific transfusions induce prolongation of cardiac allograft survival in the rat.
  708. Structure-activity relationships involving modifications to the macrolides FK-506 and Rapamycin
  709. Comparative study of CSA and FK506 versus newer immunosuppressive drugs MMF and Rapamycin on coronary endothelial function in vitro
  710. PHAS-I phosphorylation in response to foetal bovine serum (FBS) is regulated by an ERK1/ERK2-independent and Rapamycin-sensitive pathway in 3T3-L1 …
  711. Structural analysis of Rapamycin and related compounds using [M + Li]+ ions generated by liquid secondary ion mass spectrometry
  712. The gene structure and promoter analysis of mouse lymphocyte signal transduction molecule α4 that is related to the yeast TAP42 involved in a Rapamycin-sensitive …
  713. The transcriptional profile of Saccharomyces cerevisiae exposed to Rapamycin mimics the profile induced by amino acid starvation
  714. … with chiral homoallylic ethers: An application to the asymmetric synthesis od (11R, 14S)-anti-and (31R, 34S)-syn-segements of immunosuppressant Rapamycin
  715. SAFETY AND PHARMACOKINETIC PROFILE OF ASCENDING SINGLE DOSES OF ORAL LIQUID SIROLIMUS (Rapamycin) IN PEDIATRIC PATIENTS WITH STABLE …
  716. … suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a Rapamycin derivative, SDZ-RAD
  717. … factor β1 inhibits interleukin‐1‐induced but enhances ionomycin‐induced interferon‐γ production in at cell lymphoma: Comparison with the effects of Rapamycin
  718. Long-term viability of articular cartilage after microsurgical whole-joint transplantation and immunosuppression with Rapamycin, mycophenolate mofetil, and tacrolimus
  719. Effect of cyclosporin A, Rapamycin, and FK-506 on corneal epithelial cells and lymphocyte proliferation
  720. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and Rapamycin
  721. Responsiveness of preactivated B cells to IL-2 and IL-6. Effect of cyclosporine and Rapamycin.
  722. Differential effects of cyclosporin-A and Rapamycin on in vivo thymocyte maturation
  723. Immunopharmacology of Rapamycin (A review)
  724. Synergism between corticosteroids and Rapamycin for the treatment of intraocular inflammation
  725. Rapamycin induces binding activity to the terminal oligopyrimidine tract of ribosomal protein mRNA in rats
  726. Intrasplenic liver parenchymal cells in conjunction with low-dose Rapamycin and cyclosporine induce a unique and specific prolongation of rat cardiac and small bowel …
  727. Target of Rapamycin (TOR) signaling coordinates tRNA and 5S rRNA gene transcription with growth rate in yeast
  728. HPLC Analysis of Rapamycin
  729. TGF-beta Provides the Rationale for the Synergistic Immunpsuppression with Rapamycin (RAPA), Cyclosporine (CsA) and Tacrolimus (TAC)
  730. Pharmacokinetic and pharmacodynamic correlations of cyclosporine (CsA) and Rapamycin (RAPA) in 120 patients treated for at least 2 years at a single center.
  731. Effects of mycophenolic acid, Rapamycin, and carvedilol on the PDGF-induced fibronectin secretion by rat vascular smooth muscle cells: Implication of MAP kinase
  732. The Effect of Immunosuppressive Agents (FK‐506, Rapamycin) on Renal P450 Systems in Rat Models
  733. A comparison of in vivo responses to cyclosporine, FK506, and Rapamycin following allogeneic immune challenge
  734. Rapamycin inhibits the in vitro release of soluble CD23 by SAC/IL-2/IL-4-activated human peripheral blood B lymphocytes
  735. Comparison of FK‐506, Rapamycin, Ascomycin, and Cyclosporine in Mouse Models of Host‐versus‐Graft Disease and Heterotopic Heart Transplantation
  736. Generation and evaluation of putative neuroregenerative drugs: Part 2: Screening virtual libraries of novel polyketides which possess the binding domain of Rapamycin
  737. Steroids, Rapamycin, and breast cancer cells.
  738. ADDITION OF Rapamycin TO CYCLOSPORINE-PREDNISONE BASED IMMUNOSUPPRESSION REDUCES THE CLINICAL RISK OF PRETRANSPLANT ANTI …
  739. Rapamycin treatment depresses
  740. Osmotic pump delivery of Rapamycin
  741. An open-label multi-center clinical study of the efficacy and safety of Rapamycin in combination with CsA and steroid to prevent the acute rejection of kidney …
  742. inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with Rapamycin or A77 1726 (leflunomide)
  743. Prevention of cardiac allograft rejection by FK506 and Rapamycin: assessment by histology and nuclear magnetic resonance
  744. Induction of IL-5 expression by IL-2 is resistant to the immunosuppressive agents cyclosporin A and Rapamycin.
  745. Rapamycin inhibits the in vitro release of soluble interleukin-2 receptor by activated peripheral blood mononuclear cells (PBMC) independently of the mode of …
  746. Rapamycin (Sirolimus) reduces luminal narrowing after balloon angioplasty in porcine coronary arteries
  747. The Rapamycin sensitivity of human T-cell leukaemia virus type I-induced T-cell proliferation is mediated independently of the polypyrimidine motifs in the 5′ long …
  748. Signaling Pathways for Translation: Stress, Calcium, and Rapamycin
  749. Rapamycin and reduced dose cyclosporin produce effective immunosuppression for de novo renal transplant recipients
  750. Differentiation by Rapamycin
  751. Generation and evaluation of putative neuroregenerative drugs: Part 1: virtual point mutations to the polyketide Rapamycin
  752. Triglyceride (TG) elevations in renal transplant recipients treated with sirolimus (Rapamycin, RAPA) added to a cyclosporine (CsA)/prednisone (pred) regimen
  753. Rapamycin: a new immunosuppressive agent capable of inhibiting chronic rejection?
  754. Effects of Rapamycin and FK 506 on Rat Sertoli Cells In Vitro
  755. The Immunosuppressant Rapamycin Induces Inactivation
  756. Effect of immunosuppressants FK506 and Rapamycin on the function of progesterone receptor: protein” p59-HBI”, intersection between immunology and endocrinology …
  757. Effects of Rapamycin on the proliferation and the prodution of IL-2, IFN-γ, TNF-α of spleniclymphocytes in mice [J]
  758. Rapamycin-inducible Secretion of a Therapeutic Protein in the Eye After Transduction With Viral Vectors
  759. High performance liquid chromatographic isolation and spectroscopic characterization of metabolites from the bile of rats receiving Rapamycin (sirolimus) …
  760. In vitro IgE production by interleukin 4-stimulated human peripheral blood mononuclear cells is suppressed by Rapamycin
  761. Conformational sensitivity analysis of FKBP–FK506/Rapamycin complexes
  762. Rapamycin (sirolimus, RapamuneTM): A novel immunosuppressive agent
  763. Cytokine expression in a stringent, single-dose Rapamycin, renal allograft model
  764. Induction of Rapamycin sensitivity by the Gli oncogene.
  765. Conversion from cyclosporine to Rapamycin in renal transplant recipients-Report of an initial experience.
  766. IL-2 DEPENDENT Rapamycin RESISTENT SIGNALS ARE REQUIRED FOR TOLERANCE INDUCTION AND T CELL APOPTOSIS
  767. Supercritical fluid chromatography for therapeutic drug monitoring of immunosuppressants: selectivity for cyclosporine A, FK 506 (tacrolimus), and Rapamycin
  768. Total syntheses of Rapamycin and 32-(S)-dihydroRapamycin.
  769. Rapamycin does not improve renal function or reduce profibrotic gene expression in chronic allograft nephropathy
  770. THE Rapamycin ANALOGUE SDZ RAD INHIBITS LPS AND ANTI-CD3mAb INDUCED IL-10 SYNTHESIS IN VITRO AND IN HUMAN RENAL ALLOGRAFT …
  771. Studies directed towards the synthesis of Rapamycin
  772. Choosing rational combinations of therapeutic agents: Contrasting effects of costimulation blockade plus Rapamycin or cyclosporin on intragraft expression of …
  773. Effects of FK506 and Rapamycin on formation of the neural tube in chick embryos
  774. Increased LFA-1-mediated homotypic cell adhesion is associated with the G1 growth arrest induced by Rapamycin in a T cell lymphoma
  775. The biosynthesis of Rapamycin
  776. Studies towards the total synthesis of Rapamycin
  777. FOUR-YEAR CONTROL OF A CLINICAL Rapamycin ASSAY
  778. Control of translation by a novel, Rapamycin-sensitive signaling pathway.
  779. The total synthesis of (-)-Rapamycin
  780. Total synthesis of Rapamycin.
  781. Rapamycin inhibits HMGB1 expression and releases in RAW264. 7 cells induced by lipopolysaccharides in vitro
  782. Effects of Rapamycin and insulin on the cell cycle and apoptosis of hybridoma cell cultures
  783. Rapamycin inhibits proliferating cell nuclear antigen expression and arrests keratinocytes in the G 1 phase of the cell cycle in vitro.
  784. The Immunophilin Ligand Rapamycin: A Probe for the Analysis of the Relationship of Apoptosis to the Cell Cycle
  785. Comparison between effects of mycophenolate mofetil and Rapamycin on proliferation and apoptosis of cyst-lining epithelial cells of ADPKD patients
  786. Synthetic methods directed towards the synthesis of Rapamycin.
  787. … ALLOGRAFT NEPHROPATHY: A PROSPECTIVE RANDOMISED TRIAL OF CYCLOSPORIN REDUCTION WITH OR WITHOUT Rapamycin.: Abstract# 432 Poster …
  788. Methionine Interference in Rapamycin
  789. Evaluation of the Influence of FK 506, Rapamycin, and Cyclosporine on Processing and Presentation of Particulate Antigen by Macrophages: Assessment of a …
  790. Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in non-human primates
  791. Use of anti-CD25 monoclonal antibody in combination with Rapamycin to reduce or eliminate cyclosporine treatment during the induction phase of …
  792. Efficacy of 40-O-(2-hydroxyethyl)-Rapamycin in preventing chronic renal allograft rejection in rats
  793. Effect of cyclosporin A, FK506 and Rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells
  794. Coadministered neoral and the new Rapamycin derivative, SDZ RAD, for nonhuman primate lung transplantation: systematic pharmcokinetic-based trials to maximize …
  795. Effects of Rapamycin on number and activity of endothelial progenitor cells
  796. Total Synthesis of Rapamycin
  797. Rapamycin has no effect on established allograft vasculopathy
  798. Total Synthesis of Rapamycin
  799. Therapeutic monitoring of cyclosporine, FK-506, and Rapamycin
  800. Insensitivity towards inhibition by cyclosporin A, Rapamycin and tacrolimus in human intestinal lamina propria T lymphocytes
  801. Cyclosporine but not Rapamycin stimulates endothelin-1 secretion by endothelial cells: Potential significance in transplant vasculopathy
  802. Rapamycin RESCUE IN PEDIATRIC LIVER RECIPIENTS WITH TACROLIMUS TOXICITY. A PRELIMINARY EFFECT: CONCENTRATION ANALYSIS.: Abstract# 210 …
  803. Studies towards the total synthesis of Rapamycin
  804. Inhibitory Effects of Rapamycin on the Experimental Allograft Rejection
  805. Innovative technique for immunosuppresion involving administration of Rapamycin loaded formed blood elements
  806. Regulation and identification of Rapamycin sensitive phosphorylation sites of p70s6k
  807. Studies directed toward the synthesis of the southern fragment of Rapamycin
  808. Inhibitors of Mammalian Target of Rapamycin
  809. Effect of Rapamycin on allograft rejection and immune response in mice
  810. In vitro and in vivo assessment of Rapamycin as an immunosuppressive agent in the rabbit
  811. Synthetic studies on the C10-C17 fragment of Rapamycin
  812. Effects of Rapamycin on the proliferation and the prodution of IL-2, IFN-?, TNF-? of spleniclymphocytes in mice
  813. Synergism between corticosteroids and Rapamycin for the treatment of intraocular inflammation
  814. Rapamycin and C (27)-demethoxyRapamycin: An efficient stereocontrolled synthesis of the C (1)-C (20) and C (22)-C (26) fragments.
  815. The effect of Rapamycin in prologation of adrenal allograft survival in the rat
  816. inhibition of cellular transfer of experimental autoimmune uveoretinitis by Rapamycin
  817. Rapamycin and other natural products affect regulation of the growth and differentiation of Saccharomyces cerevisiae.
  818. Biosynthesis of Rapamycin by streptomyces hygroscopicus
  819. Rapamycin, FRAP and the Control of 5’TOP mRNA Translation
  820. Synergistic effects of mycophenolate mofetil (MMF) and sirolimus (Rapamycin, RAPA) in prevention of acute heart, pancreas and kidney allograft rejection and in …
  821. Therapeutic window of whole blood Rapamycin concentration in recipients of renal transplantation
  822. Syntheses and biological activities of natural products: Rapamycin, balanol and the maduropeptin chromophore.
  823. The immunosuppressive effect of Rapamycin on lymphocytic proliferation and DTH, GVHR
  824. Risk factors for Rapamycin-induced thrombocytopenia and leukopenia in renal transplant recipients
  825. Immunosuppressive effect of Rapamycin on heart allotransplantation in the rat [J]
  826. The effect of soy protein on serum lipids in kidney transplant patients receiving Rapamycin.
  827. Aberrant expression of mammalian target of Rapamycin in stage ⅢB colon cancer and its significance
  828. Rapamycin Inhibits 3T3-L1 Adipocyte Differentiation Independent of Clonal Expansion
  829. Effect of Rapamycin on the cyclosporin A-resistant CD28-mediated
  830. Synthetic approaches to the tricarbonyl subunit of Rapamycin
  831. Molecular mechanisms of action of the immunosuppressive drugs cyclosporin A, FK506 and Rapamycin.
  832. Effects of Rapamycin on chronic nephrotoxicity induced by cyclosporine A in rats
  833. Rapamycin antagonizes interleukin-6 mediated growth arrest and differentiation of myeloblastic M1 cells
  834. Cyclin D3, a key cyclin in human lymphocyte proliferation and Rapamycin-mediated immunosuppression.
  835. EXTREME HYPERLIPIDEMIA RESULTING FROM Rapamycin-DERIVED DRUG ADMINISTRATION.: Abstract# 827 Poster Board#-Session: P84-III
  836. Siloxanes as templates in asymmetric synthesis: Studies directed towards the synthesis of Rapamycin.
  837. FK 506 versus cyclosponne a for steroid-free synergistic combination therapy with Rapamycin in a discordant large animal donor xenoislet transplant model
  838. Studies of the Rapamycin-sensitive signaling network using genomics, chemical genetics, and small molecule microarrays.
  839. Rapamycin increases the expression of genes responsible for extracellular matrix remodelling compared to neoral in rat allografts
  840. Inhibitory effects of Rapamycin on intimal hyperplasia after PTCA in the porcine coronary model: a 3-month follow-up
  841. Regulation of the cell integrity pathway by Rapamycin-sensitive TOR function in budding yeast
  842. Rapamycin Inhibits Estrogen-Mediated Transcription in Breast Cancer Cell Lines
  843. Tissue Distribution of Rapamycin and Cyclosporine in the Rat: Comparison of Single vs. Dual Drug Therapy
  844. inhibition by Rapamycin of PDGF-and bFGF-induced human tenon fibroblast proliferation in vitro
  845. Effects of Rapamycin and wortmannin on the insulin stimulation of protein synthesis in rat skeletal muscle and L6 myoblasts
  846. The expression of mammalian target of Rapamycin in autogenous vein graft in rats
  847. The Effects of Immunosuppressants Rapamycin and Cyclosporin A on the Proliferation, Cell Cycle, and Cyclin Expression of Cultured Human Keratinocyte Cell Line …
  848. The effects of Rapamycin and cyclosporin a on tolerance induction through bone marrow transplantation with costimulation blockade
  849. Cyclosporin and FK506, but not Rapamycin, increase DNFB induced TNF-alpha expression in human epidermal sheets.
  850. Mass spectrometric analysis of the Rapamycin-dependent phosphorylation sites of the yeast protein kinase NPR1
  851. Effects of stent-based delivery of Rapamycin and methotrexate on neointimal formation in a porcine coronary model
  852. Effects of cyclosporin and Rapamycin on the in vitro activation of human CD8+ lymphocytes in comparison with peripheral blood mononuclear cells.
  853. Evaluation of Rapamycin coated stents by multi row detector computed angiography: comparison to quantitative angiographic results
  854. Cyclosporin A and FK506, but not Rapamycin, increase DNFB induced TNF-alpha expression in human epidermal sheets.
  855. Using natural products to elucidate molecular events within cells: Molecular mechanisms of action of cyclosporine, FK506, and Rapamycin.
  856. SDZ-RAD PREVENTS CYCLOSPORINE-INDUCED inhibition OF BRAIN ENERGY METABOLISM: COMPARISON WITH Rapamycin.: Abstract# 314 Poster Board …
  857. Rapamycin POTENTIATES NF-κB AND AP-1 ACTIVATION IN TNF-α TREATED PRIMARY RAT HEPATOCYTES.: Abstract# 308 Poster Board#-Session: P155-I
  858. The Mechanism of Insulin-Induced Clonal Expansion in Adipocyte Differentiation–the Importance of PI3 Kinae-Rapamycin-Sensitive Pathway
  859. Inhibitory effects of Rapamycin and ascomycin on hair growth induced by cyclosporin A and FK506 in mice.
  860. Effects of Rapamycin-treated HSP60-pulsed dendritic cells on the progression of the atherosclerotic plaque in mice
  861. inhibition of S6 Kinase by Rapamycin Blocks Maturation of Rana dybowskii Oocytes
  862. Relationship between multiple biological effects of Rapamycin and the inhibition of pp70 S6 protein kinase activity: Analysis in mutant clones of a T cell lymphoma.
  863. The study of Rapamycin-eluting polymer-coated stents to prevent restenosis in the porcine coronary injury model
  864. Differential effects of cyclosporine and Rapamycin on costimulation blockade induced allograft tolerance: Intragraft CTL gene expression analysis
  865. BRIEF COMMUNICATIONS: EFFECT OF Rapamycin ON RENAL ALLOGRAFT SURVIVAL IN CANINE RECIPIENTS TREATED WITH ANTILYMPHOCYTE SERUM …
  866. Rapamycin RESCUE IN PEDIATRIC LIVER RECIPIENTS WITH TACROLIMUS TOXICITY.: Abstract# 211 Poster Board#-Session: P58-I
  867. Rapamycin (RAPA) lowers dose requirements of cyclosporin (CsA) in renal transplant patients (RTx)
  868. … Lewis acid-mediated Mukaiyama aldol reaction of α-alkoxythiolketene acetals with α, β-disubstituted enals: synthesis of the C26–C33 segment of Rapamycin
  869. Rapamycin selectively inhibits translation of mRNAs encoding elongation factor and ribosomal protein
  870. FK506 versus CSA for steroid-free synergistic combination therapy with Rapamycin (Rapa) in a discordant xenoislet model
  871. SHORT TERM ANTILYMPHOCYTE SERUM, Rapamycin AND DONOR BONE MARROW SIGNIFICANTLY SUPPRESS ANTIDONOR ANTIBODY AND PROLONG …
  872. … studies n bioactive natural products. Part I, An approach towards the nootrophic agent huperzine A. Part II, Synthesis of the tricarbonyl subunit of Rapamycin
  873. EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (Rapamycin) MONO-AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT …
  874. Coadministration of neoral and the novel Rapamycin analog, sdzrad, to. lung allograft recipients: potentiation of immunosuppressive efficacy and reduction of toxicity …
  875. Rapamycin (Rapa) And Cyclosporin A (Csa) Enhance Transforming Growth Factor Beta (TGF-β1) Expression in Immortalized Rat Proximal Tubules (IRPTC)† 1840
  876. Rapamycin (RAPA) ENHANCES TRANSFORMING GROWTH FACTOR BETA (TGF-β1) EXPRESSION IN IMMORTALIZED RAT PROXIMAL TUBULES CELLS …
  877. Prevention of Arterial Restenosis by Rapamycin and Mycophenolate Mofetil: A New Role for Novel Immunosuppressants in the Prevention of Post-Balloon Angioplasty …
  878. Rapamycin synergizes with dst plus anti-CD154 to block auto and allo-immune response and induce islet allograft engraftment in spontaneous autoimmune diabetic …
  879. Mating stimulate protein phosphorylation and synthesis via Rapamycin-and wortmannin-sensitive manner in male accessory glands of D. melanogaster
  880. Combined use of mycophenolate mofetil (MMF) and Rapamycin (RAPA) in prevention of acute heart allograft rejection and reversal of ongoing cardiac allograft …
  881. Chronic Rejection in Non-human Primates: Sirolimus (Rapamycin), but not Cyclosporin, Prevents Graft Vascular Disease (GVD) in Aortic Allografts after Acute …
  882. Provocative effects of the immunosuppressants Rapamycin, tacrolimus, and dexamethasone on Pneumocystis carinii pneumonitis in contrast to the anti-Pneumocystis …
  883. Synthesis of the C-21-C-42 fragment of Rapamycin and total synthesis of Rapamycin.
  884. PMA Induced Ser/Thr Phosphorylation of IRS-1 Mediated by Rapamycin-Sensitive Pathway
  885. Desensitization of Insulin Action through Ser/Thr Phosphorylation and Degradation of IRS-1 by Activation of Rapamycin-Sensitive Pathway
  886. 24 HPLC (ESI)-MS IDENTIFICATION OF SIROLIMUS (Rapamycin) METABOLITES GENERATED IN A RABBIT MICROSOMAL SYSTEM AND CONFIRMATION WITH …
  887. Interleukin-2 and Rapamycin regulation of cyclin E-Cdk2 kinase, the Cdk inhibitor, P27KIP1, and the T lymphocyte cell cycle.
  888. 192 SENSITIVE AND SPECIFIC QUANTIFICATION OF SIROLIMUS (Rapamycin) AND ITS METABOLITES IN BLOOD AND URINE OF KIDNEY GRAFT RECIPIENTS …
  889. OP-4. Studies towards the Total Synthesis of Rapamycin
  890. 74 DETERMINATION OF Rapamycin IN WHOLE BLOOD BY HPLC
  891. # 680 In vitro evaluation of Rapamycin sensitivity and synergy with cisplatin and camptothecin in medulloblastoma
  892. Purification and characterization of a 50 kiloDalton lymphocyte-derived binding protein for cyclosporin, FK-506 and Rapamycin.
  893. … from carbohydrates: Application of the (2, 3)-Wittig rearrangement of carbohydrate-derived alpha-alkoxy tertiary allylic ethers to the syntheses of Adda and Rapamycin.
  894. Efficacy of FK-506 and Rapamycin in Prolongation of Allograft Rat Limb Survival
  895. # 764 Rapamycin effects phosphorylation of p70S6 kinase and other intermediaries in medulloblastoma
  896. I. The formal synthesis of FK-506. II. A simple synthesis of vicinal tricarbonyls. III. Studies toward the synthesis of Rapamycin.
  897. Glucose-induced polypyrimidine-tract-binding protein (PTB) to the 3´-untranslated region of the insulin mRNA is inhibited by Rapamycin
  898. METABOLISM AND PHARMACOKINETICS OF THE NEW IMMUNOSUPPRESSANT 40-O-(2-HYDROXY)-ETHYL-Rapamycin
  899. 138 Rapamycin AND CYCLOSPORINE DRUG STUDIES IN THE RAT MODEL
  900. Rapamycin: an anti-cancer immunosuppressant?
  901. Determinants of Rapamycin sensitivity in breast cancer cells
  902. Antileukemic activity of Rapamycin in acute myeloid leukemia
  903. Molecular organization of target of Rapamycin complex 2
  904. Rapamycin-induced oligospermia
  905. mTOR-targeted therapy of cancer with Rapamycin derivatives
  906. Rapamycin pre-treatment protects against apoptosis
  907. Activation of Akt and eIF4E survival pathways by Rapamycin-mediated mammalian target of Rapamycin inhibition
  908. Signaling by target of Rapamycin proteins in cell growth control
  909. Differential effects of Rapamycin on mammalian target of Rapamycin signaling functions in mammalian cells
  910. Rapamycin alleviates toxicity of different aggregate-prone proteins
  911. Prolonged Rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
  912. Rapamycin attenuates load-induced cardiac hypertrophy in mice
  913. Use of Rapamycin slows progression of cardiac transplantation vasculopathy
  914. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease
  915. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
  916. Rapamycin is an effective inhibitor of human renal cancer metastasis
  917. Maintenance immunosuppression with target-of-Rapamycin inhibitors is associated with a reduced incidence of de novo malignancies
  918. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
  919. Campath‐1H induction plus Rapamycin monotherapy for renal transplantation: results of a pilot study
  920. Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 IsMediated by p70S6 Kinase
  921. Target of Rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
  922. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by Rapamycin
  923. Characterization of the FKBP⊙ Rapamycin⊙ FRB Ternary Complex
  924. inhibition of target of Rapamycin signaling by Rapamycin in the unicellular green alga Chlamydomonas reinhardtii
  925. Insulin/IGF and target of Rapamycin signaling: a TOR de force in growth control
  926. Targeting the molecular target of Rapamycin (mTOR)
  927. inhibition of mTOR signaling with Rapamycin regresses established cardiac hypertrophy induced by pressure overload
  928. The molecular target of Rapamycin (mTOR) as a therapeutic target against cancer
  929. Regulation of adipocyte differentiation and insulin action with Rapamycin
  930. Effects of Rapamycin in the Eker rat model of tuberous sclerosis complex
  931. Targeting the mammalian target of Rapamycin (mTOR): a new approach to treating cancer
  932. Target of Rapamycin-mediated amino acid signaling in mosquito anautogeny
  933. Multiple roles of Tap42 in mediating Rapamycin-induced transcriptional changes in yeast
  934. Rapamycin impairs antigen uptake of human dendritic cells1
  935. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy
  936. Mammalian target of Rapamycin inhibition as therapy for hematologic malignancies
  937. Dissociation of raptor from mTOR is a mechanism of Rapamycin‐induced inhibition of mTOR function
  938. GβL, a positive regulator of the Rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR
  939. Mammalian target of Rapamycin: a new molecular target for breast cancer
  940. Combination of Rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
  941. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of Rapamycin and its targets
  942. Immunosuppressants and skin cancer in transplant patients: focus on Rapamycin
  943. Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients
  944. Specific binding to intracellular proteins determines arterial transport properties for Rapamycin and paclitaxel
  945. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells
  946. Targeting mammalian target of Rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
  947. Upstream of the mammalian target of Rapamycin: do all roads pass through mTOR?
  948. Rictor, a novel binding partner of mTOR, defines a Rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
  949. Phospholipase D confers Rapamycin resistance in human breast cancer cells
  950. Thr2446 is a novel mammalian target of Rapamycin (mTOR) phosphorylation site regulated by nutrient status
  951. Nephrotoxicity of Rapamycin: an emerging problem in clinical medicine
  952. Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity
  953. The mammalian target of Rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity
  954. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis
  955. Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosus
  956. Rapamycin suppresses experimental aortic aneurysm growth
  957. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling
  958. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets
  959. Antiangiogenic potential of the mammalian target of Rapamycin inhibitor temsirolimus
  960. Mammalian TOR complex 2 controls the actin cytoskeleton and is Rapamycin insensitive
  961. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice
  962. The Pim kinases control Rapamycin-resistant T cell survival and activation
  963. Akt activates the mammalian target of Rapamycin by regulating cellular ATP level and AMPK activity
  964. Mammalian target of Rapamycin, a molecular target in squamous cell carcinomas of the head and neck
  965. Finding new components of the target of Rapamycin (TOR) signaling network through chemical genetics and proteome chips
  966. Stent implantation activates RhoA in human arteries: inhibitory effect of Rapamycin
  967. Regulation of targets of mTOR (mammalian target of Rapamycin) signalling by intracellular amino acid availability.
  968. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients
  969. Sustained activation of the JNK cascade and Rapamycin-induced apoptosis are suppressed by p53/p21Cip1
  970. Combination of the mTOR inhibitor Rapamycin and CC-5013 has synergistic activity in multiple myeloma
  971. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance
  972. Gene expression-based chemical genomics identifies Rapamycin as a modulator of MCL1 and glucocorticoid resistance
  973. Rapamycin activates Tap42‐associated phosphatases by abrogating their association with Tor complex 1
  974. Preliminary observations regarding angiographic pattern of restenosis after Rapamycin-eluting stent implantation
  975. Mutasynthesis of Rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis
  976. Curcumin inhibits the mammalian target of Rapamycin‐mediated signaling pathways in cancer cells
  977. Mammalian target of Rapamycin pathway blockade slows progression of diabetic kidney disease in rats
  978. The solution structure of the FATC domain of the protein kinase target of Rapamycin suggests a role for redox-dependent structural and cellular stability
  979. Mammalian target of Rapamycin regulates IRS-1 serine 307 phosphorylation
  980. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of Rapamycin pathway
  981. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells
  982. Insights into TOR function and Rapamycin response: chemical genomic profiling by using a high-density cell array method
  983. Survival signaling by Notch1: mammalian target of Rapamycin (mTOR)–dependent inhibition of p53
  984. Antitumoral activity of Rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex
  985. Rapamycin successfully treats post‐transplant autoimmune hepatitis
  986. Increased activation of the mammalian target of Rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance
  987. Rapamycin: signaling in vascular smooth muscle
  988. Therapeutic potential of target of Rapamycin inhibitors
  989. Synergistic augmentation of Rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors
  990. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro
  991. Rheb binding to mammalian target of Rapamycin (mTOR) is regulated by amino acid sufficiency
  992. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells
  993. Inhibitory effect of Rapamycin on corneal neovascularization in vitro and in vivo
  994. Regulation of peroxisome proliferator–activated receptor-γ activity by mammalian target of Rapamycin and amino acids in adipogenesis
  995. inhibition of mTOR signaling with Rapamycin attenuates renal hypertrophy in the early diabetic mice
  996. Identification of S6 kinase 1 as a novel mammalian target of Rapamycin (mTOR)-phosphorylating kinase
  997. Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo
  998. Mammalian target of Rapamycin inhibition
  999. Phase I/II study of the mammalian target of Rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
  1000. Mechanical stimuli regulate Rapamycin-sensitive signalling by a phosphoinositide 3-kinase-, protein kinase B-and growth factor-independent mechanism
  1001. Dosing of Rapamycin is critical to achieve an optimal antiangiogenic effect against cancer
  1002. A possible linkage between AMP‐activated protein kinase (AMPK) and mammalian target of Rapamycin (mTOR) signalling pathway
  1003. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
  1004. Acute Rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies
  1005. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
  1006. AKT activity determines sensitivity to mammalian target of Rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
  1007. Inhibitors of the mammalian target of Rapamycin
  1008. Homodirectional changes in transcriptome composition and mRNA translation induced by Rapamycin and heat shock
  1009. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design
  1010. Oral Rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study
  1011. Rapamycin-mediated inhibition of mammalian target of Rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation
  1012. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma
  1013. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer
  1014. Effect of Rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer
  1015. Efficacy of a Rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models
  1016. Rapamycin confers preconditioning-like protection against ischemia–reperfusion injury in isolated mouse heart and cardiomyocytes
  1017. Drosophila target of Rapamycin kinase functions as a multimer
  1018. Targeting the Akt/mammalian target of Rapamycin pathway for radiosensitization of breast cancer
  1019. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with Rapamycin
  1020. Arabidopsis TARGET OF Rapamycin interacts with RAPTOR, which regulates the activity of S6 kinase in response to osmotic stress signals
  1021. Rapamycin in cardiovascular medicine
  1022. Mechanical stimuli and nutrients regulate Rapamycin‐sensitive signaling through distinct mechanisms in skeletal muscle
  1023. FKBP12-Rapamycin-associated protein or mammalian target of Rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus
  1024. S6K1−/−/S6K2−/− mice exhibit perinatal lethality and Rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein …
  1025. Determinants of sensitivity and resistance to Rapamycin-chemotherapy drug combinations in vivo
  1026. Brain-derived neurotrophic factor induces mammalian target of Rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal …
  1027. In vitro study of release mechanisms of paclitaxel and Rapamycin from drug-incorporated biodegradable stent matrices
  1028. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of Rapamycin by amino acids and certain cellular stresses
  1029. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways
  1030. Rapamycin‐sensitive signalling in long‐term consolidation of auditory cortex‐dependent memory
  1031. Systemic Rapamycin inhibits retinal and choroidal neovascularization in mice
  1032. inhibition of the mammalian target of Rapamycin (mTOR) by Rapamycin increases chemosensitivity of CaSki cells to paclitaxel
  1033. Target of Rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of …
  1034. Rapamycin‐treated, alloantigen‐pulsed host dendritic cells induce ag‐specific T cell regulation and prolong graft survival
  1035. Activation of mammalian target of Rapamycin in cytomegalic neurons of human cortical dysplasia
  1036. Mutation in TSC2 and activation of mammalian target of Rapamycin signalling pathway in renal angiomyolipoma
  1037. inhibition of mammalian target of Rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells
  1038. Role of mammalian target of Rapamycin signaling in compensatory renal hypertrophy
  1039. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
  1040. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy
  1041. Activation of the Akt/mammalian target of Rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers
  1042. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of Rapamycin signaling
  1043. BDNF regulates the translation of a select group of mRNAs by a mammalian target of Rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal …
  1044. Antitumor efficacy of intermittent treatment schedules with the Rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in …
  1045. The mammalian target of Rapamycin signaling network and gene regulation
  1046. Combination mammalian target of Rapamycin inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple …
  1047. Role of glycogen synthase kinase 3β in Rapamycin-mediated cell cycle regulation and chemosensitivity
  1048. Immediate response of mammalian target of Rapamycin (mTOR)‐mediated signalling following acute resistance exercise in rat skeletal muscle
  1049. Proteomic analysis reveals hyperactivation of the mammalian target of Rapamycin pathway in neurofibromatosis 1–associated human and mouse brain tumors
  1050. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
  1051. Mutual antagonism of target of Rapamycin and calcineurin signaling
  1052. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas
  1053. inhibition of corneal neovascularization by Rapamycin
  1054. Calcineurin inhibitors, but not Rapamycin, reduce percentages of CD4+ CD25+ FOXP3+ regulatory T cells in renal transplant recipients
  1055. Androgens induce prostate cancer cell proliferation through mammalian target of Rapamycin activation and post-transcriptional increases in cyclin D proteins
  1056. Dexamethasone represses signaling through the mammalian target of Rapamycin in muscle cells by enhancing expression of REDD1
  1057. In vitro release of the mTOR inhibitor Rapamycin from poly (ethylene glycol)-b-poly (ε-caprolactone) micelles
  1058. Low-dose oral Rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis
  1059. Antitumor activity of Rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer
  1060. Translational control via the mammalian target of Rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons
  1061. Rapamycin induces Smad activity in prostate cancer cell lines
  1062. Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2Bϵ mRNA in a mammalian target of Rapamycin …
  1063. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and Rapamycin on the induction of FOXP3 in human T cells
  1064. The mammalian target of Rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif
  1065. Effects of the mammalian target of Rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
  1066. Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells
  1067. Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex–mammalian target of Rapamycin pathway
  1068. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to Rapamycin
  1069. New targets for therapy in breast cancer: mammalian target of Rapamycin (mTOR) antagonists
  1070. Modulation of the mammalian target of Rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid
  1071. Human cytomegalovirus infection induces Rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase
  1072. Mammalian target of Rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor …
  1073. … predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At …
  1074. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of Rapamycin
  1075. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by Rapamycin
  1076. Rpd3p relocation mediates a transcriptional response to Rapamycin in yeast
  1077. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of Rapamycin pathway in breast cancer cells
  1078. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of Rapamycin kinase inhibitor, in patients with advanced refractory renal cell …
  1079. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy
  1080. Activation of the mammalian target of Rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes
  1081. Akt1 Activation Can Augment Hypoxia-Inducible Factor-1α Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin–Independent …
  1082. Rapamycin inhibits GM-CSF-induced neutrophil migration
  1083. The mammalian target of the Rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy
  1084. Delayed graft function and cast nephropathy associated with tacrolimus plus Rapamycin use
  1085. Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the Rapamycin gene cluster
  1086. Recent developments in targeting the mammalian target of Rapamycin (mTOR) kinase pathway
  1087. Domains of Gln3p interacting with karyopherins, Ure2p, and the target of Rapamycin protein
  1088. Rapamycin-eluting stents for the treatment of unprotected left main coronary disease
  1089. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation
  1090. Activation of mammalian target of Rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase–positive anaplastic large cell …
  1091. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer
  1092. Activation of mammalian target of Rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1
  1093. Mammalian target of Rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma …
  1094. inhibition of mammalian target of Rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras
  1095. Raptor, a binding partner of target of Rapamycin
  1096. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring …
  1097. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
  1098. Molecular mechanisms through which amino acids mediate signaling through the mammalian target of Rapamycin
  1099. … outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent …
  1100. Rapamycin biosynthesis: elucidation of gene product function
  1101. Effect of Rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Eμ-TCL1 transgenic mice
  1102. Roles of glutamate receptors and the mammalian target of Rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in …
  1103. New Rapamycin derivatives by precursor‐directed biosynthesis
  1104. Thyroid Hormone Induces Rapid Activation of Akt/Protein Kinase B-Mammalian Target of Rapamycin-p70S6K Cascade through Phosphatidylinositol 3-Kinase in …
  1105. Target of Rapamycin-dependent activation of S6 kinase is a central step in the transduction of nutritional signals during egg development in a mosquito
  1106. inhibition of mammalian target of Rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity
  1107. … growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin (PI3K/Akt/mTOR) …
  1108. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of Rapamycin
  1109. Chronic inhibition of mammalian target of Rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and …
  1110. Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2α kinase GCN2
  1111. Control of dendritic arborization by the phosphoinositide-3′-kinase–Akt–mammalian target of Rapamycin pathway
  1112. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation
  1113. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin
  1114. Mammalian target of Rapamycin as a therapeutic target in leukemia
  1115. Activation of mammalian target of Rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma
  1116. Nutrient-dependent multimerization of the mammalian target of Rapamycin through the N-terminal HEAT repeat region
  1117. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of Rapamycin
  1118. Mammalian target of Rapamycin (mTOR) inhibitors as anti-cancer agents
  1119. Long-term treatment of bile duct-ligated rats with Rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms
  1120. Mechanism by which mammalian target of Rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis
  1121. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of Rapamycin
  1122. Mammalian target of Rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab
  1123. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to Rapamycin in an Akt-dependent manner via p38 MAPK signaling
  1124. The Rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation
  1125. Pilot trial of oral Rapamycin for recalcitrant restenosis
  1126. Effect of Rapamycin on renal ischemia‐reperfusion injury in mice
  1127. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance
  1128. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of Rapamycin/p70S6K leading to increased angiogenesis and …
  1129. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression
  1130. Successful conversion to Rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation
  1131. Synergistic effect of targeting mTOR by Rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
  1132. Cyclosporin A and tacrolimus, but not Rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells
  1133. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells
  1134. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of Rapamycin (mTOR) signalling
  1135. Target of Rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding …
  1136. … sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of Rapamycin …
  1137. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway
  1138. Mammalian target of Rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway
  1139. Human cytomegalovirus infection alters the substrate specificities and Rapamycin sensitivities of raptor-and rictor-containing complexes
  1140. Regulation of Leucine Uptake by tor1+ in Schizosaccharomyces pombe Is Sensitive to Rapamycin
  1141. TCR engagement increases hypoxia-inducible factor-1α protein synthesis via Rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells
  1142. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam …
  1143. Mammalian target of Rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation
  1144. Local application of Rapamycin inhibits neointimal hyperplasia in experimental vein grafts
  1145. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by Rapamycin through a p38 MAPK …
  1146. GATA factor translation is the final downstream step in the amino acid/target-of-Rapamycin-mediated vitellogenin gene expression in the anautogenous …
  1147. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis
  1148. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty
  1149. Akt1/Akt2 and mammalian target of Rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell …
  1150. Fibronectin stimulates non–small cell lung carcinoma cell growth through activation of Akt/mammalian target of Rapamycin/S6 kinase and inactivation of LKB1/AMP …
  1151. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of Rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long …
  1152. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines: an approach to suppress R5 strains of HIV-1
  1153. … in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson’s disease by a mechanism involving mammalian target of Rapamycin …
  1154. Glucagon represses signaling through the mammalian target of Rapamycin in rat liver by activating AMP-activated protein kinase
  1155. Isolation and Characterization of Pre‐Rapamycin, the First Macrocyclic Intermediate in the Biosynthesis of the Immunosuppressant Rapamycin by S. hygroscopicus
  1156. Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: a Rapamycin-Eluting Stent Evaluated at …
  1157. A high-throughput method for screening of Rapamycin-producing strains of Streptomyces hygroscopicus by cultivation in 96-well microtiter plates
  1158. Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of Rapamycin-p70 S6 kinase 1 pathway
  1159. Comparative effects of paclitaxel and Rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling
  1160. Production of novel Rapamycin analogs by precursor-directed biosynthesis
  1161. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells1
  1162. Effects of Rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood
  1163. Predictive and prognostic role of activated mammalian target of Rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy
  1164. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of Rapamycin (mTOR)-induced negative feedback down-regulates …
  1165. A Rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and …
  1166. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of Rapamycin and for recognition by raptor
  1167. A nuclear transport signal in mammalian target of Rapamycin is critical for its cytoplasmic signaling to S6 kinase 1
  1168. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of Rapamycin (mTOR)-independent
  1169. … undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated …
  1170. Antiangiogenic and immunomodulatory effects of Rapamycin on islet endothelium: relevance for islet transplantation
  1171. Rapamycin mimics the incompatibility reaction in the fungus Podospora anserina
  1172. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties
  1173. An open prospective pilot study on the use of Rapamycin after penetrating high-risk keratoplasty
  1174. Ex vivo Rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant Rapamycin therapy
  1175. Post-transcriptional regulation of the androgen receptor by Mammalian target of Rapamycin
  1176. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its …
  1177. Efficacy of Rapamycin in patient with juvenile rheumatoid arthritis
  1178. Mammalian target of Rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation
  1179. Effects of Rapamycin on accumulation of α‐, β‐ and γ‐globin mRNAs in erythroid precursor cells from β‐thalassaemia patients
  1180. Rapamycin and chronic kidney disease: beyond the inhibition of inflammation
  1181. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of Rapamycin pathway
  1182. inhibition of the mammalian target of Rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells
  1183. LY294002 and Rapamycin co‐operate to inhibit T‐cell proliferation
  1184. The mTOR inhibitor Rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
  1185. The immunosuppressant Rapamycin exacerbates neurotoxicity of Aβ peptide
  1186. … transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of Rapamycin in transformed NK …
  1187. From Rapa Nui to Rapamycin: targeting PI3K/Akt/mTOR for cancer therapy
  1188. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of Rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways …
  1189. Statins induce mammalian target of Rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs
  1190. Target of Rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
  1191. Phophatidylinositol-3 Kinase/Mammalian Target of Rapamycin/p70S6K Regulates Contractile Protein Accumulation in Airway Myocyte Differentiation
  1192. Amino acid signaling through the mammalian target of Rapamycin (mTOR) pathway: role of glutamine and of cell shrinkage
  1193. Rapamycin: friend, foe, or misunderstood?
  1194. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ
  1195. The product of the UTH1 gene, required for Bax‐induced cell death in yeast, is involved in the response to Rapamycin
  1196. Effects of FK506 and Rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes
  1197. Sustained intraocular Rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits
  1198. Effects of Rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells
  1199. Mammalian target of Rapamycin
  1200. Rapamycin analogs for stent-based local drug delivery
  1201. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of Rapamycin pathway
  1202. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by Rapamycin
  1203. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of Rapamycin activity and increased translation under hypoxic conditions
  1204. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses Rapamycin action by stabilizing these …
  1205. Mechanisms of action of Rapamycin in gliomas
  1206. Enhancement of translation elongation in neurons by brain‐derived neurotrophic factor: Implications for mammalian target of Rapamycin signaling
  1207. Oral Rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study
  1208. Effects of combined treatment with Rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts
  1209. Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of Rapamycin (mTOR) and extracellular signal-regulated kinase (ERK …
  1210. Rapamycin and tumor growth: mechanisms behind its anticancer activity
  1211. inhibition of mammalian target of Rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-κB …
  1212. Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of Rapamycin signaling pathway
  1213. Modulation of insulin action by dietary proteins and amino acids: role of the mammalian target of Rapamycin nutrient sensing pathway
  1214. Rituximab in association with Rapamycin for post-transplant lymphoproliferative disease treatment
  1215. … macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a Rapamycin-sensitive, mTOR-related …
  1216. Rapamycin‐mediated induction of γ‐globin mRNA accumulation in human erythroid cells
  1217. Differing responses of Gat1 and Gln3 phosphorylation and localization to Rapamycin and methionine sulfoximine treatment in Saccharomyces cerevisiae
  1218. Mammalian target of Rapamycin inhibitors in combination with letrozole in breast cancer
  1219. … 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of Rapamycin signaling pathway and …
  1220. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells
  1221. Combination therapy of mycophenolate mofetil and Rapamycin in prevention of chronic renal allograft rejection in the rat1
  1222. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy
  1223. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and Rapamycin
  1224. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability
  1225. … identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and Rapamycin
  1226. Gln3 phosphorylation and intracellular localization in nutrient limitation and starvation differ from those generated by Rapamycin inhibition of Tor1/2 in …
  1227. Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury
  1228. … -inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of Rapamycin (mTOR) pathway is …
  1229. Superior T-cell suppression by Rapamycin and FK506 over Rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory …
  1230. Estrogen-induced activation of mammalian target of Rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain
  1231. … progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin pathway: progesterone receptor as …
  1232. Acceleration of apoptosis in CD4+ CD8+ thymocytes by Rapamycin accompanied by increased CD4+ CD25+ T cells in the periphery1
  1233. Intracellular network of phosphatidylinositol 3‐kinase, mammalian target of the Rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen‐activated protein kinases …
  1234. Interleukin-12-induced interferon-γ production by human peripheral blood T cells is regulated by mammalian target of Rapamycin (mTOR)
  1235. Pilot study of oral Rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial)
  1236. … artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of Rapamycin/p70 ribosomal S6 kinase …
  1237. Interferon α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of Rapamycin signaling pathway
  1238. ROS fusion tyrosine kinase activates a SH2 domain–containing phosphatase-2/phosphatidylinositol 3-Kinase/mammalian target of Rapamycin signaling axis to form …
  1239. Hyperactivation of mammalian target of Rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase
  1240. Oral Rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice
  1241. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs
  1242. inhibition of insulin signaling and adipogenesis by Rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1
  1243. Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or Rapamycin
  1244. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of Rapamycin
  1245. Insulin-like growth factor I-mediated protection from Rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling …
  1246. Efficacy of polyphenon E, red ginseng, and Rapamycin on benzo (a) pyrene-induced lung tumorigenesis in A/J mice
  1247. … of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of Rapamycin in leukemic cells
  1248. Sustained activation of the mammalian target of Rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in …
  1249. Rapamycin antagonizes NF-κB nuclear translocation activated by TNF-α in primary vascular smooth muscle cells and enhances apoptosis
  1250. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of Rapamycin
  1251. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis
  1252. Mammalian target of Rapamycin (mTOR) inhibitors
  1253. Glucose-stimulated DNA synthesis through mammalian target of Rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent …
  1254. Targeting the AIB1 oncogene through mammalian target of Rapamycin inhibition in the mammary gland
  1255. Activation of mammalian target of Rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular …
  1256. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology …
  1257. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a Rapamycin-and farnesylation-dependent manner
  1258. Rapamycin analogs with reduced systemic exposure
  1259. Mammalian target of Rapamycin and protein kinase A signaling mediate the cardiac transcriptional response to glutamine
  1260. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis
  1261. Exercise‐induced alterations in extracellular signal‐regulated kinase 1/2 and mammalian target of Rapamycin (mTOR) signalling to regulatory mechanisms of mRNA …
  1262. Mechanistic insights into impaired dendritic cell function by Rapamycin: inhibition of Jak2/Stat4 signaling pathway
  1263. Cyclin D3 is down-regulated by Rapamycin in HER-2-overexpressing breast cancer cells
  1264. Rapamycin in children after liver transplantation
  1265. inhibition of the phosphatidylinositol 3-kinase/mammalian target of Rapamycin pathway in hematologic malignancies
  1266. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal …
  1267. Activation of mammalian target of Rapamycin in postmenopausal ovarian endometriosis
  1268. Fatal infection after Rapamycin eluting coronary stent implantation
  1269. Effect of Rapamycin on the healing of the bile duct
  1270. Rapamycin in lung transplantation
  1271. Evidence for cyclin D3 as a novel target of Rapamycin in human T lymphocytes
  1272. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation
  1273. Lipase-catalyzed regioselective esterification of Rapamycin: synthesis of temsirolimus (CCI-779)
  1274. Role of oral Rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)
  1275. Structure-based design of AP23573, a phosphorus-containing analog of Rapamycin for anti-tumor therapy.
  1276. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN
  1277. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest
  1278. … of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of Rapamycin (RAD001) offers improved …
  1279. Ex vivo Rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism
  1280. Studies investigating pretransplant donor-specific blood transfusion, Rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin …
  1281. Early renal benefit of Rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients
  1282. inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung …
  1283. … Receptor Substrate-1 on Ser307 and Ser612 and Impairs the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Insulin Biosynthetic Pathway in …
  1284. Insulin facilitation of muscle protein synthesis following resistance exercise in hindlimb-suspended rats is independent of a Rapamycin-sensitive pathway
  1285. The role of heme oxygenase 1 in Rapamycin-induced renal dysfunction after ischemia and reperfusion injury
  1286. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53
  1287. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
  1288. Perturbed IFN-γ-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of Rapamycin-IFN-γ treatment
  1289. Roles of phosphatidylinositol 3′-kinase and mammalian target of Rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial …
  1290. EFFECT OF Rapamycin ON THE FATE OF P23H OPSIN ASSOCIATED WITH RETINITS PIGMENTOSA (AN AMERICAN OPHTHALMOLOGICAL SOCIETY …
  1291. Synergistic immunosuppressive effects of rosmarinic acid and Rapamycin in vitro and in vivo1
  1292. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, Rapamycin, and anti-interleukin-2 antibody1
  1293. Signaling interactions of Rapamycin combined with erlotinib in cervical carcinoma xenografts
  1294. Rapamycin inhibits release of tumor necrosis factor-[alpha] from human vascular smooth muscle cells
  1295. CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of Rapamycin pathway
  1296. Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of Rapamycin/p70 S6K pathway
  1297. Mammalian target of Rapamycin is required for thrombopoietin‐induced proliferation of megakaryocyte progenitors
  1298. The fission yeast TOR proteins and the Rapamycin response: an unexpected tale
  1299. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, Rapamycin) in pediatric patients with stable chronic renal failure undergoing …
  1300. Use of Rapamycin-impregnated stents in coronary arteries
  1301. In Vivo and In Vitro Effects of SAR 943, a Rapamycin Analogue, on Airway Inflammation and Remodeling
  1302. Farnesylthiosalicylic Acid Inhibits Mammalian Target of Rapamycin (mTOR) Activity Both in Cells and in Vitro by Promoting Dissociation of the mTOR-Raptor Complex
  1303. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of Rapamycin pathway
  1304. Pharmacokinetics of sirolimus (Rapamycin) in subjects with mild to moderate hepatic impairment
  1305. Low-dose radiation plus Rapamycin promotes long-term bone marrow chimerism
  1306. Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model
  1307. Anti–third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with Rapamycin and BM cell dose
  1308. Combination of imatinib with Rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib
  1309. Outcomes of using Firebird Rapamycin eluting stents in routine coronary intervention practice: one-year results from the pilot study of Firebird in China registry
  1310. Prolactin activates mammalian target-of-Rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 …
  1311. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug Rapamycin: A direct role as an antifibrotic agent?
  1312. Pmr1, a Golgi Ca2+/Mn2+-ATPase, is a regulator of the target of Rapamycin (TOR) signaling pathway in yeast
  1313. Rapamycin ameliorates experimental autoimmune myocarditis
  1314. First experience with Rapamycin-based immunosuppression to improve kidney function after heart transplantation
  1315. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital …
  1316. The mammalian target of Rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9 …
  1317. Differential effects of Rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling
  1318. Rapamycin causes activation of protein phosphatase-2A1 and nuclear translocation of PCNA in CD4+ T cells
  1319. Rapamycin: a new string to the antiproteinuric bow?
  1320. … the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated …
  1321. Mammalian target of Rapamycin inhibitors in sarcomas
  1322. Liposomal formulations of tacrolimus and Rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts
  1323. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts
  1324. 5‐HT stimulates eEF2 dephosphorylation in a Rapamycin‐sensitive manner in Aplysia neurites
  1325. Blockage of 2-deoxy-D-ribose-induced angiogenesis with Rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer …
  1326. Rapamycin in lung transplantation: preliminary results
  1327. Tsc1 haploinsufficiency without mammalian target of Rapamycin activation is sufficient for renal cyst formation in Tsc1+/− mice
  1328. Novel sulfur-containing Rapamycin analogs prepared by precursor-directed biosynthesis
  1329. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth
  1330. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
  1331. Akt and mammalian target of Rapamycin regulate separate systems of proteolysis in renal tubular cells
  1332. … with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of Rapamycin in breast cancer
  1333. Mammalian target of Rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional …
  1334. The effect of Rapamycin on the healing of the ureteric anastomosis and wound healing
  1335. Effect of SU11248 on gastrointestinal stromal tumor‐T1 cells: Enhancement of growth inhibition via inhibition of 3‐kinase/Akt/mammalian target of Rapamycin signaling
  1336. Combination of a Rapamycin analog (CCI‐779) and interferon‐γ is more effective than single agents in treating a mouse model of tuberous sclerosis complex
  1337. Overcoming T cell–mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and Rapamycin
  1338. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the Rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital …
  1339. Rapamycin inhibits liver growth during refeeding in rats via control of ribosomal protein translation but not cap-dependent translation initiation
  1340. … is regulated by phosphorylation and turnover of protein kinase C βII mediated by phosphatidylinositol 3-kinase-and mammalian target of Rapamycin …
  1341. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience
  1342. Heme oxygenase-1 mediates the protective effects of Rapamycin in monocrotaline-induced pulmonary hypertension
  1343. Successful treatment of a severe case of idiopathic pulmonary fibrosis with Rapamycin
  1344. Evaluation of Rapamycin chemical stability in volatile-organic solvents by HPLC
  1345. Characterization of the cloned full-length and a truncated human target of Rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay
  1346. Rapamycin reduces neointima formation during vascular injury.
  1347. Effects of aerobic exercise training on the protein kinase B (PKB)/mammalian target of Rapamycin (mTOR) signaling pathway in aged skeletal muscle
  1348. Effects of Rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice
  1349. Effects of cyclosporin A and a Rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats
  1350. Rapamycin induces a caspase‐independent cell death in human monocytes
  1351. Acute renal failure following kidney transplantation associated with myoglobinuria in patients treated with Rapamycin
  1352. Rapamycin inhibits cdk4 activation, p 21WAF1/CIP1 expression and G1‐phase progression in transformed mouse fibroblasts
  1353. Oral Rapamycin to prevent human coronary stent restenosis: a pilot study
  1354. A downstream kinase of the mammalian target of Rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability
  1355. Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of …
  1356. In rat hepatocytes glucagon increases mammalian target of Rapamycin phosphorylation on serine 2448 but antagonizes the phosphorylation of its downstream …
  1357. Podospora anserina target of Rapamycin
  1358. Mammalian target of Rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer …
  1359. Actin cytoskeleton is required for nuclear accumulation of Gln3 in response to nitrogen limitation but not Rapamycin treatment in Saccharomyces cerevisiae
  1360. Post-Rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center
  1361. Farnesylthiosalicylic acid blocks mammalian target of Rapamycin signaling in breast cancer cells
  1362. Prevention of lethal acute GVHD with an agonistic CD28 antibody and Rapamycin
  1363. Effects of simian virus 40 large and small tumor antigens on mammalian target of Rapamycin signaling: small tumor antigen mediates hypophosphorylation of eIF4E …
  1364. Rapamycin‐sensitive induction of eukaryotic initiation factor 4F in regenerating mouse liver
  1365. Nutrient restriction differentially modulates the mammalian target of Rapamycin signaling and the ubiquitin-proteasome system in skeletal muscle of cows and their …
  1366. The Saccharomyces cerevisiae phosphatase activator RRD1 is required to modulate gene expression in response to Rapamycin exposure
  1367. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of Rapamycin and simvastatin
  1368. Mammalian target of Rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option
  1369. … and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-γ is regulated by mammalian target of Rapamycin
  1370. The influence of the Rapamycin-derivate SDZ RAD on the healing of airway anastomoses
  1371. Cilomilast, tacrolimus and Rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis
  1372. The impact of cyclosporine dose reduction with or without the addition of Rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy
  1373. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of Rapamycin and cyclosporine
  1374. Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of Rapamycin-dependent …
  1375. Mammalian target of Rapamycin is a promising target for novel therapeutic strategy against cancer.
  1376. Effects of cyclosporin A, FK506 and Rapamycin on calcineurin phosphatase activity in mouse brain
  1377. Both mitogen activated protein kinase and the mammalian target of Rapamycin modulate the development of functional renal proximal tubules in matrigel
  1378. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of Rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast …
  1379. Effects of Rapamycin on cardiac and skeletal muscle contraction and crossbridge cycling
  1380. Frap, FKBP12 Rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene
  1381. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both Rapamycin-sensitive and-insensitive …
  1382. Modulation of translation‐initiation in CHO‐K1 cells by Rapamycin‐induced heterodimerization of engineered eIF4G fusion proteins
  1383. Rapamycin antagonizes cyclosporin A‐and tacrolimus (FK506)‐mediated augmentation of linker for activation of T cell expression in T cells
  1384. Activation of mammalian target of Rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL–expressing cells
  1385. Proteomic analysis of anti‐angiogenic effects by a combined treatment with vinblastine and Rapamycin in an endothelial cell line
  1386. The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of Rapamycin in the response of normal fibroblasts to ionizing radiation
  1387. Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts
  1388. Mammalian target of Rapamycin inhibitors in renal cell carcinoma: current status and future applications
  1389. Investigating mammalian target of Rapamycin inhibitors for their anticancer properties
  1390. Rapamycin treatment results in GATA factor-independent hyperphosphorylation of the proline utilization pathway activator in Saccharomyces cerevisiae
  1391. The Rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27 Kip1
  1392. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of Rapamycin inhibitor, temsirolimus
  1393. Generating Rapamycin analogues by directed biosynthesis: starter acid substrate specificity of mono-substituted cyclohexane carboxylic acids
  1394. Electron microscopic and biochemical study of the effects of Rapamycin on glycogen autophagy in the newborn rat liver
  1395. … 4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of Rapamycin (mTOR)-and non …
  1396. Rapamycin in patients with chronic renal allograft dysfunction
  1397. Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of Rapamycin, and ribosomal S6 kinase 1 signaling pathways …
  1398. … of metallothionein rescues chronic alcohol intake-induced cardiomyocyte dysfunction: role of Akt, mammalian target of Rapamycin and ribosomal p70s6 kinase
  1399. Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells
  1400. Targeting metastatic leiomyosarcoma by Rapamycin plus gemcitabine: an intriguing clinical observation
  1401. Vanadate and Rapamycin synergistically enhance insulin-stimulated glucose uptake
  1402. Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands
  1403. Cutaneous leukocytoclastic vasculitis in a patient with myelodysplatic syndrome after therapy with the Rapamycin analogue everlimus: Case report and review of the …
  1404. Determining sensitivity to Rapamycin and its analogues in breast cancer patients
  1405. Rapamycin pre‐treatment preserves viability, ATP level and catabolic capacity during carbon starvation of Saccharomyces cerevisiae
  1406. Rapamycin and FK506 reduce skeletal muscle voltage sensor expression and function
  1407. Extracellular ATP-induced proliferation of adventitial fibroblasts requires phosphoinositide 3-kinase, Akt, mammalian target of Rapamycin, and p70 S6 kinase …
  1408. The mTOR pathway in estrogen response: A potential for combining the Rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast …
  1409. inhibition of mammalian target of Rapamycin modulates expression of adhesion molecules in endothelial cells
  1410. SUMO modification through Rapamycin-mediated heterodimerization reveals a dual role for Ubc9 in targeting RanGAP1 to nuclear pore complexes
  1411. Cyclosporine and Rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage
  1412. Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced Renal Cell Carcinoma
  1413. Novel site‐specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model
  1414. The phosphatase subunit tap42 functions independently of target of Rapamycin to regulate cell division and survival in Drosophila
  1415. Rapamycin control of exocrine protein levels in saliva after adenoviral vector-mediated gene transfer
  1416. Farnesyltransferase inhibitors and Rapamycin in the treatment of multiple myeloma
  1417. RACK1 mRNA translation is regulated via a Rapamycin-sensitive pathway and coordinated with ribosomal protein synthesis
  1418. Mammalian target of Rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate
  1419. Bone morphogenetic protein-2–induced transformation involves the activation of mammalian target of Rapamycin
  1420. Rapamycin prolongs susceptibility of responding T cells to tolerance induction by CD8+ veto cells
  1421. Current status of mammalian target of Rapamycin inhibitors in lung cancer
  1422. Rapamycin inhibits vascular remodeling in an experimental model of allograft vasculopathy and attenuates associated changes in fibrosis-associated gene …
  1423. Rapamycin and dendritic cells: keep on movin’
  1424. Involvement of c-Jun NH2 terminal kinase and p38MAPK in Rapamycin-mediated inhibition of neointimal formation in rat carotid arteries
  1425. Involvement of the VDE homing endonuclease and Rapamycin in regulation of the Saccharomyces cerevisiae GSH11 gene encoding the high affinity …
  1426. Immunomodulatory effects of combination of pooled human gammaglobulin and Rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction
  1427. Six-month intravascular ultrasound follow-up of coronary bifurcation lesions treated with Rapamycin-eluting stents: technical considerations
  1428. Trace analysis of Rapamycin in human blood by micellar electrokinetic chromatography
  1429. Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of Rapamycin, additively inhibit rhabdomyosarcoma growth
  1430. Differential translation of TOP mRNAs in Rapamycin-treated human B lymphocytes
  1431. Rapamycin for androgen-independent prostrate cancer (AIPC)
  1432. Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds?
  1433. Sirolimus and everolimus: inhibitors of mammalian target of Rapamycin in liver transplantation
  1434. Rapamycin inhibits choroidal neovascularization
  1435. Deletion of HOG1 leads to Osmosensitivity in starvation-induced, but not Rapamycin-dependent Atg8 degradation and proteolysis: Further evidence for different …
  1436. Structure and function of mammalian target of Rapamycin [J]
  1437. Comparison of Rapamycin and paclitaxel eluting stent in patients with multi-vessel coronary disease
  1438. Retracted: Rapamycin Attenuates Liver Graft Injury in Cirrhotic Recipient—The Significance of Down‐Regulation of Rho‐ROCK‐VEGF Pathway
  1439. Pharmacokinetics of Rapamycin-eluting stents in miniswine coronary model.
  1440. Combination therapy with sirolimus (Rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report
  1441. Combination of the mammalian target of Rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A …
  1442. Rapamycin and chronic lung rejection
  1443. Synergistic suppression of rat neointimal hyperplasia by Rapamycin and imatinib mesylate: implications for the prevention of accelerated arteriosclerosis
  1444. An intramolecular ionic hydrogen bond stabilizes a cis amide bond rotamer of a ring‐opened Rapamycin‐degradation product
  1445. The effect of combined Rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats …
  1446. Modulation of tissue factor expression by Rapamycin and FK-506 in lipopolysaccharide-stimulated human mononuclear cells and serum-stimulated aortic smooth …
  1447. Effect of Rapamycin on hepatic osteodystrophy in rats with portasystemic shunting
  1448. Preclinical rationale for therapeutic targeting of mTOR by CC-I779 and Rapamycin in Hodgkin lymphoma
  1449. Potential role of mammalian target of Rapamycin inhibitors in breast cancer therapy
  1450. Altered centrosomes in ataxia‐telangiectasia cells and Rapamycin‐treated Chinese hamster cells
  1451. Determination of Rapamycin: quantification of the sodiated species by an ion trap mass spectrometer as an alternative to the ammoniated complex analysis by triple …
  1452. Nutritional studies on the growth of the Rapamycin-producing Streptomyces hygroscopicus
  1453. A novel technique for on‐capillary preconcentration of anionic compounds applied to the trace analysis of Rapamycin in human blood by capillary electrophoresis
  1454. … of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of Rapamycin (mTOR) inhibitor everolimus …
  1455. Glucose-induced binding of the polypyrimidine tract-binding protein (PTB) to the 3′-untranslated region of the insulin mRNA (ins-PRS) is inhibited by Rapamycin
  1456. A phase I trial of gefitinib (ZD1839) plus Rapamycin for patients with recurrent malignant glioma
  1457. Clinical use of Rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a single-center experience
  1458. Lung toxicity induced by Rapamycin
  1459. Countervailing effects of Rapamycin (sirolimus) on nuclear factor-κB activities in neointimal and medial smooth muscle cells
  1460. Dose-dependent inhibition of myointimal hyperplasia by orally administered Rapamycin
  1461. Association of Rapamycin and co-stimulation blockade using anti-B7 antibodies in renal allotransplantation in baboons
  1462. inhibition of growth and metastasis of hepatocellular carcinoma by Rapamycin: experiment with mice
  1463. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl] Rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro
  1464. Rapamycin inhibits platelet-derived growth factor-induced collagen, but not fibronectin, synthesis in rat mesangial cells
  1465. A combination of anergic cells’ adoptive transfer and Rapamycin therapy prolongs cardiac allograft survival in mice
  1466. Local application of Rapamycin inhibiting restenosis in experimental vein graft
  1467. Negative regulation of interleukin-12 production by a Rapamycin-sensitive signaling pathway: a brief communication
  1468. Rapamycin-based rescue therapy after chronic rejection in a pediatric liver transplant patient
  1469. Altered trafficking of CD8+ memory T cells after implantation of Rapamycin-eluting stents in patients with coronary artery disease
  1470. Rapamycin at six years can exhibit normal renal function without proteinuria or neoplasia after renal transplantation. A single-center experience
  1471. Expression of placental mammalian target of Rapamycin (mTOR) is altered in relation to fetal growth and mTOR regulates leucine transport
  1472. Regulation of hepatic insulin-like growth factor-binding protein-1 gene expression by insulin: central role for mammalian target of Rapamycin independent of forkhead …
  1473. Rapamycin–a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.
  1474. In vivo and in vitro effect of CCI-779 a Rapamycin analogue on HNSCC.
  1475. Pathologic assessment of cardiomyocytes in heart transplant recipients treated with Rapamycin or cyclosporine
  1476. Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, dose finding study of Rapamycin in adult patients with solid tumors
  1477. Pharmacokinetics and safety of ABT-578, a sirolimus (Rapamycin) analogue, after single intravenous bolus injection in healthy male volunteers
  1478. Rapamycin Inhibits Retinal and Choroidal Neovascularization in Mice
  1479. In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.
  1480. Dual effects of Rapamycin on immuno-suppression and tumor inhibition
  1481. Rapamycin inhibits the pathogenesis of posterior capsule opacification: experimental study on rabbit [J]
  1482. Sphingosine-1-phosphate–induced smooth muscle cell migration involves the mammalian target of Rapamycin
  1483. Phase I study of gefitinib and Rapamycin in patients with recurrent or progressive glioblastoma (Gbm)
  1484. Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early …
  1485. Effect of Rapamycin on cytokine profile in kidney transplant recipients treated with triple drug therapy
  1486. Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection
  1487. Effect of Rapamycin on Phenotype of Vascular Smooth Muscle Cell and Arterial Intimal Hyperplasia Post Balloon Injury in Rat [J]
  1488. Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. Focus on “The mTOR/p70 S6K1 pathway regulates vascular smooth muscle …
  1489. … -up of the unrestricted use of the sirolimus-eluting stent compared to the use of a standard bare metal stent as part of the Rapamycin-Eluting-Stent Evaluated at …
  1490. Observations on quadruple immunosuppression maintenance therapy using Rapamycin, low-dose cyclosporine, mycophenolate mofetil, and prednisone following …
  1491. Mode of action of FK506 and Rapamycin
  1492. Phase I study of Rapamycin (R) in combination with CYP3A4 modifier, ketoconazole (K), in patients with advanced malignancies
  1493. Renal calcium handling after Rapamycin conversion in chronic allograft dysfunction
  1494. Studies towards the synthesis of Rapamycin: Regiocontrol in the addition of carbanions to enantiomerically pure epoxides and the formation of a highly substituted …
  1495. Rapamycin.
  1496. Thrombosis caused by active Rapamycin stents
  1497. Effect of Rapamycin and dexamethasone on differentiation and maturation of murine bone marrow-derived dendritic cells
  1498. Comparison of Rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy
  1499. Why inhibitors of mammalian target of Rapamycin will be important in organ transplantation
  1500. Stent release of a Rapamycin analogue: tissue pharmacokinetics of rapid versus delayed release
  1501. Rapamycin: from the laboratory to the treatment of patients’ arteries
  1502. Experimental study on the effects of Rapamycin in prevention of rat corneal allograft rejection
  1503. Rapamycin overcomes multidrug resistance (MDR) mediated by P-glycoprotein (Pgp), Multidrug Resistance Protein-1 (MRP-1), Breast Cancer Resistance Protein …
  1504. Complete assignments of the 1H and 13C resonances of 40‐epi‐(N1‐tetrazolyl)‐Rapamycin and revised 13C assignments for Rapamycin
  1505. The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.
  1506. Oral Rapamycin for the prevention of in-stent restenosis
  1507. Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.
  1508. Surviving Rapamycin
  1509. Lack of effect of Rapamycin in anti-CCP antibody production in a rheumatoid arthritis kidney allograft recipient
  1510. Mammalian target of Rapamycin inhibitors in transplantation: novel immunosuppressive strategies with sirolimus
  1511. Efficacy of Early Use of Rapamycin for Patients after Renal Transplantation and the Complications
  1512. 1139-52 Biolimus A9: a new generation Rapamycin analogue inhibits intimal hyperplasia in a porcine model
  1513. Rapamycin eluting stents
  1514. Mammalian target of Rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole
  1515. Rapamycin: sc-3504
  1516. Investigation of Rapamycin and Rapamycin metabolites.
  1517. Inhibitors of mammalian target of Rapamycin: mechanism of action explains efficacy and toxicity
  1518. Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
  1519. Sirolimus (Rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: An initial experience in Taiwan
  1520. Clinic application of Rapamycin-eluting stent for coronary heart disease [J]
  1521. Intravitreal toxicity of Rapamycin
  1522. Two-year experience with Rapamycin in kidney transplantation
  1523. Safety and efficacy of sirolimus-eluting stent (cypher) in acute myocardial infarction: A substudy of the Rapamycin-Eluting Stent Evaluation at Rotterdam Cardiology …
  1524. Sirolimus-eluting stents for treatment of in-stent restenosis in the real world: Preliminary results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology …
  1525. Rapamycin Combined with Cyclosporine in the Prevention of Acute Renal Allograft Rejection: Randomized Prospective Control Study
  1526. Adverse effects of local or systemic application of Rapamycin for the prevention of neointimal hyperplasia
  1527. Effect of combined regimen of Rapamycin and Cyclosporine on renal transplant recipients [J]
  1528. Short-term Rapamycin for inhibition of neointima formation after balloon-mediated aortic injury in rats: is there a window of opportunity for systemic prophylaxis of …
  1529. Pilot study with oral Rapamycin in patients undergoing stenting in coronary arteries: Buenos Aires experience (ORAR trial)
  1530. CONTRASTING EFFECTS OF CYCLOSPORIN AND Rapamycin IN DE NOVO GENERATION OF ALLOANTIGEN-STIMULATED REGULATORY T CELLS.
  1531. Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis …
  1532. Effects of Rapamycin-treated HSP60-pulsed dendritic cells on the progression of the atherosclerotic plaque in mice [J]
  1533. Curcumin disrupts the complexes of the mammalian target of Rapamycin
  1534. Review on Rapamycin as a potential therapeutic agent against neurodegenerative disease
  1535. TOR (target of Rapamycin)-mediated regulation of translation
  1536. Comparison of Different Therapies Of CYPHERTM Stent For Patients with Bifurcated Lesion Using Rapamycin
  1537. Experimental study of effect of Rapamycin on proliferation of rat aortic smooth muscle cells
  1538. Influence of CTLA4Ig combined with Rapamycin on the survival of renal allografts in rats [J]
  1539. Local applied slow-releasing Rapamycin inhibits neointima hyperplasia in vein graft
  1540. Rapamycin PREVENTS INTERSTITIAL FIBROSIS IN RENAL ALLOGRAFTS THROUGH DECREASING ANGIOGENESIS AND INFLAMMATION.
  1541. … Regulatory (CD4+ CD25+ CD127LowFOXP3+) Cells to High Purity by Inhibiting Expansion of CD4+ CD25+ CD127HighFOXP3-Conventional T Cells with Rapamycin …
  1542. Rapamycin impairs the healing of the ureteric anastomosis
  1543. Effects of Rapamycin on the early development of zebrafish (Danio rerio)
  1544. The combination of arsenic trioxide and Rapamycin has potent inhibitory effects on acute myeloid leukemia (AML) cells
  1545. avb3-integrin-targeted paramagnetic nanoparticles deliver Rapamycin into the vascular wall and inhibit stenosis following balloon injury
  1546. Treatment of lesions with a high risk of stenosis. comparative study in 300 patients of Rapamycin-and paclitaxel-eluting polymer-based stents, and bare metal stents
  1547. Rapamycin Has Biological Activity in a Subset of Patients with Myelodysplastic Syndrome-Results of a Phase I/II Trial.
  1548. Effect of Mycophenolic Acid and Rapamycin on the Proliferation of Glomerular Mesangial Cell of Rat
  1549. Regulation of the mammalian target of Rapamycin complex 2 (mTORC2)
  1550. Rapamycin NOT CYCLOSPORINE INDUCES REGULATORY CD8+ FOXP3+ CELLS.
  1551. Comparison of the effects of Rapamycin-eluting stent implantation and coronary artery bypass grafting in treatment of patients with multi-vessel coronary disease
  1552. Glucose-stimulated DNA Synthesis through Mammalian Target of Rapamycin (mTOR) Is Regulated by KATP Channels
  1553. Subretinal sustained delivery of Rapamycin in the rabbit eye
  1554. Constitutive Activation of Akt and mTOR by Flt3 Internal Tandem Duplications Mediates Myeloid Leukemogenesis and Can Be Inhibited by Rapamycin.
  1555. Long-term clinical efficiency of endovascular treatment using Cypher Rapamycin-eluting stents in patients with coronary heart disease
  1556. DOES Rapamycin EFFECT WOUND HEALING?
  1557. Successful retransplantation using Rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
  1558. Rapamycin inhibits the development of gallbladder adenocarcinoma in BK5. erbB2 transgenic mice
  1559. Rapamycin disruption of mTOR-mLST8-raptor complex inhibits cell motility
  1560. In vitro Rapamycin and costimulation generates Th1/Tc1 or Th2/Tc2 central memory effectors: Differential regulation by in vivo Rapamycin after allogeneic BMT
  1561. Effect of combination of curcumin and Rapamycin on proliferation of rat glomerular mesangial cells
  1562. Signaling by Target of Rapamycin Proteins
  1563. Distinct mechanisms by which low and high Rapamycin doses raise plasma triglycerides in guinea pigs
  1564. Everolimus: a classical mammalian target of Rapamycin inhibitor?
  1565. Murine Ultrasonography Confirms That Rapamycin Is Effective Against Autoimmune Lymphoproliferative Syndrome (ALPS).
  1566. STABILIZATION OF LONG-TERM PEDIATRIC RENAL ALLOGRAFTS WITH Rapamycin.
  1567. A tissue selective Rapamycin analog inhibits MDA-MB-231 breast cancer cell-induced osteolytic bone metastases in nude mice
  1568. Rapamycin throws a master switch.
  1569. Rapamycin-CUSTOMIZED DENDRITIC CELLS ARE RESISTANT TO MATURATION INDUCED BY CD40 LIGATION—A CONDITION PIVOTAL TO THEIR …
  1570. USE OF Rapamycin IN CHILDREN POST LIVER TRANSPLANTATION
  1571. Mammalian Target of Rapamycin inhibition Synergistically Increases Cytotoxicity of Vinorelbine in Breast Cancer Cells.
  1572. The role of caspase-3 in Rapamycin-induced apoptosis of hepatocellular carcinoma BEL-7402 cells
  1573. Enhanced Killing of Chronic Myelogenous Leukemia Cells by Rapamycin and Imatinib Is Associated with Differential inhibition of 4E-BP1 and eIF4E Phosphorylation …
  1574. Rapamycin Induces Balb/C Murine CD4+CD25+Foxp3+ T Cells Proliferations.
  1575. Effect of locally administered Rapamycin and cyclosporin A on penetrating keratoplasty rejection rat model
  1576. Curcumin inhibits the mammalian target of Rapamycin-mediated signaling pathways
  1577. Bone-targeted Rapamycin analogs inhibit osteolysis and tumor growth in a PC-3-GFP intratibial bone cancer model in nude mice
  1578. The expression of mammalian target of Rapamycin and its substrates in autogenous vein graft in rats
  1579. Effects of Rapamycin on Notch1/Jagged1 signal pathway and the expression of fibronectin in TGF-β, induced rat renal intertitial fibroblasts [J]
  1580. The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.
  1581. Effect of Rapamycin on Corneal Neovascularization
  1582. THE EFFECT OF Rapamycin ON BILE DUCT HEALING
  1583. Safety and efficacy comparison between Rapamycin-eluting stent with biodegradable polymer or permanent polymer in patients with coronary artery disease
  1584. Rapamycin added to human CD25+ cell cultures activated through CD3/CD28 enriches for CD4+ CD25+ CD27+ Foxp3+ regulatory T cells
  1585. Effect of Mycophenolic Acid and Rapamycin on the Proliferation and Collagen Synthesis of the Vascular Smooth Muscle Cell of Rat
  1586. Two-year experience with Rapamycin in kidney transplantation
  1587. Effects of Rapamycin on the function of human dendritic cells
  1588. Effects of Rapamycin on Rho-kinase and p27 mRNA expressions in a porcine coronary intimal proliferation model induced by interleukin-1beta
  1589. IN CONTRAST TO CYCLOSPORIN, Rapamycin SPARES FOXP3+ CD4+ T-CELLS IN VIVO.
  1590. Rapamycin THERAPY IN PANCREAS ALLOGRAFT RECIPIENTS
  1591. Sustained Rapamycin drug delivery system in prevention of high risk corneal allograft rejection and neovascularization in rabbits
  1592. The role of GSK3β in Rapamycin-mediated cell cycle regulation
  1593. Rapamycin Treatment Results in GATA
  1594. Possible molecular target therapy with Rapamycin in MDS
  1595. Blocking mTOR by Rapamycin reduces HIF-1α function in human gastric cancer cells in vitro and inhibits angiogenesis and tumor growth in vivo
  1596. Influence of CTLA4Ig combined with Rapamycin on the survival of renal allografts in rats
  1597. Combination therapy of bevacizumab with Rapamycin in antitumor activity.
  1598. EVALUATION OF APOPTOSIS IN PERIPHERAL HUMAN LYMPHOCYTES EXPOSED TO Rapamycin.
  1599. … IN CHRONIC ALLOGRAFT NEPHROPATHY (CAN) FOLLOWING CALCINEURIN INHIBITORS (CNI) WITHDRAWAL AND CONVERSION TO Rapamycin.
  1600. Application of Rapamycin in the patients with liver injury following renal transplantation: a report of 7 cases
  1601. Establishment of a Rapamycin-resistant cell line that retains sensitivity to PI3 kinase inhibitors.
  1602. mTOR (mammalian target of Rapamycin) inhibition with RAD001 induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitizes DLBCL cells to …
  1603. A Novel Serum-Stable Micelle System for Controlled Release of Rapamycin
  1604. The effects of Rapamycin for the chole-sterol rabbits after balloon injury
  1605. Effect of New Immunosuppressant-Rapamycin on One-Way Mixed Lymphocyte Culture
  1606. inhibition of repopulation is not a determining factor for the radiosensitizing effects of Rapamycin
  1607. Antitumor efficacy of Rapamycin derivertive RAD001 in human ovarian cancer
  1608. Dendritic cells, Rapamycin and transplant tolerance
  1609. Troglitazone Exerts a Cell-Dependent Effect on the Extracellular Secretion of VEGF165 Independently from the Rapamycin Sensitivity or the Level of eIF4E …
  1610. Rapamycin inhibited the growth of hepatocellular carcinoma in nude mice
  1611. Rapamycin-Eluting Stents for the Treatment of In-Stent Restenosis
  1612. Effect of Rapamycin on Renal Ischemia Reperfusion Injury
  1613. Mutant type glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome: possible clinical application of Rapamycin
  1614. A RARE CASE OF Rapamycin INDUCED SECRETORY DIARRHEA IN A LIVER TRANSPLANT PATIENT: 544
  1615. Clinical application of domestic Rapamycin-eluting stents in coronary heart disease patients
  1616. The Studies of Antitumor Effect of Rapamycin on Human Hepatocellular Carcinoma BEL-7402 Cells in vitro
  1617. Investigation of the Function and Regulatory Mechanisms of the Mammalian Target of Rapamycin
  1618. New progress of Rapamycin in prevention and treatment of chronic allograft nephropathy
  1619. Mammalian Target of Rapamycin (mTOR)
  1620. Rapamycin treatment during fractionated radiotherapy causes cell death in 3D culture
  1621. 18F-Labeled analog of Rapamycin for PET imaging
  1622. Rapamycin-SENSITTVE SIGNAL TRANSDUCTION PATHWAYS AND THE CONTROL OF ADIPOGENESIS
  1623. Therapeutic effect of Rapamycin in the treatment of malignancies in recipients after kidney transplantation
  1624. Sirolimus (Rapamycin) impairs renal function
  1625. Rapamycin INHIBITS NK CELL FUNCTION
  1626. … WITH THYMOGLOBULIN/ZENAPAX INDUCTION, TACROLIMUS AND STEROID MAINTENANCE, COMPARING Rapamycin WITH MYCOPHENOLATE MOFETIL …
  1627. Rapamycin modifies the vascular tone of rat isolated aortas
  1628. Rapamycin-INDUCED PROTEINURIA: INCIDENCE, OUTCOME AND THERAPEUTIC HANDLING.
  1629. Prolonged survival of renal allografts with domestic Rapamycin in rats [J]
  1630. … FUNCTIONS OF REGULATORY T CELLS, LEADING, IN CONJUNCTION WITH A BRIEF SUB-THERAPEUTIC COURSE OF Rapamycin, TO ROBUST, DONOR …
  1631. Clinical Benefits of Rapamycin-Eluting Stent Implantation in Patients With Acute Coronary Syndromes
  1632. The role of phosphorylation in the regulation of the mammalian target of Rapamycin.
  1633. The clinical effect of homemade Rapamycin-eluting stent on acute myocardial infarction
  1634. Regulation of skeletal muscle differentiation by a Rapamycin-sensitive signaling pathway
  1635. THE MAMMALIAN TARGET OF Rapamycin (mTOR) AS A TARGET FOR CANCER CHEMOTHERAPY
  1636. Combination therapy targeting hypoxia inducible factor-α (HIF-1 α) and Tissue Factor (TF) by the mTOR inhibitor Rapamycin and the histone deacetylase inhibitor …
  1637. Rapamycin is efficacious against gliomas and acts as an anti-VEGF and anti-invasion agent
  1638. DIFFERENT FUNCTIONAL, HISTOLOGICAL AND INMUNOHISTOCHEMICAL PATTERNS INDUCED BY THE ASSOCIATION OF Rapamycin WITH FK506 OR …
  1639. Orally Administered Rapamycin Can Inhibit Myointimal Hyperplasia: Should It Be Used?
  1640. Effects of Rapamycin-eluted stent on platelet function in patients with coronary heart disease
  1641. Regulation of the GATA-type transcription factor Gln3p by the target of Rapamycin protein (TOR).
  1642. Combination of Rapamycin and somatostatin analogues for the treatment of nonfunctioning pituitary tumors
  1643. The experimental study on the effects of Rapamycin and statin on chronic transplant vasculopathy
  1644. Rapamycin targets Cyclin/Cdk/p21/PCNA complexes and Cyclin D1 reverses Rapamycin action by stabilizing these complexes
  1645. Rapamycin conversion for immunosuppressive therapy in the setting of renal insufficiency in patients with heart transplantation: pilot observations
  1646. Inhibitory Effect of Rapamycin on Corneal Neovascularization induced by Angiogenin in Rabbits
  1647. NURSING IMPLICATIONS REGARDING THE MANAGEMENT OF SIDE EFFECTS IN A PHASE I STUDY USING GEFITINIB WITH Rapamycin.
  1648. Clinical Contrast Investigation of Rapamycin Eluting Stent between Chinese Making and Imported
  1649. The role of mammalian target of Rapamycin (mTOR) in a rat model of autoimmune myocarditis
  1650. Effect of Rapamycin on Mouse Chronic Lymphocytic Leukemia and the Development of Nonhematopoietic Malignancies in Em-TCL1 Transgenic Mice
  1651. Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
  1652. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis
  1653. Rapamycin for Cardiac Transplant Rejection and Vasculopathy
  1654. Rapamycin synergistically enhances the cytotoxicity of paclitaxel in breast cancer cells
  1655. Oral Rapamycin attenuates progression of atherosclerotic plaque in ApoE knockout mice
  1656. Clinical Research of Rapamycin-Eluting Stent in Treatment of Multi-Vessel Coronary Disease
  1657. Rapamycin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells
  1658. Biocompatibility of Rapamycin-Batroxobin Eluting Stent in Porcine Coronary Artery
  1659. Effect of Rapamycin on anti-HLA donor antibody formation in patients with transplant coronary artery disease
  1660. Combination of the mTOR Inhibitor Rapamycin and Revlimid™(CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).
  1661. Characterization of the FKBP·Rapamycin·FRB Ternary Complex  [J. Am. Chem. Soc. 2005, 127, 4715−4721].
  1662. Is there a role for oral Rapamycin in restenosis prevention after bare-metal stent implantation?
  1663. Isolation and Genetic Analysis of Rapamycin-sensitive mutants in Aspergillus nidulans.
  1664. Overexpression of the Bad mutant (S112A) partially disrupts the ability of IGF-I to protect cells from Rapamycin-induced apoptosis
  1665. One year effect of Rapamycin eluting stent in patients with coronary heart disease
  1666. The role of mammalian target of Rapamycin (mTOR) in insulin resistance
  1667. Rapamycin AND SANGLIFEHRIN A CAN INHIBIT INTERLEUKIN-18 PRODUCTION FROM DENDRITIC CELLS IN VITRO AND IN VIVO.
  1668. MRI detection of Rapamycin and AP-Cav therapeutic rescue from endothelial over expression of Akt in transgenic mice
  1669. SENSITIVITY OF HUMAN METASTATIC MELANOMA CELLS TO THE ESTER ANALOG OF Rapamycin, CCI-779
  1670. Synergistic growth inhibition by Iressa and Rapamycin in Renal Cell Carcinoma (RCC) with wild-type VHL
  1671. Six-month results of a biodegradable polymer and Rapamycin-coating stent for coronary artery disease
  1672. The mTOR inhibitor, Rapamycin, inhibits growth of Ewing’s sarcoma in vitro and in vivo
  1673. EEEICACY AND SAFETY OF Rapamycin-BASED IMMUNOSUPPRESSION REGIMEN WITH OR WITHOUT CSA IN RENAL TRANSPLANTATION: A SYSTEMATIC …
  1674. Rapamycin Inhibits Rabbit Corneal Neovascularization Induced by Angiogenin
  1675. Preclinical analysis of Rapamycin plus EGFR or MEK1/2 inhibitors in renal cell carcinoma (RCC)
  1676. Effect of Rapamycin (RPM) on interleukin-10 gene expression in rats with postburn Staphylococcus aureus sepsis
  1677. Effect of Rapamycin on mouse CLL and development of non-hematopoietic malignancies in Eμ-TCL1 transgenic mice
  1678. Effect of isoflavones alone and in combination with Rapamycin on mTOR pathway in human glioblastoma cells (U87).
  1679. Rapamycin INHIBITS THE SPONTANEOUS FORMATION OF DE NOVO CANCER IN P53 KNOCKOUT MICE.
  1680. Urokinase-induced smooth muscle cell migration involves the mammalian target of Rapamycin
  1681. Importance of mammalian target of Rapamycin inhibitors in the prevention of cardiac allograft vasculopathy
  1682. Rapamycin enhances the number and function of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro
  1683. Clinical contrast investigation of Rapamycin eluting stent between Chinese making and imported in the treatment of coronary artery disease
  1684. Rapamycin inhibits activation of STAT3 in renal tissue of IgA nephropathy rats
  1685. The mTOR inhibitor Rapamycin inhibits proadhesive activity of arterial intimal smooth muscle cells
  1686. Identification of a highly effective Rapamycin schedule that markedly reduces the size, multiplicity and phenotypic progression of tobacco carcinogen-induced murine …
  1687. Mammals Target Protein of Rapamycin (mTOR) Expression in Adult Acute Myeloid Leukemia Patients
  1688. A Randomized Comparison Between Paclitaxel-Eluting Stents and Rapamycin-Eluting Stents for Patients With Coronary Artery Diseases
  1689. Silencing mTOR signal by small interfering RNA enhances Rapamycin-induced autophagy in malignant glioma cells.
  1690. CYCLOSPORINE AND Rapamycin ACT IN A SYNERGISTIC AND DOSE-DEPENDENT MANNER IN A MODEL OF IMMUNOSUPPRESSANT-INDUCED KIDNEY …
  1691. The role of the mammalian target of Rapamycin (mTOR) in long term potentiation
  1692. Nursing intervention of chronic renal diseases patients orally taking Rapamycin after underwent kidney transplantation [J]
  1693. The effect of Rapamycin after cyclosporin dose reduction on chronic allograft nephropathy
  1694. The Saccharomyces Cerevisiae Phosphatase Activator YPTPA1/RRD1 is Required to Modulate Gene Expression in Response to Rapamycin Exposure
  1695. COMBINATION OF Rapamycin PLUS MUTANT TGF-b/Fc TO INDUCE IMMUNE TOLERANCE.
  1696. Effect of Akt (PKB) on the activity of mammalian target of Rapamycin (mTOR)
  1697. Effect of Rapamycin Eluting Stent on Level of C-reactive Protein in Patients with Acute Coronary Syndrome After Angioplasty [J]
  1698. PI3K and mTOR signalling pathways: perspectives for Rapamycin and its derivatives as antineoplastic targeted therapies
  1699. Effectiveness and safety of Rapamycin-based immunosuppression regimens on preserving or withdrawing CsA in renal transplantation: a systematic review
  1700. The modulation of neointimal proliferation and p27 kip expression after implanting Rapamycin-eluting stents in the porcine coronary model
  1701. Different released Rapamycin eluting stents to reduce in-stent neointimal hyperplasia in a porcine coronary model
  1702. CHIMERISM PLAYS AN ACTIVE ROLE IN TRANSPLANTATION TOLERANCE INDUCED BY ALS, Rapamycin AND DONOR BONE MARROW INFUSION
  1703. Effect of Biodegradable Rapamycin-Eluting Stent on Neointimal Proliferation in Porcine Coronary Artery Model
  1704. Rapamycin INHIBITS IL-10 INDUCTION BY LATENT MEMBRANE PROTEIN 1 OF EPSTEIN BARR VIRUS.
  1705. Editorial [Hot Topic: Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia (Executive Editors: Francis J. Giles/Maher Albitar)]
  1706. A Gene Expression Connectivity Map Identifies Rapamycin as a Glucocorticoid Resistance Reversal Agent in Lymphoblastic Leukemia.
  1707. Rapamycin-sensitive TOR signaling regulates intestinal growth and morphogenesis in zebrafish
  1708. TARGET OF Rapamycin (TOR) MEDIATES THE ENDODERM-INTESTINE TRANSITION IN ZEBRAFISH: 68
  1709. Lactic-co-glycolic acid polymer with Rapamycin coated stent reduces neo-intimal formation in a porcine coronary model
  1710. The mammalian target of Rapamycin controls cell motility through its effectors S6K1 and 4E-BP1
  1711. SAFETY AND EFFICACY OF A STEROID-FREE REDUCED-DOSE NEORAL/Rapamycin MAINTENANCE IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION …
  1712. inhibition of mTOR signaling with Rapamycin attenuates renal hypertrophy in the early diabetic mice
  1713. Combinations of Cytotoxic Drugs, Ionizing Radiation, and Mammalian Target of Rapamycin (mTOR) Inhibitors
  1714. Effects of stent-based delivery of Rapamycin and methotrexate on neointimal formation in a porcine coronary model
  1715. Rapamycin MANIPULATION OF HOST-DERIVED, ALLOANTIGEN-PULSED DENDRITIC CELLS PLUS POSTOPERATIVE Rapamycin, BUT NOT FK506 …
  1716. Ex Vivo Rapamycin Generates Th2 Cells with Enhanced Mitochondrial Function and Reduced Apoptosis Via Intrinsic and Extrinsic Pathways.
  1717. combination with the immunosuppressive drug Rapamycin, seems to forestall rejection in mice. Transferring this protocol to the human clinic should be fairly straight …
  1718. Rapamycin-generated CD4+, Th2 cells modulate graft-versus-host reaction via an IL-4 dependent mechanism
  1719. The assessment of human islets for transplantation and the effect of the immunosuppressant Rapamycin on MIN-6 cells, rat and human islets
  1720. 549: The Effect of Rapamycin Immunosuppression on Native Polycystic Kidney Volumes in Renal Transplant Patients
  1721. Calcineurin inhibitors but not Rapamycin abrogate activation of the immunomodulatory enzyme indoleamine 2, 3-dioxygenase.
  1722. Translational control of gene expression in rat liver in relation to mammalian target of Rapamycin signaling
  1723. Rapamycin Protects Allografts From Rejection While Simultaneously Attacking Tumors in Immunosuppressed Mice
  1724. Rapamycin and IL-10 induce Ag-specific T regulatory type 1 cells (Tr1) and b-islet allograft tolerance in diabetic mice
  1725. In Vitro and in Vivo Cyclosporine-Induced Tumor Angiogenesis and Tumor Growth Are Blocked By Simultaneous Application of Rapamycin
  1726. Rapamycin INHIBITS EPSTEIN BARR VIRUS+ B CELL LYMPHOMA THROUGH MODULATION OF CELL CYCLE PROTEIN EXPRESSION.
  1727. Newly identified kit ITD in childhood AML induces ligand independent growth and is responsive to a synergistic effect of imatinib and Rapamycin
  1728. Effects of the immunomodulatory drugs tacrolimus, Rapamycin and cilomilast on dendritic cell function in a model of allergic contact dermatitis
  1729. Rapamycin exerts an anti-inflammatory action in vitro and in vivo by inducing monocyte apoptosis and modulating cytokine/chemokines secretion
  1730. Site specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model
  1731. Rapamycin sensitizes tumor cells to chemotherapy-induced apoptosis and induces cell cycle arrest in ALK+ anaplastic large cell lymphoma.
  1732. Sustained Rapamycin Drug Delivery System for Prevention of High Risk Corneal Allograft Rejection and Neovascularization in Rabbits
  1733. Everolimus Is Comparably Effective to Rapamycin Acting Synergistically with Imatinib in the Treatment of Constitutively Active Mutations of the Juxtamembrane …
  1734. Unrestricted Utilization of Sirolimus-Eluting Stents in the “Real World”: The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital …
  1735. Serotonin-mediated activation of Rapamycin-sensitive S6 kinase-S6 ribosomal protein signal transduction pathway in synaptosomes.
  1736. Rapamycin INHIBITS EPSTEIN BARR VIRUS+ B CELL LYMPHOMA PROLIFERATION THROUGH MODULATION OF CELL CYCLE PROTEIN EXPRESSION.
  1737. Effects of Rapamycin Eluting Stents on Blood Tissue Factor and Tissue Factor Pathway Inhibitor in Patients With Acute Coronary Syndromes
  1738. DONOR SPECIFIC TRANSFUSION COMBINED WITH Rapamycin PROLONGED THE CARDIAC GRAFT SURVIVAL IN MICE.
  1739. Activity of panitumumab plus Rapamycin against wild type (WT) and mutant epidermal growth factor receptor (EGFr)-expressing NSCLC xenografts
  1740. TACROLIMUS DECREASES, CYCLOSPORINE INCREASES, AND Rapamycin HAS NO EFFECT ON PROFIBROTIC GENE MRNA EXPRESSION IN RENAL …
  1741. Rapamycin Generated Murine Th2/Tc2 Cells Potently Abrogate Fully MHC-Mismatched Hematopoietic Stem Cell (HSC) Graft Rejection.
  1742. 548: inhibition of the mTOR Pathway by Rapamycin Reverses Renal Cystogenesis in Polycystic Kidney Disease Models
  1743. The mTOR inhibitor Rapamycin inhibits p27 protein degradation by downregulating the expression of its ubiquitin ligase Skp2 in breast cancer
  1744. Induction of apoptosis in Ewing’s Sarcoma cells by simultaneous treatment with antisense oligodeoxynucleotides (AS-ODNs) to the EWS/FLI-1 gene and Rapamycin
  1745. Construction of eukaryotic expression vector of mammalian target of Rapamycin antisense RNA and its expression in vascular smooth muscle cell
  1746. INFLUENCE OF IMMUNOPHILLINS INHIBITORS–CYCLOSPORINE-A, TACROLIMUS AND Rapamycin–ON INSULIN SECRETION IN HEART TRANSPLANT …
  1747. Targeting the ICOS-B7h Costimulatory Pathway Synergizes with Rapamycin to Regulate Alloresponses in Islet Transplantation: 0102
  1748. Short and long-term therapeutic effects of Rapamycin-eluting stent and paclitaxel-eluting stent in treatment of coronary disease with complicated lesions
  1749. The Immunomodulatory Agent Rapamycin Potentiates the Antiviral Activity of the Fusion Inhibitor T20 Against R5 Strains of HIV-1
  1750. Binding of mTOR (Mammalian Target of Rapamycin) to the Raptor-eIF4E-4EBP1 complex changes during myogenic differentiation.
  1751. COMBINATION OF Rapamycin AND ANTI-LFA-1 PREVENTS REJECTION OF RAT ISLET XENOGRAFTS.: 042
  1752. Hypoxia and Rapamycin induced changes to the cell cycle of multicellular spheroids and human tumour xenografts leading to potential therapeutic advantage
  1753. 1853: A Propsective Study With Thymoglobulin/Daclizumab Induction, Tacrolimus and Steroid Maintenance, Comparing Rapamycin With Mycophenolate Mofetil as …
  1754. Anti-angiogenic and immunomodulatory effects of Rapamycin on pancreatic islet endothelial cells: relevance for islets engraftment after transplantation
  1755. A comparison study on FTY720, 40-O-(2-hydroxyethyl)-Rapamycin and cyclosporine to prolong the survival of mouse heart allograft
  1756. Role of p53 in TRAIL-induced apoptosis in glioblastoma multiforme and modulation by taxol, Rapamycin or temozolomide
  1757. DIFFERENTIAL EFFECT OF CALCINEURIN INHIBITORS, ANTI-CD25 ANTIBODIES AND Rapamycin ON THE INDUCTION OF FOXP3 IN HUMAN T-CELLS IN VIVO …
  1758. … mechanisms regulating proliferation, antigen responsiveness, and differentiation of CD4⁺ T lymphocytes: a central role for the mammalian target of Rapamycin (mTOR …
  1759. Overexpression of a critical target of Rapamycin, translation regulatory protein 4E-BP1, is largely restricted to locally advanced breast and prostate cancers and is lost …
  1760. Receptor activator of NF-kB (RANK) and its ligand RANK-L coincide with expression of Rapamycin receptor FKBP12 in neointimal dendritic cells
  1761. The PI3K inhibitor LY294002 and the mTOR inhibitor Rapamycin sensitize melanoma cells to cisplatin and temozolomide
  1762. Rapamycin and Anti-LFA-1 Monoclonal Antibody Prevent the Rejection of Rat Islet Xenografts and Induce Tolerance in BALB/c Mice
  1763. Glucagon Represses Insulin Signaling through Mammalian Target of Rapamycin (mTOR) in Perfused Rat Liver
  1764. MYCOPHENOLATE MOFETIL (MMF)/Rapamycin (RAPA) COMPARED TO OTHER COMMON IMMUNOSUPPRESSIVE REGIMENS IN KIDNEY …
  1765. Ras Homologue Enrich in Brain (Rheb) Enhances Hypertrophic Response via the Mammalian Target of Rapamycin (mTOR)/p70S6K Pathway
  1766. … OF HUMAN BONE MARROW DERIVED MESENCHYMAL PROGENITORS—A SIGNAL TRANSDUCTION BASE FOR PLEIOTROPY OF Rapamycin DERIVATES.
  1767. grammed autophagy in the fat body during the final larval stage. TOR (target of Rapamycin) kinases, the central components of a conserved nutri-ent-sensing …
  1768. ANTI-CD25 MAB, ANTI-IL2 MAB AND IL2 BLOCK TOLERANCE INDUCTION THROUGH ANTI-CD154 MAB AND Rapamycin IN XENOGENEIC ISLET …
  1769. Schedule-dependent activity of combined epidermal growth factor receptor (EGFR) and mammalian target of Rapamycin (mTOR) targeting in PTEN negative breast …
  1770. Differential effects of the immunosuppressive agents cyclosporine A, Rapamycin and FK-506 on drug transport by the ATP-binding cassette (ABC) proteins P …
  1771. Amino acid transporter ASCT2 expression regulates mammalian Target‐of‐Rapamycin (mTOR) growth and survival signaling in human hepatoma cells
  1772. … WITHDRAWAL (PW) TRIAL IN KIDNEY TRANSPLANT PATIENTS TREATED WITH MYCOPHENOLATE SODIUM (MS) COMPARING Rapamycin® VS. C2 DOSED …
  1773. Rapamycin AND ANTI-LFA-1 THERAPY MEDIATE ISLET GRAFT SPECIFIC TOLERANCE IN CONCORDANT XENOGENEIC ISLET TRANSPLANTATION.
  1774. PHARMACOKINETICS OF ONCE A DAY DOSE OF CYCLOSPORINE IN COMBINATION WITH Rapamycin AND PREDNISONE IN RENAL TRANSPLANTATION IN …
  1775. ROLE OF THE MAMMALIAN TARGET OF Rapamycin IN THE REGULATION OF SKELETAL MUSCLE PROTEIN SYNTHESIS AND eIF2B EPSILON mRNA …
  1776. IGF-1 rescues Rapamycin-induced cell growth inhibition
  1777. CONCOMITANT USE OF CYCLOSPORINE-A (CyA) AND Rapamycin (RAPA) WITH A CONSECUTIVE CONVERSION TO RAPA AND MYCOPHENOLATE MOFETIL …
  1778. UP-02.50: A study of the role of insulin like growth factor 1 (IGF1) and Rapamycin sensitive signaling in an androgen independent prostate cancer cell line
  1779. … GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR GEFITINIB AND THE MAMMALIAN TARGET OF Rapamycin (mTOR) INHIBITOR EVEROLIMUS
  1780. QUADRUPLE IMMUNOSUPPERSSIVE MAINTENANCE THERAPY USING Rapamycin, LOW-DOSE CYCLOSPORINE, MYCOPHENOLATE MOFETIL, AND …
  1781. PJ-138 New Sesquiterpene Lactone Compared with Rapamycin Inhibits Migration Rather than Proliferation in Rat Vascular Smooth Muscle Cells
  1782. Combination therapy targeting the EWS/FLI-1 oncogene with antisense oligonucleotides and Rapamycin induces apoptosis of Ewing’s sarcoma cells in vitro and …
  1783. … 3-kinase; RTK, receptor tyrosine kinase; S6K, ribosomal S6 kinase; TNF-α, tumor necrosis factor α; TOR, target of Rapamycin; TSC, tuberous sclerosis complex …
  1784. LONG-TERM LIMB ALLOGRAFT SURVIVAL USING A SHORT COURSE OF ANTI-CD45RB MONOCLONAL ANTIBODY, LF15-0195 AND Rapamycin IN A MOUSE …
  1785. A role for HO-1 in the renal function impairment in Rapamycin-treated animals submitted to ischemic and reperfusion injury (IRI).
  1786. Bone Morphogenetic Protein 2 (BMP-2) promotes foci formation through the activation of mammalian target of Rapamycin
  1787. GSK-3/Rb12 Pathway as a Novel Target of Rapamycin in Prostate Cancer
  1788. PII‐9: Improved platelet function in renal transplant patients after conversion from azathioprin to Rapamycin
  1789. Drug-eluting stents, 5-sirolimus stents and oral Rapamycin
  1790. Autophagic Cell Death in Leukemia Cells Regulated by Ceramide and Sphingosine-1-Phosphate through Mammalian Target of Rapamycin.
  1791. 4-(N-Methyl-N-nitrosamino)-1 (3-pyridyl)-1-butanone (NNK) Restored the Cap-dependent Protein Translation Blocked by Rapamycin
  1792. The Saccharomyces cerevisiae GATA-factor activators’ response to the 14-3-3 proteins, nutrient limitation, Rapamycin and MSX treatment, and cis-acting …
  1793. 1871: Rapamycin and Ischemia on Experimental Transplant Arteriosclerosis
  1794. 1158-52 Proteomic profiling of restenotic lesions unveils increased expression of structural proteins that are inhibited by intramural delivery of Rapamycin
  1795. … and Activator of Transcription-1 (STAT1)-dependent Gene Transcription by Lipopolysaccharide and InterferonγIs Regulated by Mammalian Target of Rapamycin
  1796. P-205 STUDIES ON FUNGAL SECONDARY METABOLISM USING Rapamycin AS A MOLECULAR PROBE
  1797. Sphingosine-1-phosphate–induced smooth muscle cell migration involves the mammalian target of Rapamycin
  1798. Rapamycin: something old, something new, sometimes borrowed and now renewed
  1799. Rapamycin and mTOR kinase inhibitors
  1800. Rapamycin is a neuroprotective treatment for traumatic brain injury
  1801. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
  1802. Rapamycin prevents early steps of the development of diabetic nephropathy in rats
  1803. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
  1804. Targeting mammalian target of Rapamycin (mTOR) for health and diseases
  1805. A role for mammalian target of Rapamycin in regulating T cell activation versus anergy
  1806. A rational mechanism for combination treatment of Huntington’s disease using lithium and Rapamycin
  1807. Antitumor activity of Rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma
  1808. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
  1809. The Rapamycin-binding domain of the protein kinase mammalian target of Rapamycin is a destabilizing domain
  1810. The mammalian target of Rapamycin signaling pathway: twists and turns in the road to cancer therapy
  1811. The mammalian target of Rapamycin complex 2 controls folding and stability of Akt and protein kinase C
  1812. Rapamycin, a specific inhibitor of the mammalian target of Rapamycin, suppresses lymphangiogenesis and lymphatic metastasis
  1813. Neuroprotection of Rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement
  1814. inhibition of the mammalian target of Rapamycin impedes lymphangiogenesis
  1815. Contrasting Effects of Cyclosporine and Rapamycin in De Novo Generation of Alloantigen‐Specific Regulatory T Cells
  1816. Metformin inhibits mammalian target of Rapamycin–dependent translation initiation in breast cancer cells
  1817. Roles of rapH and rapG in positive regulation of Rapamycin biosynthesis in Streptomyces hygroscopicus
  1818. Temsirolimus, an inhibitor of mammalian target of Rapamycin
  1819. The Mammalian target of Rapamycin pathway regulates nutrient-sensitive glucose uptake in man
  1820. Silencing mammalian target of Rapamycin signaling by small interfering RNA enhances Rapamycin-induced autophagy in malignant glioma cells
  1821. Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with Rapamycin
  1822. Mammalian target of Rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
  1823. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells
  1824. mTOR inhibition by Rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
  1825. The mammalian target of Rapamycin-signaling pathway in regulating metabolism and growth,
  1826. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
  1827. Hypoxia-inducible factor 1α is regulated by the mammalian target of Rapamycin (mTOR) via an mTOR signaling motif
  1828. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol
  1829. Rapamycin treatment for a child with germline PTEN mutation
  1830. Effect of Rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
  1831. PRAS40 is a target for mammalian target of Rapamycin complex 1 and is required for signaling downstream of this complex
  1832. Use of sirolimus (Rapamycin) to treat refractory Crohn’s disease
  1833. Rapamycin affects early fracture healing in mice
  1834. Mammalian target of Rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
  1835. The role of hypothalamic mammalian target of Rapamycin complex 1 signaling in diet-induced obesity
  1836. Re-evaluating the roles of proposed modulators of mammalian target of Rapamycin complex 1 (mTORC1) signaling
  1837. Mammalian target of Rapamycin inhibitor dyslipidemia in kidney transplant recipients
  1838. Dose-and schedule-dependent inhibition of the mammalian target of Rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with …
  1839. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins
  1840. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy
  1841. Mammalian target of Rapamycin (mTOR) orchestrates the defense program of innate immune cells
  1842. Rapamycin modulates the eNOS vs. shear stress relationship
  1843. Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation
  1844. The mammalian target of Rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
  1845. Gonadal impact of target of Rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview
  1846. Phase I trial of the novel mammalian target of Rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to …
  1847. Randomized trial of three Rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
  1848. Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the Rapamycin-sensitive PI (3) K-mTOR-p70S6K pathway
  1849. The role of mammalian target of Rapamycin inhibitors in the treatment of advanced renal cancer
  1850. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and Rapamycin
  1851. Mammalian target of Rapamycin as a therapeutic target in oncology
  1852. Pilot study of Rapamycin in patients with hormone-refractory prostate cancer
  1853. Regulation of androgen receptor transcriptional activity by Rapamycin in prostate cancer cell proliferation and survival
  1854. Changes in tumor metabolism as readout for Mammalian target of Rapamycin kinase inhibition by Rapamycin in glioblastoma
  1855. Response of a neuronal model of tuberous sclerosis to mammalian target of Rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved …
  1856. inhibition of Mammalian target of Rapamycin by Rapamycin causes the regression of carcinogen-induced skin tumor lesions
  1857. Chemoprevention and treatment of experimental Cowden’s disease by mTOR inhibition with Rapamycin
  1858. Antitumor activity of Rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
  1859. In human endothelial cells Rapamycin causes mTORC2 inhibition and impairs cell viability and function
  1860. Mammalian target of Rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells
  1861. Mammalian target of Rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation
  1862. Differential impact of mammalian target of Rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
  1863. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
  1864. Dissecting the Akt/mammalian target of Rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative
  1865. Rapamycin impairs in vivo proliferation of islet beta-cells
  1866. Total synthesis of Rapamycin
  1867. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by Rapamycin
  1868. Systemic inhibition of mammalian target of Rapamycin inhibits fear memory reconsolidation
  1869. The Target of Rapamycin pathway antagonizes pha-4/FoxA to control development and aging
  1870. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+ CD25+ FOXP3+ regulatory T-cells
  1871. Mammalian target of Rapamycin in the human placenta regulates leucine transport and is down‐regulated in restricted fetal growth
  1872. The mTOR inhibitor Rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis
  1873. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1 cells and primary mouse bone marrow stromal cells
  1874. Antidepressive-like effects of Rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders
  1875. Alterations in mammalian target of Rapamycin signaling pathways after traumatic brain injury
  1876. Regulatory effects of mammalian target of Rapamycin-activated pathways in type I and II interferon signaling
  1877. Preparation of Rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation
  1878. Bnip3 mediates the hypoxia-induced inhibition on mammalian target of Rapamycin by interacting with Rheb
  1879. Sirolimus (Rapamycin): from the soil of Easter Island to a bright future
  1880. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and Rapamycin
  1881. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of Rapamycin/p70S6K1 pathway
  1882. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ …
  1883. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells
  1884. Dietary energy balance modulates signaling through the Akt/mammalian target of Rapamycin pathways in multiple epithelial tissues
  1885. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/WF1 mice
  1886. Isolation of hyperactive mutants of mammalian target of Rapamycin
  1887. P-Rex1 links mammalian target of Rapamycin signaling to Rac activation and cell migration
  1888. Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis
  1889. Bevacizumab and Rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
  1890. Phosphoprotein pathway mapping: Akt/mammalian target of Rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
  1891. Delivery of Rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells
  1892. Rapamycin regulates the phosphorylation of rictor
  1893. Inhibitors of mammalian target of Rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo
  1894. Distinct signaling mechanisms activate the target of Rapamycin in response to different B‐cell stimuli
  1895. Therapeutic effect of Rapamycin on gallbladder cancer in a transgenic mouse model
  1896. Rapamycin sensitivity of the Schizosaccharomyces pombe tor2 mutant and organization of two highly phosphorylated TOR complexes by specific and common …
  1897. Activated mammalian target of Rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma
  1898. Expression of an activated mammalian target of Rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy
  1899. The effect of immunosuppressive drug Rapamycin on regulatory CD4+ CD25+ Foxp3+ T cells in mice
  1900. Impact of Rapamycin on liver regeneration
  1901. Curcumin inhibits Akt/mammalian target of Rapamycin signaling through protein phosphatase-dependent mechanism
  1902. Combination of Rapamycin and IL-2 increases de novo induction of human CD4+ CD25+ FOXP3+ T cells
  1903. Translational control of c-MYC by Rapamycin promotes terminal myeloid differentiation
  1904. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells
  1905. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by Rapamycin and siRNA against …
  1906. Mammalian target of Rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids
  1907. Evaluation of antileukaemic effects of Rapamycin in patients with imatinib‐resistant chronic myeloid leukaemia
  1908. Antiproliferative effects of Rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
  1909. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling
  1910. Mammalian target of Rapamycin: master regulator of cell growth in the nervous system
  1911. Binding of Rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities
  1912. Epstein Barr virus, Rapamycin, and host immune responses
  1913. Regression of subependymal giant cell astrocytoma with Rapamycin in tuberous sclerosis complex
  1914. Effect of Rapamycin on wound healing: an experimental study
  1915. Saccharomyces cerevisiae FKBP12 binds Arabidopsis thaliana TOR and its expression in plants leads to Rapamycin susceptibility
  1916. ASCT2 silencing regulates mammalian target-of-Rapamycin growth and survival signaling in human hepatoma cells
  1917. Small molecule enhancers of Rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of …
  1918. Mammalian target of Rapamycin (mTOR) is involved in the neuronal differentiation of neural progenitors induced by insulin
  1919. Defects in skin γδ T cell function contribute to delayed wound repair in Rapamycin-treated mice
  1920. Effective in vivo targeting of the mammalian target of Rapamycin pathway in malignant peripheral nerve sheath tumors
  1921. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function
  1922. IL-1β-driven ST2L expression promotes maturation resistance in Rapamycin-conditioned dendritic cells
  1923. Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of Rapamycin pathway
  1924. CXCR6 induces prostate cancer progression by the AKT/mammalian target of Rapamycin signaling pathway
  1925. Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of Rapamycin and histone deacetylase inhibitors
  1926. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly (ε-caprolactone) micelles of Rapamycin
  1927. Calcineurin inhibitors and Rapamycin: cancer protection or promotion?
  1928. A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of Rapamycin (mTOR) in high-protein diet–induced weight loss
  1929. … exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/mammalian target of Rapamycin …
  1930. Endoplasmic reticulum and Golgi localization sequences for mammalian target of Rapamycin
  1931. Mammalian target of Rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute …
  1932. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro
  1933. Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen–Induced …
  1934. Rapamycin prevents the development of nephritis in lupus-prone NZB/WF1 mice
  1935. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by Rapamycin
  1936. Rapamycin as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells
  1937. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice
  1938. Intramural Delivery of Rapamycin With αvβ3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury
  1939. FK506 binding protein mediates glioma cell growth and sensitivity to Rapamycin treatment by regulating NF-κB signaling pathway
  1940. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: Rapamycin triggers dephosphorylation and delocalization of the mTORC2 …
  1941. Oncogenic tyrosine kinase NPM/ALK induces activation of the Rapamycin-sensitive mTOR signaling pathway
  1942. Target of Rapamycin (TOR) signaling controls epithelial morphogenesis in the vertebrate intestine
  1943. Antiangiogenic therapy with mammalian target of Rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
  1944. Mammalian target of Rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy
  1945. Preparation and characterization of Rapamycin-loaded PLGA coating stent
  1946. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and Rapamycin induces growth arrest of adult T-cell leukemia cells
  1947. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of Rapamycin signaling
  1948. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor with potent in …
  1949. Rapamycin retards growth and causes marked alterations in the growth plate of young rats
  1950. … fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of Rapamycin (mTOR) signaling cascade
  1951. Autophagy activation by Rapamycin eliminates mouse Mallory‐Denk bodies and blocks their proteasome inhibitor‐mediated formation
  1952. Mammalian target of Rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer
  1953. Defective TGF-β signaling sensitizes human cancer cells to Rapamycin
  1954. A retroinhibition approach reveals a tumor cell–autonomous response to Rapamycin in head and neck cancer
  1955. Effects of Rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons
  1956. inhibition of mammalian target of Rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E …
  1957. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of Rapamycin in mammary carcinomas, mammary gland …
  1958. Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
  1959. Activation of mammalian target of Rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes
  1960. … concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of Rapamycin/eIF4E …
  1961. Enhancing mammalian target of Rapamycin (mTOR)–targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-independent Akt activation
  1962. Leucine stimulates mammalian target of Rapamycin signaling in C2C12 myoblasts in part through inhibition of adenosine monophosphate-activated protein kinase
  1963. Rapamycin Inhibits Proliferation of Epstein-Barr Virus–Positive B-cell Lymphomas Through Modulation of Cell-Cycle Protein Expression
  1964. Solution structure of the Legionella pneumophila Mip-Rapamycin complex
  1965. Combined therapeutic effects of vinblastine and Rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis
  1966. Azoospermia in a renal transplant recipient during sirolimus (Rapamycin) treatment
  1967. Differential involvement of IκB kinases α and β in cytokine-and insulin-induced mammalian target of Rapamycin activation determined by Akt
  1968. The role of targeting mammalian target of Rapamycin in lung cancer
  1969. Amelioration of protein misfolding disease by Rapamycin: translation or autophagy?
  1970. Monitoring biological action of Rapamycin in renal transplantation
  1971. Efficacy of Rapamycin in scleroderma: a case study
  1972. Statin therapy, alone or with Rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study
  1973. Target of Rapamycin and LST8 proteins associate with membranes from the endoplasmic reticulum in the unicellular green alga Chlamydomonas reinhardtii
  1974. Regulation of mammalian target of Rapamycin activity in PTEN-inactive prostate cancer cells by IκB kinase α
  1975. … regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of Rapamycin
  1976. The Akt/mammalian target of Rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation
  1977. The mammalian target of Rapamycin pathway as a potential target for cancer chemoprevention
  1978. Rapamycin: brain excitability studied in vitro
  1979. Rapamycin‐mediated G1 arrest involves regulation of the Cdk inhibitor Sic1 in Saccharomyces cerevisiae
  1980. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion
  1981. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of Rapamycin pathway
  1982. Acidosis-sensing glutamine pump SNAT2 determines amino acid levels and mammalian target of Rapamycin signalling to protein synthesis in L6 muscle cells
  1983. Phosphorylation of ribosomal p70 S6 kinase and Rapamycin sensitivity in human colorectal cancer
  1984. Mammalian Target of Rapamycin Repression by 3, 3′-Diindolylmethane Inhibits Invasion and Angiogenesis in Platelet-Derived Growth Factor-D–Overexpressing …
  1985. Endothelial Akt signaling is rate-limiting for Rapamycin inhibition of mouse mammary tumor progression
  1986. Aging, stem cells, and mammalian target of Rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells
  1987. The mammalian target of Rapamycin kinase and tumor growth inhibition
  1988. Nonimmunosuppressive effects of mammalian target of Rapamycin inhibitors
  1989. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro
  1990. Interplay of PI3K and cAMP/PKA signaling, and Rapamycin-hypersensitivity in TGFβ1 enhancement of FSH-stimulated steroidogenesis in rat ovarian …
  1991. … human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase–dependent mammalian target of Rapamycin raptor complex 1 …
  1992. mTOR is the Rapamycin-sensitive kinase that confers mechanically-induced phosphorylation of the hydrophobic motif site Thr (389) in p70S6k
  1993. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells
  1994. Juvenile hormone connects larval nutrition with target of Rapamycin signaling in the mosquito Aedes aegypti
  1995. Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-κB activation
  1996. Protein phosphatase 2A and Rapamycin regulate the nuclear localization and activity of the transcription factor GLI3
  1997. Effect of Rapamycin therapy on coronary artery physiology early after cardiac transplantation
  1998. Low-dose mTOR inhibition by Rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat
  1999. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of Rapamycin
  2000. Bevacizumab and Rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer
  2001. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging
  2002. IL-2– and IL-15–induced activation of the Rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes
  2003. Mammalian Target of Rapamycin (mTOR) is Activated in Cutaneous Vascular Malformations in Vivo
  2004. Reduction of CCR5 with low-dose Rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
  2005. Evaluation of the mammalian target of Rapamycin pathway and the effect of Rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs
  2006. Differential effects of Rapamycin in anti-GBM glomerulonephritis
  2007. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy
  2008. Coupling of mammalian target of Rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2a-and glycogen synthase …
  2009. Mammalian target of Rapamycin and caspase inhibitors in polycystic kidney disease
  2010. Pharmacodynamic-guided modified continuous reassessment method–based, dose-finding study of Rapamycin in adult patients with solid tumors
  2011. Statin-dependent suppression of the Akt/mammalian target of Rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma
  2012. Impact of mammalian target of Rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic …
  2013. Antiproliferative and proapoptotic effects of Rapamycin and celecoxib in malignant melanoma cell lines
  2014. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the Rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat …
  2015. Exploiting the mammalian target of Rapamycin pathway in hematologic malignancies
  2016. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of Rapamycin eluting stents in the …
  2017. Degradation of Rapamycin and its ring-opened isomer: role of base catalysis
  2018. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with Rapamycin
  2019. Superoxide anions regulate TORC1 and its ability to bind Fpr1: Rapamycin complex
  2020. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of Rapamycin complex 1
  2021. Topical Rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
  2022. Cardiac restricted overexpression of kinase-dead mammalian target of Rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function
  2023. Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production
  2024. Mammalian target of Rapamycin (mTOR) pathway signalling in lymphomas
  2025. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and Rapamycin combination therapy
  2026. Nucleophosmin mediates mammalian target of Rapamycin–Dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes
  2027. Effects of Rapamycin on cell proliferation and phosphorylation of mTOR and p70S6K in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB
  2028. Mammalian target of Rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass
  2029. Fatty acid synthase inhibitors modulate energy balance via mammalian target of Rapamycin complex 1 signaling in the central nervous system
  2030. Rapamycin does not improve insulin sensitivity despite elevated mammalian target of Rapamycin complex 1 activity in muscles of ob/ob mice
  2031. inhibition of apoptosis through localized delivery of Rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery
  2032. Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of Rapamycin, mycophenolate, cyclosporin, azathioprine, and …
  2033. Regulatory effects of mammalian target of Rapamycin-mediated signals in the generation of arsenic trioxide responses
  2034. Leptin induces macrophage lipid body formation by a phosphatidylinositol 3-kinase-and mammalian target of Rapamycin-dependent mechanism
  2035. Non‐human primate fetal kidney transcriptome analysis indicates mammalian target of Rapamycin (mTOR) is a central nutrient‐responsive pathway
  2036. Compared effect of immunosuppressive drugs cyclosporine A and Rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG‐CoA reductase
  2037. On the action of cyclosporine A, Rapamycin and tacrolimus on M. avium including subspecies paratuberculosis
  2038. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of Rapamycin complex 1 (mTORC1)-mediated phosphorylation
  2039. Improved blood compatibility of Rapamycin-eluting stent by incorporating curcumin
  2040. Follicle-stimulating hormone increases tuberin phosphorylation and mammalian target of Rapamycin signaling through an extracellular signal-regulated kinase …
  2041. Monitoring antitumor efficacy of Rapamycin in Kaposi sarcoma
  2042. Phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer
  2043. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 …
  2044. Initial testing (stage 1) of the mTOR inhibitor Rapamycin by the pediatric preclinical testing program
  2045. Insulin‐like growth factor‐1 (IGF‐1) and leucine activate pig myogenic satellite cells through mammalian target of Rapamycin (mTOR) pathway
  2046. Rapamycin impairs β-cell proliferation in vivo
  2047. … acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of Rapamycin …
  2048. Upstream signaling inhibition enhances Rapamycin effect on growth of kidney cancer cells
  2049. Hsf1 activation inhibits Rapamycin resistance and TOR signaling in yeast revealed by combined proteomic and genetic analysis
  2050. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in Rapamycin
  2051. The YCR079w gene confers a Rapamycin-resistant function and encodes the sixth type 2C protein phosphatase in Saccharomyces cerevisiae
  2052. Combination of Rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells
  2053. … Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in …
  2054. Antiproliferative effect of Rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition
  2055. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of Rapamycin inhibitor, in patients with relapsed or refractory hematologic …
  2056. Ocular toxicity and distribution of subconjunctival and intravitreal Rapamycin in horses
  2057. Response of U87 glioma xenografts treated with concurrent Rapamycin and fractionated radiotherapy: possible role for thrombosis
  2058. Mammalian target of Rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth
  2059. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post–lung transplantation with Rapamycin treatment
  2060. Regulation of neurogenesis and epidermal growth factor receptor signaling by the insulin receptor/target of Rapamycin pathway in Drosophila
  2061. inhibition of mammalian target of Rapamycin signaling by 2-(morpholin-1-yl) pyrimido [2, 1-α] isoquinolin-4-one
  2062. Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and Rapamycin
  2063. Intracellular mechanisms of metabolism regulation: the role of signaling via the mammalian target of Rapamycin pathway and other routes
  2064. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of Rapamycin signaling in endometrial carcinoma
  2065. The mammalian target of Rapamycin pathway and its role in molecular nutrition regulation
  2066. Cotylenin A, a new differentiation inducer, and Rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2
  2067. Effects of Rapamycin in liver transplantation.
  2068. Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
  2069. Rapamycin enriches for CD4+ CD25+ CD27+ Foxp3+ regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with …
  2070. Rapamycin down-regulates LDL-receptor expression independently of SREBP-2
  2071. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of Rapamycin inhibitors in cell lines derived from childhood solid tumors
  2072. Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of Rapamycin pathway components
  2073. Effects of Rapamycin on active Heymann nephritis
  2074. Rationale for a phase I trial of erlotinib and the mammalian target of Rapamycin inhibitor everolimus (RAD001) for patients with relapsed non–small cell lung cancer
  2075. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of Rapamycin through the STAT3-SOCS3 pathway
  2076. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin module for acute myelogenous leukemia therapy: from bench to bedside
  2077. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment
  2078. … and inducible nitric-oxide synthase expression through the integrin/integrin-linked kinase/Akt/mammalian target of Rapamycin pathway in osteoblasts
  2079. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G 1 cell cycle …
  2080. Rapamycin enhances the number of alloantigen-induced human CD103+ CD8+ regulatory T cells in vitro
  2081. GADD34 inhibits mammalian target of Rapamycin signaling via tuberous sclerosis complex and controls cell survival under bioenergetic stress
  2082. Delivery of Rapamycin‐loaded nanoparticle down regulates ICAM‐1 expression and maintains an immunosuppressive profile in human CD34+ progenitor‐derived …
  2083. Four-year clinical follow-up of the Rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry
  2084. Human melanoma cytolysis by combined inhibition of mammalian target of Rapamycin and vascular endothelial growth factor/vascular endothelial growth factor …
  2085. Surgical wound‐healing complications in heart transplant recipients treated with Rapamycin
  2086. Mammalian target of Rapamycin as a target in hematological malignancies
  2087. Does addition of estradiol improve the efficacy of a Rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial
  2088. The effects of Rapamycin in the progression of renal fibrosis
  2089. Mechanism of apoptosis induced by IFN-α in human myeloma cells: role of Jak1 and Bim and potentiation by Rapamycin
  2090. p21-activated kinase 1 is activated through the mammalian target of Rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in …
  2091. Effect of supplemental dietary zinc on the mammalian target of Rapamycin (mTOR) signaling pathway in skeletal muscle and liver from post-absorptive mice
  2092. Combined treatment with triptolide and Rapamycin prolongs graft survival in a mouse model of cardiac transplantation
  2093. Synergistic effect of mTOR inhibitor Rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
  2094. Rapamycin stimulates arginine influx through CAT2 transporters in human endothelial cells
  2095. Mammalian target of Rapamycin is the key effector of phosphatidylinositol-3-OH–initiated proliferative signals in the thyroid follicular epithelium
  2096. Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of Rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer
  2097. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of Rapamycin (RAD001) decreases glioma proliferation and invasion
  2098. EMAP-II downregulation contributes to the beneficial effects of Rapamycin after vascular injury
  2099. Rescue of Degradation‐Prone Mutants of the FK506‐Rapamycin Binding (FRB) Protein with Chemical Ligands
  2100. Antiproliferative and overadditive effects of Rapamycin and FTY720 in pancreatic cancer cells in vitro
  2101. Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy
  2102. Randomized trial of Rapamycin-and paclitaxel-eluting stents with identical biodegradable polymeric coating and design
  2103. Nutrient content of diet affects the signaling activity of the insulin/target of Rapamycin/p70 S6 kinase pathway in the African malaria mosquito Anopheles gambiae
  2104. Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity
  2105. Rapamycin together with herceptin significantly increased anti‐tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells
  2106. Short-and long-term effects of cytochalasin D, paclitaxel and Rapamycin on wall thickening in experimental porcine vein grafts
  2107. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of Rapamycin pathway in Barrett’s-associated esophageal adenocarcinoma
  2108. A phase II study of oral mammalian target of Rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)
  2109. Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination
  2110. External application of Rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model
  2111. Rapamycin blunts nutrient stimulation of eIF4G, but not PKCε phosphorylation, in skeletal muscle
  2112. ABT-263 and Rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
  2113. mTOR inhibitors (Rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours
  2114. DCO2 on-line measurement used in Rapamycin fed-batch fermentation process
  2115. Identification of the Rapamycin‐sensitive phosphorylation sites within the Ser/Thr‐rich domain of the yeast Npr1 protein kinase
  2116. Golgi Manganese Transport Is Required for Rapamycin Signaling in Saccharomyces cerevisiae
  2117. How to control lymphangiogenesis: A novel role for Rapamycin
  2118. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of Rapamycin
  2119. Components of the Vid30c are needed for the Rapamycin-induced degradation of the high-affinity hexose transporter Hxt7p in Saccharomyces cerevisiae
  2120. An approach to analyse the specific impact of Rapamycin on mRNA-ribosome association
  2121. Ex vivo Rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection
  2122. Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer
  2123. Rapamycin prevents mesenteric neo‐angiogenesis and reduces splanchnic blood flow in portal hypertensive mice
  2124. Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, Rapamycin and paclitaxel
  2125. Chylous ascites in a renal transplant recipient under sirolimus (Rapamycin) treatment
  2126. Combination antifungal therapy involving amphotericin B, Rapamycin and 5-fluorocytosine using PEG-phospholipid micelles
  2127. Serotonin Induces Memory-Like, Rapamycin-Sensitive Hyperexcitability in Sensory Axons of Aplysia That Contributes to Injury Responses
  2128. Activation of the mammalian target of Rapamycin complex 1 is both necessary and sufficient to stimulate eukaryotic initiation factor 2Bɛ mRNA translation and protein …
  2129. Human herpesvirus‐8 (HHV‐8)‐associated primary effusion lymphoma in two renal transplant recipients receiving Rapamycin
  2130. An RNA Interference Screen Identifies a Novel Regulator of Target of Rapamycin That Mediates Hypoxia Suppression of Translation in Drosophila S2 Cells
  2131. Identification of AUF1 as a Rapamycin-responsive binding protein to the 5′-terminal oligopyrimidine element of mRNAs
  2132. Mitogen-stimulated and Rapamycin-sensitive glucose transporter 12 targeting and functional glucose transport in renal epithelial cells
  2133. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, Rapamycin and Bcl-2 inhibitor GX15-070
  2134. Modulation of the activities of AMP‐activated protein kinase, protein kinase B, and mammalian target of Rapamycin by limiting energy availability with 2‐deoxyglucose
  2135. PTEN and Rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway
  2136. Role of adenosine 5′-monophosphate-activated protein kinase subunits in skeletal muscle mammalian target of Rapamycin signaling
  2137. Pharmacokinetics of sirolimus (Rapamycin) in subjects with severe hepatic impairment
  2138. … Preconditioning Decreases Myocardial Infarction in Rabbits via Up-regulation of Hypoxia Inducible Factor 1 That Is Mediated by Mammalian Target of Rapamycin
  2139. Stress and IGF-I differentially control cell fate through mammalian target of Rapamycin (mTOR) and retinoblastoma protein (pRB)
  2140. … of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of the phosphoinositide 3‐kinase–Akt–mammalian target of Rapamycin …
  2141. Possible involvement of persistent activity of the mammalian target of Rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells
  2142. Cyclin B synthesis and Rapamycin‐sensitive regulation of protein synthesis during starfish oocyte meiotic divisions
  2143. Comparison of a polymer‐free Rapamycin‐eluting stent (YUKON) with a polymer‐based paclitaxel‐eluting stent (TAXUS) in real‐world coronary artery lesions
  2144. The Rheb switch 2 segment is critical for signaling to target of Rapamycin complex 1
  2145. Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma
  2146. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency …
  2147. Three‐year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus‐eluting stents: Insights from the Rapamycin‐eluting stent evaluated at …
  2148. Chronic alcohol consumption alters mammalian target of Rapamycin (mTOR), reduces ribosomal p70s6 kinase and p4E-BP1 levels in mouse cerebral cortex
  2149. Intrinsically lower AKT, mammalian target of Rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia …
  2150. … preclinical studies: timing of treatment, combination of a Rapamycin analog (CCI-779) and interferon-gamma, and comparison of Rapamycin to CCI-779
  2151. Rapamycin limits formation of active eukaryotic initiation factor 4F complex following meal feeding in rat hearts
  2152. CD8+ T‐Cell Depletion and Rapamycin Synergize with Combined Coreceptor/Stimulation Blockade to Induce Robust Limb Allograft Tolerance in Mice
  2153. Antineoplastic effect of Rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts
  2154. Mammalian target of Rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines
  2155. The Cairo kidney center protocol for Rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes
  2156. … of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of Rapamycin …
  2157. Total synthesis studies on macrocyclic pipecolic acid natural products: FK506, the antascomicins and Rapamycin
  2158. IGF-I receptor inhibition combined with Rapamycin or temsirolimus inhibits neuroblastoma cell growth
  2159. Chronic allograft dysfunction: can we use mammalian target of Rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
  2160. The mammalian target of Rapamycin complex 1 regulates leptin biosynthesis in adipocytes at the level of translation: the role of the 5′-untranslated region in the …
  2161. Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells.
  2162. Renal cortex neuronal nitric oxide synthase in response to Rapamycin in kidney transplantation
  2163. The MAP kinase-activated protein kinase Rck2p plays a role in Rapamycin sensitivity in Saccharomyces cerevisiae and Candida albicans
  2164. … Factor‐1 and Transforming Growth Factor‐β Controls the Quiescence/Cycling Switch of CD34+ Progenitors Through FoxO3 and Mammalian Target of Rapamycin
  2165. The effect of Rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal rats
  2166. Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation
  2167. Reversal of tacrolimus‐related hypertrophic cardiomyopathy after conversion to Rapamycin in a pediatric liver transplant recipient
  2168. Mechanisms of mammalian target of Rapamycin inhibition in sarcoma: present and future
  2169. siRNA targeting mammalian target of Rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy
  2170. Synthesis, characterization and antiproliferative activity of Rapamycin-loaded poly (N-isopropylacrylamide)-based nanogels in vascular smooth muscle cells
  2171. Prolongation of cardiac allograft survival by Rapamycin and the invariant natural killer T cell glycolipid agonist OCH
  2172. Rapamycin Inhibits Growth Factor-Induced Cell Cycle Regulation in Pancreatic β Cells
  2173. Molecular impacts of Rapamycin-based drug combinations: combining Rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model
  2174. Rapamycin-induced cytotoxic signal transduction pathway
  2175. Effect of rifampicin to inhibit Rapamycin-induced autophagy via the suppression of protein phosphatase 2A activity
  2176. Specific mTOR inhibitor Rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea …
  2177. Requirements of phosphatidylinositol-3 kinase and mammalian target of Rapamycin for estrogen-induced proliferation in uterine leiomyoma-and myometrium-derived …
  2178. Mass balance in Rapamycin autoxidation
  2179. Targeting the mammalian target of Rapamycin in myxoid chondrosarcoma
  2180. Acetaldehyde promotes Rapamycin-dependent activation of p70S6K and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human …
  2181. Conversion to Rapamycin immunosuppression for malignancy after kidney transplantation
  2182. Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for Rapamycin analog ABT-578: Application to active pharmaceutical ingredient process …
  2183. Non-Conventional method for evaluation and optimization of medium components for Rapamycin production by Streptomyces hygroscopicus
  2184. Administration of triiodo-L-thyronine into dorsal hippocampus alters phosphorylation of Akt, mammalian target of Rapamycin, p70S6 kinase and 4E-BP1 in rats
  2185. Possible mechanism by which Rapamycin increases cyclosporine nephrotoxicity
  2186. … Extracellular Signal-regulated Kinase 1/2 and c-Jun NH2-Terminal Kinase Downstream of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin
  2187. Adverse effects of mammalian target of Rapamycin inhibitors during the postoperative period after cardiac transplantation
  2188. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with Rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
  2189. Neointimal expression of Rapamycin receptor FK506-binding protein FKBP12: postinjury animal and human in-stent restenosis tissue characteristics
  2190. Successful treatment of post-renal transplant gastric and pulmonary Kaposi’s sarcoma with conversion to Rapamycin treatment
  2191. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer Rapamycin-eluting stent for the treatment of …
  2192. Effect of Rapamycin on hepatocyte function and proliferation induced by growth factors
  2193. Lentiviral vectors mediate nonimmunosuppressive Rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of …
  2194. Rapamycin bypasses vesicle-mediated signaling events to activate Gln3 in Saccharomyces cerevisiae
  2195. Nanoparticle albumin-bound (nab) Rapamycin as an anticancer agent
  2196. Rapamycin conditionally inhibits Hsp90 but not Hsp70 mRNA translation in Drosophila: implications for the mechanisms of Hsp mRNA translation
  2197. Differential modulation of mitogen driven proliferation and homeostasis driven proliferation of T cells by Rapamycin, Ly294002 and chlorophyllin
  2198. A phase 1b study of oral Rapamycin (sirolimus) in patients with advanced malignancies
  2199. Rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles for intraarterial local drug delivery: preparation, characterization, and in vitro/in vivo release
  2200. A Combination of Donor Specific Transfusion and Rapamycin Prolonges Cardiac Allograft Survival in Mice
  2201. Immunoassay determination of Rapamycin: reliability of the method with respect to liquid chromatography mass spectrometric quantification
  2202. Thrombin induces osteoprotegerin synthesis via phosphatidylinositol 3′‐kinase/mammalian target of Rapamycin pathway in human periodontal ligament cells
  2203. Galectin-1 upregulates glucose transporter-1 expression level via protein kinase C, phosphoinositol-3 kinase, and mammalian target of Rapamycin pathways in mouse …
  2204. inhibition of the mammalian target of Rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma
  2205. Magic with Rapamycin
  2206. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity
  2207. Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy
  2208. Phorbol 12-myristate 13-acetate and serum synergize to promote Rapamycin-insensitive cell proliferation via protein kinase C-eta
  2209. A recent application of fluoro-18-deoxyglucose positron emission tomography, treatment monitoring with a mammalian target of Rapamycin inhibitor: an example …
  2210. Orally administered Rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice
  2211. … /p70S6K signaling pathway constitutively activated in esophageal squamous cell carcinona cell lines and inhibition of the pathway by Rapamycin and siRNA against …
  2212. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and Rapamycin in xenogeneic islet transplantation
  2213. Effect of chemotherapy with cisplatin and Rapamycin against Hep-2 cells in vitro
  2214. A new trick for an old drug: mTOR inhibitor Rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence
  2215. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of Rapamycin are associated with progesterone …
  2216. … MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with Rapamycin
  2217. Rapamycin, Mycophenolate Mofetil, Methylprednisolone, and Cytotoxic T-Lymphocyte–Associated Antigen 4 Immunoglobulin–Based Conditioning Regimen to Induce …
  2218. Long-term effects of Rapamycin treatment on insulin mediated phosphorylation of Akt/PKB and glycogen synthase activity
  2219. A fast and simple method to prepare the FKBP-Rapamycin binding domain of human target of Rapamycin for NMR binding assays
  2220. Dentritic cell derived IL-18 production is inhibited by Rapamycin and sanglifehrin A, but not cyclosporine A
  2221. Hypoxia-induced hypomyelination in the developing brain is mammalian target of Rapamycin-4E-binding protein-1 signaling dependent
  2222. Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM)
  2223. Effects of mTOR inhibitor Rapamycin on Smad 3 protein and collagen type I expression in rat myocardial fibroblasts infected with coxsackie virus B 3
  2224. Synergistic effect of Rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells
  2225. A phase II study of mammalian target of Rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma …
  2226. Influence of Rapamycin on rat macrophage viability and chemotaxis toward allogenic pancreatic islet supernates
  2227. Orally administered Rapamycin does not modify rat aortic vascular tone
  2228. Rapamycin inhibits the growth of cholangiocarcinoma cells in vitro
  2229. Sirolimus (Rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant
  2230. Induction effect of Rapamycin combined paclitaxel on apoptosis of ovarian cancer cell lines A2780 and SKOV3 and the molecular mechanism
  2231. Temozolomide combined with the PI3K inhibitor LY294002 or the mTOR inhibitor Rapamycin inhibits melanoma cell growth, survival and invasion
  2232. Negative inotropic effect of Rapamycin on isolated human cardiomyocytes
  2233. PDE4B Activity Controls Glucorticoid and Rapamycin Effects in DLBCL.
  2234. Effects of Rapamycin on intracellular cholesterol homeostasis of glomerular mesangial cell in the presence of interleukin-1β
  2235. TOR (target of Rapamycin) as an anti-cancer target
  2236. The expression of mammalian target of Rapamycin in Ishikawa and HEC-1A cells
  2237. Cancer and transplantation intersect at the mammalian target of Rapamycin
  2238. Expression of connective tissue growth factor in renal interstitial fibrosis after ureteral obstruction and effects of Rapamycin thereupon: experiment with rats
  2239. Rapamycin induces Balb/c murine CD4^+ CD25^+ foxp3^+ T cells proliferations
  2240. Mannan and peptidoglycan induce COX‐2 protein in human PMN via the mammalian target of Rapamycin
  2241. Establishment of a Conjugation System for the Rapamycin Producer Streptomyces hygroscopicus NRRL5491 [J]
  2242. Effeet of Rapamycin on mTOR and eIF-4E expression in coxsackievirus B3-induced rat myocardial cells [J]
  2243. Effects of Rapamycin on human hepatocellular carcinoma xenografts in nude mice [J]
  2244. Induction of PPAR gamma signaling and autophagy as a mechanism mediating acquired Rapamycin resistance in breast cancer models
  2245. A drug interaction study of sorafenib (S) and Rapamycin (R) in patients with advanced malignancies
  2246. Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-Associated Retroperitoneal Angiomyolipoma Post–Lung Transplantation With Rapamycin Treatment
  2247. Initial use of Rapamycin after kidney transplantation
  2248. Combination of CP-751871, a human monoclonal antibody against the IGF-1 receptor, with Rapamycin results in a highly effective therapy for xenografts derived from …
  2249. Rapamycin controls multiple signalling pathways involved in cancer cell survival
  2250. Phosphatidylinositol 3-kinase/mammalian target of Rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells
  2251. Long-term limb allograft survival using a short course of anti-CD45RB monoclonal antibody, LF 15-0195, and Rapamycin in a mouse model
  2252. Resveratrol-and Rapamycin-induced Morphological Changes to Human Epithelial Colon Cancer DLD-1 Cells
  2253. Phosphoinositide 3-kinase (PI3K) and nutrient sensing mTOR (mammalian target of Rapamycin) pathways control T lymphocyte trafficking
  2254. Does the use of paclitaxel or Rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?
  2255. Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): Abrogation of Rapamycin-mediated induction of AKT …
  2256. Effect of Rapamycin on CD4 (+) CD25 (+) regulatory T cells in allo-transplantation tolerance model
  2257. Effects of constant magnetic fields on proliferation and migration of endothelial progenitor cells under Rapamycin intervention: experiment with rats
  2258. Effect of Rapamycin on expression of origin recognition complex 1 mRNA in vascular smooth muscle cells [J]
  2259. The different effects of cyclosporin A and Rapamycin on regulatory CD4+CD25+ T cells: potential relationship with transplant tolerance induction
  2260. Experimental study of stent-based delivery of Rapamycin and tirofiban on preventing in-stent thrombosis and restenosis [J]
  2261. The clinical contrast investigation of Rapamycin eluting stent between domestic-made and imported [J]
  2262. Perivascular delivery of Rapamycin in pluronic gel inhibits neointimal hyperplasia in a rat carotid artery injury model, and the complementary role of carotid …
  2263. Effect of Rapamycin on the cell cycle arrest of T lymphocytes
  2264. mTOR kinase inhibitors exhibit properties that distinguish them from Rapamycin
  2265. … insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tumor activities of Tarceva in non-small cell lung carcinoma (NSCLC) and Rapamycin in sarcoma cell …
  2266. Conversion to Rapamycin in a renal transplant patient with von Hippel-Lindau disease: encouraging results—a case report
  2267. Rapamycin to the rescue!
  2268. Changes in FDG-PET in response to Rapamycin (R) correlated with Akt pathway inhibition and not with clinical outcome
  2269. Rapamycin inhibits proliferation of cells from TSC skin tumors.
  2270. Expression of mammalian target of Rapamycin and p70 S6 kinase in rabbit periodontal tissues remodeling during orthodontic tooth movement
  2271. Glucose transporter 12 and mammalian target of Rapamycin complex 1 signaling: a new target for diabetes-induced renal injury?
  2272. Clinical Application of Mammalian Target of Rapamycin Inhibitor in Kidney Transplantation
  2273. SYNERGISTIC EFFECT OF CYCLOSPORINE IN Rapamycin-INDUCE DIABETIC DISEASE: 1937
  2274. In Vitro Release of Rapamycin Sustained Eluting Stent Detected by a New Designed Circulating Device
  2275. Cause analysis and treatment of Rapamycin-eluting stent thrombosis [J]
  2276. Elevated phosphorylated mammalian target of Rapamycin (p-mTOR) expression in human neoplasms
  2277. Comparison between the Inhibitory and Cytotoxic Effects of Rapamycin and Paclitaxel on Endothelial Cell Proliferation
  2278. Treatment with sodium butyrate and Rapamycin inhibit growth of human cervical cancer cells
  2279. Pediatric Preclinical Testing Program (PPTP) evaluation of the mTOR inhibitor Rapamycin
  2280. The application of Rapamycin drug-eluting stents in elderly patients with acute myocardial infarction [J]
  2281. Effect of mammalian target of Rapamycin inhibitors on neuroblastoma MYCN expression and tumor growth
  2282. Efficacy and Safety Study of Rapamycin in Treating Mesangial Proliferative Glomerulonephritis: Analysis of 11 Cases
  2283. Effect of Orthodontics on Mammalian Target of Rapamycin and p70 S6 Kinase in Rabbit Periodontal Tissues [J]
  2284. Rapamycin affects eIF-4E expression in rat myocardial fibroblasts infected by Coxsackievirus B3
  2285. Local applied Rapamycin inhibits intimal hyperplasia in vein graft after CABG
  2286. Human monoclonal antibody CP751871, combined with Rapamycin is effective treatment for childhood sarcoma xenografts
  2287. P1-084: Mammalian target of Rapamycin (mTOR) inhibition by RAD001 in patients (pts) with reccurent non-small cell lung cancer (NSCLC): Use of 18F …
  2288. The application of Rapamycin drug-eluting stents in elderly patients with coronary heart disease [J]
  2289. Progress of Rapamycin in hepatocellular carcinoma
  2290. Predicting Rapamycin response using pathway profile in a population of genetically engineered hHer2 driven breast tumor model
  2291. Effect of conversion from calcineurin inhibitors to Rapamycin on chronic allograft nephropathy
  2292. The mTOR inhibitor Rapamycin demonstrates activity against AML in combination with imatinib mesylate and with 5-azacytidine.
  2293. Effeet of Rapamycin on mTOR and eIF-4E expression in coxsackievirus B3-induced rat myocardial cells
  2294. Combined regimen of Rapamycin and ciclosporin in long-term follow-up in renal allograft recipients
  2295. Rapamycin modulates the maturation of rat bone marrow-derived dendritic cells
  2296. Experimental study on Rapamycin-batroxobin eluting stent and its prevention of coronary restenosis after angiophaty [J]
  2297. Cellular differentiation of Rapamycin, PI3 kinase and TOR kinase inhibitors
  2298. Histone deacetylase inhibition with LBH589 inhibits the Rapamycin insensitive Rictor-mTOR (mTORC2) complex and translation initiation factor eIF4E activation in …
  2299. 9B-6 inhibition of Smooth Muscle Proliferation by Ultrasound-Triggered Release of Rapamycin from Microbubbles
  2300. Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor Rapamycin leads to tumor regression in the RENCA model
  2301. Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) Rapamycin (ABI-009)
  2302. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
  2303. Expression and secretion of VEGF in solid tumor cells is mediated by the mammalian target of Rapamycin (mTOR)
  2304. The design and pharmacokinetics in vivo of Rapamycin-PLGA membrane eluting stent [J]
  2305. Rapamycin combined with donor bone marrow-derived immature dendritic cells induces mouse skin allograft tolerance
  2306. Anti-Proliferative Effect of Rapamycin on Human T Cell Leukemia Cell Line Jurkat by Cell Cycle Arrest and Telomerase inhibition.
  2307. Phase I study of gefitinib and Rapamycin in adult patients with recurrent glioblastoma multiforme (GBM)
  2308. Rapamycin-induced inhibition of HTLV-I LTR activity is rescued by c-Myb
  2309. Effect of RNA interference targeting mammalian target of Rapamycin on the proliferation of vascular smooth muscle cell and the intimal hyperplasia
  2310. Anti-Cancer Effects of Rapamycin on U937 Cell Line.
  2311. Comparison of inflammatory markers and angiographic outcomes after implantation of Rapamycin and paclitaxel-eluting stents
  2312. The roles of mammalian target of Rapamycin (mTOR) and p21 in the autophagy pathway after DNA mismatch repair processing of 6-thioguanine
  2313. Molecular determinants of sensitivity to Rapamycin in NSCLC
  2314. Dasatinib and Rapamycin synergistically inhibit the proliferation of cells expressing oncogenic KIT kinase via global inhibition of AKT-dependent signaling
  2315. Anti-angiogenic activity of Rapamycin in Rapamycin-sensitive and-resistant tumor xenograft models
  2316. Mammalian target of Rapamycin impairs insulin’s ability to promote protein kinase B phosphorylation in isolated rat skeletal muscle
  2317. Dual Effects of Rapamycin on Immuno-suppression and Tumor inhibition
  2318. Rapamycin Inhibits Proliferation of Human Lung Cancer Cell Lines [J]
  2319. Combination therapy with Rapamycin and atorvastatin
  2320. PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic …
  2321. The effects of Rapamycin on body weight and insulin resistance in KKAy mice
  2322. Cell Proliferation in Multiple Rat Tissues In Vivo is Rapamycin Resistant
  2323. The Effect of Rapamycin on Repair of Liver Ischemia/Reperfusion Injury
  2324. Genetically engineered murine tumor models for drug response prediction: population based pathway profiles predict response to Rapamycin in a HER2 driven breast …
  2325. The effect of Rapamycin on PSA kinetics in men without prostate cancer
  2326. Chronic exposure to Rapamycin induces endothelial dysfunction in vitro
  2327. Antiproliferative effects of mTOR inhibition with Rapamycin (RAP) either given as a single agent or in combination with carboplatin and paclitaxel in Human Head and …
  2328. P158-M Expression of c-kit, p-mTOR and p-NFKappaB in angiolymphoid hyperplasia with eosinophilia: Potential for therapy with imitanib mesylate, Rapamycin and …
  2329. Use of Rapamycin to inhibit VEGF for the treatment of primary effusion lymphoma
  2330. Rapamycin and CCI-779 suppress the growth of hepatocellular carcinoma cells
  2331. Combined effects of Rapamycin and bicalutamide in androgen-dependent and-independent prostate cancer cells
  2332. Cholangiocarcinoma cells are selectively susceptible to Rapamycin treatment
  2333. The Mammalian Target of Rapamycin and Multiple Myeloma
  2334. Rapamycin modulates the eNOS versus shear stress relationship
  2335. Effect of Rapamycin on the Proliferation and Apoptosis of Human Leukemia Cell Line HL-60 [J]
  2336. EFFECTS OF Rapamycin COMBINED IMMUNOSUPPRESSION ON RENAL FUNCTION AFTER LIVER TRANSPLANTATION
  2337. Effects of Rapamycin on proliferation, function and cell-cycle of mouse T lymphocytes in vitro
  2338. Mammalian target of Rapamycin and leukemia treatment
  2339. Clinical utility of combined administration of Rapamycin and low dose of cyciosporin a in kidney transplantation recipients
  2340. Rapamycin Induced Transactivation of EGFR: Implications in the Regulation of Cellular Apoptosis
  2341. The mammalian target of Rapamycin (mTOR). Foreword.
  2342. Mammalian Target of Rapamycin Activation Impairs
  2343. Clinical application of Rapamycin-eluting stent in coronary artery disease
  2344. Differential response of mTORC1 and mTORC2 to Rapamycin in Rapamycin-sensitive and-resistant tumor xenograft models
  2345. Effect of IGF‐I and Rapamycin on diaphragm muscle atrogenes with malnutrition
  2346. Functional genomic identification and validation of Rapamycin response genes using high throughput RNA interference
  2347. Rapamycin increases sensitivity to cisplatin in mesothelioma cell lines
  2348. Rapamycin inhibition of cell motility is associated with its suppression of synthesis of GTPases
  2349. Yeast as a Model to Study the Immunosuppressive and Chemotherapeutic Drug Rapamycin
  2350. MANAGEMENT AND LONG-TERM OUTCOMES OF WOUND-HEALING COMPLICATIONS ASSOCIATED WITH Rapamycin: 1108
  2351. Rapamycin Augments Akt Activation in In Vitro and In Vivo Models of Cardiac Hypertrophy
  2352. The study of anti-proliferation effect of Rapamycin on human breast cancer MCF-7 cells under hypoxia [J]
  2353. Rapamycin Reduces CCR5 Density Levels
  2354. Rapamycin inhibits Stearoyl-CoA Desaturase 1 expression in breast cancer cell lines.
  2355. Overexpression analysis reveals novel growth regulators in the target of Rapamycin signaling pathway
  2356. Nutrient Stimulation of eIF4G Phosphorylation, but not PKC is Rapamycin Sensitive in Skeletal Muscle
  2357. Role of Rapamycin on cultured human Tenon′ s capsule fibroblasts
  2358. Statins and Rapamycin act synergistically to enhance vascular endothelial cytoprotection
  2359. Antitumor activity of Rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
  2360. Acute Rapamycin Treatment Does Not Improve In Vivo Insulin Action in Ob/Ob or High Fat Fed Mice
  2361. Administration of Rapamycin in vivo and in vitro prolonged allograft survival associated with iTregs
  2362. THE EFFECT OF LIVER REGENERATION ON Rapamycin PHARMACOKINETICS: 1226
  2363. The Clinical Application of Rapamycin Eluting Stent in Elderly Patients with Coronary Heart Disease.
  2364. Rapamycin induced “stunning” on FDG PET/CT in pancreatic cancer
  2365. Protective Effect of Pretreated Rapamycin on Renal Ischemia-Reperfusion Injury in Rats
  2366. Rapamycin impairs skin γδ T cell function resulting in autophagy
  2367. Rapamycin aggravates the renal damage in rats with protein overload nephropathy and the protection of losartan
  2368. Observation in Safety and Short-term Efficacy of Domestic-made Rapamycin-eluting Stent
  2369. Rapamycin Treatment Exacerbates Nutrition-Induced Diabetes in Psammomys obesus.
  2370. Rapamycin‐sensitive inhibition of Id1 and p21 in C2C12 myoblasts
  2371. Effects of Rapamycin on the Liver Regeneration after Partial Hepatectomy in Rats
  2372. Statin therapy, alone or in combination with Rapamycin, does not reverse Monocotaline Pulmonary Arterial Hypertension
  2373. Comparative study on clinical outcomes of two kinds of Chinese Rapamycin-eluting stent in patients with coronary artery disease
  2374. Rapamycin rescues lactacystin-induced dopaminergic neuron injury in vivo
  2375. Modulation of cell cycle progression by combined Rapamycin-octreotide treatment in pituitary tumor cells
  2376. Local application of Rapamycin inhibits neointimal hyperplasia in experimental vein grafts
  2377. Histologic Changes After Intravitreal Injection of Rapamycin and Bevacizumab in a Porcine Model
  2378. Bevacizumab and Rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
  2379. Study on the activation of mammalian target of Rapamycin in two endometrial carcinoma cells
  2380. Study on the changes of mammalian target of Rapamycin with aging in rat kidneys
  2381. 290: Rapamycin-generated Th2 cell therapy of established acute murine GVHD requires Th2 cell secretion of both IL-4 and IL-10
  2382. Rapamycin CAN AMELIORATE CAN IN RAT ALLOGRAFTS BY AFFECTING RHO/ROCK SIGNAL PATHWAY: 2147
  2383. Clinical study on major adverse cardiac events (MACE) rate in patients implanted with Rapamycin-eluting stents [J]
  2384. Preclinical evaluation of sorafenib in combination with Rapamycin for the treatment of acute myeloid leukemia (AML)
  2385. The Development and Molecular Expression in Mammalian Cells of an HA-Tagged Plasmid Encoding for the Target Of Rapamycin (mTOR)
  2386. The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
  2387. INFLUENCE OF Rapamycin ON RENAL TUBULAR FUNCTION IN RATS WITH OR WITHOUT CYCLOSPORINE TREATMENT: 1938
  2388. Drug eluting stents: long term results in clinical practice. Comparison between Rapamycin and paclitaxel eluting stents
  2389. Nucleophosmin Mediates Mammalian Target of Rapamycin
  2390. Rapamycin inhibits activation of Stat3 in kidney tissue of IgA nephropathy rats
  2391. Leukemia Induced by Altered TRK-Signaling Is Sensitive to Rapamycin Treatment in a Preclinical Model
  2392. Mechanisms of urokinase mediated activation of the mammalian target of Rapamycin (mTOR)
  2393. UROKINASE‐INDUCED SMOOTH MUSCLE CELL MIGRATION INVOLVES THE MAMMALIAN TARGET OF Rapamycin
  2394. Anti-inflammatory properties of Rapamycin on leukocyte-endothelial cell interactions following profound hypoperfusion
  2395. Contrasting effects of Cyclosporine and Rapamycin in de novo generation of alloantigen-specific regulatory T cells (88.45)
  2396. Combination treatment of Rapamycin and low dose irradiation causes cell death in human cancer cells cultured as 3-D spheroids
  2397. Rapamycin effects on mTOR signaling in the MCF10AT series of human breast epithelial cells: a model for proliferative breast disease and carcinoma
  2398. Anti-inflammatory drugs, sirolimus, and inhibition of target of Rapamycin and its effect on vascular diseases
  2399. Effect of Rapamycin in inducing naïve murine effector T cell convert to regulatory T cell
  2400. A high throughput assay for mammalian target of Rapamycin (mTOR) kinase activity
  2401. Rapamycin INDUCES AUTOPHAGY IN ISLETS: RELEVANCE FOR ISLETS TRANSPLANTATION: 556
  2402. Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients
  2403. The Immunosuppressive drugs Rapamycin and FK506 decrease vasodilation by increasing PKCbetai‐mediated phosphorylation of eNOS Thr495
  2404. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A driven angiogenesis in part through the blockade of S6Kinase
  2405. Combined Rapamycin-octreotide treatment exerts its superior antiproliferative action by dramatically increasing p27/Kip1 expression
  2406. Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of Rapamycin (mTOR)
  2407. ST2L upregulation promotes maturation resistance in Rapamycin‐conditioned dendritic cells
  2408. P286: Mechanisms of urokinase mediated activation of the mammalian target of Rapamycin (mTOR)
  2409. Akt phosphorylates and negatively regulates hnRNPA1-mediated control of cyclin D1 and c-myc translation in response to Rapamycin
  2410. Intravitreal Rapamycin and Bevacizumab Inhibits VEGF Expression in a Swine Model of Neovascularization
  2411. Acute activation of the mammalian target of Rapamycin complex 1 does not impair in vivo insulin action in mice
  2412. Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis
  2413. Cell cycle proteins and hTERT telomerase mRNA expression are independent targets of Rapamycin in ovarian cancer cell lines
  2414. Re-evaluating the roles of proposed modulators of mammalian target of Rapamycin complex 1 (mTORC1) signaling
  2415. P39. Rapamycin and the downstream target of mTOR, ribosomal protein L29 (RPL29), regulate prostate cancer cell growth and bone metastatic potential
  2416. Thymidine phosphorylase-related migratory effect of cancer cell is abrogated by m-TOR inhibitor Rapamycin
  2417. Curcumin inhibition of the mammalian target of Rapamycin signaling pathway
  2418. Synergistic combinations of a novel PI3 Kinase inhibitor with Erlotinib and Rapamycin and the associated effects on downstream signalling
  2419. Evaluation of the mTOT inhibitor, Rapamycin in dogs with spontaneously derived osteosarcoma: A focus on preclinical pharmacokinetics and pharmacodynamics
  2420. Activation of Mammalian Target of Rapamycin (mTOR) in Esophageal Squamous Cell Carcinona Cell Line [J]
  2421. The mammalian target of Rapamycin (mTOR) signaling in thymic lymphomagenesis in Atm-/-mice
  2422. Rapamycin-induced remission of Kaposi’s sarcoma is not associated with expansion of cytotoxic T-lymphocyte subsets
  2423. The Mammalian Target of Rapamycin Plays a Critical Role in the Development of Cardiac Hypertrophy in Spontaneously Hypertensive Rats
  2424. Inhibitory effect of Rapamycin and dexamethasone on production of IL-17 and IFN-c in Vogt–Koyanagi–Harada patients
  2425. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: Identification of new targets by gene microarray profiling and miRNA
  2426. Divergent Roles of PI3K and Akt in Rapamycin-induced Cardioprotection against Ischemia-Reperfusion Injury
  2427. The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects.
  2428. Expansion of Functional Polyclonal Human T-regulatory Cell Lines Using Artificial Antigen Presenting Cells and Rapamycin.(B159)
  2429. Sepsis associated platelet dysfunction & Rapamycin sensitive pathway of lipopolysaccharide signaling
  2430. COMPARISON OF Rapamycin VS. FK506 ON EXPRESSION OF CYTOPROTECTIVE GENES IN THE RAT-KIDNEY ALLOGRAFTS UNDERGOING CHRONIC …
  2431. Synergistic effect of Rapamycin and Casodex in inhibition of cell growth and survival as well as AR transcriptional activity in androgen dependent and independent …
  2432. Clenbuterol antagonizes Rapamycin-induced atrophy in rat soleus muscle
  2433. Ocular Toxicity and Distribution of Intravitreal and Subconjunctival Rapamycin in Horses
  2434. Rapamycin Withdrawal versus Delayed Initiation: Thrombosis vs. Suppression of Neointimal Hyperplasia after Vascular Injury
  2435. Rapamycin prevents cadmium-induced neuronal apoptosis by suppression of MAPK and mTOR pathways
  2436. Changes in gene expression profile after Rapamycin treatment of ErbB2-positive/ErbB2-negative breast carcinoma in organ culture
  2437. Dual inhibition of the Akt pathway by Rapamycin and Perifosine induces synergistic anti-tumor activity in multiple myeloma
  2438. Clinical Benefits of Rapamycin-Eluting Stent Made in China Appliance and Investigation in Patients with Acute Coronary Syndromes
  2439. Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells
  2440. Effective inhibition of tumor growth in patient-derived xenografts of hepatocellular carcinoma by Rapamycin and bevacizumab
  2441. Protein kinase C (μ, θ, ϵ)-dependent Bad phosphorylation is an important signaling pathway in IGF-I rescue of sarcoma cells from Rapamycin-induced apoptosis
  2442. Enzastaurin inhibits growth of head and neck cancer cells and xenografts and synergizes with Rapamycin
  2443. Binding of novel Rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities
  2444. Combination of somatostatin analogues with Rapamycin analogues as a potential pharmaceutical treatment for non-functioning pituitary adenomas
  2445. Mammalian Target of Rapamycin (mTOR) is Essential for Murine Heart Development
  2446. A spontaneous pancreatic tumor model for monitoring pancreatic lesion and response to Rapamycin treatment through bioluminescence imaging
  2447. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: Identification of new targets using Gene Microarray profiling and MiRNA
  2448. Rapamycin regulates synthesis of transforming growth factor-beta1 and extracellular matrix in arterial neointimal smooth muscle cells
  2449. Utilization of Meso Scale Discovery ELISA technology to quantitate the in vivo pharmacodynamic effects of Rapamycin treatment on the AKT pathway
  2450. Rapamycin blocks leucine‐induced protein synthesis by suppressing mTORC1 activation in skeletal muscle of neonatal pigs
  2451. Rapamycin IS LESS FIBROGENIC THAN FK506 IN RAT MODEL OF CHRONIC ALLOGRAFT NEPHROPATHY: 2144
  2452. Identification and characterization of novel positive regulators of the Target of Rapamycin (TOR) pathway in Drosophila melanogaster
  2453. The Role of Mammalian Target of Rapamycin in the Regulation of Amino Acid Transporters in the Human Placenta
  2454. Rapamycin, mTOR inhibitor, a potent inhibitor for the cell growth and proliferation by p21-dependent mitotic arrest in human gastric cancers
  2455. Role of mechanistic Target of Rapamycin (mTOR) signaling in the crustacean molting gland
  2456. … Scale Expansion of Human Dendritic Cells with Regulatory Function from Peripheral Blood Monocytes Employing Leukapheresis and Rapamycin for Clinical Trials.
  2457. Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2 …
  2458. Rapamycin prevents tobacco-carcinogen induced lung tumorigenesis and selectively reduces lung-associated Foxp3 positive cells
  2459. Clinical observation of Rapamycin Eluting Stent in acute ST-segment elevated myocardial infarction between domestic and imported product
  2460. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: identification of new targets using l Gene microarray profiling and proteomics
  2461. EARLY IMMUNOSUPPRESSION WEANING AFTER CADAVER LIVER TRANSPLANTATION USING ATG INDUCTION AND Rapamycin: 358
  2462. inhibition effect of Rapamycin on acute graft-versus-host disease after allogeneic bone marrow transplantation in a murine model
  2463. Dual inhibition of phosphoinositide 3-kinase and mammalian target of Rapamycin as a novel therapeutic approach in human ovarian carcinoma
  2464. A small molecule inhibitor against kinase domain of mammalian target of Rapamycin (mTOR) causes autophagic cell death in glioblastoma
  2465. Effects of Imatinib and Rapamycin on the mTOR/S6 Signal Transduction Pathway in CD33+ Cell of CML
  2466. mTOR inhibitors Rapamycin and RAD001 (Everolimus) induce antiproliferative effects in GH3 cell line and human pituitary adenomas
  2467. PNEUMONITIS FROM INHIBITORS OF THE MAMMALIAN TARGET OF Rapamycin (mTOR) IN PATIENTS WITH METASTATIC CANCER
  2468. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: Characterization of induced apoptosis and inhibition of mTOR and AKT/MAP kinase pathways
  2469. Blockage of mTOR signaling pathway by Rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains
  2470. The Yaa locus Confers Apoptosis, NF-κB and Rapamycin Signaling Resistance Through Multiple Receptors in C57BL/6J Mice (129.12)
  2471. Domestic versus foreign Rapamycin-eluting stents for emergency percutaneous coronary intervention in elder patients with acute myocardial infarction: Randomized …
  2472. Tumor suppressor gene ARHI (DIRAS3) is required for spontaneous and Rapamycin-induced autophagy in normal and ovarian cancer cells
  2473. Complete Responses in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Using the mTOR Inhibitor Sirolimus (Rapamycin)
  2474. Signaling Downstream of Mammalian Target of Rapamycin Complex 1 (mTORC1) is Derepressed Following Treatment with L‐Asparaginase in the Liver of GCN2 …
  2475. MESENCHYMAL STEM CELLS ATTENUATE ACUTE REJECTION AND SYNERGIZE WITH Rapamycin LEADING TO CARDIAC ALLOGRAFT TOLERANCE: 382
  2476. inhibition of the mammalian target of Rapamycin (mTOR) for the chemoprevention of tobacco-carcinogen induced lung tumorigenesis
  2477. mTORC1 inhibition with Rapamycin or LY294002 alone but not in combination leads to AKT phosphorylation via mTORC2 in melanoma cells
  2478. Corrigendum to “Low-dose oral Rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis”[J …
  2479. FK506 VERSUS Rapamycin HAVE DIFFERENT EFFECTS ON EXPRESSION OF ANGIOPOIETINS1, 2 AND TIE2 IN RAT RENAL ALLOGRAFT WITH CAN: 1925
  2480. Combination Therapy Utilizing Murine Anti-Thymocyte Globulin (ATG) and Rapamycin for the Reversal of Overt Type 1 Diabetes in NOD Mice.
  2481. Rapamycin REDUCES VASCULAR INJURY BUT EXACERBATES PROTEINURIA IN ASSOCIATION WITH inhibition OF VEGF AND VEGF-R IN CHRONIC …
  2482. … Inhibitor Causes Growth inhibition, Cell Cycle Arrest, Apoptosis and Autophagic Cell Death in Mantle Cell Lymphoma Cell Lines: A Distinct Profile from Rapamycin.
  2483. Rapamycin PREFERENTIALLY BLOCKS THE EXPANSION OF POTENTIALLY TOLEROGENIC PLASMACYTOID DENDRITIC CELLS IN VIVO: 2217
  2484. Rapamycin DECREASES CHOLESTEROL EFFLUX AND ABCA1 PROTEIN EXPRESSION WITHIN THP-1 MACROPHAGES: 1931
  2485. TARGETED DELIVERY OF Rapamycin TO DENDRITIC CELLS USING BIODEGRADABLE MICROPARTICLES IS HIGHLY EFFECTIVE IN SUPPRESSING THEIR …
  2486. Mating Stimulates Protein Phosphorylation and Synthesis Via Rapamycin-and Wortmannin-Sensitive Pathways in the Male Accessory Glands of D. melanogaster
  2487. Dietary induced insulin resistance is independent of mammalian target of Rapamycin complex 1 (mTORC1) activity in skeletal muscle of mice
  2488. 191: Rapamycin inhibits endothelial cell recovery after hypoxic injury
  2489. Enhancement of Mammalian Target of Rapamycin Complex-2 (TORC2) Kinase Activity by Fructose-2, 6-Bisphosphate.
  2490. Effect of Rapamycin/Curcumin Co-Loaded Poly (Lactide-Co-Glycolide) Films on Blood Compatibility and Vascular Smooth Muscle Cell Proliferation
  2491. COMBINE TGF-BETA/FC AND Rapamycin FOR REGULATORY T CELLS GENERATION AND ALLOGRAFT TOLERANCE INDUCTION.: 728
  2492. The Wnt Agonist, SKL2020 Inhibits Neointimal Hyperplasia but Facilitates Re-Endothelialization, When Treated with Rapamycin in Porcine Coronary Artery Stent …
  2493. IL-1β-DRIVEN ST2 EXPRESSION PROMOTES MATURATION RESISTANCE IN Rapamycin-CONDITIONED DENDRITIC CELLS: 643
  2494. PRO-TOLEROGENIC PROPERTIES OF Rapamycin THAT FAVOR INDEFINITE HEART ALLOGRAFT SURVIVAL MEDIATED BY REGULATORY T CELLS.: 27
  2495. Mechanism of luteolin-induced apoptosis through suppressing p21 (WAF1/CIP1) expression with Rapamycin in HER2-overexpressing cancer cells
  2496. … ALLOGRAFT SURVIVAL IN UNMANIPULATED HOSTS BY POST-TRANSPLANT INFUSION OF DONOR-SPECIFIC REGULATORY T CELLS AND Rapamycin: 655
  2497. Role of the mammalian Target of Rapamycin (mTOR) Complex 1 signaling in beta‐adrenergic‐stimulated triacylglycerol (TAG) lipolysis and free fatty acid (FFA) …
  2498. A phase I study of the mTOR inhibitor sirolimus (Rapamycin) in combination with nanoparticle albumin-bound paclitaxel (ABI-007, abraxane) in advanced solid cancers
  2499. IMPACT OF IMMUNOSUPPRESSION ON UV-INDUCED SKIN-TUMORS IN MICE: Rapamycin IMPAIRS TUMOR OUTGROWTH AND SHIFTS THE MUTATION …
  2500. Dexamethasone represses signaling through mammalian target of Rapamycin (mTOR) in muscle cells by enhancing expression of REDD1
  2501. inhibition of mammalian target of Rapamycin (mTOR) induces phosphatidylinositol 3 kinase-dependent and Mnk-mediated eIF4E phosphorylation
  2502. Rapamycin, mTOR Inhibitor, a Potent Cell Growth and Proliferation Inhibitor by p21-Dependent Mitotic Arrest in Human Gastric Cancers
  2503. Rapamycin PROMOTES THE ENRICHMENT OF CD4+ CD25HIFOXP3+ T REGULATORY CELLS FROM NAIVE CD4+ T CELLS OF BABOON THAT SUPPRESS …
  2504. … with drug eluting stents but with significant cost saving: long term follow up results from the randomized, controlled ORAR III (Oral Rapamycin in Argentina) Study
  2505. PD2-4 Survival Advantage of Temsirolimus Validates a Role for Mammalian Target of Rapamycin (mTOR) in the Biology of Advanced Renal Cell Carcinoma
  2506. P3-026: A novel Bayesian dose-escalation Phase Ib study design investigating combination of the mammalian target of Rapamycin (mTOR) inhibitor RAD001 with …
  2507. Cell cycle arrest and suppression of the Akt/mammalian target of Rapamycin signaling mediated by yuanhuadine, a daphnane diterpenoid, isolated from Daphne …
  2508. … Smooth Muscle Cell Proliferation and Intimal Expansion by Phosphatidylinositol 3-Kinase–Dependent Mammalian Target of Rapamycin Raptor Complex 1 …
  2509. 155. Tumor Necrosis In Vivo Caused by a Novel Combination of Sorafenib and Rapamycin: Targeting the RAS and Motor Pathways ION Hepatocellular Carcinoma
  2510. 342: Rapamycin Prevents GVHD in Mouse Model through Novel Mechanism: Increase in Regulatory T cells
  2511. … downregulates acetyl-CoA carboxylase alpha and fatty acid synthase by activating AMP-activated protein kinase and suppressing the mammalian target of Rapamycin …
  2512. Glycogen Synthase Kinase-3 (GSK-3) Signaling to Mammalian Target of Rapamycin (mTOR) Regulates DNA Synthesis and Cell Cycle Progression in Rodent and …
  2513. THROMBOSPONDIN-1 (TSP-1) MEDIATES THE ANTI ANGIOGENIC AND IMMUNOMODULATORY EFFECTS OF Rapamycin ON PANCREATIC ISLET …
  2514. 53: Rapamycin Partially Overcomes the in vitro Protective Effect of M2–10B4 Mesenchymal Stromal Cells (MSC) to Murine mCGPR/+ Acute Promyelocytic Leukemic …
  2515. … CXC Chemokine Receptor 4 (CXCR4) by Hypoxia and the Phosphatidylinositol 3‐Kinase (PI‐3‐K)/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
  2516. 234: Rapamycin generated donor Th2/Tc2 cells prevent graft rejection by inhibition of alloreactivity and not by deletion of alloreactive T cells
  2517. FoxP3 Mediated Induction of Pim 2 Allows T Regulatory Cells to Preferentially Expand in Rapamycin
  2518. The Novel Glycolysis Inhibitor, 3-BrOP, Has Broad Activity Against Acute Lymphoblastic Leukemias and Potentiates Methotrexate and Rapamycin.
  2519. … -selective oncolytic adenovirus OBP-405 induces autophagic cell death and enhances the antitumor effect of temozolomide and Rapamycin on glioblastoma cells in …
  2520. … regulatory (CD4+ CD25+ CD127LowFOXP3+) cells to high purity by inhibiting expansion of CD4+ CD25+ CD127HighFOXP3-conventional T cells with Rapamycin
  2521. Late stage efficacy and regulated gene expression profiles by 5-aza-dC, valproic acid, suberoylanilide hydroxamic acid, and Rapamycin in mouse lung tumorigenesis
  2522. 720: inhibition of Proliferation by Rapamycin in RAT Bladder Smooth Muscle Cells
  2523. 307: Initial selection of high affinity CD25+ cells increases the purity of CD4+ CD25+ Foxp3+ T regulatory cells expanded in medium containing Rapamycin
  2524. 518: Medium term renal function of pediatric heart transplant patients on reduced calcineurin inhibitor and Rapamycin
  2525. Automated quantitative analysis of AKT/mTOR pathway in patients treated with nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) and (sirolimus) Rapamycin
  2526. 51: Rapamycin and its influence on arterial vascular function after short-term incubation
  2527. 336: Relative Contribution of CD127 Negative Selection, Rapamycin, and TGF-β to the Generation of Human Regulatory T Cells that Inhibit Alloreactivity via Dendritic …
  2528. An ATP-competitive mammalian target of Rapamycin inhibitor reveals Rapamycin-resistant functions of mTORC1
  2529. Rapamycin decelerates cellular senescence
  2530. Structure of the human mTOR complex I and its implications for Rapamycin inhibition
  2531. Delayed correlation of mRNA and protein expression in Rapamycin-treated cells and a role for Ggc1 in cellular sensitivity to Rapamycin
  2532. Rapamycin inhibits mTORC1, but not completely
  2533. Mammalian target of Rapamycin: discovery of Rapamycin reveals a signaling pathway important for normal and cancer cell growth
  2534. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1
  2535. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
  2536. Mechanisms of life span extension by Rapamycin in the fruit fly Drosophila melanogaster
  2537. Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson’s Disease
  2538. Targeting mTOR with Rapamycin: one dose does not fit all
  2539. The role of the mammalian target of Rapamycin (mTOR) in renal disease
  2540. Mammalian target of Rapamycin (mTOR): conducting the cellular signaling symphony
  2541. Potential use of Rapamycin in HIV infection
  2542. Targeting mTOR globally in cancer: thinking beyond Rapamycin
  2543. The complexes of mammalian target of Rapamycin
  2544. The mammalian target of Rapamycin: linking T cell differentiation, function, and metabolism
  2545. Not all substrates are treated equally: Implications for mTOR, Rapamycin-resistance, and cancer therapy
  2546. Rapamycin-induced phosphaturia
  2547. The mammalian target of Rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy
  2548. Mammalian target of Rapamycin complex 1: signalling inputs, substrates and feedback mechanisms
  2549. Rapamycin administration in humans blocks the contraction‐induced increase in skeletal muscle protein synthesis
  2550. Rapamycin extends maximal lifespan in cancer-prone mice
  2551. Active-site inhibitors of mTOR target Rapamycin-resistant outputs of mTORC1 and mTORC2
  2552. Nutrient-dependent regulation of autophagy through the target of Rapamycin pathway
  2553. Biosynthesis of Rapamycin and its regulation: past achievements and recent progress
  2554. inhibition of mTOR by Rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer’s disease
  2555. SIRT1 negatively regulates the mammalian target of Rapamycin
  2556. Targeting mammalian target of Rapamycin by Rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model
  2557. Characterization of the Rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis
  2558. Rapamycin and quasi-programmed aging: Four years later
  2559. A versatile role of mammalian target of Rapamycin in human dendritic cell function and differentiation
  2560. Autophagy is required for extension of yeast chronological life span by Rapamycin
  2561. Rapid inactivation of proteins by Rapamycin-induced rerouting to mitochondria
  2562. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of Rapamycin
  2563. Ku-0063794 is a specific inhibitor of the mammalian target of Rapamycin (mTOR)
  2564. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss
  2565. GOLPH3 modulates mTOR signalling and Rapamycin sensitivity in cancer
  2566. Molecular interplay between mammalian target of Rapamycin (mTOR), amyloid-β, and Tau: effects on cognitive impairments
  2567. A Rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states
  2568. Resveratrol and Rapamycin: are they anti‐aging drugs?
  2569. Metformin and Rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells
  2570. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of Rapamycin
  2571. Rapamycin protects against rotenone-induced apoptosis through autophagy induction
  2572. Protein synthesis is resistant to Rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
  2573. Rapamycin reduces seizure frequency in tuberous sclerosis complex
  2574. Pharmacological inhibition of the mammalian target of Rapamycin pathway suppresses acquired epilepsy
  2575. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of Rapamycin in cancer patients
  2576. TORC-specific phosphorylation of mammalian target of Rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2
  2577. Total synthesis of Rapamycin
  2578. Targeted inhibition of mammalian target of Rapamycin signaling inhibits tumorigenesis of colorectal cancer
  2579. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of Rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
  2580. Tti1 and Tel2 are critical factors in mammalian target of Rapamycin complex assembly
  2581. The mTOR pathway is highly activated in diabetic nephropathy and Rapamycin has a strong therapeutic potential
  2582. Role for mammalian target of Rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders
  2583. Dual inhibition of Akt/mammalian target of Rapamycin pathway by nanoparticle albumin-bound–Rapamycin and perifosine induces antitumor activity in multiple …
  2584. Long-term Rapamycin therapy in the Han: SPRD rat model of polycystic kidney disease (PKD)
  2585. Delivery of Rapamycin to dendritic cells using degradable microparticles
  2586. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and Rapamycin in vivo
  2587. CDC25B mediates Rapamycin-induced oncogenic responses in cancer cells
  2588. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with Rapamycin
  2589. Curcumin disrupts the Mammalian target of Rapamycin-raptor complex
  2590. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and Rapamycin combination therapy
  2591. Chronic Rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose …
  2592. Recent advances in the chemistry, biosynthesis and pharmacology of Rapamycin analogs
  2593. inhibition of target of Rapamycin signaling and stress activate autophagy in Chlamydomonas reinhardtii
  2594. Akt signals through the mammalian target of Rapamycin pathway to regulate CNS myelination
  2595. Beneficial effects of Mammalian target of Rapamycin inhibition on left ventricular remodeling after myocardial infarction
  2596. Mammalian target of Rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways
  2597. Activation of the mammalian target of Rapamycin (mTOR) is essential for oligodendrocyte differentiation
  2598. The Rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates
  2599. Sorafenib and Rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
  2600. Mammalian target of Rapamycin: hitting the bull’s-eye for neurological disorders
  2601. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies
  2602. Mammalian target of Rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies
  2603. inhibition of the mammalian target of Rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
  2604. A pharmacodynamic study of Rapamycin in men with intermediate-to high-risk localized prostate cancer
  2605. Bone growth during Rapamycin therapy in young rats
  2606. Regulation of placental amino acid transporter activity by mammalian target of Rapamycin
  2607. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity
  2608. Mammalian target of Rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis
  2609. Topical Rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis
  2610. New inhibitors of the mammalian target of Rapamycin signaling pathway for cancer
  2611. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses
  2612. Mammalian target of Rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
  2613. Integration of general amino acid control and target of Rapamycin (TOR) regulatory pathways in nitrogen assimilation in yeast
  2614. Specific roles of Target of Rapamycin in the control of stem cells and their progeny in the Drosophila ovary
  2615. Down-regulation of Akt/mammalian target of Rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle
  2616. Infusion of mesenchymal stem cells and Rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance
  2617. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia
  2618. Rapamycin inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164–Driven Angiogenesis, in Part by Blocking S6Kinase
  2619. Rapamycin Protects Against High Fat Diet–Induced Obesity in C57BL/6J Mice
  2620. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer
  2621. Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of Rapamycin in neonatal hypoxia-ischemia
  2622. Overexpression of phosphorylated mammalian target of Rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer
  2623. Mammalian target of Rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves
  2624. Rapamycin promotes β-amyloid production via ADAM-10 inhibition
  2625. Differential responses of human regulatory T cells (Treg) and effector T cells to Rapamycin
  2626. Monitoring mammalian target of Rapamycin (mTOR) activity
  2627. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with Rapamycin in renal cell carcinoma
  2628. Mammalian target of Rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats
  2629. Treatment with Rapamycin prevents fibrosis in tight‐skin and bleomycin‐induced mouse models of systemic sclerosis
  2630. Mammalian target of Rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage
  2631. Regulation of RNA polymerase III transcription involves SCH9-dependent and SCH9-independent branches of the target of Rapamycin (TOR) pathway
  2632. Mammalian target of Rapamycin controls dendritic cell development downstream of Flt3 ligand signaling
  2633. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of Rapamycin pathway
  2634. Long‐term administration of Rapamycin reduces adiposity, but impairs glucose tolerance in high‐fat diet‐fed KK/HlJ mice
  2635. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways
  2636. Regulation of insulin-like growth factor–mammalian target of Rapamycin signaling by microRNA in childhood adrenocortical tumors
  2637. Rapamycin prevents transforming growth factor-α–induced pulmonary fibrosis
  2638. Participation of mammalian target of Rapamycin complex 1 in Toll-like receptor 2–and 4–induced neutrophil activation and acute lung injury
  2639. Use of Rapamycin in the induction of tolerogenic dendritic cells
  2640. Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single‐blind pilot study
  2641. Insights into the domain and repeat architecture of target of Rapamycin
  2642. A novel mouse model of inflammatory bowel disease links mammalian target of Rapamycin-dependent hyperproliferation of colonic epithelium to inflammation …
  2643. Nutrient availability and lactogenic hormones regulate mammary protein synthesis through the mammalian target of Rapamycin signaling pathway
  2644. The mammalian target of Rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system
  2645. … irinotecan and Rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of Rapamycin …
  2646. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability
  2647. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication
  2648. Mammalian target of Rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade
  2649. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of Rapamycin pathway
  2650. Critical roles for mTORC2-and Rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
  2651. inhibition of the mammalian target of Rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy
  2652. Oral Rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels
  2653. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with Rapamycin
  2654. inhibition of histone deacetylase overcomes Rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
  2655. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway
  2656. Synergistic effect of Rapamycin and cisplatin in endometrial cancer cells
  2657. Activation of mammalian target of Rapamycin controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation
  2658. Mammalian target of Rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice
  2659. Uremic cardiac hypertrophy is reversed by Rapamycin but not by lowering of blood pressure
  2660. Testosterone induces cardiomyocyte hypertrophy through mammalian target of Rapamycin complex 1 pathway
  2661. Rapamycin in islet transplantation: friend or foe?
  2662. Mammalian target of Rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR
  2663. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs
  2664. Mammalian target of Rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis
  2665. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
  2666. Distinct roles for mammalian target of Rapamycin complexes in the fibroblast response to transforming growth factor-β
  2667. Expression of an activated mammalian target of Rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
  2668. The somatostatin analogue octreotide confers sensitivity to Rapamycin treatment on pituitary tumor cells
  2669. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways
  2670. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
  2671. ATP-competitive inhibitors of the mammalian target of Rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines
  2672. Gastric mammalian target of Rapamycin signaling regulates ghrelin production and food intake
  2673. The potential benefits of Rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation
  2674. Target of Rapamycin signaling in leukemia and lymphoma
  2675. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation
  2676. Targeted inhibition of mammalian target of Rapamycin for the treatment of advanced renal cell carcinoma
  2677. Target of Rapamycin (TOR) mediates the transduction of nutritional signals into juvenile hormone production
  2678. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice
  2679. Phase II trial of the oral mammalian target of Rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia
  2680. Mammalian target of Rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma
  2681. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of Rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple …
  2682. Mammalian target of Rapamycin: biological function and target for novel anticancer agents
  2683. Mammalian target of Rapamycin signaling activation patterns in neuroendocrine tumors of the lung
  2684. inhibition of mammalian target of Rapamycin as a therapeutic strategy in the management of bladder cancer
  2685. Randomised trial of three Rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results
  2686. inhibition of mammalian target of Rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells
  2687. Perifosine inhibits mammalian target of Rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy
  2688. The effect of Rapamycin on bone growth in rabbits
  2689. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs
  2690. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with Rapamycin or cyclophosphamide
  2691. Rapamycin induces transactivation of the EGFR and increases cell survival
  2692. Mammalian target of Rapamycin inhibitors Rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
  2693. Adiponectin modulates C-jun N-terminal kinase and mammalian target of Rapamycin and inhibits hepatocellular carcinoma
  2694. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates Rapamycin sensitivity in colorectal cancer
  2695. High entrapment efficiency of chitosan/polylactic acid/tripolyphotspate nanosized microcapsules for Rapamycin by an emulsion-evaporation approach
  2696. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of Rapamycin inhibition
  2697. Chemical genetics screen for enhancers of Rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase
  2698. Immune regulation by Rapamycin: moving beyond T cells
  2699. First report on a series of HIV patients undergoing Rapamycin monotherapy after liver transplantation
  2700. … leucine content of a complete meal directs peak activation but not duration of skeletal muscle protein synthesis and mammalian target of Rapamycin signaling in rats
  2701. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model
  2702. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer
  2703. Mammalian target of Rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock
  2704. The tuberous sclerosis proteins regulate formation of the primary cilium via a Rapamycin-insensitive and polycystin 1-independent pathway
  2705. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to Rapamycin treatment in vitro
  2706. Different effects of FK506, Rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets
  2707. Downregulation of Akt/mammalian target of Rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia
  2708. Dual targeting of AKT and mammalian target of Rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor
  2709. Mammalian target of Rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation
  2710. Effect of Rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
  2711. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of Rapamycin signaling pathway
  2712. … skeletal muscle protein synthesis via an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of Rapamycin complex 1 signaling
  2713. Signaling events downstream of mammalian target of Rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor …
  2714. A phase I study of the mammalian target of Rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
  2715. Morpholine derivatives greatly enhance the selectivity of mammalian target of Rapamycin (mTOR) inhibitors
  2716. Intravesical delivery of Rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer
  2717. Complex regulation of mammalian target of Rapamycin complex 1 in the basomedial hypothalamus by leptin and nutritional status
  2718. Mammalian target of Rapamycin regulates vascular endothelial growth factor–dependent liver cyst growth in polycystin‐2–defective mice
  2719. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis
  2720. Generation of high-yield Rapamycin-producing strains through protoplasts-related techniques
  2721. An expeditious route to fluorinated Rapamycin analogues by utilising mutasynthesis
  2722. Mechanisms involved in the enhancement of mammalian target of Rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice
  2723. Mammalian target of Rapamycin and diabetes: what does the current evidence tell us?
  2724. Mammalian target of Rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients
  2725. Treatment of refractory oral erosive lichen planus with topical Rapamycin: 7 cases
  2726. Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of Rapamycin–mediated cyclin D1 expression and Rb phosphorylation
  2727. Tubers and tumors: Rapamycin therapy for benign and malignant tumors
  2728. The pre-clinical assessment of Rapamycin-eluting, durable polymer-free stent coating concepts
  2729. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus Rapamycin but not atorvastatin or doxycycline in tuberous …
  2730. EGFR signaling through an Akt-SREBP-1–dependent, Rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy
  2731. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents
  2732. Expansion of the target of Rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity
  2733. Long‐term blood vessel removal with combined laser and topical Rapamycin antiangiogenic therapy: Implications for effective port wine stain treatment
  2734. R1507, a fully human monoclonal antibody targeting IGF‐1R, is effective alone and in combination with Rapamycin in inhibiting growth of osteosarcoma xenografts
  2735. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of Rapamycin …
  2736. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model
  2737. Mammalian target of Rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in …
  2738. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1
  2739. Activated mammalian target of Rapamycin is a potential therapeutic target in gastric cancer
  2740. Mutual regulation of hypoxia-inducible factor and mammalian target of Rapamycin as a function of oxygen availability
  2741. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients
  2742. Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver
  2743. inhibition of human T-cell proliferation by mammalian target of Rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5)
  2744. Mammalian target of Rapamycin is activated in association with myometrial proliferation during pregnancy
  2745. Expression status and prognostic significance of mammalian target of Rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy
  2746. A phase 2 study of the oral mammalian target of Rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
  2747. Mammalian target of Rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes
  2748. Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of Rapamycin
  2749. Rapamycin for refractory acute graft-versus-host disease
  2750. Life span extension by resveratrol, Rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging
  2751. Nucleus accumbens core mammalian target of Rapamycin signaling pathway is critical for cue-induced reinstatement of cocaine seeking in rats
  2752. New approach for local delivery of Rapamycin by bioadhesive PLGA-carbopol nanoparticles
  2753. Activation of the mammalian target of Rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics
  2754. … triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c‐Jun N‐terminal kinase, Akt and mammalian target of Rapamycin …
  2755. Rapamycin induces autophagic flux in neurons
  2756. Development and characterization of liposomal formulations for Rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells
  2757. A pilot trial of the mTOR (mammalian target of Rapamycin) inhibitor RAD001 in patients with advanced B-CLL
  2758. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of Rapamycin and epidermal growth factor …
  2759. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of Rapamycin (mTOR): Optimization of the 1-substituent
  2760. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with Rapamycin-eluting stents
  2761. The target of Rapamycin complex 2 controls dendritic tiling of Drosophila sensory neurons through the Tricornered kinase signalling pathway
  2762. Mammalian target of Rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy
  2763. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors
  2764. Targeted therapy of human osteosarcoma with 17AAG or Rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways
  2765. Conversion to Rapamycin immunosuppression for malignancy after kidney transplantation
  2766. cAMP-dependent activation of mammalian target of Rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4
  2767. Immunosuppression using the mammalian target of Rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement
  2768. Late progression of renal pathology and cyst enlargement is reduced by Rapamycin in a mouse model of nephronophthisis
  2769. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitors
  2770. Oral Rapamycin reduces tumour burden and vascularization in Lkb1+/− mice
  2771. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype
  2772. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
  2773. Broadening the therapeutic scope for Rapamycin treatment
  2774. Dual phosphoinositide 3-kinase/mammalian target of Rapamycin blockade is an effective radiosensitizing strategy for the treatment of non–small cell lung cancer …
  2775. Upregulation of the mammalian target of Rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic β-cells leads to increased β-cell mass and …
  2776. mTORC1 inhibition via Rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes
  2777. Mammalian target of Rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis
  2778. Effects of metformin on mammalian target of Rapamycin in a mouse model of endometrial hyperplasia
  2779. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC Min/+ mice
  2780. Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by Rapamycin
  2781. Early and late effects of the immunosuppressants Rapamycin and mycophenolate mofetil on UV carcinogenesis
  2782. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of Rapamycin pathway activation in head and neck squamous cell carcinoma
  2783. Differing effects of systemically administered Rapamycin on consolidation and reconsolidation of context vs. cued fear memories
  2784. The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of Rapamycin signaling
  2785. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of Rapamycin complex-2 and AKT-1
  2786. Rapamycin-induced Gln3 dephosphorylation is insufficient for nuclear localization: Sit4 and PP2A phosphatases are regulated and function differently
  2787. Melatonin attenuates methamphetamine‐induced deactivation of the mammalian target of Rapamycin signaling to induce autophagy in SK‐N‐SH cells
  2788. Monotherapy Rapamycin allows an increase of CD4+ CD25bright+ FoxP3+ T cells in renal recipients
  2789. Rapamycin: the cure for all that ails
  2790. Activation of mammalian target of Rapamycin signaling in spatial learning
  2791. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of Rapamycin in differentiated and anaplastic thyroid cancer
  2792. Comparison of radiosensitizing effects of the mammalian target of Rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell …
  2793. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling network in normal myelopoiesis and leukemogenesis
  2794. MYC activity mitigates response to Rapamycin in prostate cancer through eukaryotic initiation factor 4E–binding protein 1–mediated inhibition of autophagy
  2795. Successful control of intractable hypoglycemia using Rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases
  2796. Generation of high Rapamycin producing strain via rational metabolic pathway‐based mutagenesis and further titer improvement with fed‐batch bioprocess …
  2797. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia
  2798. Rapamycin-Insensitive Up-Regulation of MMP2 and Other Genes in Tuberous Sclerosis Complex 2–Deficient Lymphangioleiomyomatosis-Like Cells
  2799. Increasing longevity through caloric restriction or Rapamycin feeding in mammals: common mechanisms for common outcomes?
  2800. Rapamycin inhibits anal carcinogenesis in two preclinical animal models
  2801. Overexpression of the mammalian target of Rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer
  2802. Mammalian target of Rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein–protein interactions …
  2803. Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of Rapamycin signaling and glucose uptake in an ERBB2 transgenic …
  2804. A phosphatidylinositol 3-kinase/protein kinase B-independent activation of mammalian target of Rapamycin signaling is sufficient to induce skeletal muscle hypertrophy
  2805. … -1, 3, 5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of Rapamycin inhibitors: discovery of …
  2806. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-α expression in macrophages by reducing IL-10 expression
  2807. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo
  2808. Pneumonitis associated with mammalian target of Rapamycin inhibitors in renal transplant recipients: a single-center experience
  2809. Discovery of potent and selective inhibitors of the mammalian target of Rapamycin (mTOR) kinase
  2810. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235
  2811. Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway
  2812. Mammalian target of Rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
  2813. Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of Rapamycin/S6 kinase 2 pathway
  2814. Treatment with Rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces …
  2815. Rapamycin and CCI‐779 inhibit the mammalian target of Rapamycin signalling in hepatocellular carcinoma
  2816. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies Rapamycin mechanism of action
  2817. Preclinical in vivo evaluation of Rapamycin in human malignant peripheral nerve sheath explant xenograft
  2818. Hypersensitivity of Ph-positive lymphoid cell lines to Rapamycin: Possible clinical application of mTOR inhibitor
  2819. Mammalian target of Rapamycin complex 1 is involved in differentiation of regenerating myofibers in vivo
  2820. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex
  2821. Treating triple-negative breast cancer by a combination of Rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study
  2822. Antitumoral activity of Rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma
  2823. Aberrant hyperactivation of akt and Mammalian target of Rapamycin complex 1 signaling in sporadic chordomas
  2824. HIV-associated nephropathy: role of mammalian target of Rapamycin pathway
  2825. The Rapamycin-regulated gene expression signature determines prognosis for breast cancer
  2826. … acid starvation of Saccharomyces cerevisiae and Candida albicans acetolactate synthase (ilv2Δ) mutants is influenced by the carbon source and Rapamycin
  2827. Combined Bcl-2/Mammalian Target of Rapamycin inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non–Small Cell Lung …
  2828. Rapamycin down-regulates inducible nitric oxide synthase by inducing proteasomal degradation
  2829. Functional interaction of mammalian target of Rapamycin complexes in regulating mammalian cell size and cell cycle
  2830. Efficacy, tolerance, and safety of mammalian target of Rapamycin inhibitors as rescue immunosuppressants in liver transplantation
  2831. Rapamycin induces the TGFβ1/Smad signaling cascade in renal mesangial cells upstream of mTOR
  2832. … 3-kinase (PI3K) and the mammalian target of Rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin− Rapamycin conjugates
  2833. Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of Rapamycin (mTOR) pathway
  2834. Hepatitis C virus NS5A activates the mammalian target of Rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between …
  2835. Naive CD4 t cell proliferation is controlled by mammalian target of Rapamycin regulation of GRAIL expression
  2836. Activation of the mammalian target of Rapamycin signalling pathway in epidermal tumours and its correlation with cyclin‐dependent kinase 2
  2837. The effects of Rapamycin on lens epithelial cell proliferation, migration, and matrix formation: an in vitro study
  2838. Distinct phosphatase requirements and GATA factor responses to nitrogen catabolite repression and Rapamycin treatment in Saccharomyces cerevisiae
  2839. Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate
  2840. … protects mouse and human hematopoietic progenitors from γ-irradiation through extracellular signal-regulated kinase/mammalian target of Rapamycin …
  2841. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment
  2842. Dramatic improvement in pulmonary hypertension with Rapamycin
  2843. High expression of mammalian target of Rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma
  2844. Phase Ib study of weekly mammalian target of Rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
  2845. Expression of EBV latent antigens, mammalian target of Rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic …
  2846. Identification of functional FKB protein in Echinococcus granulosus: its involvement in the protoscolicidal action of Rapamycin derivates and in calcium homeostasis
  2847. The role of phosphoinositide 3‐kinase and phosphatidic acid in the regulation of mammalian target of Rapamycin following eccentric contractions
  2848. Placental mammalian target of Rapamycin and related signaling pathways in an ovine model of intrauterine growth restriction
  2849. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro
  2850. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers Rapamycin sensitivity
  2851. Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines
  2852. Activation of the AKT and mammalian target of Rapamycin pathways and the inhibitory effects of Rapamycin on those pathways in canine malignant melanoma cell lines
  2853. Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex: Case report
  2854. Rapamycin-eluting stents in the arterial duct: experimental observations in the pig model.
  2855. Device-based local delivery of siRNA against mammalian target of Rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation
  2856. mTOR inhibitor Rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
  2857. Exploring mammalian target of Rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
  2858. Target of Rapamycin (TOR)-like 1 kinase is involved in the control of polyphosphate levels and acidocalcisome maintenance in Trypanosoma brucei
  2859. Rapid modification of proteins using a Rapamycin-inducible tobacco etch virus protease system
  2860. Concurrent and sequential administration of chemotherapy and the Mammalian target of Rapamycin inhibitor temsirolimus in human cancer cells and xenografts
  2861. Mammalian target of Rapamycin complex 1 (mTORC1) signaling in energy balance and obesity
  2862. Bortezomib can suppress activation of Rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates
  2863. Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice
  2864. Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD
  2865. Polylactide-glycoli acid and Rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes
  2866. Regulation of cell death and epileptogenesis by the mammalian target of Rapamycin (mTOR): a double-edged sword?
  2867. Rapamycin inhibits growth of cholangiocarcinoma cells.
  2868. The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of …
  2869. Rapamycin induces autophagy in islets: relevance in islet transplantation
  2870. Mammalian target of Rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes
  2871. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) …
  2872. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells
  2873. Evaluation of in vivo antineoplastic effects of Rapamycin in patients with chemotherapy-refractory AML
  2874. Expression and mechanism of mammalian target of Rapamycin in age-related renal cell senescence and organ aging
  2875. Rapid improvement of nephrogenic systemic fibrosis with Rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase
  2876. Inactivation of mammalian target of Rapamycin increases STAT1 nuclear content and transcriptional activity in α4-and protein phosphatase 2A-dependent …
  2877. Testing intravitreal toxicity of Rapamycin in rabbit eyes
  2878. Antagonism of the mammalian target of Rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant …
  2879. ATP-mediated protein kinase B Akt/mammalian target of Rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes …
  2880. Delayed re-endothelialization with Rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3β inhibitor
  2881. Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR)
  2882. inhibition of mammalian target of Rapamycin signaling potentiates the effects of all‐trans retinoic acid to induce growth arrest and differentiation of human acute …
  2883. Rapamycin enhances chemotherapy‐induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells
  2884. Pilot study: Rapamycin in advanced hepatocellular carcinoma
  2885. Mammalian target of Rapamycin as a novel target in the treatment of hepatocellular carcinoma.
  2886. Mammalian target of Rapamycin: a new target in prostate cancer
  2887. MAPK, phosphatidylinositol 3-kinase, and mammalian target of Rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic …
  2888. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage
  2889. The Rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells
  2890. Rapamycin and the transcription factor C/EBPβ as a switch in osteoclast differentiation: implications for lytic bone diseases
  2891. Mammalian target of Rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma …
  2892. Rapamycin inhibits lung metastasis of B16 melanoma cells through down‐regulating alphav integrin expression and up‐regulating apoptosis signaling
  2893. Mammalian target of Rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain …
  2894. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) inhibitor
  2895. Effect of Rapamycin on lifespan in Drosophila
  2896. Luteinizing hormone stimulates mammalian target of Rapamycin signaling in bovine luteal cells via pathways independent of AKT and mitogen-activated protein kinase …
  2897. The effect of Rapamycin on angiogenesis in chick chorioalantoic membrane
  2898. Mammalian target of Rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual …
  2899. Regulation of gastric hormones by systemic Rapamycin
  2900. Effect of combination treatment of Rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells
  2901. Distinct subsets of Sit4 holophosphatases are required for inhibition of Saccharomyces cerevisiae growth by Rapamycin and zymocin
  2902. Activation of phosphatidylinositol 3-kinase/Akt-mammalian target of Rapamycin signaling pathway in the hippocampus is essential for the acquisition of morphine …
  2903. Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and …
  2904. Critical and diverse involvement of Akt/mammalian target of Rapamycin signaling in human lung carcinomas
  2905. … yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for …
  2906. Phosphoinositide 3-kinase (PI3K) and the nutrient sensing mTOR (mammalian target of Rapamycin) pathways control T cell migration
  2907. Glycogen synthase kinase-3 and mammalian target of Rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets
  2908. Periadventitial Rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts
  2909. Inhibitory effect of Rapamycin and dexamethasone on production of IL-17 and IFN-γ in Vogt–Koyanagi–Harada patients
  2910. Rap1 promotes multiple pancreatic islet cell functions and signals through mammalian target of Rapamycin complex 1 to enhance proliferation
  2911. Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by Rapamycin-mediated AMPK activation and mTOR inhibition
  2912. Rapamycin‐Conditioned Donor Dendritic Cells Differentiate CD4+CD25+Foxp3+ T Cells In Vitro with TGF‐β1 for Islet Transplantation
  2913. Mammalian Target of Rapamycin–Dependent Acinar Cell Neoplasia after Inactivation of Apc and Pten in the Mouse Salivary Gland: Implications for Human Acinic Cell …
  2914. The Drosophila FoxA ortholog Fork head regulates growth and gene expression downstream of Target of Rapamycin
  2915. Rescue immunosuppression with mammalian target of Rapamycin inhibitor drugs in liver transplantation
  2916. In-vitro release of Rapamycin from a thermosensitive polymer for the inhibition of vascular smooth muscle cell proliferation
  2917. Influence of combined treatment of low dose Rapamycin and cyclosporin A on corneal allograft survival
  2918. Low-dose Rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex
  2919. Rapamycin attenuates the severity of murine adriamycin nephropathy
  2920. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells
  2921. Stage 2 combination testing of Rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program
  2922. Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma
  2923. Human Protein Phosphatase PP6 Regulatory Subunits Provide Sit4-Dependent and Rapamycin–Sensitive Sap Function in Saccharomyces cerevisiae
  2924. … cell marker upregulation in normal cutaneous vessels following pulsed‐dye laser exposure and its abrogation by concurrent Rapamycin administration: implications for …
  2925. Monitoring kidney and renal cyst volumes applying MR approaches on a Rapamycin treated mouse model of ADPKD
  2926. Rapamycin promotes the expansion of CD4+ Foxp3+ regulatory T cells after liver transplantation
  2927. … cells treated with mammalian target of Rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and Rapamycin
  2928. Effective treatment of advanced colorectal cancer by Rapamycin and 5-FU/oxaliplatin monitored by TIMP-1
  2929. Anti-CD154 mAb and Rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation
  2930. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of Rapamycin complex 2
  2931. Comparison of three Rapamycin dosing schedules in A/J Tsc2+/-mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice …
  2932. Effect of Rapamycin on cue-induced drug craving in abstinent heroin addicts
  2933. Adenosine 5′-monophosphate-activated protein kinase-mammalian target of Rapamycin cross talk regulates brown adipocyte differentiation
  2934. Intracellular parasitism with Toxoplasma gondii stimulates mammalian‐target‐of‐Rapamycin‐dependent host cell growth despite impaired signalling to S6K1 and 4E …
  2935. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of Rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia
  2936. The synergic effects of Rapamycin and extremely low frequency electromagnetic field on angiogenesis
  2937. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient
  2938. Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells
  2939. Combined inhibition of MEK and mammalian target of Rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their …
  2940. Structural basis for the association of the redox-sensitive target of Rapamycin FATC domain with membrane-mimetic micelles
  2941. NV‐128, a novel isoflavone derivative, induces caspase‐independent cell death through the Akt/mammalian target of Rapamycin pathway
  2942. Activating transcription factor 4 and CCAAT/enhancer-binding protein-β negatively regulate the mammalian target of Rapamycin via Redd1 expression in response to …
  2943. Epidermal growth factor receptor and mammalian target of Rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives
  2944. Chemopreventive efficacy of Rapamycin on Peutz–Jeghers syndrome in a mouse model
  2945. … Stents Results in Better Clinical Outcomes During 6-Year Follow-Up Than Bare-Metal Stents: An Analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At …
  2946. … repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin …
  2947. … of the epidermal growth factor receptor/mammalian target of Rapamycin pathway by epidermal growth factor receptor inhibitors and Rapamycin results in reduced cell …
  2948. inhibition of the mammalian target of Rapamycin promotes cyclic AMP-induced differentiation of NG108-15 cells
  2949. Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase–protein kinase B–mammalian target of Rapamycin signaling
  2950. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling network in cancer stem cell biology
  2951. … -6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the …
  2952. PI3K signaling regulates Rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells
  2953. Silymarin inhibits endothelial progenitor cells’ senescence and protects against the antiproliferative activity of Rapamycin: preliminary study
  2954. inhibition of voltage-gated K+ channels in dendritic cells by Rapamycin
  2955. Phase I study of the oral mammalian target of Rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
  2956. Regulation by FK506 and Rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR
  2957. … using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at …
  2958. Rrd1 isomerizes RNA polymerase II in response to Rapamycin
  2959. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of Rapamycin activity and p27Kip1 …
  2960. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism
  2961. If mammalian target of metformin indirectly is mammalian target of Rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in …
  2962. The transcription factor SP1 regulates centriole function and chromosomal stability through a functional interaction with the mammalian target of Rapamycin/raptor …
  2963. Involvement of autophagy via mammalian target of Rapamycin (mTOR) inhibition in tributyltin-induced neuronal cell death
  2964. Rapamycin protects heart from ischemia/reperfusion injury independent of autophagy by activating PI3 kinase-Akt pathway and mitochondria KATP channel
  2965. … peroxisome proliferator-activated receptor (PPAR) γ protein translation by suppressing the mammalian target of Rapamycin (mTOR) signaling pathway in …
  2966. SP600125 negatively regulates the mammalian target of Rapamycin via ATF4-induced Redd1 expression
  2967. … in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of Rapamycin
  2968. Rapamycin Inhibits VEGF‐Induced Microvascular Hyperpermeability In Vivo
  2969. Iron deficiency down-regulates the Akt/TSC1-TSC2/mammalian Target of Rapamycin signaling pathway in rats and in COS-1 cells
  2970. Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of Rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a …
  2971. Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by Rapamycin in human myeloma cells
  2972. Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases
  2973. inhibition of mammalian target of Rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E …
  2974. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of Rapamycin
  2975. … by leucine supplementation in malnourished rats: possible involvement of the phosphatidylinositol 3-phosphate kinase/mammalian target protein of Rapamycin …
  2976. Rapamycin inhibits cholangiocyte regeneration by blocking interleukin‐6–induced activation of signal transducer and activator of transcription 3 after liver …
  2977. A role for mammalian target of Rapamycin–mTOR-pathway in non alcoholic steatohepatitis related-cirrhosis
  2978. Targeting mammalian target of Rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines
  2979. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with Rapamycin plus tacrolimus in liver transplant patient
  2980. Rapamycin promotes the enrichment of CD4+ CD25hiFoxP3+ T regulatory cells from naive CD4+ T cells of baboon that suppress antiporcine xenogenic response in …
  2981. Rapamycin, but not cyclosporine A, inhibits vascularization and incorporation of implanted surgical meshes
  2982. Rapamycin‐treated mature dendritic cells have a unique cytokine secretion profile and impaired allostimulatory capacity
  2983. Rapamycin induces autophagy and exacerbates metabolism associated complications in a mouse model of type 1 diabetes
  2984. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by Rapamycin and bevacizumab in an intrahepatic model
  2985. Inducible somatic oocyte destruction in response to Rapamycin requires wild-type regulation of follicle cell epithelial polarity
  2986. Cutaneous T‐cell lymphoma cells are sensitive to Rapamycin
  2987. … ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of Rapamycin …
  2988. Mammalian target of Rapamycin (mTOR) and S6 kinase down-regulate phospholipase D2 basal expression and function
  2989. Rapamycin enhances the susceptibility of both androgen-dependent and-independent prostate carcinoma cells to docetaxel
  2990. The phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin signaling network and the control of normal myelopoiesis
  2991. CD4+ Foxp3+ regulatory T cells converted by Rapamycin from peripheral CD4+ CD25˜. naive T cells display more potent regulatory abilityin vitro
  2992. Chemistry and pharmacology of Rapamycin and its derivatives
  2993. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of Rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and …
  2994. Mammalian target of the Rapamycin pathway is involved in non-alcoholic fatty liver disease
  2995. Antiproliferative effects of Rapamycin and celecoxib in angiosarcoma cell lines
  2996. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of Rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung …
  2997. mTOR inhibitor Rapamycin suppresses striatal post-ischemic LTP
  2998. Ribosomal protein S6 kinase is a critical downstream effector of the target of Rapamycin complex 1 for long-term facilitation in Aplysia
  2999. FK506 and Rapamycin neuroprotect erection and involve different immunophilins in a rat model of cavernous nerve injury
  3000. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells
  3001. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and Rapamycin …
  3002. Lysosomal accumulation of mTOR is enhanced by Rapamycin
  3003. Systemic Rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation
  3004. Beclin 1 self‐association is independent of autophagy induction by amino acid deprivation and Rapamycin treatment
  3005. High expression levels of the mammalian target of Rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma
  3006. … of the effects of NF-κB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264. 7 cells: synergistic effects of Rapamycin on LPS-induced …
  3007. Combined administration of a mutant TGF-β1/Fc and Rapamycin promotes induction of regulatory T cells and islet allograft tolerance
  3008. Evidence for cell cycle-dependent, Rapamycin-resistant phosphorylation of ribosomal protein S6 at S240/244
  3009. Rapamycin reduces high-amplitude, mechanical stretch-induced apoptosis in pulmonary microvascular endothelial cells
  3010. Effect of low-dose Rapamycin on tumor growth in two human hepatocellular cancer cell lines
  3011. The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells
  3012. Rapamycin: could it enhance vaccine efficacy?
  3013. Rapamycin and tacrolimus differentially modulate acute graft‐versus‐host disease in rats after liver transplantation
  3014. Infarct size is increased in female post-MI rats treated with Rapamycin
  3015. Protein kinase C-δ and phosphatidylinositol 3-kinase/Akt activate mammalian target of Rapamycin to modulate NF-κB activation and intercellular adhesion …
  3016. Glutamate-dependent phosphorylation of the mammalian target of Rapamycin (mTOR) in Bergmann glial cells
  3017. Rapid regression of lymphadenopathy upon Rapamycin treatment in a child with autoimmune lymphoproliferative syndrome
  3018. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitors: discovery of PKI …
  3019. mTOR, the mammalian target of Rapamycin
  3020. Oral Rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice
  3021. Glucagon acts in a dominant manner to repress insulin-induced mammalian target of Rapamycin complex 1 signaling in perfused rat liver
  3022. Targeting heat‐shock protein 90 improves efficacy of Rapamycin in a model of hepatocellular carcinoma in mice
  3023. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
  3024. inhibition of human immunodeficiency virus (HIV‐1) infection in human peripheral blood leucocytes‐SCID reconstituted mice by Rapamycin
  3025. Mammalian target of Rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells
  3026. Effects of Rapamycin on prostate cancer PC-3 cells
  3027. Five‐year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus‐eluting stents: Insights from the Rapamycin‐eluting stent evaluated at …
  3028. … of essential amino acid deficiency in the anterior piriform cortex, that requires the uncharged tRNA/GCN2 pathway, is sensitive to wortmannin but not Rapamycin
  3029. Failed rescue therapy with Rapamycin after paraquat intoxication
  3030. mTOR pathway inhibitors in cancer therapy: moving past Rapamycin
  3031. A spectrophotometric assay for routine measurement of mammalian target of Rapamycin activity in cell lysates
  3032. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and Rapamycin in a renal transplant recipient
  3033. Rapamycin in combination with donor-specific CD4+ CD25+ Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation
  3034. Shiga toxin 1-induced proinflammatory cytokine production is regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling pathway
  3035. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of Rapamycin (mTOR) with selectivity over PI3Kα
  3036. Timing of conversion to mammalian target of Rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation
  3037. Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of Rapamycin: Hit to lead studies
  3038. Fission yeast TOR and Rapamycin
  3039. Activated mammalian target of Rapamycin is associated with T regulatory cell insufficiency in nasal polyps
  3040. Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4+ memory T cells in mice
  3041. A functional link between polo-like kinase 1 and the mammalian target-of-Rapamycin pathway?
  3042. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of Rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines …
  3043. Experience with everolimus (RAD001), an oral mammalian target of Rapamycin inhibitor, in patients with systemic mastocytosis
  3044. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor
  3045. Rapamycin impairs trabecular bone acquisition from high‐dose but not low‐dose intermittent parathyroid hormone treatment
  3046. Steady-state kinetic and inhibition studies of the mammalian target of Rapamycin (mTOR) kinase domain and mTOR complexes
  3047. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell …
  3048. Impact of mammalian target of Rapamycin inhibition on autosomal-dominant polycystic kidney disease
  3049. Limited utility of Rapamycin in severe, refractory Wegener’s granulomatosis
  3050. Rescuing 3T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of Rapamycin/p70 S6 kinase (S6K1) pathway and serine …
  3051. MYC activity mitigates response to Rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy
  3052. Target of Rapamycin in the oriental fruit fly Bactrocera dorsalis (hendel): its cloning and effect on yolk protein expression
  3053. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists
  3054. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of Rapamycin
  3055. Molecular pathways involved in hair follicle tumor formation: all about mammalian target of Rapamycin?
  3056. Posttransplantation Therapeutic Rapamycin Concentration Protects Nitric Oxide–Related Vascular Endothelial Function: Comparative Effects in Rat Thoracic Aorta …
  3057. Controversies in breast cancer: the mammalian target of Rapamycin as a target for breast cancer therapy
  3058. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of Rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed …
  3059. AZD6244 (ARRY‐142886) enhances the antitumor activity of Rapamycin in mouse models of human hepatocellular carcinoma
  3060. Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with Rapamycin
  3061. Comparison of Rapamycin-and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction
  3062. Regulation of protein kinase Cδ downregulation by protein kinase Cε and mammalian target of Rapamycin complex 2
  3063. Rapamycin reduces proteinuria and renal damage in the rat remnant kidney model
  3064. How does the mammalian target of Rapamycin (mTOR) influence CD8 T-cell differentiation?
  3065. Alteration of REDD1-mediated mammalian target of Rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer
  3066. Immunohistochemical analysis of the mammalian target of Rapamycin signalling pathway in extramammary Paget’s disease
  3067. Preventing restenosis after implantation of bare stents with oral Rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow …
  3068. Rapamycin can Inhibit the Development of Chlamydia pneumoniae, which Might Partly Contribute to the Prevention of In-stent Restenosis
  3069. Depletion of mammalian target of Rapamycin (mTOR) via siRNA mediated knockdown leads to stabilization of β-catenin and elicits distinct features of …
  3070. Indirect antitumor effects of mammalian target of Rapamycin inhibitors against Kaposi sarcoma in transplant patients
  3071. … -pyrrolo [2, 3-b] pyridin-3-yl) methylene-4-hydroxybenzofuran-3 (2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of Rapamycin …
  3072. Inhibitors of the mammalian target of Rapamycin and transplant tolerance
  3073. Clinical implications of proteinuria in renal transplant recipients switching to Rapamycin for chronic allograft dysfunction
  3074. Transforming growth factor beta 1 (TGF-β1) and Rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs
  3075. Descending serotonergic facilitation mediated by spinal 5-HT3 receptors engages spinal Rapamycin-sensitive pathways in the rat
  3076. … replacement in 6-aryl-1H-pyrazolo [3, 4-d] pyrimidines and 2-arylthieno [3, 2-d] pyrimidines: ATP-competitive inhibitors of the mammalian target of Rapamycin (mTOR)
  3077. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with polycystic kidney disease
  3078. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells
  3079. Protection from Rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling
  3080. Suppression of mTOR complex 2‐dependent AKT phosphorylation in melanoma cells by combined treatment with Rapamycin and LY294002
  3081. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with Rapamycin in human orthotopic primary pancreatic cancer xenografts
  3082. Effects of delayed Rapamycin treatment on renal fibrosis and inflammation in experimental ischemia reperfusion injury
  3083. Cutting edge: Expression of the transcription factor E74-like factor 4 is regulated by the mammalian target of Rapamycin pathway in CD8+ T cells
  3084. Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of Rapamycin–dependent endometrial hyperplasia and carcinoma
  3085. Rapamycin inhibits yeast nucleotide excision repair independently of Tor kinases
  3086. ID2‐VEGF‐related Pathways in the Pathogenesis of Kaposi’s Sarcoma: A Link Disrupted by Rapamycin
  3087. Phosphorylation of translation factors in response to anoxia in turtles, Trachemys scripta elegans: role of the AMP-activated protein kinase and target of Rapamycin …
  3088. Novel mechanism of Rapamycin in GVHD: increase in interstitial regulatory T cells
  3089. Low-dose calcineurin inhibitor regimen combined with mammalian target of Rapamycin inhibitors preserves kidney functions in renal transplant recipients without …
  3090. Rapamycin for chemoprevention of upper aerodigestive tract cancers
  3091. Mutation of a phosphorylatable residue in Put3p affects the magnitude of Rapamycin-induced PUT1 activation in a Gat1p-dependent manner
  3092. Spreading of mesothelioma cells is Rapamycin‐sensitive and requires continuing translation
  3093. Rapamycin enhances platelet aggregation induced by adenosine diphosphate in vitro
  3094. Insulin resistance without elevated mammalian target of Rapamycin complex 1 activity in muscles of mice fed a high-fat diet
  3095. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of Rapamycin (mTOR)
  3096. Serine 2481-autophosphorylation of mammalian target of Rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: Confocal …
  3097. Mammalian target of Rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction
  3098. Select nutrients in the ovine uterine lumen. VI. Expression of FK506-binding protein 12-Rapamycin complex-associated protein 1 (FRAP1) and regulators and effectors …
  3099. The effect of Rapamycin liposome gutta inhibiting rat corneal neovascularization
  3100. Retracted: CCR5 blockade in combination with Rapamycin prolongs cardiac allograft survival in mice
  3101. Rapamycin joins the aging fray: maybe Ponce de Leon visited Rapa Nui, not Florida
  3102. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with Rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo
  3103. Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with Rapamycin
  3104. Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans
  3105. Late conversion to mammalian target of Rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years
  3106. … between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At …
  3107. … growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of Rapamycin …
  3108. Rapamycin suppresses the expansion and differentiation of porcine neonatal pancreas cell clusters
  3109. The possible cellular mechanism for extending lifespan of mice with Rapamycin
  3110. Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease
  3111. … posttranscriptional regulation of insulin-like growth factor-I receptor level via glycogen synthase kinase-3β and mammalian target of Rapamycin in adrenal chromaffin …
  3112. Preparation of electrospun poly (L-lactide-co-caprolactone-co-glycolide)/phospholipid polymer/Rapamycin blended fibers for vascular application
  3113. Combined effect of Rapamycin and cisplatin on survival of Hep-2 cells in vitro
  3114. Adenosine-triphosphate promoting repair of spinal cord injury by activating mammalian target of Rapamycin/signal transducers and activators of transcription 3 signal …
  3115. Mammalian target of Rapamycin complex 1 signaling opposes the effects of anchorage loss, leading to activation of Cdk4 and Cdc6 stabilization
  3116. Rapamycin for Kaposi’s sarcoma and graft-versus-host disease in bone marrow transplant recipient
  3117. Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma
  3118. First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free Rapamycin (2%)-eluting stents
  3119. Mammalian target of Rapamycin and autosomal dominant polycystic kidney disease
  3120. Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation
  3121. Effect of Rapamycin on leukemia cell lines
  3122. inhibition of IGF-I receptor signaling in combination with Rapamycin or temsirolimus increases MYC-N phosphorylation
  3123. Role of GLUT1 in the Mammalian Target of Rapamycin Pathway: Mechanisms of Regulation.
  3124. Exendin-4 protects pancreatic beta cells from the cytotoxic effect of Rapamycin by inhibiting JNK and p38 phosphorylation
  3125. inhibition of mammalian target of Rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies
  3126. Monitoring Molecular-Specific Pharmacodynamics of Rapamycin In vivo with Inducible Gal4→ Fluc Transgenic Reporter Mice
  3127. Combination of tipifarnib and Rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling …
  3128. Pretreatment with intraluminal Rapamycin nanoparticle perfusion inhibits neointimal hyperplasia in a rabbit vein graft model
  3129. Rapamycin prevents Concanavalin A‐induced liver injury by inhibiting lymphocyte activation
  3130. Treatment algorithms in metastatic renal cell carcinoma, including the potential role of the novel oral mammalian target of Rapamycin inhibitor Everolimus
  3131. Cyclooxygenase 2 mediates the antiangiogenic effect of Rapamycin in Ewing sarcoma
  3132. Rapamycin selectively reduces the association of transcripts containing complex 5′ UTRs with ribosomes in C4‐2B prostate cancer cells
  3133. Regioselective lipase-catalyzed acylation of 41-desmethoxy-Rapamycin without vinyl esters
  3134. Rapamycin inhibits poly (ADP-ribosyl) ation in intact cells
  3135. Early loss of mammalian target of Rapamycin complex 1 (mTORC1) signalling and reduction in cell size during dominant-negative suppression of hepatic …
  3136. Combination Regimens of nab-Rapamycin (ABI-009) Effective Against MDA-MB-231 Breast-Tumor Xenografts.
  3137. Rapamycin Inhibits Activator Protein-1 But Not Nuclear Factor-κB Activity of Mature Bone Marrow-Derived Dendritic Cells
  3138. Autosomal dominant polycystic kidney disease (ADPKD): Rapamycin as a new treatment option
  3139. Synthesis of the northern sector (C8–C19) of Rapamycin via Chan rearrangement and oxidation of an α-acyloxyacetate
  3140. Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report
  3141. Effects of Rapamycin on Breast Cancer Cell Migration through the Cross-Talk of MAPK Pathway.
  3142. inhibition of mammalian target of Rapamycin: the janus face of immunosuppression?
  3143. Effect of Rapamycin on proliferated human umbilical vein endothelial cell
  3144. … 5‐(2‐chloroethyl)‐2‐acetoxy‐benzyl]‐4‐(2‐chloroethyl)‐phenyl acetate inhibits phosphoinositide 3‐kinase/Akt/mammalian target of Rapamycin signalling through JNK …
  3145. Progression of graft fibrosis under mammalian target of Rapamycin inhibitor‐based regimen
  3146. Effects of Rapamycin on the differentiation and function of macrophages in vitro
  3147. Monotherapy Rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab
  3148. Rapamycin enhances lipopolysaccharide-induced apoptosis and lung injury
  3149. Rapamycin treatment suppresses epileptogenic activity in conditional Pten knockout mice
  3150. Influence of Rapamycin on autophagy and apoptosis of two lepidoptera cell lines.
  3151. Effect of Rapamycin on proliferation of acute myeloid leukemia cell lines HL-60 and HL-60/VCR
  3152. A phase II trial of a mammalian target of Rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.
  3153. Molecular pathways in metastatic renal cell carcinoma: the evolving role of mammalian target of Rapamycin inhibitors
  3154. Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of Rapamycin (mTOR) inhibitor temsirolimus in metastatic …
  3155. Effect of Rapamycin and Cyclosporin A on the expression of TLR5 and Foxp3 in allorejection
  3156. Combination therapy of 5-fluorouracil with Rapamycin for hormone receptor-negative human breast cancer
  3157. … of D-cyclin translation inhibition in myeloma cells treated with mTOR inhibitors: rationale for combined treatment with ERK inhibitors and Rapamycin
  3158. Dual inhibition of Akt/mTOR pathway by nab-Rapamycin and perifosine induces anti-tumor activity in multiple myeloma
  3159. Forever young, slim and fit: Rapamycin to the rescue
  3160. Evaluation of a Rapamycin‐regulated serotype 2 adeno‐associated viral vector in macaque parotid glands
  3161. Recent developments of Rapamycin analogues
  3162. Combination of Rapamycin and IL-2 do not affect antigen presentation ability of rat B cell and could promote Tregs proliferation and inhibitory activity
  3163. Mammalian target of Rapamycin: MasTOR mediator of cellular changes in pathological states?
  3164. Use of a cocktail regimen consisting of soluble galectin-1, Rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes
  3165. Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to Rapamycin
  3166. Mammalian target of Rapamycin, Akt, and phosphatidylinositol 3-kinase signaling
  3167. Prevention of hepatic tumor growth and metastasis in rats with Rapamycin
  3168. Effect of Rapamycin on apoptosis in human myelodysplastic syndrome cell line MUTZ-1 and its possible mechanisms
  3169. A phase I dose-finding and pharmacodynamic study of Rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
  3170. Antitumor activity, and antiangiogenic activity of nanoparticle albumin-bound nab-Rapamycin in combination with nab-paclitaxel.
  3171. Mammalian target of Rapamycin (mTOR)-induced pneumonitis: Single-institution experience and treatment.
  3172. inhibition of cell growth by Rapamycin through targeting mammalian target of Rapamycin signaling pathway in nasopharyngeal carcinoma
  3173. Study advance of Rapamycin in the field of transplantation immunology [J]
  3174. Release test of Rapamycin in drug-eluting stents
  3175. The mechanism and influence of Rapamycin on proliferation of NIH3T3 fibroblasts transfected with mTOR gene [J]
  3176. Effects of Rapamycin on angiogenesis and tumor progression in human hepatocellular carcinoma implantation mice
  3177. Correlation factors of vascular restenosis and safety following Rapamycin drug-eluting stent implantation
  3178. Mammalian target of Rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma
  3179. Regulation of bone formation using Rapamycin-induced BMP2 expression system: influence of implanted cell number
  3180. Active-site inhibitors of mTOR target Rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol
  3181. Effect of Rapamycin on proliferation, apoptosis and regulation of chemokine receptor CXCR4 in RPMI8226 cells
  3182. Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3‐kinase (PI3K) and the mammalian target of Rapamycin (mTOR)
  3183. Rapamycin and HIV Replication in Liver Transplant Recipients
  3184. Effects of Rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles on distribution of cell cycle, expression of p27 protein, and proliferation of human umbilical …
  3185. Rapamycin induces apoptosis of lung adenocarcinoma cell A549 under hypoxia and its molecular mechanism
  3186. A phase I study of sirolimus (Rapamycin) and bevacizumab in patients with advanced malignancies.
  3187. Effects of Rapamycin on collagen type Ⅰ expression in rat myocardial cell induced by CVB 3
  3188. Abstract C65: Enhanced antitumor effect by the combination of a PI3K inhibitor ZSTK474 with an mTOR inhibitor Rapamycin
  3189. A stimulating new role for Rapamycin
  3190. Synergistic augmentation of cisplatin-induced apoptosis in HeLa cells by Rapamycin
  3191. Evaluation for synergistic suppression of breast cancer proliferation by Chloroquine in combination with the Rapamycin derivative, Rad001
  3192. Rapamycin enhances lifespan: At last, an advantage for transplant recipients?
  3193. Rapamycin reverses glucocorticoid resistance in human T-cell acute lymphoblastic leukemia CEM-C1 cells [J]
  3194. Effects of Rapamycin on nephropathy of diabetic rats and expressions of vascular endothelial growth factor and its receptor [J]
  3195. Interference of mTOR expression enhances sensitivity of esophageal squamous cell carcinoma EC9706 cells to Rapamycin
  3196. Can phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibition ERase them all?
  3197. Tuberous Sclerosis Complex and the Mammalian Target of Rapamycin Pathways
  3198. Comparison of the MEIA and HPLC assays for the measurement of Rapamycin concentration in blood of recipients after renal transplantation [J]
  3199. Effects of simvastatin on Rapamycin-treated cardiac microvascular endothelial cells
  3200. Combined Rapamycin eye drop in nanometer vector and poly (lactic acid) wafers of cyclosporine A effectively prevents high-risk corneal allograft rejection in rabbits
  3201. Mammalian target of Rapamycin inhibitors in the treatment of malignancy after organ transplantation
  3202. Target of Rapamycin modulators of and use thereof
  3203. Essential Role of Mammalian Target of Rapamycin (mTOR) in LH-dependent Testosterone Production in Rat Leydig Cells.
  3204. Rapamycin inhibits growth and metastasis of gallbladder cancer GBC-SD cells.
  3205. Pharmacological studies of a novel inhibitor of the mammalian target of Rapamycin (mTOR) signaling pathway
  3206. Effects of Rapamycin on mTOR/p70S6K signaling pathway and tumor growth in xenografted esophageal squamous cell carcinoma.
  3207. Effect of Rapamycin (serolimus) on in vitro cultured human keratinocytes
  3208. Mesenchymal stem cells combined with Rapamycin immuno-regulates the spleniclymphocytes in allogenic mice.
  3209. Effect of Rapamycin on the interaction between Salmonella typhi plasmid pR_ (ST98) and macrophages [J]
  3210. Expression of JAK/STAT signal transduction pathway and the effects of Rapamycin in lupus nephritis-prone MRL/lpr mice
  3211. CIRCULATING CD4CD25 HIGH CD127 LOW REGULATORY T-CELLS AFTER INTRACORONARY IMPLANTATION OF Rapamycin-ELUTING STENTS: PP. 2.73
  3212. Preparation and production efficiency of Rapamycin ointment
  3213. The influence of coronary stenting with Rapamycin-eluting stents on the number of circulating CD4+ CD25high+ regulatory T-cells
  3214. Effect of Rapamycin on Phenotype of Vascular Smooth Muscle Cell and Arterial Intimal Hyperplasia in Rat Cardiac Allograft
  3215. Mammalian target of Rapamycin inhibitors in clinical practice: Case reports of everolimus in renal cell carcinoma
  3216. Application of stereocontrolled aldol coupling to synthesis of segments of immunosuppressants FK-506 and Rapamycin
  3217. Abstract C63: Biological characterization of GSK2126458, a novel and potent inhibitor of phosphoinositide 3‐kinase and the mammalian target of Rapamycin (mTOR)
  3218. Current perspectives in metastatic renal cell carcinoma treatment: the role of mammalian target of Rapamycin (mTOR) inhibition
  3219. Rapamycin decreases proinflammatory and profibrogenic gene expression in experimental NASH
  3220. Expression of mammalian target of Rapamycin and eIF4E signal pathway in cerebral glioma and its clinical significance [J]
  3221. Conditional protein stabilization via the small molecules Shld-1 and Rapamycin increases the signal-to-noise ratio with tet-inducible gene expression
  3222. A case of Kaposi’s sarcoma in the Rapamycin era
  3223. OSI-027, a potent and selective small molecule mTORC1/mTORC2 kinase Inhibitor is mechanistically distinct from Rapamycin
  3224. eIF4E Expression Predicts Apoptosis in Response to Epidermal Growth Factor Receptor inhibition and Mammalian Target of Rapamycin inhibition in Triple Negative …
  3225. Rapamycin and PD98059 collaborative inhibit mammalian target of Rapamycin pathway in the prevention and treatment of mouse colorectal cancer
  3226. Effect of Rapamycin on the growth of hepatocellular carcinoma in nude mice
  3227. Rapamycin-based GvHD prophylaxis after T-cell replete unmanipulated haploidentical peripheral stem cell transplantation for advanced leukaemias: preliminary …
  3228. Effect of Rapamycin administration in humans on the skeletal muscle protein anabolic response to essential amino acid ingestion
  3229. Differential Regulation of TLR4-Mediated TNF-a Release by Mammalian Target of Rapamycin and Glycogen Synthase Kinase-3 in Alveolar Macrophages from …
  3230. A newly developed Rapamycin-eluting stent with a biodegradable polymer reduces neointimal formation while allowing greater endothelialization
  3231. CONVERSION TO LOW DOSE TACROLIMUS OR Rapamycin 3 MONTHS AFTER KIDNEY TRANSPLANT: A PROSPECTIVE, PROTOCOL BIOPSY GUIDED STUDY …
  3232. The Effect of Rapamycin on Cardiac Allograft Vasculopathy in Rats
  3233. Abstract A94: effects of different modes of calorie restriction on mammalian target of Rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pads and tumors
  3234. Rapamycin-Based GvHD Prophylaxis Is Effective in T-Cell Replete Unmanipulated Haploidentical Peripheral Stem Cell Transplantation for Advanced Haematological …
  3235. Role of Rapamycin in renal ischemia-reperfusion injury
  3236. Symbol Domestic Rapamycin-eluted stent for treatment of acute myocardial infarction in 108 cases
  3237. Rapamycin Used in Kidney Transplantation Patients in China: A Meta-analysis of Clinical Curative Effects
  3238. Conversion to Rapamycin in liver transpant recipients with renal insufficiency
  3239. Genomewide Profiling of Rapamycin Sensitivity in Saccharomyces cerevisiae on Synthetic Medium
  3240. Effect of Rapamycin (serolimus) on in vitro cultured human oral mucosa keratinocytes
  3241. Effects of Rapamycin and paclitaxel on different human prostate cancer cells and xenografts
  3242. The Generation of Novel Fluorinated Rapamycin Analogues
  3243. Treg and Rapamycin effects on humoral immunity in young and old mice (84.12)
  3244. EXPERIENCE WITH Rapamycin IN PEDIATRIC LIVER TRANSPLANTATION: 1434
  3245. Inhibitory effect of Rapamycin on proliferation of H_ (22) hepatic cancer in mice
  3246. Effect of Rapamycin on Postoperative Fibrosis After Filtration Surgery in a Rabbit Model
  3247. The mammalian target of Rapamycin in translation and folding
  3248. Effect of Rapamycin on the proliferation and apoptosis of glomerular mesangial cells
  3249. Transcriptional Profile Changes Induced by Rapamycin in Breast Cancer Maintained in Organ Culture.
  3250. Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells.
  3251. Effect of Rapamycin on regulator T cells induced by TGF-β1 in vitro
  3252. Study of long-term safety and efficacy of domestic Firebird Rapamycin-eluting stent
  3253. The Role of Mammalian Target of Rapamycin in the Early Development of Mouse Zygotes
  3254. Efficacy of Rapamycin drug-eluting stents in elderly patients with coronary heart disease
  3255. Insights into hepatic carcinogenesis: The effect of Rapamycin on rat liver cell lines
  3256. Rapamycin combined with cisplatin in inhibiting the proliferation of ovarian cancer SKOV-3 cells [J]
  3257. Development of Selective Inhibitors of the Mammalian Target of Rapamycin
  3258. Rapamycin is a potent inhibitor of skin tumor promotion by TPA
  3259. Antiproliferative and antiangiogenic effect of Rapamycin on ADPKD cystic lining epithelial cells
  3260. Abstract B141: Effects of AZD8055, a novel mTOR kinase inhibitor, in human cancer cells developing resistance to Rapamycin
  3261. Abstract A41: Evaluation of maximum tolerated dose of aerosolized Rapamycin in A/J mice
  3262. Rapamycin combined with nimuatine suppresses growth and proliferation of human U87MG glioma cells
  3263. Effect of mTOR inhibition by Rapamycin on promotion of skin tumors in BK5. Aktwt transgenic mice
  3264. Characterization of the Effects and Functions of Sumoylation Through Rapamycin-Mediated Heterodimerization
  3265. Black and white: Rapamycin as a regulator of cardiac mTOR signaling
  3266. Immunomodulatory Effect of Rapamycin on Innate Immune Response Genes
  3267. Clenbuterol increases PGC1a promoter activity via a Rapamycin sensitive mechanism
  3268. Active-Site inhibition of the Mammalian Target of Rapamycin
  3269. Effect of Rapamycin on cell prolification of glomerular mesangial cells by high glucose
  3270. The role of mammalian target of Rapamycin complex 1 in hepatic physiology and disease
  3271. Anti-Leukemia Effect of Rapamycin Alone or Plus Daunorubicin on Acute Lymphoblastic Leukemia Cell Lines
  3272. Rapamycin reduces primary effusion lymphoma progression by targeting VEGF production and VEGF responses
  3273. A Combined Approach of Classical Mutagenesis and Rational Metabolic Engineering for the Improved Production of Rapamycin in Streptomyces hygroscopicus …
  3274. Rapamycin-Induced Abundance Changes in the Proteome of Budding Yeast
  3275. Inhibitory effect of Rapamycin on human renal tubular epithelial-myofibroblast transition
  3276. Rapamycin sensitizes Jurkat T-ALL cells to dexamethasone-induced apoptosis
  3277. Effects of Rapamycin on cell proliferation and apoptosis of melanoma B-16 cells
  3278. The influence of Rapamycin combined with 5-Aza-cdR to interfere in the in vitro culture of MCF-7 cell line
  3279. Mammalian Target of Rapamycin Signaling in Regulation of Aging of Human RPE
  3280. The therapeutic value of Rapamycin in a novel mouse model for tuberous scelrosis
  3281. Novel therapeutic strategy for breast cancer: mammalian target of Rapamycin inhibition
  3282. Effects of Rapamycin on growth and mTOR/4EBP1 Signalling Pathway in Xenograft of Esophageal Squamous Cell Carcinoma
  3283. Comparison of Rapamycin and Mitomycin for Reduction of Postoperative Fibrosis After Filtration Surgery in a Rabbit Model
  3284. Rapamycin enhances G protein signaling in the budding yeast Saccharomyces Cerevisiae
  3285. Pharmacokinetics characterization of Rapamycin ointment in rabbit aqueous humor
  3286. Effects of Rapamycin on nephropathy and expression of VEGF and VEGF receptors in PAN nephritic mice [J]
  3287. … Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the MammalianTarget of Rapamycin …
  3288. The Regulation of STAT1 Nuclear Content by Mammalian Target of Rapamycin
  3289. Mammalian Target of Rapamycin Regulates STAT1 Localization in Lung Epithelial Cells.
  3290. Rapamycin-Induced Allograft Tolerance: Elucidating Mechanisms and Biomarker Discovery
  3291. Rapamycin prevents the post‐exercise increase in protein synthesis and alters cell signaling in human skeletal muscle
  3292. The Rapamycin-sensitive phosphoproteome reveals that TOR controls PKA 3 toward some but not all substrates 4
  3293. CLONING AND CHARACTERIZATION OF THE PARTIAL Rapamycin-BIOSYNTHETIC GENE CLUSTER FROM ACTINOPLANES SP. N902-109
  3294. Expression of mammalian target of Rapamycin/P70S6K in pathologic scars
  3295. Rapamycin‐sensitive Co‐localization of mTOR to the Mitotic Spindle
  3296. Abstract B143: Distinct antitumor mechanisms of VEGFR inhibitor tivozanib (AV‐951) and mTOR inhibitor Rapamycin support rational combination for solid tumors to …
  3297. Effectiveness of Rapamycin drug-eluting stent (Excel stent) in treatment of patients with coronary artery disease
  3298. Defining the clinical role of the mammalian target of Rapamycin (mTOR) in lung cancer
  3299. BETA-CATENIN TARGET GENES ARE UPREGULATED DURING PARTIAL BLADDER OUTLET OBSTRUCTION AND INHIBITED BY Rapamycin
  3300. Effect of Rapamycin on TGF-β1-induced epithelial-mesenchymal transition in LoVo colonic adenocarcinoma cells
  3301. Tolerability of the mTOR inhibitor Rapamycin in cirrhotic patients with advanced hepatocellular carcinoma
  3302. Clinical Application of Domestic Rapamycin-Eluting Stent in the Emergency Intervention of Acute Coronary Syndrome (ACS)
  3303. Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss
  3304. Effect of Rapamycin on regulating Toll-like receptor-4 gene expression in rats with acute liver failure
  3305. The influence of Rapamycin on expression of CCR7 in the rats with renal fibrosis induced by adriamycin
  3306. Rapamycin induces proliferation of CD4~+ CD25~+ FoxP3~+ T regulatory cells in rats
  3307. Mammalian target of Rapamycin complex 2 regulates helper T cell differentiation and function (47.31)
  3308. BLADDER SMOOTH MUSCLE CELL GROWTH IS MEDIATED BY MAMMALIAN TARGET OF Rapamycin (mTOR)
  3309. Expression and significance of phosphorylation-mammalian target of Rapamycin in endometrial carcinoma
  3310. High Levels Of Mammalian Target Of Rapamycin (mTOR) In Pulmonary Hypertension
  3311. Transscleral Passive Delivery of Rapamycin in Rabbit Using a Visulex® Topical Application Device
  3312. Inhibitory effect of Rapamycin on connective tissue growth factor-stimulated cell proliferation and fibronectin secretion in myofibroblasts
  3313. Treatment of malignant gliomas with systemic Rapamycin and convection-enhanced delivery of nanoliposomal CPT-11
  3314. e0519 Rapamycin suppress KrÜppel-Like Factor 2 expression: mechanism of endothelial dysfunction associated with drug-eluting stents
  3315. The mammalian target of Rapamycin inhibitor RAD001 (everolimus) in early breast cancer
  3316. Mammalian target of Rapamycin inhibitors for the targeted therapy of non-small cell lung cancer
  3317. Chronic Rapamycin Therapy Ameliorates Hypertrophy and Systolic Dysfunction in Severe Chronic Heart Failure Due to Pressure Overload
  3318. Physiologic Stimulation Of Bladder Smooth Muscle Cell Growth Is Mediated By Mammalial Target Of Rapamycin (mTOR)
  3319. Treatment of Non-left Main Bifurcation Lesions Using the Rapamycin-Eluting Stent
  3320. Determination of Encapsulation Efficiency of Rapamycin-loaded Poly (lactic-co-glycolic) acid Nanoparticles by HPLC
  3321. Elucidation of chemopreventive effects of aerosolized Rapamycin and dietary myoinositol by mechanistic biomarkers in mouse lung
  3322. Expansion of CD3+/CD4+/CD25+/Foxp3+ T cells in Rapamycin-treated lupus patients (143.52)
  3323. Mammalian target of Rapamycin (mTOR) inhibitors with therapeutic potential for colitis
  3324. PATHOLOGICAL ANGIOGENESIS IN VASCULAR TUMORS IS DRIVEN BY AKT1 AND INHIBITED BY TOPICAL Rapamycin
  3325. Combination Of Simvastatin And Rapamycin Abrogates TSC2-null Tumor Growth In Nude Mice And Improves Animal Survival
  3326. Pathological angiogenesis in vascular tumors is driven by endothelial Akt1 and inhibited by Rapamycin
  3327. Effect of intravenous injection of apoptotic cells combined with Rapamycin on regulatory T cells in rhesus monkey
  3328. Rapamycin Inhibits Store-Operated Ca2+ Entry in Cells Isolated from Endarterectomized Tissues of Patients with Chronic Thromboembolic Pulmonary Hypertension.
  3329. Immune regulatory effect of Rapamycin and cyclosporine A on experimental corneal allograft survival
  3330. Effect of Rapamycin Eluting Stent for inhibition of Neointimal Hyperplasia in Diabetic Porcine Model
  3331. Supplemental Information Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster
  3332. Effects of high glucose and Rapamycin intervention on expression of type Ⅳ collagen and matrix metalloproteinase-9 in podocytes
  3333. Cigarette Smoke And Rapamycin Up-regulate Matrix Metalloproteinase-1 Expression In Endothelial Cells Through mTOR Activation
  3334. Preparation and in vitro release study of Rapamycin in poly (lactic-co-glycolic) acid microsphere for topical administration
  3335. PDGFR alpha is overexpressed in synovial sarcomas and can mediate Rapamycin induced Akt activation
  3336. Enhanced tumor cytotoxicity of a combinational therapy using liposomal copper-doxorubicin, Rapamycin, and ultrasound
  3337. Rapamycin-CONDITIONED HUMAN DENDRITIC CELLS EXHIBIT INCREASED IL-12P70 PRODUCTION UPON EXPOSURE TO PRO-INFLAMMATORY …
  3338. Rapamycin eye drops inhibit rat corneal neovascularization: Role of vascular endothelial growth factor and inflammatory factor☆
  3339. The mammalian target of Rapamycin signaling pathway in bovine mammary epithelial cells
  3340. Characterisation of the effects and mechanism of action of Rapamycin and genistein on acute myeloid leukemia using high-throughput techniques
  3341. New Drug Development in Sarcoma: Exploration of Novel Targets, Particularly the Mammalian Target of Rapamycin (mTOR) Pathway
  3342. 45A: TARGETED SITE SPECIFIC IMMUNOSUPPRESSION WITH TOPICAL Rapamycin AND MYCOPHENOLIC ACID IN COMPOSITE TISSUE …
  3343. 1, 4-phenylenebis (methylene) selenocyanate (p-XSC) inhibits mammalian target of Rapamycin complex 2 (mTORC2) signaling in prostate cancer cells
  3344. Pre-clinical and Clinical Study Results for the Coracto™ Rapamycin-eluting Stent–A New-generation Drug-eluting Stent
  3345. The Protective Effect of mammalian Target of Rapamycin (mTOR) in Cisplatin Induced Nephropathy
  3346. Contact-dependent suppression pathways in non-human primate Tregs expanded ex vivo in the presence of Rapamycin (141.36)
  3347. The effects of l-leucine, contractions, and Rapamycin on the Akt/mTOR pathway in rat skeletal muscle
  3348. Rapamycin IMPAIRS PROLIFERATION OF TRANSPLANTED ISLET BETA CELLS: 791
  3349. Rapamycin inhibits epidermal cell proliferation in a xenograft model of tuberous sclerosis skin tumors
  3350. Effect of the combination of retinoic acid and Rapamycin on cerebellar granule cell and medulloblastoma proliferation
  3351. Nutrient signaling, mammalian target of Rapamycin and ovine conceptus development
  3352. Effect of combination of CCR5 antisense peptide nucleic acid and lose-dose Rapamycin on islet allograft survival
  3353. Rapamycin inhibits cyst growth, IGF-1-mediated VEGF secretion and cell proliferation in polycystin-2 defective mice
  3354. Is Oral Rapamycin Plus Bare Metal Stents a Feasible Alternative to Drug‐Eluting Stents? Lessons Learned from Argentina Observational and Randomized Studies …
  3355. Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd.
  3356. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism in the Krebs cycle
  3357. Combination of antagonists of growth hormone-releasing hormone antagonist (GHRH) with Rapamycin as a potential therapy in human breast cancers.
  3358. Role of mammalian target of Rapamycin signalling in bone destruction by gingival squamous cell carcinoma
  3359. Rapamycin potentiates the effects of paclitaxel in uterine papillary serous carcinoma (UPSC) cells through inhibition of cell proliferation and induction of apoptosis
  3360. Symbol Effect of Rapamycin-poly (lactide-acid)/magnetic microsphere composite materials on the proliferation of vascular smooth muscle cells
  3361. Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma
  3362. Effects of Mycophenolic Acid and Rapamycin on Toll-like Receptor Expression in Hypoxic Human Proximal Tubular Epithelial Cells
  3363. The Impact of Iron Deficiency During Development on Mammalian Target of Rapamycin Signaling, Neuronal Structure, and Learning and Memory Behavior
  3364. Mammalian Target of Rapamycin: A Bump in the Pathway to NF-κB Activation and ICAM-1 Expression in Endothelial Cells.
  3365. Increased Frequency Of Regulatory T-Cells And Selection Of Highly Potent CD62L+ Cells During Treatment Of Human Lung Recipients With Rapamycin
  3366. The IGF-1 receptor targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with Rapamycin in models of childhood sarcoma
  3367. Targeting mammalian target of Rapamycin (mTOR) signaling in the Han: SPRD rat, a model for polycystic kidney disease
  3368. Chemical Genetic Dissection of TOR Signaling Through Identification and Characterization of Small Molecule Enhancers of Rapamycin
  3369. Mammalian Target of Rapamycin Signaling and the Suprachiasmatic Circadian Clock
  3370. Abstract# 3712: OXA-01, a novel potent mTORC1/TORC2 inhibitor displays improved anti-tumor activity in comparison to Rapamycin, an mTORC1 selective inhibitor
  3371. inhibition of mammalian target of Rapamycin induces phenotypic reversion in three-dimensional cultures of malignant breast epithelial cells
  3372. Rapamycin mediated inhibition of mTOR prevents postprandial activation of the unfolded protein response and upregulation of fatty acid synthase
  3373. Distinct phosphatase requirements and GATA factor responses to nitrogen catabolite repression and Rapamycin treatment in S. cerevisiae
  3374. Use of Rapamycin Reveals Evidence of the Physiological Roles of FKBP12 and FKBP12. 6 In Cardiac Excitation-Contraction Coupling
  3375. e0520 Statin effects in stent thrombosis induced by Rapamycin releasing from drug-eluting stents through KrÜppel-Like Factor 2 overexpression
  3376. Rapamycin enhanced in vitro and in vivo activity of dexamethasone against acute lymphoblastic leukemia and lymphoma preclincal models via inhibition of p70S6 …
  3377. Human T Cell Rapamycin Resistance And Th1/Tc1 Polarization Augment Xenogeneic Graft-Versus-Host Disease
  3378. Abstract# 4363: inhibition of mammalian target of Rapamycin (mTOR) in advanced pancreatic cancer-the results of two prospective phase II studies.
  3379. In vitro enhancing oxidative phosphorylation by Rapamycin in proliferative CD8+ T cells during antigenic priming augments the generation of long-lived memory T cells …
  3380. Comparasion of therapeutic effects of Chinese Rapamycin-eluting stent and imported paclitaxel-eluting stent in treatment of acute myocardial infarction
  3381. Generation of tolerogenic human DC through Rapamycin conditioning and genetic modification with HLA-G.
  3382. Prolonged Exposure of Myeloid Dendritic Cells To Rapamycin enhances LPS-induced IL-12p70 production, but does not promote Th1 responses (141.29)
  3383. The mammalian target of Rapamycin mediates the angiogenic and chemotactic effects of leptin in human hepatic stellate cells.
  3384. Calorie restriction and Rapamycin, but not exercise, inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity
  3385. Abstract# LB-135: Grapefruit juice significantly increases bioavailability of weekly Rapamycin (sirolimus)-evidence of safety and activity in a phase 1 study
  3386. Mammalian Target of Rapamycin (mTOR)-mediated Effect on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  3387. Vitamin K_3 induces autophagy in HeLa cells through downregulating the mammalian target of Rapamycin (mTOR) pathway
  3388. Pharmacodynamic (PD) study of pre-prostatectomy Rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials …
  3389. Effects of high-fat vs. low-fat diets on mammalian target of Rapamycin signaling and metabolic measures in spontaneously hypertensive rats
  3390. Anti-liver fibrotic effect of Salvia miltiorthiza and Shugan-Huayu powder combining with or without Rapamycin in animal models.
  3391. Rapidly Inducible Protein Modification Using Rapamycin-mediated Complementation Of Tobacco Etch Virus (TEV) Protease
  3392. Modulatory Role of Mammalian Target of Rapamycin in Regulating Endothelial ICAM‐1 Expression and Lung PMN Recruitment
  3393. Erratum: Mammalian target of Rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial …
  3394. Rapamycin AND MYCOPHENOLIC ACID, BUT NOT CYCLOSPORIN A, IMPAIR HUMAN NK CELL CYTOLYTIC ACTIVITY DUE TO DIFFERENTIAL EFFECTS ON …
  3395. 198 Modulation of CCR5 density with low doses of the transplant drug Rapamycin sensitizes Vicriviroc-resistant R5 HIV-1
  3396. Rapamycin and IL-2 Prevents Lethal Acute Graft-Versus Host Disease by Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells.
  3397. Abstract# 4648: Rapamycin inhibits tube formation of lymphatic endothelial cells by targeting TORC1-mediated expression of Flt4
  3398. Abstract LB-74: A high-throughput RNAi sensitization screen of Rapamycin identifies targets for rational drug combination strategies
  3399. Abstract# 2770: Over-expression of the mammalian target of Rapamycin (mTOR): a novel biomarker for poor survival in resected early stage non-small cell lung cancer
  3400. Abstract# 2014: ATP competitive inhibitors of the mammalian target of Rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with …
  3401. The Mammalian Target of Rapamycin (mTOR) Is a Novel Regulator of HMW-Hyaluronan-Mediated Pulmonary Endothelial Barrier Enhancement.
  3402. COMBINED ADMINISTRATION OF A NOVEL MUTANT TGF-β1/FC AND Rapamycin MODULATES THE IMMUNE BALANCE BETWEEN TREG AND TH17 AND …
  3403. CD28: FC AND Rapamycin CAN PREVENT TH17-MEDIATED ALLOGRAFT REJECTION IN MOUSE PANCREATIC ISLET TRANSPLANTATION MODEL: 700
  3404. Androgen receptor antagonist bicalutamide sensitizes androgen-independent prostate cancer cells to mTOR inhibitor Rapamycin by regulating phosphorylation of …
  3405. Abstract# 1735: Rapamycin inhibits hyperactivation of mTORC1 signaling in a novel xenograft model of tuberous sclerosis complex skin tumors
  3406. ET-29. ONCOLYTIC VIRUS COMBINED WITH Rapamycin TARGETING BRAIN TUMOR-INITIATING CELLS
  3407. … Multicenter phase I clinical trial of an insulin like growth factor (IGF‐R) inhibitor (IMC‐A12) in combination with a mammalian target of Rapamycin (mTOR) inhibitor (CCI …
  3408. Mouse Oocytes Promote the Mechanistic Target of Rapamycin (Serine/Threonine Kinase, mTOR) Pathway in Cumulus Cells by Suppressing the Expression of DNA …
  3409. … oral protein: time‐dependent concordance/discordance between muscle protein synthesis (MPS) and mammalian target of Rapamycin (mTOR)‐associated signaling
  3410. Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of Rapamycin in myelodysplastic syndrome
  3411. Rapamycin CONDITIONED DENDRITIC CELLS FOR IN VITRO DIFFERENTIATION OF DONOR-SPECIFIC CD4+ CD25+ FOXP3+ REGULATORY T CELLS FOR …
  3412. … DEVELOPMENT OF CD8+ CD44+ CD62L+ MEMORY T CELLS PROMOTE SPECIFIC TOLERANCE TO CARDIAC ALLOGRAFTS FOLLOWING Rapamycin …
  3413. Abstract# 4050: Increased cytotoxicity with nifurtimox and Rapamycin combination therapy in neuroblastoma.
  3414. The Effect of Insulin-like Growth Factor 1 (IGF-1) and Exercise on the Protein Expression of Mammalian Target of Rapamycin (mTOR) and Androgen Receptor (AR) in …
  3415. Abstract# 3711: Superior cellular anti-tumor effects of a dual mTORC1/mTORC2 kinase inhibitor OXA-01 relative to the mTORC1 inhibitor Rapamycin
  3416. Erratum 2: Testosterone induces cardiomyocyte hypertrophy through mammalian target of Rapamycin complex 1 pathway
  3417. Erratum 2: Testosterone induces cardiomyocyte hypertrophy through mammalian target of Rapamycin complex 1 pathway (vol 202, pg 299, 2009)
  3418. Abstract# 156: Is irinotecan and Rapamycin combination, targeting mTOR/HIF-1 alpha axis, a new effective therapy in high grade brain tumors?
  3419. Intra-Nuclear Function for PP2A Phosphatase: Pph21/22 Are Required for Rapamycin-Induced GATA Factor Binding to the DAL5 Promoter in Yeast
  3420. Activating transcription factor 4 negatively regulates the mammalian target of Rapamycin via Redd1 expression in response to 2-deoxyglucose
  3421. Abstract# 5237: The combination of Rapamycin and bicalutamide induce apoptosis in prostate cancer cells by simultaneously inhibiting the mTORC1/eIF4 and AR …
  3422. TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than Rapamycin
  3423. Abstract# 2824: The Src inhibitor AZD0530 enhances the anti-tumor effect of Rapamycin in hepatocellular carcinoma (HCC) cells
  3424. Abstract LB-159: An orthotopic model of head and neck squamous carcinoma reveals that mTOR inhibition with Rapamycin halts lymph node metastasis
  3425. Abstract# 3842: High expression of mTOR (mammalian target of Rapamycin) is associated with better outcome in non-small cell lung cancer
  3426. Abstract# 1079: CD133 expression is affected by Rapamycin in cancer cells.
  3427. Abstract# 2879: inhibition of mammalian target of Rapamycin as a therapeutic strategy in the management of bladder cancer
  3428. Abstract# 3757: Antiproliferative effects of Rapamycin and doxorubicin combination on human Erbb2 overexpressing breast epithelial cell lines.
  3429. Abstract# 2818: Growth inhibition of human breast cancer cells with an iron chelator and a dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor
  3430. Abstract# 2302: NVP-BEZ235 a dual inhibitor of phosphatidylinositol 3-Kinase (PI3 Kinase) and mammalian target of Rapamycin (mTOR) potently enhances the effects …
  3431. Liposomal KRN7000 (RGI-2001) Synergizes with Low-Dose Rapamycin in Preventing GvHD by promoting expansion of naturally-Occurring CD4+FOXP3+ …
  3432. Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H …
  3433. … : HQO-0601, an amide-containing 3, 4-dihydroquinolinone derivative, against human hematologic malignancies through inhibition of mammalian target of Rapamycin …
  3434. Rapamycin slows aging in mice
  3435. Fighting neurodegeneration with Rapamycin: mechanistic insights
  3436. Target of Rapamycin (TOR) in nutrient signaling and growth control
  3437. Rapamycin and glucose-target of Rapamycin (TOR) protein signaling in plants
  3438. Rapamycin passes the torch: a new generation of mTOR inhibitors
  3439. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity
  3440. Autophagy activation by Rapamycin reduces severity of experimental osteoarthritis
  3441. Protein translocation as a tool: The current Rapamycin story
  3442. Relieving autophagy and 4EBP1 from Rapamycin resistance
  3443. Chronic inhibition of mammalian target of Rapamycin by Rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
  3444. Paradoxical aspects of Rapamycin immunobiology in transplantation
  3445. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
  3446. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice
  3447. TOR signaling and Rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO
  3448. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
  3449. The mammalian target of Rapamycin regulates cholesterol biosynthetic gene expression and exhibits a Rapamycin-resistant transcriptional profile
  3450. A photocleavable Rapamycin conjugate for spatiotemporal control of small GTPase activity
  3451. Target of Rapamycin signaling regulates metabolism, growth, and life span in Arabidopsis
  3452. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice
  3453. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
  3454. Rapamycin and other longevity‐promoting compounds enhance the generation of mouse induced pluripotent stem cells
  3455. mTOR and Rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression
  3456. Inducing autophagy by Rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits
  3457. … enhances the anti-tumor activity of the mTOR inhibitor Rapamycin in multiple breast cancer cell lines mainly by suppressing Rapamycin-induced AKT signaling
  3458. Common toxicities of mammalian target of Rapamycin inhibitors
  3459. Topical Rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex
  3460. Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis
  3461. Activating mutations of TOR (target of Rapamycin)
  3462. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells
  3463. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function
  3464. Mammalian target of Rapamycin: a signaling kinase for every aspect of cellular life
  3465. Mammalian target of Rapamycin: a central node of complex signaling cascades
  3466. Induction of tolerance to factor VIII by transient co‐administration with Rapamycin
  3467. Once again on Rapamycin-induced insulin resistance and longevity: despite of or owing to
  3468. Haploinsufficiency of target of Rapamycin attenuates cardiomyopathies in adult zebrafish
  3469. Stability of human Rapamycin-expanded CD4+ CD25+ T regulatory cells
  3470. Autophagy and cardiovascular aging: lesson learned from Rapamycin
  3471. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice
  3472. A pulse Rapamycin therapy for infantile spasms and associated cognitive decline
  3473. Hyperplexing: a method for higher-order multiplexed quantitative proteomics provides a map of the dynamic response to Rapamycin in yeast
  3474. Rapamycin protects against myocardial ischemia–reperfusion injury through JAK2–STAT3 signaling pathway
  3475. Mammalian target of Rapamycin and the kidney. I. The signaling pathway
  3476. The ketogenic diet inhibits the mammalian target of Rapamycin (mTOR) pathway
  3477. Preventive and therapeutic effects of Rapamycin, a mammalian target of Rapamycin inhibitor, on food allergy in mice
  3478. Shedding new light on neurodegenerative diseases through the mammalian target of Rapamycin
  3479. Lifelong Rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signaling
  3480. Mammalian target of Rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth
  3481. Mammalian target of Rapamycin signaling in diabetic cardiovascular disease
  3482. Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice
  3483. Folate-conjugated Rapamycin slows progression of polycystic kidney disease
  3484. Mammalian target of Rapamycin (mTOR) signaling network in skeletal myogenesis
  3485. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy
  3486. Chronic mTOR inhibition by Rapamycin induces muscle insulin resistance despite weight loss in rats
  3487. Wound healing complications and the use of mammalian target of Rapamycin inhibitors in kidney transplantation: a critical review of the literature
  3488. Rapamycin increases oxidative stress response gene expression in adult stem cells
  3489. inhibition of mammalian target of Rapamycin reduces epileptogenesis and blood–brain barrier leakage but not microglia activation
  3490. Rapamycin As an Antiaging Therapeutic?: Targeting Mammalian Target of Rapamycin to Treat Hutchinson–Gilford Progeria and Neurodegenerative Diseases
  3491. Successful treatment of angiofibromata of tuberous sclerosis complex with Rapamycin
  3492. Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats
  3493. Rapamycin Causes Upregulation of Autophagy and Impairs Islets Function Both In Vitro and In Vivo
  3494. Therapeutic role of mammalian target of Rapamycin (mTOR) inhibition in preventing epileptogenesis
  3495. Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose Rapamycin impairs autophagic flux in …
  3496. Prevention of age-related macular degeneration–like retinopathy by Rapamycin in Rats
  3497. Mammalian target of Rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer’s disease?
  3498. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of Rapamycin (mTOR) pathway
  3499. Current and future directions in mammalian target of Rapamycin inhibitors development
  3500. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with Rapamycin
  3501. Target of Rapamycin regulates development and ribosomal RNA expression through kinase domain in Arabidopsis
  3502. Mammalian target of Rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids
  3503. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by Rapamycin
  3504. inhibition of mammalian target of Rapamycin augments lipopolysaccharide-induced lung injury and apoptosis
  3505. New nanoformulation of Rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis
  3506. Combinatorial effects of lapatinib and Rapamycin in triple-negative breast cancer cells
  3507. Phase II study of the mammalian target of Rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
  3508. Impaired autophagy in neurons after disinhibition of mammalian target of Rapamycin and its contribution to epileptogenesis
  3509. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann–Sträussler–Scheinker disease
  3510. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of Rapamycin (mTOR) complex 2
  3511. Rapamycin reverses elevated mTORC1 signaling in lamin A/C–deficient mice, rescues cardiac and skeletal muscle function, and extends survival
  3512. Retinoic acid and Rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells
  3513. Rapamycin increases rDNA stability by enhancing association of Sir2 with rDNA in Saccharomyces cerevisiae
  3514. Review of cytomegalovirus infection findings with mammalian target of Rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients
  3515. Low‐Dose Rapamycin Treatment Increases the Ability of Human Regulatory T Cells to Inhibit Transplant Arteriosclerosis In Vivo
  3516. Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of Rapamycin on protein synthesis
  3517. Managing stomatitis in patients treated with Mammalian target of Rapamycin inhibitors.
  3518. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutation
  3519. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug
  3520. inhibition of mechanistic target of Rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice
  3521. Therapeutic value of prenatal Rapamycin treatment in a mouse brain model of tuberous sclerosis complex
  3522. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage
  3523. Rapamycin slows aging in mice
  3524. Amino acids activate mammalian target of Rapamycin complex 2 (mTORC2) via PI3K/Akt signaling
  3525. Suppression of replicative senescence by Rapamycin in rodent embryonic cells
  3526. inhibition of the mammalian target of Rapamycin blocks epilepsy progression in NS‐Pten conditional knockout mice
  3527. The mTOR inhibitor Rapamycin suppresses DNA double-strand break repair
  3528. Autophagy stimulation by Rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis
  3529. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study
  3530. Differing effects of Rapamycin or calcineurin inhibitor on T‐regulatory cells in pediatric liver and kidney transplant recipients
  3531. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by Rapamycin
  3532. Post-treatment with Rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy
  3533. Mammalian target of Rapamycin and the kidney. II. Pathophysiology and therapeutic implications
  3534. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF
  3535. Optimization of Rapamycin-loaded acetalated dextran microparticles for immunosuppression
  3536. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
  3537. Mammalian target of Rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α
  3538. Stress-responsive sestrins link p53 with redox regulation and mammalian target of Rapamycin signaling
  3539. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons
  3540. Oral Rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation
  3541. Oral adverse events associated with tyrosine kinase and mammalian target of Rapamycin inhibitors in renal cell carcinoma: a structured literature review
  3542. Efficacy and safety of sorafenib in combination with mammalian target of Rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation
  3543. Involvement of the mammalian target of Rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists
  3544. N‐acetylcysteine reduces disease activity by blocking mammalian target of Rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double …
  3545. … lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of Rapamycin
  3546. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG
  3547. Rapamycin-induced glucose intolerance: hunger or starvation diabetes
  3548. Induction of biogenic magnetization and redox control by a component of the target of Rapamycin complex 1 signaling pathway
  3549. Rapamycin resistance is linked to defective regulation of Skp2
  3550. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts
  3551. Roles of the mammalian target of Rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis
  3552. The mTOR inhibitor Rapamycin has limited acute anticonvulsant effects in mice
  3553. Multiple roles for mammalian target of Rapamycin signaling in both glutamatergic and GABAergic synaptic transmission
  3554. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma
  3555. Rapamycin-induced enhancement of vaccine efficacy in mice
  3556. Regulating mammalian target of Rapamycin to tune vaccination-induced CD8+ T cell responses for tumor immunity
  3557. Biosynthesis of the immunosuppressants FK506, FK520, and Rapamycin involves a previously undescribed family of enzymes acting on chorismate
  3558. A comprehensive review of everolimus clinical reports: a new mammalian target of Rapamycin inhibitor
  3559. Selective activation of Akt1 by mammalian target of Rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis
  3560. Rab5 proteins regulate activation and localization of target of Rapamycin complex 1
  3561. Mutations in the Arabidopsis homolog of LST8/GβL, a partner of the target of Rapamycin kinase, impair plant growth, flowering, and metabolic adaptation to long days
  3562. Mammalian target of Rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy
  3563. Expanding human T regulatory cells with the mTOR-inhibitor Rapamycin
  3564. Effects of Rapamycin and TOR on aging and memory: implications for Alzheimer’s disease
  3565. Naturally secreted amyloid-β increases mammalian target of Rapamycin (mTOR) activity via a PRAS40-mediated mechanism
  3566. Phospholipase D mediates nutrient input to mammalian target of Rapamycin complex 1 (mTORC1)
  3567. Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders
  3568. Plasma membrane recruitment and activation of the AGC kinase Ypk1 is mediated by target of Rapamycin complex 2 (TORC2) and its effector proteins Slm1 and Slm2
  3569. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells
  3570. Mycobacterial induction of autophagy varies by species and occurs independently of mammalian target of Rapamycin inhibition
  3571. Third target of Rapamycin complex negatively regulates development of quiescence in Trypanosoma brucei
  3572. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)
  3573. Rapamycin attenuates airway hyperreactivity, goblet cells, and IgE in experimental allergic asthma
  3574. mTOR inhibition with Rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
  3575. Progeria, Rapamycin and normal aging: recent breakthrough
  3576. Resveratrol inhibits inflammatory responses via the mammalian target of Rapamycin signaling pathway in cultured LPS-stimulated microglial cells
  3577. High-dose Rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
  3578. Systemic inhibition of the mammalian target of Rapamycin (mTOR) pathway reduces neuropathic pain in mice
  3579. The differential effects of prenatal and/or postnatal Rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis …
  3580. Induction of autophagy by palmitic acid via protein kinase C-mediated signaling pathway independent of mTOR (mammalian target of Rapamycin)
  3581. Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of Rapamycin signaling
  3582. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells
  3583. The mTOR kinase inhibitor Rapamycin decreases iNOS mRNA stability in astrocytes
  3584. Insulin-like peptides and the target of Rapamycin pathway coordinately regulate blood digestion and egg maturation in the mosquito Aedes aegypti
  3585. Heightened uterine mammalian target of Rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice
  3586. inhibition of the mammalian target of Rapamycin pathway by Rapamycin blocks cocaine-induced locomotor sensitization
  3587. Tolerance induction by exosomes from immature dendritic cells and Rapamycin in a mouse cardiac allograft model
  3588. Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate
  3589. Characterization of the metabolic phenotype of Rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells
  3590. Light regulation of protein dimerization and kinase activity in living cells using photocaged Rapamycin and engineered FKBP
  3591. Mammalian target of Rapamycin signaling is a key regulator of the transit-amplifying progenitor pool in the adult and aging forebrain
  3592. Metformin promotes progesterone receptor expression via inhibition of mammalian target of Rapamycin (mTOR) in endometrial cancer cells
  3593. A critical role for non-coding RNA GAS5 in growth arrest and Rapamycin inhibition in human T-lymphocytes
  3594. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of Rapamycin complex 1 (mTORC1) signaling
  3595. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical Rapamycin: optimizing a treatment protocol
  3596. Mapping the spatio-temporal pattern of the mammalian target of Rapamycin (mTOR) activation in temporal lobe epilepsy
  3597. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression
  3598. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of Rapamycin complex 1 activity
  3599. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor
  3600. Mammalian target of Rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons
  3601. Mammalian target of Rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1
  3602. Proteomic identification of novel targets regulated by the mammalian target of Rapamycin pathway during oligodendrocyte differentiation
  3603. Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of Rapamycin complex 1 (mTORC1)
  3604. The influence of co-solvents on the stability and bioavailability of Rapamycin formulated in self-microemulsifying drug delivery systems
  3605. Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of Rapamycin pathway
  3606. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2
  3607. Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy
  3608. inhibition of mTOR by Rapamycin in the amygdala or hippocampus impairs formation and reconsolidation of inhibitory avoidance memory
  3609. Convergence of the mammalian target of Rapamycin complex 1-and glycogen synthase kinase 3-β–signaling pathways regulates the innate inflammatory response
  3610. Rapamycin for Treatment of Epilepsy: Antiseizure, Antiepileptogenic, Both, or Neither? Rapamycin for Treatment of Epilepsy
  3611. Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis
  3612. Stimulation of autophagy by Rapamycin protects neurons from remote degeneration after acute focal brain damage
  3613. The physiology and pathophysiology of Rapamycin resistance: implications for cancer
  3614. Combination therapy targeting Akt and mammalian target of Rapamycin improves functional outcome after controlled cortical impact in mice
  3615. Rapamycin paradox resolved
  3616. Combining mTOR inhibitors with Rapamycin-resistant T cells: a two-pronged approach to tumor elimination
  3617. Circadian regulation of mammalian target of Rapamycin signaling in the mouse suprachiasmatic nucleus
  3618. Mammalian Target of Rapamycin (mTOR) Inhibitors
  3619. Dietary restriction but not Rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS
  3620. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study
  3621. Rapamycin reduces reactive oxygen species in cultured human corneal endothelial cells
  3622. mTOR-dependent regulation of PHLPP expression controls the Rapamycin sensitivity in cancer cells
  3623. Mammalian target of Rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells
  3624. Targeting the mammalian target of Rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives
  3625. … mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of Rapamycin …
  3626. Consolidation and reconsolidation of contextual fear memory requires mammalian target of Rapamycin-dependent translation in the dorsal hippocampus
  3627. Effects of cyclosporine, tacrolimus and Rapamycin on renal calcium transport and vitamin D metabolism
  3628. AMP-dependent kinase/mammalian target of Rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications
  3629. Ghrelin contributes to derangements of glucose metabolism induced by Rapamycin in mice
  3630. TORC1 of fission yeast is Rapamycin‐sensitive
  3631. Target-of-Rapamycin complex 1 (Torc1) signaling modulates cilia size and function through protein synthesis regulation
  3632. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of Rapamycin inhibitors
  3633. The tuberous sclerosis complex–mammalian target of Rapamycin pathway maintains the quiescence and survival of naive T cells
  3634. Low dose Rapamycin exacerbates autoimmune experimental uveitis
  3635. Rapamycin impairs proliferation of transplanted islet β cells
  3636. The role of mammalian target of Rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes
  3637. Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and Rapamycin administration
  3638. Kinome-wide selectivity profiling of ATP-competitive mammalian target of Rapamycin (mTOR) inhibitors and characterization of their binding kinetics
  3639. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of Rapamycin complex 1 and FoxO4
  3640. Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in Rapamycin resistance in hepatocellular carcinoma
  3641. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of Rapamycin (mTOR) pathways
  3642. Redox regulates mammalian target of Rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway
  3643. Campylobacter jejuni induces colitis through activation of mammalian target of Rapamycin signaling
  3644. Mechanistic target of Rapamycin inhibitors in solid organ transplantation: from benchside to clinical use
  3645. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of Rapamycin …
  3646. Differing effects of Rapamycin and mTOR kinase inhibitors on protein synthesis
  3647. Coupling nutrient sensing to metabolic homoeostasis: the role of the mammalian target of Rapamycin complex 1 pathway
  3648. Impairment of object recognition memory by Rapamycin inhibition of mTOR in the amygdala or hippocampus around the time of learning or reactivation
  3649. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) kinase inhibitor (GDC-0980) …
  3650. Phosphatidic acid activates mammalian target of Rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an …
  3651. A topical combination of Rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients …
  3652. Assessing the effectiveness of Rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
  3653. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of Rapamycin
  3654. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer
  3655. PDGF receptor alpha is an alternative mediator of Rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma
  3656. The emerging role of mammalian target of Rapamycin inhibitors in the treatment of sarcomas
  3657. Differential effects of Rapamycin on rods and cones during light-induced stress in albino mice
  3658. Evaluation of Rapamycin-induced cell death
  3659. Rapid cytoplasmic turnover of yeast ribosomes in response to Rapamycin inhibition of TOR
  3660. … mammalian target of Rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of Rapamycin …
  3661. Rapamycin attenuates the expression of cocaine‐induced place preference and behavioral sensitization
  3662. The mammalian target of Rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
  3663. L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of Rapamycin
  3664. Starvation and Rapamycin differentially regulate host cell lysosome exocytosis and invasion by Trypanosoma cruzi metacyclic forms
  3665. Paradoxical effects of Rapamycin on experimental house dust mite-induced asthma
  3666. Magnetic nanoparticles and Rapamycin encapsulated into polymeric nanocarriers
  3667. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases
  3668. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73
  3669. Rapamycin inhibits transforming growth factor β‐induced peritoneal angiogenesis by blocking the secondary hypoxic response
  3670. Calorie restriction and Rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity
  3671. Facial angiofibromas treated with topical Rapamycin: an excellent choice with fast response
  3672. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients
  3673. Regulatory T cells require mammalian target of Rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice
  3674. Spinal cord NMDA receptor-mediated activation of mammalian target of Rapamycin is required for the development and maintenance of bone cancer-induced pain …
  3675. SIRT1 is required for the effects of Rapamycin on high glucose-inducing mesangial cells senescence
  3676. The Akt/mammalian target of Rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas
  3677. inhibition of Rapamycin-induced autophagy causes necrotic cell death associated with Bax/Bad mitochondrial translocation
  3678. Emerging roles for mammalian target of Rapamycin inhibitors in the treatment of solid tumors and hematological malignancies
  3679. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of Rapamycin pathway and deregulation of local dendritic translation in a mouse …
  3680. Novel synergistic antitumor effects of Rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model
  3681. Mammalian target of Rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells
  3682. The mechanism of mTOR (mammalian target of Rapamycin) in a mouse model of polycystic ovary syndrome (PCOS)
  3683. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) dual inhibitors
  3684. Mammalian target of Rapamycin signaling in the podocyte
  3685. Transcriptional regulation of gene expression during osmotic stress responses by the mammalian target of Rapamycin
  3686. Mao-B elevation decreases parkin’s ability to efficiently clear damaged mitochondria: protective effects of Rapamycin
  3687. Immunoregulatory properties of Rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation
  3688. Novel feedback inhibition of surface antigen synthesis by mammalian target of Rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and …
  3689. A Hexane Fraction of Guava Leaves (Psidium guajava L.) Induces Anticancer Activity by Suppressing AKT/Mammalian Target of Rapamycin/Ribosomal p70 S6 …
  3690. Clinical activity of mammalian target of Rapamycin inhibitors in solid tumors
  3691. A novel application of topical Rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex
  3692. Targeting notch pathway enhances Rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
  3693. Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle
  3694. Mammalian target of Rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges
  3695. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of Rapamycin inhibitors
  3696. Grape polyphenols inhibit Akt/mammalian target of Rapamycin signaling and potentiate the effects of gefitinib in breast cancer
  3697. Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro
  3698. Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells
  3699. Effect of dietary choline on growth, intestinal enzyme activities and relative expressions of target of Rapamycin and eIF4E-binding protein2 gene in muscle …
  3700. Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of Rapamycin (mTOR)-dependent inhibition of …
  3701. Role of mammalian target of Rapamycin in hypoxic or ischemic brain injury: potential neuroprotection and limitations
  3702. Spinal phosphinositide 3-Kinase–Akt–Mammalian target of Rapamycin signaling cascades in inflammation-induced hyperalgesia
  3703. Enteric-delivered Rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence
  3704. Mechanistic or mammalian target of Rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging
  3705. Intermittent supplementation with Rapamycin as a dietary restriction mimetic
  3706. Modularity and hormone sensitivity of the Drosophila melanogaster insulin receptor/target of Rapamycin interaction proteome
  3707. The histone H3 lysine 56 acetylation pathway is regulated by target of Rapamycin (TOR) signaling and functions directly in ribosomal RNA biogenesis
  3708. TOR: target of Rapamycin
  3709. Ksp1 kinase regulates autophagy via the target of Rapamycin complex 1 (TORC1) pathway
  3710. Multiple site acetylation of Rictor stimulates mammalian target of Rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein
  3711. Clinical outcomes in kidney transplant recipients receiving long‐term therapy with inhibitors of the mammalian target of Rapamycin
  3712. Rapamycin preconditioning attenuates transient focal cerebral ischemia/reperfusion injury in mice
  3713. … of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of Rapamycin complex 1 (mTORC1) …
  3714. Mammalian target of Rapamycin and head and neck squamous cell carcinoma
  3715. Rapamycin-insensitive mTORC1 activity controls eIF4E: 4E-BP1 binding
  3716. Mammalian target of Rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN
  3717. Rapamycin suppresses axon sprouting by somatostatin interneurons in a mouse model of temporal lobe epilepsy
  3718. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling network in cancer stem cells
  3719. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of Rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase …
  3720. Mechanistic mammalian target of Rapamycin (mTOR) cell signaling: effects of select nutrients and secreted phosphoprotein 1 on development of mammalian …
  3721. The mTOR (mammalian target of Rapamycin) kinase maintains integrity of mTOR complex 2
  3722. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
  3723. Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a Rapamycin analogue library
  3724. Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures
  3725. A retrospective review of oral low-dose sirolimus (Rapamycin) for the treatment of active uveitis
  3726. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by Rapamycin
  3727. Drosophila insulin and target of Rapamycin (TOR) pathways regulate GSK3 beta activity to control Myc stability and determine Myc expression in vivo
  3728. Rapamycin treatment inhibits CHO cell death in a serum‐free suspension culture by autophagy induction
  3729. Mammalian target of Rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing
  3730. Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus–Related Burkitt’s Lymphoma
  3731. A combined approach of classical mutagenesis and rational metabolic engineering improves Rapamycin biosynthesis and provides insights into methylmalonyl-CoA …
  3732. The risk of skin rash and stomatitis with the mammalian target of Rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis
  3733. Rapamycin reduces oxidative stress in frataxin-deficient yeast cells
  3734. Advantage of Rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single‐center trial at 10 …
  3735. Phosphorylation of Raptor by p38β participates in arsenite-induced mammalian target of Rapamycin complex 1 (mTORC1) activation
  3736. Synergistic activity of Rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis
  3737. … and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK) 1/2, and mammalian target of Rapamycin complex 1 (mTORC1) …
  3738. LST8 regulates cell growth via target-of-Rapamycin complex 2 (TORC2)
  3739. The mammalian target of Rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases
  3740. Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells
  3741. Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of Rapamycin
  3742. Dissecting mammalian target of Rapamycin to promote longevity
  3743. Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium
  3744. Impact of Rapamycin on peritoneal fibrosis and transport function
  3745. Predictive biomarkers for the activity of mammalian target of Rapamycin (mTOR) inhibitors
  3746. Rapamycin‐Induced Hypophosphatemia and Insulin Resistance Are Associated With mTORC2 Activation and Klotho Expression
  3747. Phospshoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) dual inhibitors: discovery and structure–activity relationships of a series of quinoline and …
  3748. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of Rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition
  3749. Activation of mammalian target of Rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma
  3750. Dual inhibition of phosphatidylinositol 3‐kinase/Akt and mammalian target of Rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid …
  3751. S6 kinase 1 is required for Rapamycin-sensitive liver proliferation after mouse hepatectomy
  3752. Metabolic regulation, mitochondria and the life-prolonging effect of Rapamycin: a mini-review
  3753. Induction of melanogenesis by Rapamycin in human MNT-1 melanoma cells
  3754. Calcineurin inhibitor sparing regimens using m‐target of Rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
  3755. The mammalian target of Rapamycin pathway as a therapeutic target in multiple myeloma
  3756. … and its associated cell death by “sphingolipid rheostat”: reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of Rapamycin …
  3757. Rapamycin sensitive mTOR activation mediates nerve growth factor (NGF) induced cell migration and pro-survival effects against hydrogen peroxide in retinal pigment …
  3758. Regulation of the glutamate transporter EAAT3 by mammalian target of Rapamycin mTOR
  3759. Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of Rapamycin (mTOR)
  3760. The mammalian target of Rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in …
  3761. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex …
  3762. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitors, enhance tumor and endothelial cell …
  3763. An elaborate regulation of Mammalian target of Rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors
  3764. Rapamycin-induced posterior reversible encephalopathy in a kidney transplantation patient
  3765. Mammalian target of Rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma
  3766. … secretion via down-regulation of surface expression of adrenergic α2A receptor through the mTOR (mammalian target of Rapamycin) pathway: implication in …
  3767. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation
  3768. Beta cell function during Rapamycin monotherapy in long-term type 1 diabetes
  3769. Temporal regulation of Rapamycin on memory CTL programming by IL-12
  3770. Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and-9: an in vitro study
  3771. TGFβ‐and bleomycin‐induced extracellular matrix synthesis is mediated through Akt and mammalian target of Rapamycin (mTOR)
  3772. cAMP inhibits mammalian target of Rapamycin complex-1 and-2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity
  3773. Enhanced delivery of Rapamycin by V156K-apoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration
  3774. Interpreting mammalian target of Rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes
  3775. First report of a novel abluminal groove filled biodegradable polymer Rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK …
  3776. Autophagy induced by Rapamycin and carbon‐starvation have distinct proteome profiles in Aspergillus nidulans
  3777. An emerging role for the mammalian target of Rapamycin in “pathological” protein translation: relevance to cocaine addiction
  3778. Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate
  3779. inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235
  3780. Regulation of mammalian target of Rapamycin and mitogen activated protein kinase pathways by BCR–ABL
  3781. mTOR in podocyte function: is Rapamycin good for diabetic nephropathy?
  3782. Yin Yang 1 deficiency in skeletal muscle protects against Rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling
  3783. ULK1, mammalian target of Rapamycin, and mitochondria: linking nutrient availability and autophagy
  3784. Mammalian target of Rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells
  3785. Forced degradation studies of Rapamycin: Identification of autoxidation products
  3786. Inactivation of mammalian target of Rapamycin (mTOR) by Rapamycin in a murine model of lipopolysaccharide-induced acute lung injury
  3787. Pharmacological targeting of mammalian target of Rapamycin inhibits ovarian granulosa cell tumor growth
  3788. Innovations therapy: mammalian target of Rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
  3789. Nitrogen-responsive regulation of GATA protein family activators Gln3 and Gat1 occurs by two distinct pathways, one inhibited by Rapamycin and the other by …
  3790. Myopathy caused by mammalian target of Rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function
  3791. Remarkable inhibition of mTOR signaling by the combination of Rapamycin and 1, 4‐phenylenebis (methylene) selenocyanate in human prostate cancer cells
  3792. Regulatory T cells expanded by Rapamycin in vitro suppress colitis in an experimental mouse model
  3793. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or Rapamycin enhances the antitumor growth effect in neuroblastoma
  3794. Localized ultrasound enhances delivery of Rapamycin from microbubbles to prevent smooth muscle proliferation
  3795. inhibition of Akt (ser473) phosphorylation and Rapamycin-resistant cell growth by knockdown of mammalian target of Rapamycin with small interfering RNA in vascular …
  3796. Myxoma virus combined with Rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors
  3797. Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention
  3798. Rapamycin suppresses ROS-dependent apoptosis caused by selenomethionine in A549 lung carcinoma cells
  3799. Curcumin dually inhibits both mammalian target of Rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex …
  3800. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor Rapamycin
  3801. Rapamycin regulates bleomycin-induced lung damage in SP-C-deficient mice
  3802. Therapeutic efficacy of polyclonal tregs does not require Rapamycin in a low-dose irradiation bone marrow transplantation model
  3803. Effects of intermittent and chronic calorie restriction on mammalian target of Rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pad tissues and …
  3804. Onychopathy induced by temsirolimus, a mammalian target of Rapamycin inhibitor
  3805. … ) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of Rapamycin (mTOR) pathway in …
  3806. Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells
  3807. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia
  3808. Akt/mammalian target of Rapamycin signaling pathway regulates neurite outgrowth in cerebellar granule neurons stimulated by methylcobalamin
  3809. Sorafenib enhances the therapeutic efficacy of Rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA
  3810. V‐AKT murine thymoma viral oncogene homolog/mammalian target of Rapamycin activation induces a module of metabolic changes contributing to growth in insulin …
  3811. Overexpression of the mammalian target of Rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study
  3812. Unrestrained mammalian target of Rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to …
  3813. Rapamycin has age‐, treatment paradigm‐, and model‐specific anticonvulsant effects and modulates neuropeptide Y expression in rats
  3814. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of Rapamycin (mTOR)-dependent survivin …
  3815. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of Rapamycin (mTOR) in renal cell cancer
  3816. Ex vivo Rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice
  3817. Hypoxia‐inducible factor and mammalian target of Rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
  3818. Multi-timescale dynamics study of FKBP12 along the Rapamycin–mTOR binding coordinate
  3819. Rapamycin: killing two birds with one stone
  3820. Immunomodulatory synergy by combining atorvastatin and Rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE)
  3821. Structure–activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) dual inhibitors: investigations of various 6, 5-heterocycles …
  3822. FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of Rapamycin pathway and inhibiting RTP801 expression in Parkinson’s …
  3823. Uterine histotroph and conceptus development: select nutrients and secreted phosphoprotein 1 affect mechanistic target of Rapamycin cell signaling in ewes
  3824. MicroRNA-100 regulates neovascularization by suppression of mammalian target of Rapamycin in endothelial and vascular smooth muscle cells
  3825. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from Rapamycin
  3826. Rapamycin inhibits formation of urethral stricture in rabbits
  3827. Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats
  3828. Rapamycin inhibits the proliferation and apoptosis of gastric cancer cells by down regulating the expression of survivin.
  3829. Topical Rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of …
  3830. Early use of mammalian target of Rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation
  3831. … )phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of …
  3832. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of Rapamycin (mTOR) inhibitor as second-line …
  3833. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of Rapamycin in acute myeloid leukemia cells
  3834. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency
  3835. Effects of STAT3 gene silencing and Rapamycin on apoptosis in hepatocarcinoma cells
  3836. Mammalian target of Rapamycin as a target in hematological malignancies
  3837. … ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of Rapamycin complex 1), FOXM1 …
  3838. Osmotic stress regulates mammalian target of Rapamycin (mTOR) complex 1 via c-Jun N-terminal Kinase (JNK)-mediated Raptor protein phosphorylation
  3839. Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts
  3840. Activation of the phosphoinositide‐3‐kinase and mammalian target of Rapamycin signaling pathways are associated with shortened survival in patients with malignant …
  3841. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by Rapamycin
  3842. Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of Rapamycin in pancreatic endocrine tumour cells
  3843. Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ-MafB axis
  3844. Insulin‐like growth factor I regulates G2/M progression through mammalian target of Rapamycin signaling in oligodendrocyte progenitors
  3845. … method validation of Rapamycin in ocular matrix by QTRAP LC–MS/MS: Application to rabbit anterior tissue distribution by topical administration of Rapamycin …
  3846. Target of Rapamycin complex 2 signals to downstream effector yeast protein kinase 2 (Ypk2) through adheres-voraciously-to-target-of-Rapamycin-2 protein 1 …
  3847. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of Rapamycin as a therapeutic strategy for acute leukemia …
  3848. Mammalian target of Rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients
  3849. A Burkholderia pseudomallei macrophage infectivity potentiator-like protein has Rapamycin-inhibitable peptidylprolyl isomerase activity and pleiotropic effects on …
  3850. Multifaceted role of insulin-like growth factors and mammalian target of Rapamycin in skeletal muscle
  3851. Local delivery of Rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats
  3852. Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication
  3853. … -mediated activation of phospholipase D and mammalian target of Rapamycin (mTOR) regulates proliferation and Rapamycin sensitivity of hepatocarcinoma …
  3854. Blocking mTORC1 activity by Rapamycin leads to impairment of spatial memory retrieval but not acquisition in C57BL/6J mice
  3855. Phosphatidylinositol 3-kinase/AKT/mammalian target of Rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers?
  3856. Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor Rapamycin
  3857. Mammalian target of Rapamycin signaling pathway contributes to glioma progression and patients’ prognosis
  3858. The mTOR-inhibitor Rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response
  3859. … molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3‐kinase/v‐akt murine thymoma viral oncogene/mammalian target of Rapamycin) pathway in bladder …
  3860. Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation
  3861. The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of Rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 …
  3862. Phosphorylated mammalian target of Rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell …
  3863. IL-33 induces innate lymphoid cell–mediated airway inflammation by activating mammalian target of Rapamycin
  3864. … recognition memory consolidation involves activation of the extracellular signal-regulated kinase (ERK) and mammalian target of Rapamycin (mTOR) pathways in the …
  3865. Improved insulin sensitivity by Rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes
  3866. Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond Rapamycin
  3867. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of Rapamycin pathway signaling limits the antitumor …
  3868. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with Rapamycin, an mTOR inhibitor and anti-aging drug
  3869. Dual targeting of phosphoinositide 3-kinase and mammalian target of Rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
  3870. Topical 0.1% Rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients
  3871. Rapamycin inhibits hydrogen peroxide-induced loss of vascular contractility
  3872. Rapamycin sensitive ROS formation and Na+/H+ exchanger activity in dendritic cells
  3873. Rheb, an activator of target of Rapamycin, in the blackback land crab, Gecarcinus lateralis: cloning and effects of molting and unweighting on expression in skeletal …
  3874. Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of Rapamycin in rat hippocampus and prefrontal …
  3875. Phosphatidylinositol 3, 5-bisphosphate plays a role in the activation and subcellular localization of mechanistic target of Rapamycin 1
  3876. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of Rapamycin pathway
  3877. Regulation of mammalian target of Rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences
  3878. Non-clear cell renal cell carcinoma: does the mammalian target of Rapamycin represent a rational therapeutic target?
  3879. Rapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease
  3880. Mammalian target of Rapamycin inhibition in polycystic kidney disease: From bench to bedside
  3881. Rapamycin suppresses the recurrent excitatory circuits of dentate gyrus in a mouse model of temporal lobe epilepsy
  3882. Relief with Rapamycin: mTOR inhibition protects against radiation-induced mucositis
  3883. Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells
  3884. Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of Rapamycin in LS174T colon cancer cells
  3885. Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1α induction
  3886. Controlled release formulations of IL-2, TGF-β1 and Rapamycin for the induction of regulatory T cells
  3887. Differential regulation of the p73 cistrome by mammalian target of Rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis
  3888. Rapamycin (sirolimus) protects against hypoxic damage in primary heart cultures via Na+/Ca2+ exchanger activation
  3889. Surface crystallization of Rapamycin on stents using a temperature induced process
  3890. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor GDC-0980 and prediction of its …
  3891. Rapamycin impairs UV induction of mutant‐p53 overexpressing cell clusters without affecting tumor onset
  3892. Chemoprevention of age-related macular regeneration (AMD) with Rapamycin
  3893. FOXO3a reactivation mediates the synergistic cytotoxic effects of Rapamycin and cisplatin in oral squamous cell carcinoma cells
  3894. Cooperative benefit for the combination of Rapamycin and imatinib in tuberous sclerosis complex neoplasia
  3895. Rapamycin‐sensitive signals control TCR/CD28‐driven Ifng, Il4 and Foxp3 transcription and promoter region methylation
  3896. Topical use of Rapamycin in herpetic stromal keratitis
  3897. Flt3L combined with Rapamycin promotes cardiac allograft tolerance by inducing regulatory dendritic cells and allograft autophagy in mice
  3898. Rho-associated kinase connects a cell cycle-controlling anchorage signal to the mammalian target of Rapamycin pathway
  3899. Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma
  3900. Transcript abundance of hormone receptors, mammalian target of Rapamycin pathway-related kinases, insulin-like growth factor I, and milk proteins in porcine …
  3901. Mammalian target of Rapamycin regulates expression of β-catenin in hepatocellular carcinoma
  3902. Everolimus: a new mammalian target of Rapamycin inhibitor for the treatment of advanced renal cell carcinoma
  3903. Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes
  3904. mTORC1 activity as a determinant of cancer risk–rationalizing the cancer-preventive effects of adiponectin, metformin, Rapamycin, and low-protein vegan diets
  3905. Efficacy of ganitumab (AMG 479), alone and in combination with Rapamycin, in Ewing’s and osteogenic sarcoma models
  3906. Potent, selective, and orally bioavailable inhibitors of the mammalian target of Rapamycin kinase domain exhibiting single agent antiproliferative activity
  3907. NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of Rapamycin (mTOR) signaling in T …
  3908. The E3 ubiquitin ligase protein associated with Myc (Pam) regulates mammalian/mechanistic target of Rapamycin complex 1 (mTORC1) signaling in vivo …
  3909. Mammalian target of Rapamycin complex 2 regulates inflammatory response to stress
  3910. Sindbis virus replication, is insensitive to Rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells
  3911. Potent, selective, and orally bioavailable inhibitors of mammalian target of Rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine
  3912. Rapamycin combined with allogenic immature dendritic cells selectively expands CD4+ CD25+ Foxp3+ regulatory T cells in rats
  3913. Identification of mammalian target of Rapamycin as a direct target of fenretinide both in vitro and in vivo
  3914. Positively charged amphiphilic chitosan derivative for the transscleral delivery of Rapamycin
  3915. Growth hormone improves growth retardation induced by Rapamycin without blocking its antiproliferative and antiangiogenic effects on rat growth plate
  3916. New developments in mammalian target of Rapamycin inhibitors for the treatment of sarcoma
  3917. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of Rapamycin pathway
  3918. Mammalian target of Rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines
  3919. Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor 1 expression: a potential prothrombotic mechanism of drug-eluting stents
  3920. Rapamycin inhibits the invasive ability of thyroid cancer cells by down‐regulating the expression of VEGF‐C in vitro
  3921. Antileukaemia effect of Rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line
  3922. 5′-Adenosine monophosphate-activated protein kinase–mammalian target of Rapamycin axis as therapeutic target for age-related macular degeneration
  3923. Toxicity spectrum of inhibitors of mammalian target of Rapamycin in organ transplantation: etiology, pathogenesis and treatment
  3924. Nuclear factor of activated T-cell c3 inhibition of mammalian target of Rapamycin signaling through induction of regulated in development and DNA damage response …
  3925. inhibition of mammalian target of Rapamycin: two goals with one shot?
  3926. The FKBP–Rapamycin binding domain of human TOR undergoes strong conformational changes in the presence of membrane mimetics with and without the regulator …
  3927. Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with Rapamycin by the pediatric preclinical testing program
  3928. Rapamycin inhibits lipopolysaccharide induction of granulocyte‐colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing …
  3929. … study of 3-in-1 poly (ethylene glycol)-block-poly (D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and Rapamycin
  3930. Intranuclear function for protein phosphatase 2A: Pph21 and Pph22 are required for Rapamycin-induced GATA factor binding to the DAL5 promoter in yeast
  3931. mTORC1/2 and Rapamycin in female Han: SPRD rats with polycystic kidney disease
  3932. Mammalian target of Rapamycin (mTOR) phosphorylates inositol 1, 4, 5-trisphosphate receptor type 2 and increases its Ca2+ release activity
  3933. inhibition of Mammalian target of Rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress
  3934. Evaluation of an AAV2-based Rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system
  3935. Target of Rapamycin (TOR) controls vitellogenesis via activation of the S6 kinase in the fat body of the tick, Haemaphysalis longicornis
  3936. Effect of complementary pathway blockade on efficacy of combination enzastaurin and Rapamycin
  3937. The expression of URGCP gene in prostate cancer cell lines: correlation with Rapamycin
  3938. Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with Rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells
  3939. Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with Rapamycin
  3940. Local application of Rapamycin inhibits vein graft restenosis in rabbits
  3941. Drosophila larvae lacking the bcl-2 gene, buffy, are sensitive to nutrient stress, maintain increased basal target of Rapamycin (Tor) signaling and exhibit …
  3942. … proteolysis system by amino acids and insulin involves the adenosine monophosphate-activated protein kinase and mammalian target of Rapamycin pathways in rat …
  3943. Targeted inhibition of mammalian target of Rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro
  3944. Rapamycin induces differentiation of glioma stem/progenitor cells by activating autophagy
  3945. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of Rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer …
  3946. Rapamycin: A rheostat for CD8+ T-cell-mediated tumor therapy
  3947. Intranasal Rapamycin rescues mice from staphylococcal enterotoxin B-induced shock
  3948. A double whammy for aging? Rapamycin extends lifespan and inhibits cancer in inbred female mice
  3949. Aberrant expression of the mammalian target of Rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell …
  3950. Effects of FTY720 and Rapamycin on inflammation in taurocholate-induced acute pancreatitis in the rat
  3951. A novel method for the elution of sirolimus (Rapamycin) in drug-elution stents
  3952. Krüppel‐like factor 4 is induced by Rapamycin and mediates the anti‐proliferative effect of Rapamycin in rat carotid arteries after balloon injury
  3953. Adiponectin inhibits PDGF-induced mesangial cell proliferation: regulation of mammalian target of Rapamycin-mediated survival pathway by adenosine 5 …
  3954. Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells
  3955. Regulation of karyopherin α1 and nuclear import by mammalian target of Rapamycin
  3956. Nuclear PIM1 confers resistance to Rapamycin-impaired endothelial proliferation
  3957. Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodeling
  3958. Mechanism of activation of AMPK and upregulation of OGG1 by Rapamycin in cancer cells
  3959. The translational response of the human mdm2 gene in HEK293T cells exposed to Rapamycin: a role for the 5′-UTRs
  3960. Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin pathway inhibits dendritic cell activation by blocking IκB …
  3961. Combination of ATP-competitive mammalian target of Rapamycin inhibitors with standard chemotherapy for colorectal cancer
  3962. Antitumor efficacy of mammalian target of Rapamycin inhibitor therapy in liver transplant recipients with oncological disease: a case-control study
  3963. The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling
  3964. Effects of Rapamycin on expression of Bcl-2 and Bax in human lens epithelial cells and cell cycle in rats
  3965. Rapamycin treatment causes developmental delay, pigmentation defects, and gastrointestinal malformation on Xenopus embryogenesis
  3966. Systemic Rapamycin alone may not be a treatment option for malignant glioma: evidence from an in vivo study
  3967. Cardiovascular risk in kidney transplant recipients receiving mammalian target of Rapamycin inhibitors
  3968. Morphoproteomics demonstrates activation of mammalian target of Rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of mTOR in …
  3969. Effect of combination of Rapamycin and cisplatin on human cervical carcinoma Hela cells
  3970. Indications and effectiveness of the mammalian target of Rapamycin in liver transplantation
  3971. Rapamycin prevents interstitial fibrosis in renal allografts through decreasing angiogenesis and inflammation
  3972. Rapamycin induced ultrastructural and molecular alterations in glomerular podocytes in healthy mice
  3973. Conversion to low-dose tacrolimus or Rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study
  3974. Rapamycin‐mediated suppression of renal cyst expansion in del34 Pkd1−/− mutant mouse embryos: An investigation of the feasibility of renal cyst prevention in the …
  3975. Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen …
  3976. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by Rapamycin
  3977. Combined targeting of the VEGFr/EGFr and the mammalian target of Rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior …
  3978. One‐year clinical outcome of a randomized trial of polymer‐free paclitaxel‐eluting stents versus biodegradable polymer‐based Rapamycin‐eluting stents in patients …
  3979. Chronic hypoxia impairs murine hippocampal development and depletes the postnatal progenitor pool by attenuating mammalian target of Rapamycin …
  3980. inhibition of mammalian target of Rapamycin signaling by everolimus induces senescence in adult T‐cell leukemia/lymphoma and apoptosis in peripheral T‐cell …
  3981. The inhibitory effect of Rapamycin on the oval cell response and development of preneoplastic foci in the rat
  3982. Insulin-induced neurite-like process outgrowth: acceleration of tau protein synthesis via a phosphoinositide 3-kinase∼ mammalian target of Rapamycin pathway
  3983. Rapamycin for life: a step to immortality
  3984. Target of Rapamycin (TOR)–Based Therapy for Cardiomyopathy: Evidence From Zebrafish and Human Studies
  3985. Rapamycin as immunosuppressant in murine transplantation model
  3986. Effect of feeding a high-protein diet following an 18-hour period of feed withholding on mammalian target of Rapamycin-dependent signaling in skeletal muscle of …
  3987. Destabilization of TNF-α mRNA by Rapamycin
  3988. Rapamycin-based inducible translocation systems for studying phagocytosis
  3989. Immunoexpression status and prognostic value of mammalian target of Rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas
  3990. Targeting the dysregulated mammalian target of Rapamycin pathway in organ transplantation: killing 2 birds with 1 stone
  3991. Rapamycin and 3-methyladenine regulate apoptosis and autophagy in bone-derived endothelial progenitor cells
  3992. Expression of the mammalian target of Rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma
  3993. … and effectiveness of oral Rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral Rapamycin in Argentina (ORAR) III …
  3994. Mammalian target of Rapamycin expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence
  3995. Chronic inhibition of mTOR by Rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
  3996. Poly (ethylene glycol)-block-poly (2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for Rapamycin delivery: in vitro characterization and biodistribution
  3997. Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease–antiprotease system by the mTOR inhibitor Rapamycin
  3998. Enhanced sensitivity to Rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75-1 human breast cancer cells
  3999. Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in Saccharomyces cerevisiae
  4000. Differential Regulation of Simultaneous Antitumor and Alloreactive CD8+ T‐Cell Responses in the Same Host by Rapamycin
  4001. Mammalian Target of Rapamycin inhibition in Macrophages of Asymptomatic HIV+ Persons Reverses the Decrease in TLR-4–Mediated TNF-α Release through …
  4002. Gene expression profile in response to doxorubicin–Rapamycin combined treatment of HER-2–overexpressing human mammary epithelial cell lines
  4003. … tumour necrosis factor (TNF)‐α‐induced apoptosis through eukaryotic translation initiation factor 2α (eIF2α)‐and mammalian target of Rapamycin complex 1 (mTORC1 …
  4004. Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4+CD25+Foxp3+ regulatory T cell expansion
  4005. Activation of mammalian target of Rapamycin in diffuse large B-cell lymphoma: a clinicopathological study
  4006. Rapamycin regulates the expression and activity of krüppel-like transcription factor 2 in human umbilical vein endothelial cells
  4007. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of Rapamycin (mTOR) in LHBetaTag retinal tumors
  4008. Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of Rapamycin inhibitor INK128 administered by intermittent dosing regimens in …
  4009. Characterization of Foxp3 gene from grass carp (Ctenopharyngodon idellus): a Rapamycin-inducible transcription factor in teleost immune system
  4010. RETRACTED: Enhanced cellular uptake and in vivo pharmacokinetics of Rapamycin loaded cubic phase nanoparticles for cancer therapy
  4011. Bevacizumab and Rapamycin can decrease corneal opacity and apoptotic keratocyte number following photorefractive keratectomy
  4012. Are we ready to move away from nature? The Rapamycin story
  4013. … renal angiomyolipomas and lymphangioleiomyomatosis presenting after two successive pregnancies successfully treated with surgery and Rapamycin
  4014. Biochemical and pharmacological inhibition of mTOR by Rapamycin and an ATP-competitive mTOR inhibitor
  4015. Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype
  4016. Rapamycin selectively alters serum chemistry in diabetic mice
  4017. Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are Rapamycin and vascular endothelial growth factor …
  4018. The combination of the novel glycolysis inhibitor 3-BrOP and Rapamycin is effective against neuroblastoma
  4019. … Akt hyperphosphorylation and an oxidative stress-mediated cell death in serum starved SK-N-SH human neuroblastoma cells that are augmented by Rapamycin
  4020. Use of factorial design for evaluation of factors affecting the chemical stability of sirolimus (Rapamycin) in solid dosage form.
  4021. Drosophila poly suggests a novel role for the Elongator complex in insulin receptor–target of Rapamycin signalling
  4022. … ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of Rapamycin complex 1 (mTORC1) …
  4023. Immunohistochemical evidence of dysregulation of the mammalian target of Rapamycin pathway in primary and metastatic pheochromocytomas
  4024. Effect of Rapamycin on high glucose-induced autophagy impairment, oxidative stress and premature senescence in rat mesangial cells in vitro
  4025. A role of the mammalian target of Rapamycin (mTOR) in glutamate-induced down-regulation of tuberous sclerosis complex proteins 2 (TSC2)
  4026. Role of Rapamycin‐Induced Autophagy in Pancreatic Islets
  4027. Rapamycin Generates Graft-Homing Murine Suppressor CD8+ T Cells That Confer Donor-Specific Graft Protection
  4028. Positive regulation of inositol 1,4,5‐trisphosphate‐induced ca2+ release by mammalian target of Rapamycin (mTOR) in RINm5F cells
  4029. inhibition by Rapamycin of the lipoteichoic acid-induced granulocyte-colony stimulating factor expression in mouse macrophages
  4030. Markers for efficacy of mammalian target of Rapamycin inhibitor
  4031. Immunosuppressive drug Rapamycin restores sporulation competence in industrial yeasts
  4032. Immunosuppression in kidney donors with Rapamycin and tacrolimus. Proinflammatory cytokine expression
  4033. … stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (Rapamycin-eluting stent evaluated at …
  4034. Mechanisms mediating the cardioprotective effects of Rapamycin in ischaemia–reperfusion injury
  4035. Rapamycin inhibition of baculovirus recombinant (BVr) ribosomal protein S6 kinase (S6K1) is mediated by an event other than phosphorylation
  4036. A phase I, open label, dose escalation study of an oral mammalian target of Rapamycin inhibitor INK128 administered once daily in patients with advanced …
  4037. Mammalian target of Rapamycin inhibitors for treatment in tuberous sclerosis
  4038. Prognostic markers in renal cell carcinoma: A focus on the ‘mammalian target of Rapamycin‘pathway
  4039. Is proteinuria reversible, after withdrawal of mammalian target of Rapamycin inhibitors?
  4040. Rapamycin induces heme oxygenase-1 in liver but inhibits bile flow recovery after ischemia
  4041. Enhanced Rapamycin production in Streptomyces hygroscopicus by integrative expression of aveR, a LAL family transcriptional regulator
  4042. Expansion of CD4+ CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and Rapamycin
  4043. The phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy
  4044. Everolimus vs. Rapamycin for treating diabetic nephropathy in diabetic mouse model
  4045. RNA polymerase II degradation in response to Rapamycin is not mediated through ubiquitylation
  4046. Akt (protein kinase B) isoform phosphorylation and signaling downstream of mTOR (mammalian target of Rapamycin) in denervated atrophic and hypertrophic …
  4047. … of three enzymes for fatty acid synthesis into mouse milk in association with fat globules, and rapid decrease of the secreted enzymes by treatment with Rapamycin
  4048. inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to Rapamycin
  4049. Comparative assessment of mammalian target of Rapamycin inhibitor‐eluting stents in the treatment of coronary artery bifurcation lesions: The CASTOR‐Bifurcation …
  4050. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of Rapamycin inhibitor, temsirolimus, in a preclinical mammary …
  4051. Rapamycin inhibiting Jurkat T cells viability through changing mRNA expression of serine/threonine protein phosphatase 2A
  4052. Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of Rapamycin
  4053. The target of Rapamycin: structure and functions
  4054. Artemisinin and Rapamycin compromise nitric oxide-driven and hypoxia-triggered acute articular synovitis in mice
  4055. Multimodal imaging of growth and Rapamycin-induced regression of colonic adenomas in APC mutation-dependent mouse
  4056. Forever young? Exploring the link between Rapamycin, longevity and cancer
  4057. Identification of novel Rapamycin derivatives as low-level impurities in active pharmaceutical ingredients
  4058. Deoxyribose protects against Rapamycin-induced cytotoxicity in colorectal cancer cells in vitro
  4059. Rapamycin-induced tumor vasculature remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation
  4060. Mammalian target of Rapamycin inhibitors in organ transplantation: an unkept promise
  4061. Study on the rat intestinal absorption of Rapamycin formulated in self-microemulsifying drug delivery system by single-pass intestinal perfusion technique [J]
  4062. Synergistic cytotoxic effects of Rapamycin and idarubicin on human acute T-cell lymphoblastic leukemia Jurkat cells
  4063. Impact of pyrrolidine dithiocarbamate and interleukin-6 on mammalian target of Rapamycin complex 1 regulation and global protein translation
  4064. Molecular characterization and functional analysis of Cashmere goat mammalian target of Rapamycin
  4065. Tumor growth effects of Rapamycin on human biliary tract cancer cells
  4066. Decrease in transient receptor potential melastatin 6 mRNA stability caused by Rapamycin in renal tubular epithelial cells
  4067. Rapamycin and a hyaluronic acid-carboxymethylcellulose membrane did not lead to reduced adhesion formations in a rat abdominal adhesion model
  4068. inhibition of mammalian target of Rapamycin signaling by CCI-779 (Temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts …
  4069. Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of Rapamycin inhibitors in patients with renal transplantation
  4070. Ex vivo transfer of adenovirus-mediated CTLA4Ig gene combined with a short course of Rapamycin therapy prolongs free flap allograft survival
  4071. From node to pathway blockade: lessons learned from targeting mammalian target of Rapamycin.
  4072. A study about drug combination therapy of Schisandra sphenanthera extract and Rapamycin in healthy subjects
  4073. Nonobese diabetic natural killer cells: a barrier to allogeneic chimerism that can be reduced by Rapamycin
  4074. Rapamycin synergizes with low dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosis
  4075. Metabolic function of a suboptimal transplanted islet mass in nonhuman primates on Rapamycin monotherapy
  4076. Switching from calcineurin inhibitors to mammalian target of Rapamycin inhibitors—finally caught the right wave?
  4077. The phosphatidylinositol 3′ kinase-Akt-mammalian target of Rapamycin pathway in smooth muscle tumors of the uterus: selected protein expression patterns and …
  4078. Targeted therapy in sarcomas: mammalian target of Rapamycin inhibitors from bench to bedside
  4079. REDV/Peptide conjugated Rapamycin-loaded polymer matrix for endothelial cells selectivity
  4080. Rapamycin protects against dominant negative-HNF1A-induced apoptosis in INS-1 cells
  4081. A simple and efficient route to the FKBP-binding domain from Rapamycin
  4082. Functional analysis of the single Est1/Ebs1 homologue in Kluyveromyces lactis reveals roles in both telomere maintenance and Rapamycin resistance
  4083. Linking molecular feature space and disease terms for the immunosuppressive drug Rapamycin
  4084. Effect of Rapamycin on immunity induced by vector-mediated dystrophin expression in mdx skeletal muscle
  4085. Modified Rapamycin targets PKD
  4086. Prevalence and clinical significance of mammalian target of Rapamycin phosphorylation (p-mTOR) and vascular endothelial growth factor (VEGF) in clear cell …
  4087. Gastric mammalian target of Rapamycin signaling, hormone production and energy metabolism
  4088. Rapamycin in lipoproteins for enhanced delivery
  4089. Combined use of Rapamycin and leflunomide in prevention of acute cardiac allografts rejection in rats
  4090. Effect of nab-Rapamycin versus Rapamycin in colorectal cancer cell lines and associations with KRAS and PI3K mutations.
  4091. Improvement of Rapamycin fermentation with culture condition optimization and rational strain breeding
  4092. Meta-analysis of immunosuppressive therapy with target-of-Rapamycin inhibitor instead of calcineurin inhibitor after kidney transplantation operation
  4093. The isomerase Rrd1 mediates rapid loss of the Sgs1 helicase in response to Rapamycin
  4094. Mammalian Target of Rapamycin
  4095. Long-Term Maintenance Therapy for Post–Cardiac Transplant Monoclonal Lymphoproliferative Disorder: Caveat Mammalian Target of Rapamycin
  4096. Rapamycin effect on senescence and autophagy processes in human cell lines
  4097. Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of Rapamycin pathway in non-small cell lung cancer
  4098. … microenvironment, induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of Rapamycin (mTOR), in mantle …
  4099. Rapamycin inhibits the proliferation of prostate cancer cell line 22RV1 and activity of S6K1
  4100. Amphiphilic chitosan nanomicelles for the topical delivery of Rapamycin
  4101. Effect of Rapamycin combined with cisplatin on head and neck squamous cancer cells regulated by CCL19
  4102. Phosphatidykinosital 3-Kinase and Mammalian Target of Rapamycin Pathway in Non–Small-Cell Lung Cancer
  4103. Chemosensitivity enhancement of Rapamycin on hepatocellular carcinoma and related mechanism
  4104. Progress of Rapamycin and its derivatives in anti-tumor activity [J]
  4105. 40‐O ‐[2‐Hydroxyethyl]Rapamycin modulates human dendritic cell function during exposure to Aspergillus fumigatus
  4106. A phase I trial of escalating dose of the Rapamycin analog everolimus in combination with the kinase inhibitor midostaurin in patients (pts) with relapsed, refractory or …
  4107. Rapamycin impacts positively on longevity, despite glucose intolerance induction
  4108. Treatment of pulmonary and retroperitoneal lymphangioleiomyomatosis with Rapamycin: a case presentation and literature review
  4109. Glycogen synthase kinase (GSK)-3 and mammalian target of Rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1)
  4110. Constitutive activation of mTOR pathway by leucine causes heart hypertrophy which can be blocked by Rapamycin
  4111. Rapamycin inhibits IL-33-induced airway inflammation
  4112. Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of Rapamycin (mTOR) kinase inhibitor, in vitro in clear cell renal cell carcinoma (RCC)
  4113. Effects of Rapamycin and tacrolimus on mature endothelial cells and endothelial progenitor cells
  4114. An investigation of reversal of imatinib resistance in the Bcr‐Abl positive imatinib‐resistant cell line K562r by dasatinib, nilotinib, Rapamycin and bortezomib
  4115. Frequent activation of mammalian target of Rapamycin in primary lung adenocarcinoma and preinvasive lesion
  4116. Role of Rapamycin in cholangiocytes regeneration after liver transplantation
  4117. Activation of PI3K/AKT and MAPK pathway through a PDGFRb-dependent feedback loop is involved in Rapamycin resistance in hepatocellular carcinoma
  4118. Retraction: Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts
  4119. The Regulation of Mammalian Target of Rapamycin
  4120. Dual inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias.
  4121. BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of Rapamycin by blocking Rapamycin-induced AKT activation.
  4122. Mammalian target of Rapamycin (mTOR) sigaling pathway involved in the inhibition of silence information regulator1 (Sirt1) on fat deposition of mice.
  4123. Mdx mice have a defect in autophagy that is restored by Rapamycin‐loaded nanoparticle treatment
  4124. Dissecting Rapamycin Responses
  4125. Pretreatment of isolated vein with Rapamycin nanoparticles inhibits vein graft stenosis in rabbits
  4126. Comment on “Stability of human Rapamycin-expanded CD4+ CD25+ T regulatory cells” Haematologica 2011; 96 (9): 1357–65
  4127. Expression of mammalian target of Rapamycin in colon cancer and its effect on proliferation and apoptosis of human colon cancer HT-29 cells
  4128. Oral Rapamycin does not mimic caloric restriction in mice
  4129. A Burkholderia pseudomallei Mip-like protein has Rapamycin inhibitable peptidyl-prolyl isomerase activity and has pleiotropic effects on virulence
  4130. Effects of Rapamycin on glucose metabolism and insulin resistance in obese mice [J]
  4131. Effects of Rapamycin on growth and proliferation of human non-small cell lung cancer cell line A549
  4132. A synthetic lethality combination with chloroquine and Rapamycin on chemosensitization
  4133. Preparation and Release Behavior of Rapamycin-Loaded Micelles [J]
  4134. OChiPEG micelles proven to facilitate the transscleral delivery of Rapamycin
  4135. Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-kinase (PI3K)/mammalian Target of Rapamycin (mTOR) Dual Inhibitors
  4136. Effects of Rapamycin on Dia2 Localization
  4137. Rapamycin-mediated interaction of spleen γδT lymphocytes and lung macrophages in acute lung injury of mice induced by lipopolysaccharide
  4138. Anti-aging gene klotho deficiency causes hypertension and vascular dysfunction via upregulation of mammalian target of Rapamycin (mTOR)
  4139. Metformin and Rapamycin inhibit proliferation and alter glucose metabolism in endometrial and ovarian cancer cell lines
  4140. Acquired Omenn-Like Syndrome, a Novel Posttransplant Autoaggression Syndrome Reversed by Rapamycin
  4141. Rapamycin augments the NMDA-mediated TNF suppression of MRSA-stimulated RAW264. 7 murine macrophages
  4142. Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
  4143. Rapamycin Relieves ER Stress and Improves Function in Hearts Subjected to High Workload
  4144. Mammalian Target of Rapamycin (mTOR) inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy
  4145. Mechanistic target of Rapamycin small interfering RNA and Rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal …
  4146. The antitumor effect of GDC-0941 alone and in combination with Rapamycin in breast cancer cells
  4147. inhibition of TGF-β1-induced extracellular matrix production in primary human pulmonary fibroblasts by Rapamycin
  4148. Effects of combination treatment of Rapamycin and adriamycin on proliferation and migration of hepatoma cell BEL-7402 and their mechanisms [J]
  4149. Progress and extensive meaning of mammalian target of Rapamycin involved in restoration of nervous system injury
  4150. Akt/mammalian target of Rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody
  4151. β‐hydroxy‐β‐methyl butyrate (HMB) stimulates mammalian target of Rapamycin complex 1 (mTORc1) signaling via a phosphatidylinositol‐3‐kinase (PI3K)‐dependent …
  4152. The study on the clinical efficacy of Rapamycin eluting stent in patients with multivessel coronary disease [J]
  4153. Rapamycin Inhibits Proliferation and Invasion of Human Bladder Carcinoma Cell Line T24 in vitro
  4154. Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells
  4155. Is There a Role for Mammalian Target of Rapamycin inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?
  4156. Effect of casamino acid on intergeneric conjugation in Rapamycin-producing Streptomyces hygroscopicus ATCC29253
  4157. Does Rapamycin Still Have a Role? Experience and Lessons from the Last Decade: 1116
  4158. Rapamycin pre-treatment abrogates Tumour Necrosis Factor-α down-regulatory effects on LXR-αand PXR mRNA expression via inhibition of c-Jun N …
  4159. Resveratrol, Rapamycin and MG‐132 as inducers of autophagy in ARPE‐19 cells
  4160. The Effect of Low-dose Rapamycin on Prolonging High-Risk Corneal Allograft Survival in a Mouse Model
  4161. Rapamycin pre-treatment abrogates Tumour Necrosis Factor-a down-regulatory effects on LXR-a and PXR mRNA expression via inhibition of c-Jun N-terminal …
  4162. Can Rapamycin Improve Cognitive Problems Caused by Chemotherapy?
  4163. Abstract B111: Early and Delayed Rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice
  4164. Strain Development and Optimization of Small Scale Culture Condition for Improving Rapamycin Production
  4165. Systemic Immunomodulation with SA-FasL Protein-Engineered Donor Splenocytes Under Transient Cover of Rapamycin Induces Robust Tolerance to Cardiac …
  4166. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV‐infected perforin‐deficient mice
  4167. Therapeutic effects of Rapamycin on experimental autoimmune uveoretinitis
  4168. A feasibility study of Rapamycin with hyper-CVAD chemotherapy in adults with acute lymphoblastic leukemia (ALL) and other aggressive lymphoid malignancies and …
  4169. Studies on inhibitory effect of Rapamycin on growth and metastasis of PC3 cells
  4170. THE EXPRESSION OF GENES ASSOCIATED WITH OSTEOBLAST DIFFERENTIATION AND THE MAMMALIAN TARGET OF Rapamycin (mTOR) IN THE BLOOD …
  4171. P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic …
  4172. Hormonal and nutrient signalling to protein kinase B and mammalian target of Rapamycin in pancreatic beta-cells
  4173. PS212. Peri-Adventitial Delivery of a Nanoparticle Albumin-Bound Rapamycin Reduces Luminal Stenosis in a Porcine Femoral Artery Balloon Injury Model
  4174. Comparative study of immunosuppression of HuangQi glycoprotein, triptolide, Rapamycin and hydrocortisone in vitro [J]
  4175. Effects of Rapamycin on immune function of T1DM mouse and the related molecular mechanism
  4176. Chronic Treatment with Rapamycin Attenuates Diabetes-Associated Adverse Effects and Protects Against Myocardial Ischemia/Reperfusion Injury in Type II Diabetic …
  4177. Role of the Mammalian Target of Rapamycin (mTOR) Signalling Pathway in Podocytes in Glomerular Disease
  4178. TCT-601 Real-world experience of the polymer-free Rapamycin-eluting YUKON-Choice stent: five-year results from a prospective registry
  4179. Correction: inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer’s Disease
  4180. 1081 the number of aberrantly expressed constituents of the mammalian target of Rapamycin pathway: correlation with oncologic outcomes in clear cell renal cell …
  4181. The FKBP-Rapamycin binding domain of human TOR undergoes strong conformational changes in the presence of membrane mimetics with and without the regulator …
  4182. Effects of Rapamycin-induced oligomerization of parvalbumin, Stim1 and Orai1 in puncta formation
  4183. Differential Modulation of mTORC1 and mTORC2 Signaling by Rapamycin During Pro-Arteriosclerotic Differentiation of Mesenchymal Stem Cells: 1485
  4184. Development of mammalian target of Rapamycin inhibitors
  4185. Translational research of the relationship between Rapamycin and hepatocellular carcinoma
  4186. Effects of Rapamycin on the Expression of HIF-1α and VEGF in Leukemic Cell Lines SUP-B15
  4187. NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and …
  4188. Rapamycin: Advantages of Immunosuppressive Therapy with Less Neurotoxicity (P04. 166)
  4189. Study on the Effects of Rapamycin Reverse AMN107 resistance on k562/AO2 Cells
  4190. Activation of AMP-activated protein kinase (AMPK) enhances Radiosensitization via inhibition of mTOR pathway in Rapamycin-resistant non-small cell lung cancer …
  4191. Neuroprotective Effect of Rapamycin in Optic Nerve Transection Model
  4192. Rapamycin enhances chemosensitivity of endometrial cancer cells to adriamycin [J]
  4193. Inhibitory effects of Rapamycin on proliferation of chronic myelogenous leukemia cells and its mechanism
  4194. The Effects of Rapamycin on Endothelial Cell Migration and Vascular Endothelial Growth Factor Expression
  4195. Oral Rapamycin prevents artery restenosis after stent implantation by inhibiting mammalian target of Rapamycin (mTOR)
  4196. Translation of 5′ terminal oligopyrimidine tract (5′ TOP) mRNAs in Aplysia californica is regulated by the target of Rapamycin (TOR)
  4197. S35 Rapamycin inhibits IL-33-induced, nuocyte-driven airway inflammation
  4198. Effect of Dose and Standard Therapy on the Anti-Remodeling Effects of Rapamycin in Experimental Heart Failure
  4199. Efficacy of the program of Rapamycin combined with CNI in chronic allograft nephropathy
  4200. Mammalian target of Rapamycin in gastric cancer
  4201. Rapamycin Impacts T Cell Associated Markers In A Model Of Acute Lung Injury
  4202. 6intact plasticity and learning in Rheb1 mUtant mice: implications for Rapamycin treatments
  4203. NF-κB Mediates Resistance to Rapamycin in Neuroblastoma
  4204. Abstract A175: Role of MnSOD and hydrogen peroxide in Rapamycin-induced cytostasis.
  4205. Preparation and Characterization of Rapamycin incorporated drug delivery carrier
  4206. Study on the protective effects of Rapamycin on cerebral ischemia-reperfusion injury in rats
  4207. STUDY OF ANTITUMOR EFFECT OF Rapamycin ON HUMAN HEPATOCELLULAR CARCINOMA HEPG-2 CELLS IN VITRO
  4208. Low Dose Rapamycin Exacerbates Autoimmune Experimental Uveitis
  4209. Targeting the target of Rapamycin (TOR): looking to mother nature
  4210. Research on the pharmaceutical distribution of Rapamycin nanometer vector eye drop in rabbit eyes
  4211. Paradoxical effect of Rapamycin on S6 phosphorylation in rats with or without seizures
  4212. Inhibitory effects of Rapamycin on proliferation and migration of human umbilical vein endothelial cells
  4213. Enzymatic and biochemical characterization of the Target Of Rapamycin (TOR) signaling pathway
  4214. Effects of Rapamycin on mTOR Signaling Pathway in Human Pancreatic Cancer Cell Line SW1990
  4215. Immunosuppressants FK506 and Rapamycin function as reversal
  4216. Rapamycin prevents muscle growth and the increase in MHCIIa induced by voluntary wheel running
  4217. Rapamycin aggravates experimental non alcoholic steatohepatitis in mice
  4218. Application of macroporous adsorption resin in separation and purification of Rapamycin
  4219. Determination of Rapamycin in blood vessel of dogs by LC-MS/MS
  4220. Effects of Rapamycin on cholesterol homeostasis and secretory function of 3T3-L1 cells
  4221. Mammalian target of Rapamycin: Immunosuppressive drugs
  4222. Rapamycin increases the sensitivity of glioma-initiating cells to radiation
  4223. Rapamycin dose-dependently promotes differentiation and cell death in an in vitro model of malignant gliomas
  4224. … of soluble interleukine-2 receptor in blood of patients with ischemic heart disease after coronary artery angioplasty with implantation of stents with Rapamycin covering
  4225. Inhibitory effects of Rapamycin on proliferation of chronic myelogenous leukemia cells and its mechanism
  4226. Effects of intrathecal injection Rapamycin on neuropathic pain behaviors in mice
  4227. The Immunosuppressive Drug Rapamycin Inhibits Several Molecular Mechanisms Involved in Tummor Development: 1648
  4228. Role of Rapamycin-Induced Autophagy in Pancreatic B-Cell Function: 1326
  4229. Preparation and characterization of Rapamycin nanoparticles and its effect in vein graft
  4230. Rapamycin administration does not impair basal protein metabolism in human skeletal muscle
  4231. Modulation of gastric nesfatin by Rapamycin
  4232. P7170: A potent and oral phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) inhibitor with anti-tumor …
  4233. Rapamycin Reduces Reactive Oxygen Species in Cultured Human Corneal Endothelial Cells
  4234. The role of Tacrolimus and Rapamycin on recurrence in HCC patients after liver transplantation
  4235. Oral Rapamycin Therapy Confers Protection Against Pneumococcal Pneumonia In Young Mice
  4236. Effect of Rapamycin inhibit liver fibrosis in rat with obstructive jaundice
  4237. Mechanisms of Rapamycin Toxicity in Pancreatic Beta Cells
  4238. Characterization of the Mechanistic Target of Rapamycin in the Mouse Ovary
  4239. Mammalian target of Rapamycin inhibitors and tumor therapy
  4240. The Role of Mammalian Target of Rapamycin in Hypertensive Rat Atria
  4241. Abstract C225: Differential regulation of simultaneous antitumor and alloreactive CD8+ T cell responses in the same host by Rapamycin.
  4242. Rapamycin Increases Infarct Size and is Detrimental During Acute Ischemia-Reperfusion
  4243. Rapamycin to prevent artery restenosis after stent implantation: an intravascular ultrasound study [J]
  4244. Effects of intrathecal injection Rapamycin on neuropathic pain bahaviors in mice: 14AP4-4
  4245. The effects of Rapamycin on the proliferation and apoptosis of human retinal pigment epithelium cells in vitro
  4246. Growth factor dependent regulation of p70S6 kinase: Evaluation of domain specific signals sensitive to Rapamycin
  4247. Clinical response to intravitreal Rapamycin in a retinal neovascularization model
  4248. Rapamycin-induced alteration of the DC maturation process sustains their capacity to induce regulatory T cells
  4249. … The ATP-competitive mammalian target of Rapamycin (mTOR) inhibitors suppress proliferation and induce apoptosis in the acquired Rapamycin resistant breast cancer …
  4250. Nanoparticles For Delivery Of Rapamycin To Glioblastoma And Glioblastoma-Derived Stem Cells
  4251. Adjuvant Rapamycin Improves The Outcomes Of Severe H1N1 Pneumonia And Acute Respiratory Distress Syndrome
  4252. Characterization of the yeast Rapamycin-sensitive phosphoproteome
  4253. Rapamycin in patients with advanced hepatocellular carcinoma progressing on prior antiangiogenic therapy.
  4254. Rapamycin Reduces TNF-α mRNA via Regulating 3’AU Rich Element Region
  4255. Apoptosis of renal cells induced by TNF-α and NF-κB in diabetic rats and intervention of Rapamycin
  4256. inhibition of Mammalian Target of Rapamycin (mTOR) in Epidermis
  4257. Comparison of the efficacy of FK506 and Rapamycin application on liver cancer liver transplant patients after surgery
  4258. Abstract P212: Haploinsufficiency of Target of Rapamycin Attenuates Different Forms of Cardiomyopathies in Adult Zebrafish
  4259. Antitumor activity of Rapamycin in combination with ectopic expression of Beclin 1 in multidrug‐resistant cancer cells
  4260. Tumor necrosis factor-related apoptosis-inducing ligand participates in injury of vascular endothelial cells induced by Rapamycin in vitro
  4261. Advances in Technology Based on the Combination of Rapamycin and FRB Domain Mediated Protein-protein Interactions
  4262. Structural characterization of Rapamycin and its analoges by electrospray ionization mass spectrometry
  4263. Long-term oral delivery of encapsulated Rapamycin is not detrimental to immunity in old mice (178.11)
  4264. Role of Rapamycin target protein signal transduction in regulating muscle volume
  4265. Rapamycin inhibits generation of memory CD8 T cells that localize to mucosal tissues (46.23)
  4266. Effect of Rapamycin and metformin on skin tumor promotion in mice overweight and obese
  4267. Effects of low dosage Rapamycin on expression of the vascular endothelial growth factor in diabetic nephropathy rats
  4268. Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy
  4269. Effect of Rapamycin on Filamentous Fungal Cell Walls
  4270. Chronic Rapamycin administration maintains mitochondrial protein synthesis in heart and skeletal muscle
  4271. Insulin-Like Peptides and the Target of Rapamycin Pathway Coordinately Regulate Blood
  4272. Observation on the Clinical Effects of Domestic-made Rapamycin Drug-eluting Stents for Treatment of Ischemic Cardiomyopathy [J]
  4273. Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice
  4274. Effect of Rapamycin on Aspergillus nidulans cell wall material properties
  4275. Prediction of the course of osteoarthrosis from mTOR (mammalian target of Rapamycin) gene expression
  4276. The influence of Rapamycin on BTLA expression of human peripheral blood T lymphocytes
  4277. Nesfatin-1 action in the brain increases insulin sensitivity through Akt kinase/AMP-dependent protein kinase/target of Rapamycin complex 2 pathway in diet …
  4278. Study on the effect of Rapamycin on RelB expression of immature dendritic cell
  4279. Rapamycin Inhibits Innate and Adaptive Immune Functions of Human Plasmacytoid Dendritic Cells: 2003
  4280. Akt/mammalian Target of Rapamycin Counteract the Akt/mammalian Target of Rapamycin Counteract the Growth Factor I Receptor Monoclonal Antibody
  4281. Rapamycin attenuates the development of chronic hypoxia-induced pulmonary hypertension in mice
  4282. Expression and clinical significance of phosphorylation of mammalian target protein of Rapamycin in human glioma
  4283. Effect of Rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway
  4284. Differential Rapamycin sensitivity distinguishes two distinct populations of tumor cells in murine glioma
  4285. Rapamycin Reverses Fibrotic Differentiation Of Mesenchymal Stromal Cells From Human Lung Allografts
  4286. Effect of Rapamycin on the expression of transforming growth factor and osteopontin in the diabetic nephropathy rats
  4287. CD44-Tropic Polymeric Nanocarrier for Breast Cancer Targeted Rapamycin
  4288. Effect of Rapamycin on expressions of connective tissue growth factor and fibronectin in renal interstitial fibroblasts
  4289. The Effectiveness of Foxp3+ Treg on Carcinoma of Liver Transplantation in Tacrolimus and Rapamycin
  4290. Separation of Rapamycin from fermentation broth using high-speed counter-current chromatography
  4291. Collagen from Aged Mice Exposed to Short-term Caloric Restriction and Rapamycin Display Unique Properties
  4292. Lymphoid Hyperplasia In A Patient With Common Variable Immunodeficiency Treated With Steroids And Rapamycin
  4293. Study on the Effects of Rapamycin on Cell Proliferation, Apoptosis and Autophagy in Human Acute Lymphoblastic Cell Line SUP-B15
  4294. EFFECTS OF INHIBITING THE MAMMALIAN TARGET OF Rapamycin (mTOR) PATHWAY AND TELOMERASE IN BREAST CANCER CELLS
  4295. Rapamycin Causes miRNA-20a Mediated Suppression of Egln3/prolylhydroxylase-3 and Protects against Ischemia/Reperfusion Injury in Type II Diabetic Heart
  4296. Real-time Therapeutic Window of Blood Concentration of Rapamycin in Recipients of Renal Transplantation Determined by Microparticle Enzyme Immunoassay …
  4297. Rapamycin inhibition of TorC1 and nitrogen limitation control Gln3 and Gat1 localization by distinct regulatory pathways
  4298. Identification of a new tumor suppressor pathway modulating Rapamycin sensitivity in colorectal cancer
  4299. Effect of mammalian target of Rapamycin on side population cells in hepatocellular carcinoma cell line Hep3B
  4300. Comparison of the inhibitory effect of Rapamycin and Pirarubicin on bladder cancer T24 cell [J]
  4301. Acute Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure‐overloaded rat myocardium
  4302. The enhancement of radio-sensitivity via autophagy induced by Rapamycin with glioma-initiating cells in vivo
  4303. Ryanodine downregulates the expression of p-eNOS (Thr495) and improves the functions of Rapamycin treated endothelial outgrowth cells
  4304. The effect of long-term Rapamycin treatment on hippocampal synaptic function in a mouse model of Alzheimer’s disease
  4305. Abstract P117: Does Mammalian Target of Rapamycin Complex-2 Regulate Protein Degradation Pathways in the Heart?
  4306. Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia
  4307. Five-year follow-up of China-made firebird Rapamycin drug-eluting stent in elderly patients with acute ST elevation myocardial infarction [J]
  4308. Synergistic Effect of Flt3L and Rapamycin On Immune Tolerance Induction Via Plasmacytoid Dendritic Cells and Treg.
  4309. Primary discuss on flow-cell elution release test method at stability of Rapamycin on drug-eluting stents
  4310. Abnormal Retinal Ganglion Cell Activity Is Attenuated By Rapamycin In A Mouse Model Of Tuberous Sclerosis
  4311. Target of Rapamycin Regulates Development and Ribosomal RNA Expression through Kinase Domain in Arabidopsis1 [W][OA]
  4312. Interaction effects between AMP-activated protein kinase and mammalian target of Rapamycin signaling pathways Symbol
  4313. The Effects of Rapamycin and Stromal Cell Derived Factor-1α on the Biological Function of Endothelial Outgrowth Cell
  4314. The Effects of Rapamycin on Expression of Hypoxia Signal Molecules in Human Acute Myeloid Leukemic Cell Line HL-60 Under Hypoxia
  4315. The mTOR inhibitor, Rapamycin, sensitises solid tumour cell lines to isoprenoid induced toxicity
  4316. THE ANTI-RESTENOSIS EFFECTS OF Rapamycin AND PACLITAXEL ELUTING STENT IN SUSSCROTA DOMESTICA CORONARY ARTERY
  4317. Transcriptional regulation of gene expression during osmotic stress responses by the mammalian target of Rapamycin
  4318. Rapamycin and Adiponectin in Vascular Smooth Muscle Cells: Implications in the Development of Drug-Eluting Stents
  4319. Calcineurin Inhibitor Transfer to Rapamycin Can Improve Graft Function in Living Donor Kidney Transplantation with Older Donors: 580
  4320. Mammalian Target Of Rapamycin In Combination With Chemotherapy: Upstream Regulation Of Anaerobic Glycolysis To Target The Chemoresistant Cell Population …
  4321. Rapamycin increased development of CD4~+ CD25~ h ighFoxp3~+ T cells of peripheral blood in liver transplant recipients
  4322. Preparation and characterization of Rapamycin-loaded nanoemulsions as an approach for increasing anti-proliferative activity. i. phase behavior study
  4323. The Effects Of Mitomycin, Rapamycin And Bevacizumab On Corneal Haze After Photorefractive Keratectomy
  4324. THE mTORC1 INHIBITOR Rapamycin INDUCES A SPECIFIC PRO-INFLAMMATORY PHENOTYPE FAVORING IL-12 IN LPS-STIMULATED IMMUNE CELLS …
  4325. Rapamycin Reduces Macrophages While Cyclosporine A Reduces Neutrophils In The Retina In Mouse Endotoxin-induced Uveitis
  4326. Preemptive Use of Mammalian Target of Rapamycin Inhibitors in Living Donor Transplantation
  4327. Role of Rapamycin in protection against cerebral ischemia-induced brain injury is related to neurogenesis in discrete brain regions in rat
  4328. Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib
  4329. … imaging of kidney cysts: volumetric assessment in patients affected by autosomal dominant polycystic kidney disease (ADPKD) type I in treatment with Rapamycin
  4330. Perifosine inhibits growth of Rapamycin resistant cells through activating GSK3β
  4331. Rapamycin and Podocyte Apoptosis/Injury in Renal Allograft Biopsies: 2290
  4332. Application of Rapamycin-Eluting Stent with Biodegradable Polymer Coating in Patients Receiving Emergency Percutaneous Coronary Intervention
  4333. Rapamycin is a Deceptive Tool for Probing Functional Interactions Between FK506-Binding Proteins and Ryanodine Receptors
  4334. Rapamycin inhibits lymph node metastasis in an orthotopic model of head and neck squamous cell carcinoma: A possible role for a suppression of VEGFR-3 …
  4335. Mammalian Target of Rapamycin and Tristetraprolin Regulate Iron Homeostasis in Cardiac Cells
  4336. Cytotoxic and cystostatic properties of Rapamycin are due to differential effects on the phosphorylation of mTORC1 substrates S6 kinase and 4E-BP1
  4337. The differential effects of prenatal and/or postnatal Rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis …
  4338. ARABIDOPSIS LST8 proteins interact with target of Rapamycin and over-expression of LST8 results in plants being hypersensitive to light
  4339. Study on autophagy induced by Rapamycin in melanoma cell line M14 and changes in the expression of Bcl-2 and Bax in progress of autophagy
  4340. Mammalian target of Rapamycin (mTOR) inhibitors in pediatric kidney transplantation: A systematic review
  4341. The Effect of Rapamycin Paired with Traumatic Memory Activation on Cognitive Performance in Veterans Diagnosed with PTSD
  4342. Mammalian Target of Rapamycin (mTOR) inhibition Attenuates Angiotensin II-Induced Hypertension and Endothelial Dysfunction
  4343. Rapamycin Treatment Shifts Balance of Autophagy and Apoptosis during Murine Cytomegalovirus (MCMV) Infection of the Retina or RPE Cells
  4344. Combination of Rapamycin with sorafenib as a therapeutic strategy against colorectal cancers with mutational activation of KRAS and PIK3CA
  4345. Abstract A75: Calorie restriction and Rapamycin, but not exercise, inhibit mammary tumor growth in a mouse model of postmenopausal obesity
  4346. Regulatory role of the mechanistic target of Rapamycin (mTOR) on the expression of osmotic stress response genes in mammalian cells
  4347. Effect Of Rapamycin And IL-2 On Regulatory CD4+ CD25+ Foxp3+ T Cells In Mice After Allogenic Penetrating Keratoplasty
  4348. Why is Rapamycin effective against Kaposi sarcoma? An analysis of molecular pathways reveals posttranslational silencing of PTEN
  4349. Interaction between the rabphillin-3A-like gene and phosphorylation of mammalian target of Rapamycin (mTOR) in colorectal cancer
  4350. Rapamycin increased development of CD4+ CD25high Foxp3+ T cells of peripheral blood in liver transplant recipients
  4351. Enhancement of the long term efficacy of BCG vaccine against experimental tuberculosis in mice through Rapamycin induced modulation of CD4 and CD8 T cell …
  4352. Heterogeneity In Responsiveness Of Mesenchymal Stromal Cell From Individual IPF Patients To mTOR Inhibitor Rapamycin And Its Correlation To Dysregulation In …
  4353. Efficacy of homemade biodegradable Rapamycin drug-eluting stent implantation: Compared with bare-metal stents
  4354. Glutamine starvation and Rapamycin inhibition of TorC1 elicit transcription of distinct groups of nitrogen‐responsive genes
  4355. Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of Rapamycin (mTOR) kinase inhibitor, in vitro in urothelial carcinoma of the bladder
  4356. Effects of RhoC-siRNA combined with Rapamycin on invasion and metastasis of hepatocellular carcinoma cell Bel7402
  4357. Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with Rapamycin
  4358. Identification of interacting partners of mammalian target of Rapamycin complex 1 (mTORC1) assembly in human lymphocytes
  4359. Statins and Rapamycin synergistically induce dendritic cell KLF2 expression and tolerogenic function in vivo (P1610)(56.8)
  4360. Chronic Rapamycin Treatment Causes a Deficit in Optokinetic Tracking in Male Mice and Does Not Prevent Tracking Deficits in the Ins2Akita Mouse Model of Diabetic …
  4361. inhibition of mammalian target of Rapamycin (mTOR) signaling by Temsirolimus as a potential therapeutic strategy for esophageal cancer treatment
  4362. PIM kinase inhibition blocks activation of mTOR pathway components and enhances Rapamycin-mediated tumor growth inhibition in prostate cancers
  4363. Evaluation of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based Rapamycin-eluting stents in treatment with coronary heart disease
  4364. Mammalian target of Rapamycin regulate kidney oxygen consumption by controlling mitochondrial function via regulation of uncoupling protein 2
  4365. Mammalian Target of Rapamycin Regulates Cardiac Iron Homeostasis in vitro and in vivo through Modulation of Tristetraprolin Expression
  4366. Functional analysis of the single Est1/Ebs1 homologue in K. lactis reveals roles in both telomere maintenance and Rapamycin resistance
  4367. Abstract P6-11-03: Site-Specific, Concomitant Delivery of Rapamycin and Paclitaxel in Breast Cancer: Consequent Synergistic Efficacy Enhancement
  4368. Amino Acids and Insulin are Both Necessary for an Amplified Response of Protein Synthesis Through the Mammalian Target of Rapamycin Signaling Pathway
  4369. Selective ATP-competitive inhibitors of TOR suppress Rapamycin insensitive function of Torc2 in S. cerevisae
  4370. WITHDRAWN: Mammalian target of Rapamycin (mTOR) inhibition in polycystic kidney disease (PKD): From bench to bedside
  4371. P-459 Role of the mammalian target of Rapamycin (mTOR) during human follicular development
  4372. IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ-Dependent Apoptosis of Alloreactive CD4+ T Cells and Limit Graft-Versus-Host Diseas
  4373. Genetic variants in the mammalian target of Rapamycin (mTOR) signaling pathway as predictors of clinical response and survival in women with ovarian cancer
  4374. Re: Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma
  4375. Dual-frequency ultrasound-mediated delivery of Rapamycin from microbubbles decreases drug dose needed to reduce neointima formation in vivo
  4376. In vitro profibrotic effects of Rapamycin on basal or TGF-β1 induced primary human lung fibroblast: ECM production and turnover, migration and differentiation
  4377. Immune Blot Analysis on Expression of the Mammalian Target of Rapamycin in Goat Fetal Fibroblasts with Recombinant Polyclonal Antibody
  4378. Abstract LB-7: HPV-associated HNSCC: widespread mTOR pathway activity and preclinical evaluation of mTOR inhibitors Rapamycin and RAD-001
  4379. Oral Rapamycin to Reduce Intimal Hyperplasia After Bare Metal Stent Implantation-A Prospective Randomized Intravascular Ultrasound Study
  4380. The mammalian target of Rapamycin complex 2 (mTORC2) negatively regulates the innate inflammatory response
  4381. Tacrolimus and Rapamycin do not elevate cholesterol synthesis in post‐transplant patients, but may impair response to multi‐nutrient dietary intervention
  4382. First report of a novel abluminal groove filled biodegradable polymer Rapamycin-eluting stent inde novocoronary artery disease: results of the first in man FIREHAWK …
  4383. Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of Rapamycin (mTOR) pathway in …
  4384. … Therapeutic Potential of Targeting Dysregulated Signaling Axes in Squamous Cell Carcinoma: Another Kinase of Transcription and Mammalian Target of Rapamycin
  4385. Genetic variants in the mammalian target of Rapamycin (mTOR) signaling pathway as predictors of survival and clinical response in women with ovarian cancer
  4386. Re: Hypoxia-Inducible Factor and Mammalian Target of Rapamycin Pathway Markers in Urothelial Carcinoma of the Bladder: Possible Therapeutic Implications
  4387. Rapamycin-insensitive mTORC1 activity controls eIF4E: 4E-BP1 binding [version 1; referees: 3 approved]
  4388. Combination of LC3 II shRNA and genistein completely inhibited Rapamycin-induced autophagy and promoted apoptosis in human malignant neuroblastoma cell lines
  4389. Rapamycin Enhances Protective Effect of Sildenafil against Doxorubicin Cardiotoxicity and Potentiates Cancer Cell Killing
  4390. … type CD8+ t-cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high doses atg induction and Rapamycin
  4391. P158 All-trans retinoic acid and Rapamycin synergize with transforming growth factor-B to induce regulatory T cells but confer distinct in vivo migratory capacities
  4392. IL-12hi Rapamycin-Conditioned Dendritic Cells Induce Apoptosis of Alloreactive CD4+ T Cells in an Ifn-γ-Dependent Manner and Inhibit Graft-Versus-Host Disease
  4393. Mammalian target of Rapamycin (mTOR) signaling proteins are highly expressed in mamamry tumors of MMTV-TGF-β mice
  4394. NOVEL INSIGHTS INTO BONE MORPHOGENETIC PROTEIN (BMP) AND MAMMALIAN TARGET OF Rapamycin (mTOR) SIGNALING AXIS IN PROSTATE …
  4395. To assess coronary atherosclerotic plaque by IVUS-VH and the level of hs-CRP in serum, to observe is involved Rapamycin-eluting in-stent restenosis
  4396. A Stable Chitosan-coated Nanomicelle Combination Of Vitamin E-TPGS And Cholesterol-PEG For The Topical Administration And Scleral Retention Of Rapamycin
  4397. Risk of rash and stomatitis with everolimus, a mammalian target of Rapamycin (mTOR) inhibitor: A meta-analysis.
  4398. Selective ATP-competitive inhibitors of TOR suppress Rapamycin insensitive function of TORC2 in S. cerevisiae
  4399. P94 Rapamycin helps maintain the regulatory phenotype of cytochrome P450IID6-specific Treg expanded from patients with autoimmune hepatitis type 2 by reducing …
  4400. Mammalian Target of Rapamycin Inhibitor and Anti-Death Receptor Agonistic Antibody: a Novel Combination Therapy for the Treatment of Hepatocellular Carcinoma …
  4401. A Global Kinase and Phosphatase Interaction Network in the Budding Yeast Reveals Novel Effectors of the Target of Rapamycin (TOR) Pathway
  4402. CD4 T helper cell profiling in heart and liver transplant recipients: Comparison between CNI-, Rapamycin-and anti-CD25 mAB-based immunosuppression
  4403. Rapamycin Eluting Biodegradable Extravascular Stent Prevents Vein Graft Stenosis at Long Term in a Canine Model
  4404. Risk of rash and stomatitis with temsirolimus, a mammalian target of Rapamycin (mTOR) inhibitor: A meta-analysis.
  4405. Differential effects of Rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ Treg subpopulations
  4406. Combined grape polyphenols regulate mammalian target of Rapamycin (mTOR) signaling via a dual mechanism of Akt inhibition and AMPK activation
  4407. ET-04. COMBINED MYXOMA VIROTHERAPY WITH Rapamycin TARGETING BRAIN TUMOR-INITIATING CELLS
  4408. Mammalian Target of Rapamycin Signal Inhibitors (imTOR) Use in First and Relapse BK Polyomavirus Nephritis (BKVN) in Renal Allograft Recipients: 2556
  4409. Adventitial Nab-Rapamycin Injection Reduces Porcine Femoral Artery Luminal Stenosis Induced by Balloon Angioplasty via inhibition of Medial Proliferation and …
  4410. IL-12 combined with Rapamycin enhances the ellular immunity induced by PRRS attenuated vaccine
  4411. UCHL1 protein synthesis upon Rapamycin treatment involves its antisense RNA trough embedded SINEB2 repeat
  4412. Evaluation of NIH-Defined Chronic Graft-Versus-Host-Disease in a Rapamycin-Based Haploidentical Stem Cell Transplantation: Analysis of 113 Consecutive Patients …
  4413. The Internal Ribosome Entry Site-Medaited Expression of VEGF Rescues HS Sultan Tumor Cells From Mammalian Target of Rapamycin (mTOR)-Inhibitors Induced …
  4414. Comparison between Oral Rapamycin Plus Bare Metal Stent versus Drug Eluting Stent for the Prevention of Restenosis in the Treatment of Coronary Disease with …
  4415. Rapamycin delays xenogeneic acute graft-versus-host disease (aGvHD) in NOD/SCID/IL2Rg NULL (NSG) mice: impact of regulatory T cells
  4416. Effects of 1-methyl-4-phenyl pyridinium on mammalian Rapamycin target signaling pathway in human neuroblastoma cells
  4417. 1070 DEVELOPMENT OF A Rapamycin SENSITIVE CELL LINE FROM UROTHELIAL CARCINOMA WITH SARCOMATOID FEATURES
  4418. The mTOR inhibitor Rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells
  4419. … CELLS AGAINST HYPOXIA AND SERUM DEPRIVATION-INDUCED APOPTOSIS VIA AMP-ACTIVATED PROTEIN KINASE/MAMMALIAN TARGET OF Rapamycin …
  4420. Mammalian Target of Rapamycin Inhibitors Versus Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF TKI) as Second-Line Therapy in …
  4421. Marinobufagenin induced uremic cardiomyopathy: the role of passive immunization, Rapamycin, and CD40 signaling in the generation of renal fibrosis
  4422. inhibition of Mammalian Target of Rapamycin (mTOR) Complex 1 and 2 by PP242 Induces G1 Growth Arrest in Pancreatic Ductal Adenocarcinoma and when …
  4423. Preconditioning with Rapamycin and CTLA4-Ig in Dogs Given Donor Antigen and 1Gy Total Body Irradiation (TBI) Before Dog-Leukocyte-Antigen (DLA)-Identical …
  4424. Rapamycin: one drug, many effects
  4425. Duration of Rapamycin treatment has differential effects on metabolism in mice
  4426. Rapamycin extends life and health in C57BL/6 mice
  4427. Longevity, aging and Rapamycin
  4428. Rapamycin unbalances the polarization of human macrophages to M 1
  4429. Rapamycin extends murine lifespan but has limited effects on aging
  4430. Mammalian target of Rapamycin signaling in cardiac physiology and disease
  4431. Evidence for Rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms
  4432. The role of target of Rapamycin signaling networks in plant growth and metabolism
  4433. Rapamycin, autophagy, and Alzheimer’s disease
  4434. mTORC1 phosphorylation sites encode their sensitivity to starvation and Rapamycin
  4435. Rapamycin extends life-and health span because it slows aging
  4436. Rapamycin inhibits the growth of glioblastoma
  4437. Late‐life Rapamycin treatment reverses age‐related heart dysfunction
  4438. Rapamycin and aging: when, for how long, and how much?
  4439. Mammalian target of Rapamycin (mTOR) pathways in neurological diseases
  4440. Rapamycin increases survival in ALS mice lacking mature lymphocytes
  4441. MIR181A regulates starvation- and Rapamycin-induced autophagy through targeting of ATG5
  4442. A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict Rapamycin sensitivity
  4443. Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction
  4444. Mammalian target of Rapamycin (mTOR) inhibition with Rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative …
  4445. Large FK506-binding proteins shape the pharmacology of Rapamycin
  4446. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury
  4447. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
  4448. Systemic analysis of inducible target of Rapamycin mutants reveal a general metabolic switch controlling growth in Arabidopsis thaliana
  4449. Mechanistic target of Rapamycin complex 2 protects the heart from ischemic damage
  4450. Mice fed Rapamycin have an increase in lifespan associated with major changes in the liver transcriptome
  4451. RAB3GAP1 and RAB3GAP2 modulate basal and Rapamycin-induced autophagy
  4452. Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation
  4453. Altered proteome turnover and remodeling by short‐term caloric restriction or Rapamycin rejuvenate the aging heart
  4454. Rapamycin allosterically inhibits the proteasome
  4455. Activation of mammalian target of Rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants
  4456. Induced regulatory T cells promote tolerance when stabilized by Rapamycin and IL-2 in vivo
  4457. Sugar metabolism and the plant target of Rapamycin kinase: a sweet operaTOR?
  4458. Therapeutic effects of Rapamycin on MPTP-induced Parkinsonism in mice
  4459. Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke
  4460. Rapamycin is neuroprotective in a rat chronic hypertensive glaucoma model
  4461. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells
  4462. Rapamycin alleviates cisplatin-induced ototoxicity in vivo
  4463. Mutations in mammalian target of Rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations
  4464. Rapamycin induces ILT3highILT4high dendritic cells promoting a new immunoregulatory pathway
  4465. Co-delivery of cisplatin and Rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation
  4466. Preserving youth: does Rapamycin deliver?
  4467. Mammalian target of Rapamycin inhibition in hepatocellular carcinoma
  4468. Convergence of ubiquitylation and phosphorylation signaling in Rapamycin-treated yeast cells
  4469. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder
  4470. The role of mechanistic target of Rapamycin (mTOR) complexes signaling in the immune responses
  4471. Mammalian target of Rapamycin inhibitor-associated stomatitis
  4472. Scopolamine rapidly increases mammalian target of Rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses
  4473. Local intra-articular injection of Rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis
  4474. Rapamycin-induced metabolic defects are reversible in both lean and obese mice
  4475. Chronic Rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s …
  4476. Taking aim at Alzheimer’s disease through the mammalian target of Rapamycin
  4477. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension
  4478. Driving neural regeneration through the mammalian target of Rapamycin
  4479. Metabolomic response of Chlamydomonas reinhardtii to the inhibition of target of Rapamycin (TOR) by Rapamycin
  4480. Rapamycin rescues ABT-737 efficacy in small cell lung cancer
  4481. Chronic Rapamycin treatment causes diabetes in male mice
  4482. Mammalian target of Rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review
  4483. Weekly administration of Rapamycin improves survival and biomarkers in obese male mice on high‐fat diet
  4484. Hepatic signaling by the mechanistic target of Rapamycin complex 2 (mTORC2)
  4485. Rapamycin encapsulated in dual-responsive micelles for cancer therapy
  4486. Molecular determinants of outcome with mammalian target of Rapamycin inhibition in endometrial cancer
  4487. Rapamycin, anti-aging, and avoiding the fate of Tithonus
  4488. Molecular and genetic crosstalks between mTOR and ERRα are key determinants of Rapamycin-induced nonalcoholic fatty liver
  4489. Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson’s disease
  4490. Short-term treatment with Rapamycin and dietary restriction have overlapping and distinctive effects in young mice
  4491. Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors
  4492. Differential effects of Rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+ CD25+ FOXP3+ T regulatory cell …
  4493. Rapamycin suppresses brain aging in senescence-accelerated OXYS rats
  4494. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and Rapamycin as a potential new approach for the treatment of MPNSTs
  4495. Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage
  4496. Mammalian target of Rapamycin (mTOR) mediates tau protein dyshomeostasis: implication for Alzheimer disease
  4497. Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium
  4498. Mechanistic target of Rapamycin controls homeostasis of adipogenesis
  4499. Rapamycin limits the growth of established experimental abdominal aortic aneurysms
  4500. Lamins are Rapamycin targets that impact human longevity: a study in centenarians
  4501. Multifaceted effects of Rapamycin on functional recovery after spinal cord injury in rats through autophagy promotion, anti-inflammation, and neuroprotection
  4502. A systematic review of conversion from calcineurin inhibitor to mammalian target of Rapamycin inhibitors for maintenance immunosuppression in kidney transplant …
  4503. Beneficial metabolic effects of Rapamycin are associated with enhanced regulatory cells in diet-induced obese mice
  4504. Mechanistic target of Rapamycin (mTOR) is essential for murine embryonic heart development and growth
  4505. Mammalian target of Rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury
  4506. Cell cycle regulation by the nutrient-sensing mammalian target of Rapamycin (mTOR) pathway
  4507. Mammalian target of Rapamycin promotes oligodendrocyte differentiation, initiation and extent of CNS myelination
  4508. Enhancing autophagy with activated protein C and Rapamycin protects against sepsis-induced acute lung injury
  4509. (R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function
  4510. Mechanistic target of Rapamycin inhibition extends cellular lifespan in dendritic cells by preserving mitochondrial function
  4511. Different patterns of Akt and ERK feedback activation in response to Rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells
  4512. Contact inhibition and high cell density deactivate the mammalian target of Rapamycin pathway, thus suppressing the senescence program
  4513. High‐dose Rapamycin blocks mossy fiber sprouting but not seizures in a mouse model of temporal lobe epilepsy
  4514. Rapamycin treatment improves neuron viability in an in vitro model of stroke
  4515. Genetic reduction of mammalian target of Rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene …
  4516. Nitrogen source activates TOR (target of Rapamycin) complex 1 via glutamine and independently of Gtr/Rag proteins
  4517. The use of sirolimus (Rapamycin) in the management of refractory inflammatory bowel disease in children
  4518. RETRACTED: Rapamycin induces of protective autophagy in vascular endothelial cells exposed to oxygen–glucose deprivation
  4519. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial
  4520. M (o) TOR of pseudo-hypoxic state in aging: Rapamycin to the rescue
  4521. Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2
  4522. Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of Rapamycin (mTOR)
  4523. Mechanistic target of Rapamycin complex 1 expands Th17 and IL-4+ CD4− CD8− double-negative T cells and contracts regulatory T cells in systemic lupus …
  4524. Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury
  4525. Colocalized delivery of Rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway
  4526. Reduced mammalian target of Rapamycin activity facilitates mitochondrial retrograde signaling and increases life span in normal human fibroblasts
  4527. Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic Rapamycin feeding in male and female mice
  4528. Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice
  4529. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and Rapamycin sensitivity
  4530. Mammalian target of Rapamycin as a rational therapeutic target for breast cancer treatment
  4531. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase
  4532. mTOR signaling in liver regeneration: Rapamycin combined with growth factor treatment
  4533. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
  4534. Low-dose Rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study
  4535. Disruption of mammalian target of Rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis
  4536. Mechanistic target of Rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus
  4537. Activation of mTORC1 signaling and protein synthesis in human muscle following blood flow restriction exercise is inhibited by Rapamycin
  4538. A feasibility and efficacy study of Rapamycin and erlotinib for recurrent pediatric low‐grade glioma (LGG)
  4539. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with Rapamycin
  4540. Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of Rapamycin pathway
  4541. Acute systemic Rapamycin induces neurobehavioral alterations in rats
  4542. Mammalian target of Rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex
  4543. Effects of the mTOR inhibitor Rapamycin on monocyte-secreted chemokines
  4544. Efficacy of Rapamycin against glioblastoma cancer stem cells
  4545. Mammalian target of Rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells
  4546. Periadventitial application of Rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis
  4547. Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of Rapamycin (mTOR) inhibition
  4548. Rapamycin and interleukin-1β impair brain-derived neurotrophic factor-dependent neuron survival by modulating autophagy
  4549. Mammalian target of Rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial …
  4550. Topical Rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions
  4551. Rapamycin up-regulation of autophagy reduces infarct size and improves outcomes in both permanent MCAL, and embolic MCAO, murine models of stroke
  4552. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway
  4553. Mechanistic target of Rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function
  4554. Correction of glycogen storage disease type III with Rapamycin in a canine model
  4555. Mammalian target of Rapamycin and its downstream signalling components are activated in psoriatic skin
  4556. First left–right comparative study of topical Rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex
  4557. Reprogramming of the microRNA transcriptome mediates resistance to Rapamycin
  4558. The role of diacylglycerol kinase ζ and phosphatidic acid in the mechanical activation of mammalian target of Rapamycin (mTOR) signaling and skeletal …
  4559. Mammalian target of Rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer’s disease pathology
  4560. Metabolic control by target of Rapamycin and autophagy during ageing-a mini-review
  4561. Rapamycin improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders
  4562. Inducing autophagy: a comparative phosphoproteomic study of the cellular response to ammonia and Rapamycin
  4563. Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function
  4564. Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence
  4565. Effects of Rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia
  4566. Rheb and mammalian target of Rapamycin in mitochondrial homoeostasis
  4567. Role of Akt and mammalian target of Rapamycin in functional outcome after concussive brain injury in mice
  4568. Conversion to mammalian target of Rapamycin inhibitors increases risk of de novo donor‐specific antibodies
  4569. Intra-articular administration of gelatin hydrogels incorporating Rapamycin–micelles reduces the development of experimental osteoarthritis in a murine model
  4570. Rapamycin rescues the poor developmental capacity of aged porcine oocytes
  4571. A Rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren’s …
  4572. Prenatal Rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice
  4573. Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression
  4574. inhibition of mammalian target of Rapamycin with Rapamycin reverses hypertrophic cardiomyopathy in mice with cardiomyocyte-specific knockout of PTEN
  4575. Skeletal muscle-derived myonectin activates the mammalian target of Rapamycin (mTOR) pathway to suppress autophagy in liver
  4576. Combined treatment of Rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver
  4577. Protection Against Epithelial Damage During Candida albicans Infection Is Mediated by PI3K/Akt and Mammalian Target of Rapamycin Signaling
  4578. Insulin and Target of Rapamycin signaling orchestrate the development of ovarian niche-stem cell units in Drosophila
  4579. Neuroprotective effects of autophagy induced by Rapamycin in rat acute spinal cord injury model
  4580. Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance
  4581. Isoleucine, leucine, methionine, and threonine effects on mammalian target of Rapamycin signaling in mammary tissue
  4582. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of Rapamycin on human neuroendocrine tumors
  4583. Rapamycin prevents drug seeking via disrupting reconsolidation of reward memory in rats
  4584. Target of Rapamycin signalling mediates the lifespan-extending effects of dietary restriction by essential amino acid alteration
  4585. Adjuvant treatment with a mammalian target of Rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute …
  4586. Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy
  4587. Mechanism of metformin-dependent inhibition of mammalian target of Rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) …
  4588. Beyond control of protein translation: what we have learned about the non-canonical regulation and function of mammalian target of Rapamycin (mTOR)
  4589. Mammalian target of Rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function
  4590. Dihydroartemisinin inhibits the mammalian target of Rapamycin-mediated signaling pathways in tumor cells
  4591. The rationale of targeting mammalian target of Rapamycin for ischemic stroke
  4592. Beneficial role of Rapamycin in experimental autoimmune myositis
  4593. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of Rapamycin (mTOR)
  4594. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of Rapamycin (mTOR) pathway, through endoplasmic reticulum stress to induce …
  4595. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86
  4596. The role of mammalian target of Rapamycin inhibitors in the management of post‐transplant malignancy
  4597. Differences in Mammalian target of Rapamycin gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity
  4598. Proteasome-dependent activation of mammalian target of Rapamycin complex 1 (mTORC1) is essential for autophagy suppression and muscle remodeling …
  4599. Current models of mammalian target of Rapamycin complex 1 (mTORC1) activation by growth factors and amino acids
  4600. microRNA‑199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of Rapamycin
  4601. RhoA modulates signaling through the mechanistic target of Rapamycin complex 1 (mTORC1) in mammalian cells
  4602. Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model
  4603. The immunosuppressive agents Rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid …
  4604. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of Rapamycin) by IκB kinase α (IKKα)
  4605. Differential effects of Rapamycin and dexamethasone in mouse models of established allergic asthma
  4606. Antitumor effects of Rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy
  4607. Rapamycin and omega‐1: mTOR‐dependent and‐independent Th2 skewing by human dendritic cells
  4608. Rapamycin inhibits FBXW7 loss-induced epithelial–mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells
  4609. Rapamycin resistance: mTORC1 substrates hold some of the answers
  4610. Mammalian target of Rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection
  4611. Prolonged Rapamycin treatment led to beneficial metabolic switch
  4612. Blockade of mTOR signaling via Rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions
  4613. Ribosomal protein S6, a target of Rapamycin, is involved in the regulation of rRNA genes by possible epigenetic changes in Arabidopsis
  4614. PML mediates glioblastoma resistance to mammalian target of Rapamycin (mTOR)-targeted therapies
  4615. Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells
  4616. TGF-β/Smad3 activates mammalian target of Rapamycin complex-1 to promote collagen production by increasing HIF-1α expression
  4617. Successful treatment of subungual fibromas of tuberous sclerosis with topical Rapamycin
  4618. Laser phototherapy accelerates oral keratinocyte migration through the modulation of the mammalian target of Rapamycin signaling pathway
  4619. PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with Rapamycin in rats
  4620. Activation of mammalian target of Rapamycin signaling in skeletal muscle of neonatal chicks: Effects of dietary leucine and age
  4621. Single Rapamycin administration induces prolonged downward shift in defended body weight in rats
  4622. Comparison of Rapamycin schedules in mice on high-fat diet
  4623. Inhalable Particles Containing Rapamycin for Induction of Autophagy in Macrophages Infected with Mycobacterium tuberculosis
  4624. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of Rapamycin signaling
  4625. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating Rapamycin-induced Akt phosphorylation
  4626. Cross-talk between sirtuin and mammalian target of Rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation
  4627. A novel topical Rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex
  4628. Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy
  4629. Fluorescence tomography of Rapamycin-induced autophagy and cardioprotection in vivo
  4630. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a)
  4631. Mechanistic target of Rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer …
  4632. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of Rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung …
  4633. Bone effects of mammalian target of Rapamycin (mTOR) inhibition with everolimus
  4634. Rapamycin increases mitochondrial efficiency by mtDNA-dependent reprogramming of mitochondrial metabolism in Drosophila
  4635. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and Rapamycin
  4636. inhibition of mammalian target of Rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat
  4637. Resveratrol prevents Rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells
  4638. Combined SFK/mTOR inhibition prevents Rapamycin-induced feedback activation of AKT and elicits efficient tumor regression
  4639. Topical Rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial
  4640. Mammalian target of Rapamycin cell signaling pathway contributes to the protective effects of ischemic postconditioning against stroke
  4641. Combination of autophagy inducer Rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells
  4642. Effects of AMP-activated protein kinase (AMPK) signaling and essential amino acids on mammalian target of Rapamycin (mTOR) signaling and protein …
  4643. Chemical injury-induced corneal opacity and neovascularization reduced by Rapamycin via TGF-β1/ERK pathways regulation
  4644. Comparative metabolic profiling-based improvement of Rapamycin production by Streptomyces hygroscopicus
  4645. Anti-remodeling effects of Rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade
  4646. Treating brain tumor–initiating cells using a combination of myxoma virus and Rapamycin
  4647. Superiority of Rapamycin over tacrolimus in preserving nonhuman primate Treg half‐life and phenotype after adoptive transfer
  4648. Anti-angiogenic effects of mammalian target of Rapamycin inhibitors in a mouse model of oxygen-induced retinopathy
  4649. Topical Rapamycin (sirolimus) for facial angiofibromas
  4650. Mammalian target of Rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1α
  4651. Systemic inhibition of mTOR kinase via Rapamycin disrupts consolidation and reconsolidation of auditory fear memory
  4652. The antiaging activity and cerebral protection of Rapamycin at micro‐doses
  4653. Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN‐deficient human fibroblasts
  4654. Acute Rapamycin treatment improved glucose tolerance through inhibition of hepatic gluconeogenesis in rainbow trout (Oncorhynchus mykiss)
  4655. Amino acids activate mammalian target of Rapamycin (mTOR) complex 1 without changing Rag GTPase guanyl nucleotide charging
  4656. Mammalian target of Rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion
  4657. The general control nonderepressible‐2 kinase mediates stress response and longevity induced by target of Rapamycin inactivation in Caenorhabditis elegans
  4658. The incidence, management, and evolution of Rapamycin‐related side effects in kidney transplant recipients
  4659. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of Rapamycin (mTOR)
  4660. Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti‐Tumour Potency on Prostate Cancer Cells
  4661. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2
  4662. Behavioural and EEG effects of chronic Rapamycin treatment in a mouse model of tuberous sclerosis complex
  4663. The mammalian target of Rapamycin signalling pathway is involved in osteoblastic differentiation of vascular smooth muscle cells
  4664. Subcellular distribution and activity of mechanistic target of Rapamycin in aged retinal pigment epithelium
  4665. LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway
  4666. inhibition of mammalian target of Rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis
  4667. Mammalian target of Rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations
  4668. Rapamycin attenuates bleomycin-induced pulmonary fibrosis in rats and the expression of metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in lung …
  4669. Mammalian target of Rapamycin and Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton
  4670. Combined mTOR inhibitor Rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
  4671. Phosphorylated mammalian target of Rapamycin is associated with an adverse outcome in oral squamous cell carcinoma
  4672. Rapamycin alleviates brain edema after focal cerebral ischemia reperfusion in rats
  4673. Alternative mammalian target of Rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway …
  4674. … resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of Rapamycin, protein kinase B, or …
  4675. Mammalian target of Rapamycin inhibition and mycobacterial survival are uncoupled in murine macrophages
  4676. Transcriptional profiling of Rapamycin-treated fibroblasts from hypertrophic and keloid scars
  4677. p53/TAp63 and AKT regulate mammalian target of Rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of …
  4678. Young and old genetically heterogeneous HET 3 mice on a Rapamycin diet are glucose intolerant but insulin sensitive
  4679. Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated …
  4680. Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis
  4681. Pan-mammalian target of Rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 …
  4682. Rapamycin treatment of Mandibuloacral dysplasia cells rescues localization of chromatin-associated proteins and cell cycle dynamics
  4683. Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of Rapamycin (mTOR) pathway: potential for novel anticancer therapeutics
  4684. … characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic Rapamycin treatment
  4685. Impairing the production of ribosomal RNA activates mammalian target of Rapamycin complex 1 signalling and downstream translation factors
  4686. inhibition of the mammalian target of Rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells
  4687. Rapamycin-induced autophagy aggravates pathology and weakness in a mouse model of VCP-associated myopathy
  4688. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with Rapamycin
  4689. Mammalian target of Rapamycin (mTOR) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: predictors, management, and …
  4690. Systematic combination screening reveals synergism between Rapamycin and sunitinib against human lung cancer
  4691. Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions
  4692. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical Rapamycin
  4693. West nile virus-induced activation of mammalian target of Rapamycin complex 1 supports viral growth and viral protein expression
  4694. Rapamycin Augments Human DC IL‐12p70 and IL‐27 Secretion to Promote Allogeneic Type1 Polarization Modulated by NK Cells
  4695. Rapamycin inhibits smooth muscle cell proliferation and obstructive arteriopathy attributable to elastin deficiency
  4696. Resveratrol potentiates Rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet
  4697. The Mammalian target of Rapamycin inhibitors in breast cancer: current evidence and future directions
  4698. Disruption of an hTERT–mTOR–RAPTOR protein complex by a phytochemical perillyl alcohol and Rapamycin
  4699. Clinical impacts of mammalian target of Rapamycin expression in human colorectal cancers
  4700. The mTOR inhibitor Rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells
  4701. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical Rapamycin and concomitant laser therapy
  4702. Mammalian target of Rapamycin-independent S6K1 and 4E-BP1 phosphorylation during contraction in rat skeletal muscle
  4703. Rapamycin in preventive (very low) doses
  4704. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of Rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through …
  4705. Administration of low doses of IL‐2 combined to Rapamycin promotes allogeneic skin graft survival in mice
  4706. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of Rapamycin inhibitors
  4707. Rapamycin slows IgA nephropathy progression in the rat
  4708. Rapamycin inhibits transforming growth factor β1-induced fibrogenesis in primary human lung fibroblasts
  4709. Murine dendritic cell Rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction
  4710. Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for Rapamycin
  4711. … (Astyanax fasciatus mexicanus): effects on feeding and on the brain expression levels of tyrosine hydroxylase, mechanistic target of Rapamycin and appetite-related …
  4712. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to Rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma
  4713. The effects of Rapamycin on regulatory T cells: its potential time-dependent role in inducing transplant tolerance
  4714. Combination of Rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition
  4715. Mammalian target of Rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis
  4716. Rapamycin reduces burn wound progression by enhancing autophagy in deep second‐degree burn in rats
  4717. … matrix-modulated Heartless signaling in Drosophila blood progenitors regulates their differentiation via a Ras/ETS/FOG pathway and target of Rapamycin …
  4718. Rapamycin induces autophagy in the melanoma cell line M14 via regulation of the expression levels of Bcl‑2 and Bax
  4719. A phase I study of decitabine and Rapamycin in relapsed/refractory AML
  4720. … amino acid sensing controls adult germline stem cell number via the amino acid response pathway and independently of Target of Rapamycin signaling in Drosophila
  4721. … -type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and Rapamycin
  4722. Palmitate induces mRNA translation and increases ER protein load in islet β-cells via activation of the mammalian target of Rapamycin pathway
  4723. Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model
  4724. Increasing leucine concentration stimulates mechanistic target of Rapamycin signaling and cell growth in C2C12 skeletal muscle cells
  4725. Characterization and pharmacokinetic analysis of crystalline versus amorphous Rapamycin dry powder via pulmonary administration in rats
  4726. Olanzapine activates hepatic mammalian target of Rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs
  4727. Environmental signaling through the mechanistic target of Rapamycin complex 1: mTORC1 goes nuclear
  4728. Mammalian target of Rapamycin signaling activation patterns in pancreatic neuroendocrine tumors
  4729. A novel Rapamycin-polymer conjugate based on a new poly (ethylene glycol) multiblock copolymer
  4730. Mechanical activation of mammalian target of Rapamycin pathway is required for cartilage development
  4731. Rapamycin inhibits oxidative and angiogenic mediators in diabetic retinopathy
  4732. The mTOR inhibitor Rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling
  4733. Target of Rapamycin (TOR) kinase in Trypanosoma brucei: an extended family
  4734. Crystalline coating of Rapamycin onto a stent: Process development and characterization
  4735. Equivalent benefit of Rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis
  4736. Berberine sensitizes Rapamycin‑mediated human hepatoma cell death in vitro
  4737. Regulation of blood–testis barrier (BTB) dynamics during spermatogenesis via the “Yin” and “Yang” effects of mammalian target of Rapamycin complex 1 (mTORC1) …
  4738. Topical Rapamycin systematically suppresses the early stages of pulsed dye laser‐induced angiogenesis pathways
  4739. Studies on process optimization methods for Rapamycin production using Streptomyces hygroscopicus ATCC 29253
  4740. Mammalian target of Rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC …
  4741. Branched-chain amino acids enhance premature senescence through mammalian target of Rapamycin complex I-mediated upregulation of p21 protein
  4742. Effects of the immunosuppressant Rapamycin on the expression of human α2 (I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts
  4743. Cumulative number of altered biomarkers in mammalian target of Rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell …
  4744. Mammalian target of Rapamycin complex 1 activation negatively regulates Polo-like kinase 2-mediated homeostatic compensation following neonatal seizures
  4745. Chemical genetics of Rapamycin-insensitive TORC2 in S. cerevisiae
  4746. Rapamycin promoted thrombosis and platelet adhesion to endothelial cells by inducing membrane remodeling
  4747. Relative resistance to mammalian target of Rapamycin inhibition in vascular smooth muscle cells of diabetic donors
  4748. AMP‐activated protein kinase counteracts brain‐derived neurotrophic factor‐induced mammalian target of Rapamycin complex 1 signaling in neurons
  4749. YM155 reverses Rapamycin resistance in renal cancer by decreasing survivin
  4750. β-hydroxy-β-methylbutyrate facilitates pi3k/akt-dependent mammalian target of Rapamycin and foxo1/3a phosphorylations and alleviates tumor necrosis factor α …
  4751. Mechanistic target of Rapamycin complex 1 (mTORC1)-mediated phosphorylation is governed by competition between substrates for interaction with raptor
  4752. CD44-tropic polymeric nanocarrier for breast cancer targeted Rapamycin chemotherapy
  4753. Mechanistic target of Rapamycin complex 1 signaling regulates cell proliferation, cell survival, and differentiation in regenerating zebrafish fins
  4754. Bidirectional regulation of nuclear factor-κB and mammalian target of Rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular …
  4755. Kinetics of Rapamycin production by Streptomyces hygroscopicus MTCC 4003
  4756. Growth differentiation factor 15 stimulates Rapamycin-sensitive ovarian cancer cell growth and invasion
  4757. Carrier free Rapamycin loaded drug eluting stent: in vitro and in vivo evaluation
  4758. Exome sequencing reveals de novo germline mutation of the mammalian target of Rapamycin (mTOR) in a patient with megalencephaly and intractable seizures
  4759. Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of Rapamycin inhibitory activities for sotalol, glyburide, metipranolol …
  4760. Uth1 is a mitochondrial inner membrane protein dispensable for post‐log‐phase and Rapamycin‐induced mitophagy
  4761. Requirement of Mammalian target of Rapamycin complex 1 downstream effectors in cued fear memory reconsolidation and its persistence
  4762. Rapamycin enhances HBV production by inducing cellular autophagy
  4763. Rapamycin-induced modulation of HIV gene transcription attenuates progression of HIVAN
  4764. Improvement of the antiproliferative effect of Rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes
  4765. Mammalian target of Rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma
  4766. A novel semisynthetic inhibitor of the FRB domain of mammalian target of Rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells
  4767. Mammalian target of Rapamycin is essential for cardiomyocyte survival and heart development in mice
  4768. Dysregulation of mammalian target of Rapamycin pathway in upper tract urothelial carcinoma
  4769. … of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of Rapamycin activity in the …
  4770. A Rapamycin-releasing perivascular polymeric sheath produces highly effective inhibition of intimal hyperplasia
  4771. MNK kinases facilitate c-myc IRES activity in Rapamycin-treated multiple myeloma cells
  4772. Hyperactivation of mammalian target of Rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced …
  4773. Rapamycin induces pluripotent genes associated with avoidance of replicative senescence
  4774. Electrospun Rapamycin-eluting polyurethane fibers for vascular grafts
  4775. Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-κB activation
  4776. Blockade of epidermal growth factor receptor/mammalian target of Rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells
  4777. Rheb (Ras homologue enriched in brain)-dependent mammalian target of Rapamycin complex 1 (mTORC1) activation becomes indispensable for cardiac …
  4778. Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of Rapamycin pathway
  4779. Rapamycin inhibits acrolein‐induced apoptosis by alleviating ROS‐driven mitochondrial dysfunction in male germ cells
  4780. Low concentration of Rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice
  4781. Mammalian target of Rapamycin complex 1 (m TORC 1) may modulate the timing of anagen entry in mouse hair follicles
  4782. Chronic Rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo
  4783. Rheb activation in subventricular zone progenitors leads to heterotopia, ectopic neuronal differentiation, and Rapamycin-sensitive olfactory micronodules and dendrite …
  4784. MicroRNA-21 mediates the Rapamycin-induced suppression of endothelial proliferation and migration
  4785. Rapamycin modulates markers of mitochondrial biogenesis and fatty acid oxidation in the adipose tissue of db/db mice
  4786. Role of GAS5 noncoding RNA in mediating the effects of Rapamycin and its analogues on mantle cell lymphoma cells
  4787. Inhibitory effect of paclitaxel and Rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade
  4788. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer
  4789. Eukaryotic Initiation Factor 2α-a Downstream Effector of Mammalian Target of Rapamycin-Modulates DNA Repair and Cancer Response to Treatment
  4790. Production of Rapamycin in Streptomyces hygroscopicus from glycerol-based media optimized by systemic methodology
  4791. Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice
  4792. Neuronal-specific iron deficiency dysregulates mammalian target of Rapamycin signaling during hippocampal development in nonanemic genetic mouse models
  4793. Targeted inhibition of mammalian target of Rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells
  4794. The role of mammalian target of Rapamycin (mTOR) inhibition in the treatment of advanced breast cancer
  4795. Anorexigenic and orexigenic hormone modulation of mammalian target of Rapamycin complex 1 activity and the regulation of hypothalamic agouti-related protein …
  4796. Rapamycin inhibits BMP‐7‐induced osteogenic and lipogenic marker expressions in fetal rat calvarial cells
  4797. Over-expression of phosphorylated mammalian target of Rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study
  4798. Rapamycin prolongs female reproductive lifespan
  4799. Mechanistic target of Rapamycin (mTOR) signaling genes in decapod crustaceans: cloning and tissue expression of mTOR, Akt, Rheb, and p70 S6 kinase in the green …
  4800. Relevance of the mammalian target of Rapamycin pathway in the prognosis of patients with high-risk non–muscle invasive bladder cancer
  4801. Spatiotemporal control of vascular endothelial growth factor expression using a heat-shock-activated, Rapamycin-dependent gene switch
  4802. Rapamycin‐sensitive mTORC1 signaling is involved in physiological primordial follicle activation in mouse ovary
  4803. TORC 1 signaling inhibition by Rapamycin and caffeine affect lifespan, global gene expression, and cell proliferation of fission yeast
  4804. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of Rapamycin inhibitors
  4805. microRNA regulation of mammalian target of Rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity
  4806. gln3 mutations dissociate responses to nitrogen limitation (nitrogen catabolite repression) and Rapamycin inhibition of TorC1
  4807. Next generation of mammalian target of Rapamycin inhibitors for the treatment of cancer
  4808. Mammalian target of Rapamycin in inflammatory skin conditions
  4809. Alterations in the Ure2 αCap domain elicit different GATA factor responses to Rapamycin treatment and nitrogen limitation
  4810. PI3Kδ inhibition augments the efficacy of Rapamycin in suppressing proliferation of Epstein− Barr virus (EBV)+ B cell lymphomas
  4811. Accumulation of dephosphorylated 4EBP after mTOR inhibition with Rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene
  4812. inhibition of Rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers
  4813. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase
  4814. Mis-regulation of mammalian target of Rapamycin (mTOR) complexes induced by albuminuria in proximal tubules
  4815. Morphoproteomic profiling of the mammalian target of Rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing’s …
  4816. The search continues: looking for predictive biomarkers for response to mammalian target of Rapamycin inhibition in endometrial cancer
  4817. Rapamycin protects against Aβ-induced synaptotoxicity by increasing presynaptic activity in hippocampal neurons
  4818. Expression of budding yeast FKBP12 confers Rapamycin susceptibility to the unicellular red alga Cyanidioschyzon merolae
  4819. Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways
  4820. Breast cancer tissue slices as a model for evaluation of response to Rapamycin
  4821. Metformin and Rapamycin are master-keys for understanding the relationship between cell senescent, aging and cancer
  4822. GSK3β, but not GSK3α, inhibits the neuronal differentiation of neural progenitor cells as a downstream target of mammalian target of Rapamycin complex1
  4823. Rapamycin‐loaded poly (ε‐caprolactone)‐poly (ethylene glycol)‐poly (ε‐caprolactone) nanoparticles: preparation, characterization and potential application in …
  4824. Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of Rapamycin
  4825. Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of Rapamycin (mTOR)
  4826. Role of mammalian target of Rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: A case report
  4827. Dual phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal …
  4828. inhibition of mammalian target of Rapamycin signaling pathway decreases retinoic acid stimulated gene 8 expression in adult mouse testis
  4829. Role of the mammalian target of Rapamycin (mTOR) complexes in pancreatic β-cell mass regulation
  4830. Rapamycin promotes Schwann cell migration and nerve growth factor secretion
  4831. Arsenic trioxide overcomes Rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer
  4832. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of Rapamycin inhibitors via S6 kinase …
  4833. Phase I/IIa trial of the mammalian target of Rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced …
  4834. Phosphoinositide-3 kinase/protein kinase-B/mammalian target of Rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?
  4835. SOX 2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of Rapamycin complex 1 signaling pathway
  4836. … proliferation by negatively regulating phosphodiesterase-4, extracellular signal-regulated kinase, Akt/mammalian target of Rapamycin kinase, and nuclear factor …
  4837. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of Rapamycin signaling pathway
  4838. Autoimmune pancreatitis in MRL/Mp mice is a T cell-mediated disease responsive to cyclosporine A and Rapamycin treatment
  4839. Rapamycin does not affect post-absorptive protein metabolism in human skeletal muscle
  4840. Comparative effects of PP242 and Rapamycin on mTOR signalling and NOTCH signalling in leukemia cells
  4841. Rapamycin attenuates endothelial apoptosis induced by low shear stress via mTOR and sestrin1 related redox regulation
  4842. Mammalian target of Rapamycin inhibitor Rapamycin enhances anti‐leukemia effect of imatinib on P h+ acute lymphoblastic leukemia cells
  4843. … synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of Rapamycin (mTOR) C1-dependent and …
  4844. Mammalian target of Rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer
  4845. A phase I trial of sunitinib and Rapamycin in patients with advanced non-small cell lung cancer
  4846. Autoregulation of the mechanistic target of Rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism
  4847. Dysregulation of the mammalian target of Rapamycin and p27Kip1 promotes intimal hyperplasia in diabetes mellitus
  4848. Ferulic acid induces mammalian target of Rapamycin inactivation in cultured mammalian cells
  4849. Rapamycin ameliorates neuropathic pain by activating autophagy and inhibiting interleukin-1β in the rat spinal cord
  4850. Staurosporine induces dopaminergic neurite outgrowth through AMP-activated protein kinase/mammalian target of Rapamycin signaling pathway
  4851. Osteolysis and pain due to experimental bone metastases are improved by treatment with Rapamycin
  4852. Effect of Rapamycin and interleukin-2 on regulatory CD4+ CD25+ Foxp3+ T cells in mice after allogenic corneal transplantation
  4853. The mechanistic target for Rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo
  4854. Trilayer micelles for combination delivery of Rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1)
  4855. Over‐expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by Rapamycin and is sufficient to ameliorate Alzheimer’s‐like deficits in mice …
  4856. Role of energy‐and nutrient‐sensing kinases AMP‐activated Protein Kinase (AMPK) and Mammalian Target of Rapamycin (mTOR) in Adipocyte Differentiation
  4857. Rapamycin ameliorates nephropathy despite elevating hyperglycemia in a polygenic mouse model of type 2 diabetes, NONcNZO10/LtJ
  4858. Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells
  4859. Analysis of Rapamycin induced autophagy in Dictyostelium discoideum
  4860. Role of inhibitors of mammalian target of Rapamycin in the treatment of luminal breast cancer
  4861. Ptc6 is required for proper Rapamycin-induced down-regulation of the genes coding for ribosomal and rRNA processing proteins in S. cerevisiae
  4862. Evaluation of the prognostic significance of altered mammalian target of Rapamycin pathway biomarkers in upper tract urothelial carcinoma
  4863. Rapamycin induces apoptosis when autophagy is inhibited in T-47D mammary cells and both processes are regulated by Phlda1
  4864. p38α senses environmental stress to control innate immune responses via mechanistic target of Rapamycin
  4865. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M
  4866. Rapamycin regulates iTreg function through CD39 and Runx1 pathways
  4867. Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid …
  4868. Mammalian target of Rapamycin complex 2 modulates αβTCR processing and surface expression during thymocyte development
  4869. Oncogenic mutations in adenomatous polyposis coli (Apc) activate mechanistic target of Rapamycin complex 1 (mTORC1) in mice and zebrafish
  4870. Metabolomic evaluation of Mitomycin C and Rapamycin in a personalized treatment of pancreatic cancer
  4871. Rapamycin treatment of healthy pigs subjected to acute myocardial ischemia-reperfusion injury attenuates cardiac functions and increases myocardial necrosis
  4872. Comparison of posterior capsule opacification in rabbit eyes receiving different administrations of Rapamycin
  4873. Mammalian tribbles homologs at the crossroads of endoplasmic reticulum stress and mammalian target of Rapamycin pathways
  4874. Inhibitory effects of Rapamycin on the different stages of hepatic fibrosis
  4875. Regulation of mammalian target of Rapamycin complex 1 by Bcl-2 and Bcl-XL proteins
  4876. Transforming growth factor β integrates Smad 3 to mechanistic target of Rapamycin complexes to arrest deptor abundance for glomerular mesangial cell …
  4877. Genetic interactions between protein phosphatases CaPtc2p and CaPph3p in response to genotoxins and Rapamycin in Candida albicans
  4878. Syntaxin13 expression is regulated by mammalian target of Rapamycin (mTOR) in injured neurons to promote axon regeneration
  4879. Combination of cetuximab and Rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma
  4880. Oedema, solid organ transplantation and mammalian target of Rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs)
  4881. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of Rapamycin
  4882. Rapamycin is less fibrogenic than Cyclosporin A as demonstrated in a rat model of chronic allograft nephropathy
  4883. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with Rapamycin
  4884. Effects of dissolved oxygen level on Rapamycin production by pellet-form of Streptomyces hygroscopicus
  4885. Mammalian target of Rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease
  4886. … factor‐1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3‐kinase/Akt/mammalian target protein of Rapamycin pathway in multiple …
  4887. … increase the phosphorylation of tuberous sclerosis complex‐2 (TSC2) and alter the targeting of TSC2 and the mechanistic target of Rapamycin to the lysosome
  4888. … transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of Rapamycin (mTOR)/ribosomal S6 …
  4889. Rapamycin attenuates bladder hypertrophy during long-term outlet obstruction in vivo: tissue, matrix and mechanistic insights
  4890. Rapamycin delays salivary gland atrophy following ductal ligation
  4891. Mechanistic target of Rapamycin in common carp: cDNA cloning, characterization, and tissue expression
  4892. Rapamycin inhibits pre-B acute lymphoblastic leukemia cells by downregulating DNA and RNA polymerases
  4893. … -associated protein/microtubule affinity-regulating kinase 4 (MARK4) is a negative regulator of the mammalian target of Rapamycin complex 1 (mTORC1)
  4894. Rapamycin regulates biochemical metabolites
  4895. Mammalian target of Rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL)
  4896. The roles of juvenile hormone, insulin/target of Rapamycin, and ecydsone signaling in regulating body size in Drosophila
  4897. … 1 (REDD1) promotes cell survival during serum deprivation by sustaining repression of signaling through the mechanistic target of Rapamycin in complex 1 (mTORC1)
  4898. Rapamycin blocks fibrocyte migration and attenuates bronchiolitis obliterans in a murine model
  4899. Myxoid liposarcoma and the mammalian target of Rapamycin pathway
  4900. … protein 2A promotes the epithelial-mesenchymal transition in nasopharyngeal carcinoma via metastatic tumor antigen 1 and mechanistic target of Rapamycin …
  4901. Rapamycin reduces renal hypoxia, interstitial inflammation and fibrosis in a rat model of unilateral ureteral obstruction
  4902. Rapamycin-induced modulation of miRNA expression is associated with amelioration of HIV-associated nephropathy (HIVAN)
  4903. Interferon alpha and Rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro
  4904. Mammalian target of Rapamycin complex 1 activation in podocytes promotes cellular crescent formation
  4905. Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D
  4906. … triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of Rapamycin and glycogen synthase …
  4907. Role of phosphatidylinositol-3-kinase (PI3K) and the mammalian target of Rapamycin (mTOR) signalling pathways in porcine reproductive and respiratory syndrome …
  4908. Beclin 1 is required for starvation-enhanced, but not Rapamycin-enhanced, LC3-associated phagocytosis of Burkholderia pseudomallei in RAW 264.7 cells
  4909. Gingipain‐dependent degradation of mammalian target of Rapamycin pathway proteins by the periodontal pathogen Porphyromonas gingivalis during invasion
  4910. It may be possible to delay the onset of neurodegenerative diseases with an immunosuppressive drug (Rapamycin)
  4911. Suppression of AKT phosphorylation restores Rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells
  4912. Rapamycin protects kidney against ischemia reperfusion injury through recruitment of NKT cells
  4913. Effects of combined administration of Rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats
  4914. Divergent tissue and sex effects of Rapamycin on the proteasome-chaperone network of old mice
  4915. Immunohistochemical expression of the mammalian target of Rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases
  4916. Metabolic effects of acute thiamine depletion are reversed by Rapamycin in breast and leukemia cells
  4917. Mechanistic target of Rapamycin (mTOR) signaling during ovulation in mice
  4918. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with Rapamycin and metformin
  4919. Resveratrol inhibits the phosphatidylinositide 3‑kinase/protein kinase B/mammalian target of Rapamycin signaling pathway in the human chronic myeloid …
  4920. mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of Rapamycin in vitro and in vivo
  4921. inhibition of mTOR kinase via Rapamycin blocks persistent predator stress-induced hyperarousal
  4922. All‐trans retinoic acid and Rapamycin synergize with transforming growth factor‐β1 to induce regulatory T cells but confer different migratory capacities
  4923. Activation of mammalian target of Rapamycin contributes to pain nociception induced in rats by BmK I, a sodium channel-specific modulator
  4924. Long-term treatment with mammalian target of Rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis
  4925. Mammalian target of Rapamycin pathway is up-regulated by both acute endurance exercise and chronic muscle contraction in rat skeletal muscle
  4926. Differential regulation of carbon partitioning by the central growth regulator target of Rapamycin (TOR)
  4927. Granulocyte macrophage colony‐stimulating factor promotes regeneration of retinal ganglion cells in vitro through a mammalian target of Rapamycin‐dependent …
  4928. Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of Rapamycin complex 2)
  4929. Effects of breed and dietary nutrient density on the growth performance, blood metabolite, and genes expression of target of Rapamycin (TOR) signalling pathway of …
  4930. Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy
  4931. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant …
  4932. Labor inhibits placental mechanistic target of Rapamycin complex 1 signaling
  4933. Increased mammalian target of Rapamycin complex 2 signaling promotes age-related decline in CD4 T cell signaling and function
  4934. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and …
  4935. Low-dose Rapamycin unmasks the protective potential of targeting intragraft NF-κB for islet transplants
  4936. Familial multiple discoid fibromas: unique histological features and therapeutic response to topical Rapamycin
  4937. Expression of molecular markers associated with the mammalian target of Rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes …
  4938. Structure-guided mutation of the conserved G3-box glycine in Rheb generates a constitutively activated regulator of mammalian target of Rapamycin (mTOR)
  4939. Adventitial nab-Rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial …
  4940. … pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1–mammalian target of Rapamycin …
  4941. A reversed phase high performance liquid chromatographic method for determination of Rapamycin
  4942. Effects of limiting energy availability via diet and physical activity on mammalian target of Rapamycin-related signaling in rat mammary carcinomas
  4943. Pentoxifylline and propentofylline prevent proliferation and activation of the mammalian target of Rapamycin and mitogen activated protein kinase in cultured spinal …
  4944. Activation of mammalian target of Rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor‐mediated Eph receptor 2 (EphA2) is required for …
  4945. Rapamycin‐resistant effector T‐cell therapy
  4946. Activation of the Akt/mammalian target of Rapamycin pathway in myxofibrosarcomas
  4947. Confirmation of the cellular targets of benomyl and Rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae
  4948. Effects of advanced age on whole-body protein synthesis and skeletal muscle mechanistic target of Rapamycin signaling in horses
  4949. Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of Rapamycin activity
  4950. Effect of inhibiting the signal of mammalian target of Rapamycin on memory T cells
  4951. Mammalian target of Rapamycin coordinates iron metabolism with iron-sulfur cluster assembly enzyme and tristetraprolin
  4952. Antiangiogenic therapy using sunitinib combined with Rapamycin retards tumor growth but promotes metastasis
  4953. Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells
  4954. Rapamycin attenuates visible light-induced injury in retinal photoreceptor cells via inhibiting endoplasmic reticulum stress
  4955. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis
  4956. Mechanistic/mammalian target protein of Rapamycin signaling in hematopoietic stem cells and leukemia
  4957. Coupled cell morphology investigation and metabolomics analysis improves Rapamycin production in Streptomyces hygroscopicus
  4958. … nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of Rapamycin and focal adhesion …
  4959. Diversified targets of FKBP25 and its complex with Rapamycin
  4960. Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia
  4961. Topical application of Rapamycin ointment ameliorates Dermatophagoides farina body extract‐induced atopic dermatitis in NC/Nga mice
  4962. T cells and lung injury. Impact of Rapamycin
  4963. Autophagic inhibitor attenuates Rapamycin-induced inhibition of proliferation in cultured A549 lung cancer cells
  4964. inhibition of mammalian target of Rapamycin by Rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells
  4965. Biodegradable Rapamycin-eluting nano-fiber membrane-covered metal stent placement to reduce fibroblast proliferation in experimental stricture in a canine model
  4966. Activation of mammalian target of Rapamycin mediates rat pain-related responses induced by BmK I, a sodium channel-specific modulator
  4967. Immune memory–boosting dose of Rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute …
  4968. Conversion from calcineurin inhibitor–based immunosuppression to mammalian target of Rapamycin inhibitors or belatacept in renal transplant recipients
  4969. Rapamycin resistant murine th9 cells have a stable in vivo phenotype and inhibit graft-versus-host reactivity
  4970. Rapamycin inhibits Toll-like receptor 4-induced pro-oncogenic function in head and neck squamous cell carcinoma
  4971. Novel targeting of Phoshatidylinositol-3 Kinase and Mammalian Target of Rapamycin (mTOR) in renal cell carcinoma
  4972. Draft genome sequence of Streptomyces Rapamycinicus strain NRRL 5491, the producer of the immunosuppressant Rapamycin
  4973. Should mammalian target of Rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
  4974. ScFKBP12 bridges Rapamycin and AtTOR in Arabidopsis
  4975. … of microRNA-99a promotes cell invasion and down-regulates E-cadherin expression in pancreatic cancer cells by regulating mammalian target of Rapamycin
  4976. The effect of bortezomib and Rapamycin on telomerase activity in mantle cell lymphoma
  4977. Effects of Chronic Akt/mTOR inhibition by Rapamycin on Mechanical Overload–Induced Hypertrophy and Myosin Heavy Chain Transition in Masseter Muscle
  4978. New strategies to overcome resistance to mammalian target of Rapamycin inhibitors in breast cancer
  4979. MEDI-573, alone or in combination with mammalian target of Rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas
  4980. Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system
  4981. Immunohistochemical analysis of the mechanistic target of Rapamycin and hypoxia signalling pathways in basal cell carcinoma and trichoepithelioma
  4982. Chronic mechanistic target of Rapamycin inhibition: preventing cancer to delay aging, or vice versa?
  4983. Tribbles homolog 3 attenuates mammalian target of Rapamycin complex-2 signaling and inflammation in the diabetic kidney
  4984. IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ–Dependent Apoptosis of Alloreactive CD4+ T Cells In Vitro and Reduce Lethal Graft-Versus …
  4985. Phase 2 clinical trial of Rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation
  4986. … of cost-effectiveness of oral Rapamycin plus bare-metal stents versus first generation of drug-eluting stents (from the Randomized Oral Rapamycin in Argentina [ORAR …
  4987. Dysregulation of mammalian target of Rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder
  4988. … protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of Rapamycin …
  4989. Rapid regulation of nuclear proteins by Rapamycin‐induced translocation in fission yeast
  4990. Induction of cytokines and growth factors by Rapamycin in the microenvironment of brain metastases of lung cancer
  4991. Association of mammalian target of Rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment
  4992. Short-term Rapamycin treatment in mice has few effects on the transcriptome of white adipose tissue compared to dietary restriction
  4993. Mechanistic target of Rapamycin (mTOR) dependent regulation of thioredoxin interacting protein (TXNIP) transcription in hypoxia
  4994. The mammalian target of Rapamycin pathway in the basolateral amygdala is critical for nicotine-induced behavioural sensitization
  4995. Metastatic perivascular epithelioid cell tumor responding to mammalian target of Rapamycin inhibition
  4996. A new functional role for mechanistic/mammalian target of Rapamycin complex 1 (mTORC1) in the circadian regulation of L-type voltage-gated calcium …
  4997. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by Rapamycin in vitro and further improved by hyaluronan in vivo
  4998. The Akt-mTOR pathway in Down’s syndrome: the potential use of Rapamycin/rapalogs for treating cognitive deficits
  4999. Effects of level of nutrient intake and age on mammalian target of Rapamycin, insulin, and insulin-like growth factor-1 gene network expression in skeletal …
  5000. Mammalian target of Rapamycin complex I (mTORC1) activity in ras homologue enriched in brain (Rheb)-deficient mouse embryonic fibroblasts
  5001. Precursor engineering and cell physiological regulation for high level Rapamycin production by Streptomyces hygroscopicus
  5002. Rictor/mammalian target of Rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3
  5003. Clinicopathologic significance and function of mammalian target of Rapamycin activation in esophageal squamous cell carcinoma
  5004. Rapamycin and mTOR inhibitors probably have therapeutic effects for post-operative cognitive dysfunction
  5005. The impact of everolimus versus other Rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: A meta-analysis of 16 …
  5006. A domain in the transcription activator Gln3 specifically required for Rapamycin responsiveness
  5007. Combination of rituximab and mammalian target of Rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma
  5008. Dysregulation of the mammalian target of Rapamycin pathway in chromophobe renal cell carcinomas
  5009. Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy
  5010. … CYP2E1: miR-132/-212 targeting of CYP2E1 and role of phosphatidylinositol 3-kinase, Akt (protein kinase B), mammalian target of Rapamycin signaling in regulating …
  5011. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for Rapamycin-induced feedback activation of PI3K and AKT
  5012. MicroRNA-21 is induced by Rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM)
  5013. Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of Rapamycin (mTOR)
  5014. Adenosine triphosphate promotes locomotor recovery after spinal cord injury by activating mammalian target of Rapamycin pathway in rats
  5015. Multi-scale optical imaging of the delayed type hypersensitivity reaction attenuated by Rapamycin
  5016. The combination of Rapamycin and MAPK inhibitors enhances the growth inhibitory effect on Nara-H cells
  5017. Rapamycin prevents N‐methyl‐D‐aspartate‐induced retinal damage through an ERK‐dependent mechanism in rats
  5018. Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of Rapamycin
  5019. Adenosine Monophosphate–activated Protein Kinase/Mammalian Target of Rapamycin–dependent Autophagy Protects Human Dental Pulp Cells against Hypoxia
  5020. The novel phosphoinositide 3‐kinase–mammalian target of Rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant …
  5021. Biological constraints limit the use of Rapamycin-inducible FKBP12-Inp54p for depleting PIP 2 in dorsal root ganglia neurons
  5022. Mammalian target of Rapamycin complex 1 (mTORC1) plays a role in Pasteurella multocida toxin (PMT)-induced protein synthesis and proliferation in Swiss …
  5023. Target of Rapamycin signaling regulates high mobility group protein association to chromatin, which functions to suppress necrotic cell death
  5024. Rapamycin-binding FKBP25 associates with diverse proteins that form large intracellular entities
  5025. Characterization of the immersion properties of the peripheral membrane anchor of the FATC domain of the kinase “target of Rapamycin” by NMR, oriented CD …
  5026. Stathmin Regulates Hypoxia-Inducible Factor-1 Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma
  5027. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to Rapamycin
  5028. CD4+CD25−Nrp1+ T Cells Synergize with Rapamycin to Prevent Murine Cardiac Allorejection in Immunocompetent Recipients
  5029. Enteral delivery of proteins stimulates protein synthesis in human duodenal mucosa in the fed state through a mammalian target of Rapamycin–independent pathway
  5030. Tuberous sclerosis associated with polycystic kidney disease: effects of Rapamycin after renal transplantation
  5031. Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1–Bad–Bak pathway in peritoneal carcinomatosis
  5032. Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway
  5033. Earle’s balanced salts solution and Rapamycin differentially regulate the Bacillus Calmette-Guerin-induced maturation of human dendritic cells
  5034. First-line Mammalian target of Rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell …
  5035. Addition of Rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice
  5036. Limitations of IL-2 and Rapamycin in immunotherapy of type 1 diabetes
  5037. Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by Rapamycin
  5038. Pretreatment of Rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells
  5039. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3
  5040. Rapamycin reduces Drosophila longevity under low nutrition
  5041. Insulin infusion stimulates whole-body protein synthesis and activates the upstream and downstream effectors of mechanistic target of Rapamycin signaling in the …
  5042. Bioprocess engineering aspects of Rapamycin (sirolimus) production: a review on past achievements and recent perspectives
  5043. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of Rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and …
  5044. Rapamycin enhances TNF-α-induced secretion of IL-6 and IL-8 through suppressing PDCD4 degradation in orbital fibroblasts
  5045. Visible effects of Rapamycin (sirolimus) on human skin explants in vitro
  5046. Mammalian target of Rapamycin pathway activity in alveolar soft part sarcoma
  5047. Long-term effects of conversion from cyclosporine to Rapamycin on testicular function and morphology in a rat transplantation model
  5048. The enhancement of Rapamycin production using Streptomyces hygroscopicus through a simple pH-shifted control
  5049. Rrd1p, an RNA polymerase II-specific prolyl isomerase and activator of phosphoprotein phosphatase, promotes transcription independently of Rapamycin response
  5050. … significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of Rapamycin signaling pathway in …
  5051. Activation of mammalian target of Rapamycin (mTOR) in triple negative feline mammary carcinomas
  5052. Placental, lipid, and glucidic effects of mammalian target of Rapamycin inhibitors: impact on fetal growth and metabolic disorders during pregnancy after solid organ …
  5053. The antiviral immune response in human conventional dendritic cells is controlled by the mammalian target of Rapamycin
  5054. inhibition of Rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells
  5055. Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells
  5056. Mammalian target of Rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials
  5057. Synthesis of Rapamycin glycoconjugates via a CuAAC-based approach
  5058. Galectin-9 in combination with Rapamycin induces cardiac allograft tolerance in mice
  5059. Rapamycin attenuates pulmonary allergic vasculitis in murine model by reducing TGF-β production in the lung
  5060. Rapamycin in fibrotic diseases: beneficial or detrimental agent?
  5061. Recovery from Rapamycin: drug-insensitive activity of yeast target of Rapamycin complex 1 (TORC1) supports residual proliferation that dilutes Rapamycin …
  5062. Rapamycin and PF4 induce apoptosis by upregulating Bax and down-regulating survivin in MNU-induced breast cancer
  5063. Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of Rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung …
  5064. Down regulation of mammalian target of Rapamycin decreases HIF-1α and survivin expression in anoxic lung adenocarcinoma A549 cell to elemene and/or irradiation
  5065. Efficacy and safety of Rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis
  5066. Oral erlotinib, but not Rapamycin, causes modest acceleration of bladder and hindlimb recovery from spinal cord injury in rats
  5067. p21WAF1/CIP1 expression is differentially regulated by metformin and Rapamycin
  5068. Alcohol consumption mitigates apoptosis and mammalian target of Rapamycin signaling in myocardium
  5069. Insights from yeast into whether the Rapamycin inhibition of heat shock transcription factor (Hsf1) can prevent the Hsf1 activation that results from treatment …
  5070. Immunotherapy with tolerogenic dendritic cells alone or in combination with Rapamycin does not reverse diabetes in NOD mice
  5071. Mammalian target of Rapamycin complex 2 signaling pathway regulates transient receptor potential cation channel 6 in podocytes
  5072. Successful mammalian target of Rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic …
  5073. Anti‐LFA‐1 or Rapamycin overcome costimulation blockade‐resistant rejection in sensitized bone marrow recipients
  5074. Interferon alpha and Rapamycin inhibit the growth of carcinoid and medullary thyroid cancer in vitro
  5075. In vitro and in vivo evaluation of Rapamycin-eluting nanofibers coated on cardia stents
  5076. Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro
  5077. eIF4E-Overexpression imparts perillyl alcohol and Rapamycin-mediated regulation of telomerase reverse transcriptase
  5078. Clinical significance of aberrant mammalian target of Rapamycin expression in stage IIIB colon cancer
  5079. Multifaceted aging and Rapamycin
  5080. Effect of Rapamycin on spleen size in longstanding renal transplant recipients
  5081. Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of Rapamycin …
  5082. Effect of Rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer
  5083. MicroRNA-100 promotes migration and invasion through mammalian target of Rapamycin in esophageal squamous cell carcinoma
  5084. Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of Rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in …
  5085. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis
  5086. Mammalian target of Rapamycin complex 1 (mTORC1)-mediated phosphorylation stabilizes ISCU protein: implications for iron metabolism
  5087. Sequential use of mammalian target of Rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors
  5088. The effects of viscosity and aeration rate on Rapamycin production in an airlift bioreactor by using Streptomyces hygroscopicus
  5089. Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of Rapamycin (mTOR)
  5090. Genetic Findings in Obsessive–Compulsive Disorder Connect to Brain‐Derived Neurotropic Factor and Mammalian Target of Rapamycin Pathways: Implications for …
  5091. Limited significance of activated Akt-mammalian target of Rapamycin signaling pathway in prostate cancer progression
  5092. Fusogenic pH sensitive liposomal formulation for Rapamycin: improvement of antiproliferative effect
  5093. The synergistic effect of Rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells
  5094. Transcriptome profiling of CTLs regulated by Rapamycin using RNA-Seq
  5095. Application of Response Surface Methodology To Formulation Optimization of Rapamycin Loaded Magnetic Fe3O4/Carboxymethylchitosan Nanoparticles
  5096. Dual inhibition of phosphatidylinositol 3′-kinase and mammalian target of Rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous …
  5097. Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model
  5098. Signaling mechanisms that suppress the cytostatic actions of Rapamycin
  5099. Identification of the novel interacting partners of the mammalian target of Rapamycin complex 1 in human CCRF-CEM and HEK293 cells
  5100. … augment resistance exercise–induced increases in phosphatidylinositol 3 kinase/protein kinase B–mammalian target of Rapamycin pathway markers indicative of …
  5101. Rapamycin represses myotube hypertrophy and preserves viability of C2C12 cells during myogenesis in vitro
  5102. Dedifferentiated adenoid cystic carcinoma of the trachea: a case report with respect to the immunohistochemical analyses of mammalian target of Rapamycin pathway …
  5103. Distinct sensitivity of CD8+ CD4− and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and Rapamycin in Notch1-induced T-ALL mouse model
  5104. Chronic intermittent hypoxia increases β cell mass and activates the mammalian target of Rapamycin/hypoxia inducible factor 1/vascular endothelial growth factor A …
  5105. … of thrones” in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of Rapamycin inhibitors battling for …
  5106. Dietary protein decreases exercise endurance through Rapamycin-sensitive suppression of muscle mitochondria
  5107. Characterization of residue-dependent differences in the peripheral membrane association of the FATC domain of the kinase ‘target of Rapamycin‘by NMR and …
  5108. hcrcn81 is upregulated by Rapamycin treatment in human colorectal adenocarcinoma cells
  5109. Role of Mammalian Target of Rapamycin (mTOR) in muscle growth
  5110. Contrasting effects of chronic, systemic treatment with mTOR inhibitors Rapamycin and metformin on adult neural progenitors in mice
  5111. Inhibitory effect and significance of Rapamycin on the mammalian target of Rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells
  5112. Crosstalk between Edc4 and mammalian target of Rapamycin complex 1 (mTORC1) signaling in mRNA decapping
  5113. Protein kinase C and P2Y12 take center stage in thrombin‐mediated activation of mammalian target of Rapamycin complex 1 in human platelets
  5114. Significance of mTOR (mammalian target of Rapamycin) activity in human lymphomas
  5115. Combination treatment with asiaticoside and Rapamycin: A new hope for in‑stent restenosis
  5116. EGF signalling and Rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry
  5117. MicroRNAs and the cellular response to Rapamycin: potential role in diagnosis and therapy
  5118. Expression of set is downregulated by Rapamycin in human colorectal cancer cells
  5119. Reactivation versus clearance of Mycobacterium tuberculosis using mammalian target of Rapamycin inhibitors in patients with cancer can be context dependent
  5120. Rapamycin inhibition of CFA-induced lymphangiogenesis in PLN is independent of mast cells
  5121. Short-course Rapamycin treatment preserves airway epithelium and protects against bronchiolitis obliterans
  5122. Telomerase expression abrogates Rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells
  5123. Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hosts
  5124. Effects of Rapamycin on DC-SIGN expression and biological functions in DC
  5125. Differential gene expression profile of first-generation and second-generation Rapamycin-resistant allogeneic T cells
  5126. Expression of mammalian target of Rapamycin in atherosclerotic plaques is decreased under diabetic conditions: A mechanism for Rapamycin resistance
  5127. Mammalian target of Rapamycin complex 1 as an inducer of neurotrophic factors in dopaminergic neurons
  5128. … shows requirement of two processes: a destabilization of eIF4E: 4E-BP complex and a great stimulation of the 4E-BP-degradation mechanism, both Rapamycin …
  5129. A window into immunosuppressant immunoregulation: recipient conversion to Rapamycin increases potentially tolerogenic immune cells
  5130. A novel strategy inducing autophagic cell death in Burkitt’s lymphoma cells with anti-CD19-targeted liposomal Rapamycin
  5131. Differential role of Rapamycin and torin/KU63794 in inflammatory response of 264.7 RAW macrophages stimulated by CA-MRSA
  5132. Rapamycin decreases expression of thymidylate synthase and enhances the response to pemetrexed in preclinical studies and a Phase I/II clinical study of subjects …
  5133. Effects of Rapamycin on airway remodeling in asthmatic mice
  5134. Interleukin‐15 gene therapy and the mammalian target of Rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer
  5135. Effects of Rapamycin on biological characteristics of bone marrow mesenchymal stem cells from patients with aplastic anemia
  5136. Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor
  5137. … of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of Rapamycin pathway: evidence for a …
  5138. Kruppel-like factor 2 might mediate the Rapamycin-induced arterial thrombosis in vivo: implications for stent thrombosis in patients.
  5139. Molecular insights into the stabilization of protein–protein interactions with small molecule: The FKBP12–Rapamycin–FRB case study
  5140. Mammalian target of Rapamycin: a novel pathway in vascular calcification
  5141. Improvement of microbial strain and fermentation process of Rapamycin biosynthesis
  5142. Temporary placement of a paclitaxel or Rapamycin-eluting stent is effective to reduce stenting induced inflammatory reaction and scaring in benign cardia …
  5143. Combined antiangiogenic and mammalian target of Rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation
  5144. Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with Rapamycin
  5145. inhibition of intimal hyperplasia by local perivascular application of Rapamycin and imatinib mesilate after carotid balloon injury
  5146. Mammalian target of Rapamycin inhibitor abrogates abnormal osteoclastogenesis in neurofibromatosis type 1
  5147. Rapamycin: Current and Future Uses
  5148. Attenuation of the activated mammalian target of Rapamycin pathway might be associated with renal function reserve by a low-protein diet in the rat remnant kidney …
  5149. Combination of Rapamycin and Imatinib in Treating Refractory Chronic Myeloid Leukemia Myeloid Blast Crisis: a Case Report025B3
  5150. A new Rapamycin-abluminally coated chitosan/heparin stent system accelerates early re-endothelialisation and improves anti-coagulant properties in porcine coronary …
  5151. Rapamycin helps to maintain colony forming efficiency in corneal epithelial cells
  5152. Influence of GABA on brain protein synthesis mediated by the mammalian target on the Rapamycin pathway
  5153. Establishment of an orthotopic mouse non-muscle invasive bladder cancer model expressing the mammalian target of Rapamycin signaling pathway
  5154. Loss of hydrophobic motif and activation loop phosphorylation is a consequence and not the mechanism of S6 kinase 1 inhibition by Rapamycin.
  5155. Activation of mammalian target of Rapamycin signaling pathway markers in minute adenocarcinoma of the prostate
  5156. Mammalian target of Rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma‐induced malignant pleural effusion
  5157. Prophylaxis for Post-Traumatic Epilepsy: Can Your Kinase Do That? inhibition of Epileptogenesis with Rapamycin
  5158. Balloon coating with Rapamycin using an on-site coating device
  5159. Acute Rapamycin (RAP) exposure induce developmental, neurobehavioral and immunal toxicities in embryonic zebrafish
  5160. … determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of Rapamycin, in human plasma
  5161. The yeast 14-3-3 proteins Bmh1 and Bmh2 differentially regulate Rapamycin-mediated transcription
  5162. Downregulation of RelA (p65) by Rapamycin inhibits murine adipocyte differentiation and reduces fat mass of C57BL/6J mice despite high fat diet
  5163. Dietary Rapamycin selectively improves arterial function in old mice
  5164. Designing and in-vitro characterization of micelle forming amphiphilic PEGylated Rapamycin nanocarriers for the treatment of gastric cancer.
  5165. A functional autophagy pathway is required for Rapamycin-induced degradation of the Sgs1 helicase in Saccharomyces cerevisiae
  5166. Selective Substitution of 31/42–OH in Rapamycin Guided by an in Situ IR Technique
  5167. Calcineurin inhibitor conversion to Rapamycin can improve graft function in living donor kidney transplantation with older donors
  5168. Preventing primate GvHD using a novel antagonistic anti-CD28 antibody plus Rapamycin: downregulation of CD8 activation and preservation of the naïve cell …
  5169. Designing and In-Vitro Characterization of Micelle Forming Amphiphilic PEGylated Rapamycin Nanocarriers for the Treatment of Gastric Cancer
  5170. Activation of mammalian target of Rapamycin (mTOR) in human restenosis
  5171. Centenarian lamins: Rapamycin targets in longevity
  5172. The immunosuppressant tributyltin oxide blocks the mTOR pathway, like Rapamycin, albeit by a different mechanism
  5173. Rapamycin down‐regulates REDD1 to blunt cell death: a potential way to maintain retinal ganglion cell function as in glaucoma
  5174. Mechanism for the synergistic effect of Rapamycin and resveratrol on hyperinsulinemia may involve the activation of protein kinase B
  5175. Enrichment of soymeal medium to increase the Rapamycin production by Streptomyces hygroscopicus
  5176. Predictive value of phosphorylated mammalian target of Rapamycin for disease‑free survival in breast cancer patients receiving neoadjuvant chemotherapy
  5177. Rapamycin for the treatment of refractory extensive chronic graft-versus-host disease
  5178. Effects of Rapamycin on expression of ten kinds autophagy-related miRNAs in RAW264. 7 macrophages
  5179. Rapamycin‐responsiveness and Gln3‐Tor1 interaction are associated with different target sites on the Gln3 protein (609.13)
  5180. Effect of intrathecal Rapamycin on diabetic neuropathic pain in rats
  5181. Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of Rapamycin (mTOR) inhibitors.
  5182. Expression and clinical significance of serine-threonine kinase/mammalian target of Rapamycin/p70 S6K signal pathway in oral squamous cell carcinoma.
  5183. Rapamycin to the rescue
  5184. Hyper-Activation of the Target of Rapamycin (Tor) Kinase 1 Decreases Intracellular Glutathione Content in Saccharomyces cerevisiae as Revealed by LC-MS/MS …
  5185. P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) shows anti-tumor …
  5186. Inhibitory effect of Rapamycin on the proliferation of Rhesus retinal vascular endothelial cells
  5187. Hanga Roa Hospital and Rapamycin
  5188. BG-12 (DIMETHYL fumarate) is neuroprotective in the murine cuprizone/Rapamycin model of demyelination and neurodegeneration (P05. 184)
  5189. Anticancer benefits of early versus late use of Rapamycin in a rat model of urothelial carcinoma
  5190. Rapamycin improves learning and memory ability in ICR mice with pilocarpine-induced temporal lobe epilepsy
  5191. Icotinib combined with Rapamycin in a renal transplant recipient with epidermal growth factor receptor‑mutated non‑small cell lung cancer: A case report
  5192. Hepatoprotective effect of Rapamycin in rats with obstructive jaundice
  5193. Effect of chemotherapy with cisplatin and Rapamycin on HeLa cells in vitro
  5194. Phosphatidylinositol-3 kinase-Akt-mammalian target of Rapamycin signaling pathway mediates contractility of human endometriotic stromal cells: A promising …
  5195. Antimycin induces apoptosis in Rapamycin resistant SW620 colorectal cancer cells
  5196. Novel stratification of the recurrence risk following surgical extirpation of clear cell renal cell carcinoma using tissue biomarkers in the mammalian target of Rapamycin …
  5197. The effects of mammalian target of Rapamycin inhibitors on serum uric acid levels in renal transplant patients
  5198. Chronic Rapamycin treatment decreases markers of autophagy and mitophagy in a sex‐specific manner (1094.8)
  5199. Risk evaluation and mitigation strategies: a focus on the mammalian target of Rapamycin inhibitors
  5200. Effects of Rapamycin on Dia2 in S. cerevisiae
  5201. Neointima reduction with IVUS and Rapamycin microbubbles: In Vivo swine model results
  5202. inhibition of mammalian target of Rapamycin induces renal mitochondrial uncoupling in rats
  5203. Mammalian target of Rapamycin regulates androgen receptor and Akt phosphorylation in prostate cancer 22RV1 cells
  5204. Targeting the mammalian target of Rapamycin pathway in osteosarcoma using combinative chemotherapy
  5205. Different Responses of Neointimal Cells to Imatinib Mesylate and Rapamycin Compared with Normal Vascular Smooth Muscle Cells
  5206. Interacting to control size: the roles of juvenile hormone, insulin/target of Rapamycin and ecydsone signaling in regulating body size in Drosophila.
  5207. Top-Accessed Article: Topical Rapamycin
  5208. Critical analysis of the potential for therapeutic targeting of mammalian target of Rapamycin (mTOR) in gastric cancer
  5209. Interferon‑α enhances the susceptibility of renal cell carcinoma to Rapamycin by suppressing mTOR activity
  5210. Influence of Rapamycin on Zea Mays Seedlings
  5211. Resistant mechanism about Rapamycin and solution
  5212. RhoA regulates the mechanistic target of Rapamycin complex 1 (mTORC1)
  5213. Effect of Rapamycin on pulmonary fibrosis in rats
  5214. Global Proteomics remodeling of cardiac aging and pressure-overload induced heart failure is attenuated by suppression RF target of Rapamycin
  5215. Acquired resistance to Rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
  5216. Effect of Rapamycin on the potential metastasis of squamous cell carcinoma in vitro
  5217. Effects of mammalian-target-of-Rapamycin pathway on lapatinib resistance in breast cancer MDA-MB-231 cells
  5218. A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) inhibitor PF-05212384 plus …
  5219. B7-H1 Expression Is Critical to Cardiac Allograft Tolerance Induced By the Combination Therapy of Mesenchymal Stem Cells and Rapamycin.: Abstract# 2272
  5220. Use of mammalian target of Rapamycin inhibitor for treating pathologies including neurodegenerative diseases (Alzheimer’s disease), neuroinflammatory diseases and …
  5221. Involvement of Mammalian Target of Rapamycin Complexes in GM3 Mediated Melanoma Metastasis
  5222. Effects of Rapamycin on growth, apoptosis, and DDAH2 expression in liver cancer cells
  5223. Regulation of gene expression of mammalian target of Rapamycin
  5224. Effect of gluteus medius muscle sample collection depth on postprandial mammalian target of Rapamycin signaling in mature Thoroughbred mares
  5225. Abstract B18: Targeting Rapamycin-induced autophagy in cancer
  5226. … unprotected left main. Mid term results from a Prospective, Multicenter and Controlled Argentina Registry with a Cobalt-Chromium Rapamycin Eluting Stent, FIREBIRD …
  5227. Epithelial to mesenchymal transition and Rapamycin sensitivity in cancer cell lines.
  5228. Regulation of the Mechanistic Target of Rapamycin by Cellular Stress.
  5229. Chronic Rapamycin Treatment Confers Partially Reversible Diabetes Mellitus
  5230. Rapamycin promotes Glt1 expression and glutamate uptake inastrocyte
  5231. Modulation of endothelial cell-T cell interactions by Rapamycin
  5232. Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of Rapamycin (mTOR).
  5233. Periadventitial Application of Rapamycin-Loaded Nanoparticles Produces Sustained inhibition of
  5234. Mammalian Target of Rapamycin (mTOR)
  5235. Rapamycin As Treatment Of Lymphangioleiomyomatosis: Favorable Response In Different Clinical Manifestations
  5236. Regulation of the Target of Rapamycin Signaling Pathway in Saccharomyces cerevisiae
  5237. Effects of Rapamycin on atrial fibrosis in rats
  5238. Effects of Rapamycin on Monocytes from Pediatric Patients with Tuberous Sclerosis
  5239. Topical Rapamycin as a Treatment for Fibrofolliculomas in Birt-Hogg-Dubé
  5240. Effects of Rapamycin on proliferation of EC9706 cells transfected with p70S6K-siRNA
  5241. Research progress on feedback activation mechanism of mammalian target of Rapamycin in tumors
  5242. Mice Fed Rapamycin Have an Increase in Lifespan Associated with Major Changes in the
  5243. Perillyl alcohol and Rapamycin‐mediated inhibition of migration and invasion
  5244. Effect of Rapamycin in Proliferation and Apoptosis of Human Tongue Squamous Cell Carcinoma
  5245. Effects of Rapamycin combined with rosiglitazone on lung injury in septic rats
  5246. A novel way for neurodegenerative diseases within cell and animal model by autophagy induced with Rapamycin treatment
  5247. An aqueous clear Rapamycin topical drop for retinal delivery
  5248. P442 COMPARISON OF THE INHIBITORY EFFECTS OF Rapamycin ON THE DIFFERENT STAGES OF HEPATIC FIBROSIS
  5249. Determinants of sensitivity and resistance to Rapamycin-chemotherapy drug combinations in vivo. Cancer Res
  5250. The protective role of mammalian target of Rapamycin in the injury of podosytes induced by adriamycin
  5251. Rapamycin-resistant HIF-1α expression in hepatocellular carcinoma (HCC) cells and high sensitivity of endothelial cells within HCC tissues to Rapamycin.
  5252. Investigation into the effects and mechanisms of Rapamycin treatment in two mouse models of Complex I-deficient neurological pathology
  5253. TCT-837 Everolimus-eluting versus other Rapamycin derivatives-eluting stents in patients with coronary artery disease: a meta-analysis of 16 randomized trials
  5254. Rapamycin Augments Dendritic Cell Mediated Tumor Immunity
  5255. Novel Heregulin-Mediated Pathways To Mammalian Target Of Rapamycin Complex 1
  5256. B58 EXPERIMENTAL MODELS OF PULMONARY HYPERTENSION II: inhibition Of mTOR By Rapamycin Blocks Systemic Angiogenesis
  5257. P101 The effect of Rapamycin in cardiac mTORC2-deficient mice under pressure overload conditions.
  5258. A in vivo Study on the Neuroprotective Effects of Rapamycin Against Neurotoxic Aβ in Rats
  5259. … between the risk grade of gastrointestinal stromal tumor and expression of mammalian target of Rapamycin and phosphorylated mammalian target of Rapamycin
  5260. Addition of Rapamycin to Anti-CD3 Antibody Improves Long-Term Glycaemia Control in
  5261. The phosphatidyl-inositol 3-kinase/Akt/mammalian target of Rapamycin pathway as a therapeutic target in head and neck cancer
  5262. Mammalian Target of Rapamycin in Renal Cell Carcinoma
  5263. Dynamical models of the mammalian Target of Rapamycin network in ageing
  5264. Effects of Rapamycin administration on the diabetic rat placenta and embryo
  5265. Induction of central memory to BCG vaccine in mice through Rapamycin (P4300)
  5266. Differential Effects of Rapamycin Treatment on Cardiac Pathology in Lean and Obese Rats
  5267. The mechanistic target of Rapamycin pathway in sarcomas: from biology to therapy
  5268. Reperfusion Therapy With Rapamycin Protects Type 2 Diabetic Mouse Heart
  5269. Effect of Rapamycin Combined with Cisplatin on Apoptosis and Autophagy of Ovarian Cancer Cell Line SKOV3
  5270. mTOR Inhibitor MLN0128 has Antitumor Efficacy in Cell Lines With Intrinsic and Acquired Rapamycin-Resistance.
  5271. Rapamycin Effects on Antigen-Specific CD8 T cell Migration
  5272. Medium-and long-term efficacy and safety of domestic and imported Rapamycin-eluting stents
  5273. Rapamycin Induced Autophagy and Suppression in Human Leukemia Cells Proliferation
  5274. Role of mammalian target of Rapamycin in ischemia‐reperfusion induced kidney injury (692.11)
  5275. Cargo and Carrier Effects of Rapamycin-Loaded Perfluorocarbon Nanoparticles
  5276. Treating brain tumors with targeted-micelles containing Rapamycin
  5277. Mammalian target of Rapamycin inhibitors: the beginning of the end or the end of the beginning?
  5278. Effects of cyclosporine A and Rapamycin on the ability of dendritic cells to activate T cells
  5279. Experimental study on intraocular posterior capsule opacification in intraocular lens treated by Rapamycin
  5280. The Ure2 αCap Is Required for GATA Factor Responses to Rapamycin, But Not Nitrogen Limitation
  5281. Mammalian target of Rapamycin inhibitors for heart transplant patients
  5282. Rapamycin INHIBITS THORACIC AORTIC ANEURYSM FORMATION THROUGH SUPPRESSION OF PRO-INFLAMMATORY MEDIATORS
  5283. Outcome Of Rapamycin Therapy For Post Transplant-Lymphoproliferative Disorder After Kidney Transplantation: Case Series
  5284. The protective effects of Rapamycin on intestinal ischemia/reperfusion induced remote lung injury in mice
  5285. mTOR inhibitor MLN0128 Has antitumor efficacy in cell lines with intrinsic and acquired Rapamycin resistance in vitro and in vivo.
  5286. Long-term effectiveness and safety of Rapamycin-eluting stents in percutaneous coronary intervention of patients with coronary artery disease
  5287. Abstract A35: Identification of pro-survival Rapamycin-dependent microRNA (Rapa-miRs) in tuberous sclerosis complex
  5288. EFFECTS OF THE ANTI-AGING AGENT Rapamycin ON DISC MATRIX HOMEOSTASIS: GP75.
  5289. Mammalian target of Rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease
  5290. The mammalian target of Rapamycin regulates lipid metabolism in osteoarthritic human articular cartilage
  5291. Abstract B035: Preneoplastic transformation of murine mammary stem cells by aging and inhibition by Rapamycin
  5292. Rapamycin prevents cadmium-induced neuronal cell death via suppressing MAPK and Akt/mTOR network
  5293. Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin
  5294. Topical Rapamycin for the treatment of facial angiofibromas with tuberous sclerosis complex
  5295. Correction: Mice Fed Rapamycin Have an Increase in Lifespan Associated with Major Changes in the Liver Transcriptome
  5296. B57 EXPERIMENTAL MODELS OF PULMONARY HYPERTENSION I: Effects Of Rapamycin On Pulmonary Vascular Remodeling Of Allergic Vasculitis In Murine …
  5297. Rapamycin reduces podocyte adhesion damage caused by sublytic C5b-9 via autophagy activation
  5298. Mammalian target of Rapamycin (mTOR): Structure, signaling pathways and biological effects
  5299. Porous Silicon Microparticle Formulation as an Intravitreal Delivery System for Rapamycin
  5300. Effect Of Long Term Rapamycin Treatment On mTOR Signalling Network In Colon And Liver Of C57bl/6 Mice
  5301. Synergistic Effects of Metformin in Combination with Rapamycin on Hepatocellular Carcinoma Cell Lines
  5302. Related research in mammalian target of Rapamycin signaling pathway and autophagy.
  5303. Rapamycin inhibits proliferation of human stomach cancer SGC-7901 cell line in vetro via downregulation of HIF-1α and VEGF
  5304. Perivascular Administration of Rapamycin Through Nanoparticles Prolongs inhibition of Arterial Restenosis
  5305. Abstract A163: A diverse array of mutations in mTOR are hyperactivating and correlate with Rapamycin sensitivity.
  5306. Developing a mouse model to study the metabolic role of the mammalian target of Rapamycin complex 1 in adipose tissue
  5307. Rapamycin increases radiosensitivity of cancer cells by induction of premature senescence.
  5308. Effect of LY294002 and Rapamycin on bim and bax in coxsackievirus B3 induced HeLa cells
  5309. Regulation of protein deposition by mammalian target of Rapamycin in piglets.
  5310. Rapamycin FOR THE TREATMENT OF AUTO-ANTIBODY INDUCED HAEMOLYSIS, IN A PATIENT WITH Β-THALASSEMIA MAJOR
  5311. Effect of NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor, on radiosensitivity of oral cancer cell line through G2/M phase …
  5312. The role of mammalian target of Rapamycin (mTOR) in macrophage polarization
  5313. Rapamycin‐Regulated Ubiquitin Specific Peptidases Expression in Cardiocytes
  5314. Different distribution and expression of mammalian target of Rapamycin complex in the kidney of diabetic nephropathy mice
  5315. … MECHANISMS OF RIGHT VENTRICULAR DYSFUNCTION: Worsening Right Ventricular Dysfunction By Fueling An Impaired Autophagic Flux With Rapamycin
  5316. Rapamycin is a chemopreventive and chemotherapeutic agent for ras-driven epidermal squamous cell carcinoma: evidence from mouse models.
  5317. mTOR inhibition by Rapamycin Alleviates Mitochondrial Disease in the Ndufs4-Mouse Model of Leigh Syndrome
  5318. Activation of mammalian target of Rapamycin contributes to rat nociceptive behaviors
  5319. Reperfusion Therapy With Rapamycin in Diabetic Heart: Essential Role of STAT3 Signaling
  5320. The role of mammalian target of Rapamycin (mTOR) in skin carcinogenesis
  5321. Activation of mammalian target of Rapamycin complex 1 (m TORC1) impairs urine concentration in mice
  5322. Distribution and significance of mammalian target of Rapamycin during differentiation of rat bone marrow mesenchymal stem cells into neurons
  5323. Correction: Beneficial Role of Rapamycin in Experimental Autoimmune Myositis
  5324. The effect of FK506 and Rapamycin on the expression of Foxp3+ Treg in liver cancer patients undergoing liver transplant and its clinical relevance
  5325. Effect study of Rapamycin on the expression of tumor helicase RECQ1 in glioma patients
  5326. Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein
  5327. Activation and its clinical significance of the mammalian target of Rapamycin pathway and its downstream proteins in gastric cancer
  5328. Activation and its clinical significance of the mammalian target of Rapamycin pathway and its downstream proteins in gastric cancer
  5329. Chronic Rapamycin Treatment Improves Cardiac Function by Attenuating Oxidative Stress and Altering Contractile Proteins in Type 2 Diabetic Mice
  5330. Retraction: Mammalian target of Rapamycin inhibitors for treatment in tuberous sclerosis
  5331. Rapamycin induces neuronal differentiation and decreases prion-like proteins in human glioblastoma cell cultures
  5332. SYSTEMIC Rapamycin TO PREVENT IN-STENT STENOSIS IN PERIPHERAL PULMONARY ARTERIAL DISEASE: EARLY CLINICAL EXPERIENCE
  5333. Build of lentiviral mediated RNA interference of mammalian target of Rapamycin
  5334. Effects of Rapamycin on the expression of HGF and TGF—β in chronic renal fibrosis of rats
  5335. A67 CLINICAL AND CELLULAR ASPECTS OF LYMPHANGIOLEIOMYOMATOSIS: Rapamycin As Treatment Of Lymphangioleiomyomatosis: Favorable Response In …
  5336. Tyrosine kinase inhibitors and mammalian target of Rapamycin inhibitors related to cardiac toxicity
  5337. Rapamycin Restores Cerebral Blood Flow and Blood Brain Barrier Integrity in APOE4 Carriers
  5338. Rapamycin Ameliorates Renal Ischemia/Reperfusion Injury via Remodeling Immune Microenvironment. SM J Urol. 2015; 1 (2): 1010
  5339. Iron Metabolism and Rapamycin (sirolimus)-Induced Microcytic Anemia in Renal Transplant Patients
  5340. The Role of the Mammalian Target of Rapamycin (mTOR) in Cytotoxic T Lymphocytes
  5341. Rapamycin Promotes Expansion of CD4+ CD25+ FOXP3+ Regulatory T Cells by Modulating Fatty Acid Metabolism?
  5342. Rapamycin modulates anti-and pro-thrombotic gene expressions via Kruppel-like factor 2: in vitro studies
  5343. Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of Rapamycin, Immune Aspects)
  5344. Subacute Treatment With Rapamycin Reverses Cardiac Aging by Proteome Remodeling and Improved Mitochondrial Energy Metabolism
  5345. Rapamycin Attenuates Cardiac Expression of Anti‐inflammatory AT2R and Anti‐Apoptotic MCL1
  5346. Regulation of the mammalian target of Rapamycin signaling by grape polyphenols in breast cancer (766.6)
  5347. Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution
  5348. OP0285 Liver Mitochondria Dysfunction Precedes the Onset of SLE in Lupus-Prone Mice and is Ameliorated by Rapamycin and 3-Pehpc
  5349. Rapamycin Suppresses Astrocytic and Microglial Activation and Reduced Development of Neuropathic Pain after Spinal Cord Injury in Mice.
  5350. Npr2 regulates autophagy via Gtr1‐Gtr2‐dependent target of Rapamycin complex 1 signaling (539.11)
  5351. Rapamycin combined with atorvastatin attenuate oxidative stress injury in rat vascular smooth muscle cells.
  5352. Chronic Treatment With Novel Nanoformulated Micelles of Rapamycin, Rapatar, Protects Diabetic Heart Against Ischemia/reperfusion Injury
  5353. Targeting multiple components of the mammalian target of Rapamycin (mTOR) signaling: A novel combination therapy to improve pancreatic cancer treatment.
  5354. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function
  5355. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
  5356. The Mammalian Target of Rapamycin Activation is Required for Monocyte Proinflammatory Response in Patients with Coronary Artery Disease
  5357. Expression and its clinical significance of mammalian target of Rapamycin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine neoplasm
  5358. Expression and its clinical significance of mammalian target of Rapamycin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine neoplasm
  5359. Rapamycin enhances the TNF-α-induced secretion of IL-6 and IL-8 by suppressing PDCD4 degradation in orbital fibroblasts
  5360. Rapamycin Promotes Expansion of CD4+ CD25+ FOXP3+ Regulatory T Cells By Modulating Fatty Acid Metabolism?: Abstract# D2799
  5361. Rapamycin Ameliorates Proteinuria and Restores Nephrin and Podocin Expression in Experimental Membranous Nephropathy
  5362. Elucidating The Regulatory Mechanisms Of The Mammalian Target Of Rapamycin Complex 1 (mTORc1) In Protein Homeostasis
  5363. Rapamycin promotes memory CD8 T cell development by regulating the Bim/Bcl-2 balance
  5364. Intra-articular administration of gelatin hydrogels incorporating Rapamycin-micelle reduces development of experimental osteoarthritis in a murine model
  5365. Research progress on the regulation of milk protein synthesis by essential amino acids through mammalian target of Rapamycin signaling pathway.
  5366. Hypoxia Regulation of Sensitivity to the Mechanistic Target of Rapamycin Kinase inhibition (mTORki) in Glioblastoma Multiforme
  5367. Rapamycin Expands and Confers Resistance to Apoptosis of Human Inducible Regulatory T Cells (TRI)
  5368. A Diverse Array of Cancer-Associated mTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
  5369. A Diverse Array of Cancer-Associated mTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
  5370. Rapamycin can overcome ABT-737 resistance in patient-derived SCLC xenograft models.
  5371. gln3 Mutations Dissociate Responses to Nitrogen Catabolite Repression and Rapamycin inhibition of TorC1
  5372. inhibition of the mammalian Target of Rapamycin (mTOR) does not alter nitric oxide or superoxide levels in human skin
  5373. Evidence that chronic inhibition of the mammalian Target of Rapamycin (mTOR) reduces skin blood flow in humans
  5374. Experimental study on the preventive effect of paclitaxel and Rapamycin composite drug-eluting stent on coronary restenosis in minipigs
  5375. Induction of Autophagy with Rapamycin overcomes Bcl‐2’s deleterious effects on stroke outcome
  5376. Donor Specific Transfusion Combined With Anti-CD134L and Rapamycin Inhibits Accelerated Rejection Mediated By Alloantigen-Primed Memory Cells in Mice …
  5377. Oral Rapamycin (eRapa) safely prevents carcinogen-induced dermal carcinogenesis through an interferon-γ-dependent mechanism (TUM7P. 931)
  5378. Rapamycin Can Reduce Apoptosis of CD4+ CD25+ Regulatory T Cells from Mouse Model of Severe Aplastic Anemia
  5379. Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease
  5380. Rapamycin, an inhibitor of mTOR signaling pathway, reverses lithium‐induced cell proliferation in renal collecting ducts
  5381. The Mammalian Target of Rapamycin Complex 2 in Angiogenesis: An in vitro Analysis Using The Endothelial Tube Formation Assay
  5382. inhibition of mTOR With Rapamycin Reverses Cardiomyocyte-Specific Knockout of Pten-Induced Hypertrophic Cardiomyopathy
  5383. Efficient Induction and Expansion Of CD8+ CD28+ Foxp3+ Regulatory T Cells By TGF-beta1 and Rapamycin
  5384. Rapamycin-induced renal magnesium wasting associates with decreased TRPM6 expression and EGF stimulation
  5385. Rapamycin modulates the course of hepatitis B virus (HBV) infection in hydrodynamic injection mouse model: the role of Treg in HBV persistence
  5386. Effects of Rapamycin on granulation formation in response to centrally doubled coiled stents as a tracheal substitute
  5387. … I: Selective Tsc1 Deletion In Smooth Muscle Results In mTOR Signaling Activation And Development Of Pulmonary Hypertension That Can Be Reversed By Rapamycin
  5388. Investigation of a Putative Role for the Protein Kinase TOR (Target of Rapamycin) in microRNA-Mediated Gene Silencing in Drosophila Melanogaster
  5389. Effects of Rapamycin on transforming growth factor-β2-induced epithelial-myofibroblast transition of human lens epithelial cells
  5390. Impact of Rapamycin on phenotype and tolerogenic function of dendritic cells via intravital optical imaging
  5391. Correlation between release of Rapamycin from Porous Silicon (pSi) and the color shifting of pSi monitored by a digital camera: a prototype of non-invasive …
  5392. Polycystic Kidney Disease: Literature Review on the Mechanism of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Reduction of Cyst Growth in Patients …
  5393. Neuroprotective Effect of Rapamycin (Autophagy Enhancer) in Transgenic SOD1-G93A Mice of Amyotrophic Lateral Sclerosis
  5394. Construction of a stable mouse fibroblast line targeting mammalian target of Rapamycin by lentivirus mediated short hairpin RNA
  5395. Abstract A168: Hepatitis B virus pre-S2 mutant stimulates aerobic glycolysis through mammalian target of Rapamycin signaling in tumorigenesis.
  5396. Activation of mammalian target of Rapamycin (mTOR) in triple negative feline mammary carcinomas
  5397. Molecular basis of the Rapamycin insensitivity of target of Rapamycin complex 2
  5398. Alternative Rapamycin treatment regimens mitigate the impact of Rapamycin on glucose homeostasis and the immune system
  5399. The mechanistic target of Rapamycin: the grand conducTOR of metabolism and aging
  5400. The enigma of Rapamycin dosage
  5401. inhibition of the mechanistic target of Rapamycin (mTOR)–Rapamycin and beyond
  5402. Transient Rapamycin treatment can increase lifespan and healthspan in middle-aged mice
  5403. Toward Rapamycin analog (rapalog)-based precision cancer therapy
  5404. Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins
  5405. Activation of mTOR (mechanistic target of Rapamycin) in rheumatic diseases
  5406. Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island
  5407. Health effects of long-term Rapamycin treatment: the impact on mouse health of enteric Rapamycin treatment from four months of age throughout life
  5408. How longevity research can lead to therapies for Alzheimer’s disease: The Rapamycin story
  5409. Rapamycin and rapalogs for tuberous sclerosis complex
  5410. Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
  5411. Rapamycin blocks induction of the thermogenic program in white adipose tissue
  5412. New perspectives on mTOR inhibitors (Rapamycin, rapalogs and TORKinibs) in transplantation
  5413. Activation of the mechanistic target of Rapamycin in SLE: explosion of evidence in the last five years
  5414. About-face on the metabolic side effects of Rapamycin
  5415. Mammalian target of Rapamycin inhibition with Rapamycin mitigates radiation-induced pulmonary fibrosis in a murine model
  5416. Nanomicellar topical aqueous drop formulation of Rapamycin for back-of-the-eye delivery
  5417. Site-specific bioalkylation of Rapamycin by the RapM 16-O-methyltransferase
  5418. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
  5419. Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes
  5420. Synergistic antitumor activity of Rapamycin and EF24 via increasing ROS for the treatment of gastric cancer
  5421. Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts
  5422. Mechanistic target of Rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy
  5423. Dysregulation of mammalian target of Rapamycin signaling in mouse models of autism
  5424. Intermittent administration of Rapamycin extends the life span of female C57BL/6J mice
  5425. The opposing actions of target of Rapamycin and AMP-activated protein kinase in cell growth control
  5426. Mammalian target of Rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia
  5427. p53 and Rapamycin are additive
  5428. Rapamycin enhances survival in a Drosophila model of mitochondrial disease
  5429. Acute resistance exercise activates Rapamycin‐sensitive and‐insensitive mechanisms that control translational activity and capacity in skeletal muscle
  5430. Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways
  5431. Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury
  5432. Rapamycin inhibits tumor growth of human osteosarcomas
  5433. Mammalian target of Rapamycin: its role in early neural development and in adult and aged brain function
  5434. Rapamycin preserves gut homeostasis during Drosophila aging
  5435. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to Rapamycin
  5436. Familial cortical dysplasia caused by mutation in the mammalian target of Rapamycin regulator NPRL3
  5437. The combination of Rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells
  5438. Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes
  5439. Rapamycin protection of livers from ischemia and reperfusion injury is dependent on both autophagy induction and mammalian target of Rapamycin complex 2-Akt …
  5440. Stem cell guidance through the mechanistic target of Rapamycin
  5441. Target of Rapamycin complex 2 regulates actin polarization and endocytosis via multiple pathways
  5442. Efficacy and safety of mammalian target of Rapamycin inhibitors in vascular anomalies: a systematic review
  5443. Target of Rapamycin is a key player for auxin signaling transduction in Arabidopsis
  5444. Metformin and Rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms
  5445. Co-loaded paclitaxel/Rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy
  5446. Pharmacological inhibition of ULK1 kinase blocks mammalian target of Rapamycin (mTOR)-dependent autophagy
  5447. Metformin potentiates Rapamycin and cisplatin in gastric cancer in mice
  5448. Testing efficacy of administration of the antiaging drug Rapamycin in a nonhuman primate, the common marmoset
  5449. Impact of Rapamycin on status epilepticus induced hippocampal pathology and weight gain
  5450. Light-cleavable Rapamycin dimer as an optical trigger for protein dimerization
  5451. Mutations in the mammalian target of Rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy
  5452. Target of Rapamycin (TOR) plays a critical role in triacylglycerol accumulation in microalgae
  5453. Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy
  5454. Mammalian target of Rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients
  5455. Co-delivery of Rapamycin-and piperine-loaded polymeric nanoparticles for breast cancer treatment
  5456. Rapamycin alleviates oxidative stress-induced damage in rat erythrocytes
  5457. 3D molecular MR imaging of liver fibrosis and response to Rapamycin therapy in a bile duct ligation rat model
  5458. Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner
  5459. Rapamycin attenuates acute lung injury induced by LPS through inhibition of Th17 cell proliferation in mice
  5460. Tomato FK506 binding protein 12KD (FKBP12) mediates the interaction between Rapamycin and target of Rapamycin (TOR)
  5461. Rapamycin does not prevent increases in myofibrillar or mitochondrial protein synthesis following endurance exercise
  5462. The 4E-BP–eIF4E axis promotes Rapamycin-sensitive growth and proliferation in lymphocytes
  5463. Recent advances in mammalian target of Rapamycin inhibitor use in heart and lung transplantation
  5464. Mitochondrial quality control via the PGC1α-TFEB signaling pathway is compromised by parkin Q311X mutation but independently restored by Rapamycin
  5465. … of resistance exercise training, matching deuterium oxide‐derived measures of muscle protein synthesis and mechanistic target of Rapamycin complex 1 signaling
  5466. Oral mucosal injury caused by mammalian target of Rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice
  5467. Subacute calorie restriction and Rapamycin discordantly alter mouse liver proteome homeostasis and reverse aging effects
  5468. Intermittent dosing of Rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex
  5469. Integration of transcriptomics and metabolomics data specifies the metabolic response of Chlamydomonas to Rapamycin treatment
  5470. Rapamycin plays a neuroprotective effect after spinal cord injury via anti‐inflammatory effects
  5471. Sqstm1 knock-down causes a locomotor phenotype ameliorated by Rapamycin in a zebrafish model of ALS/FTLD
  5472. PAT4 levels control amino-acid sensitivity of Rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer
  5473. Classic K aposi’s sarcoma treated with topical Rapamycin
  5474. Optimization of a series of triazole containing mammalian target of Rapamycin (mTOR) kinase inhibitors and the discovery of CC-115
  5475. Effect of metformin, Rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice
  5476. Unraveling the role of the Target of Rapamycin signaling in sphingolipid metabolism
  5477. Blood–brain barrier leakage after status epilepticus in Rapamycin‐treated rats I: Magnetic resonance imaging
  5478. Inhibiting the Mammalian target of Rapamycin blocks the development of experimental cerebral malaria
  5479. Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to Rapamycin in lupus‐prone mice
  5480. Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice
  5481. Neuroprotective effect of Rapamycin on spinal cord injury via activation of the Wnt/β-catenin signaling pathway
  5482. Rapamycin reduced ischemic brain damage in diabetic animals is associated with suppressions of mTOR and ERK1/2 signaling
  5483. Local therapeutic efficacy with reduced systemic side effects by Rapamycin-loaded subcapsular microspheres
  5484. The neuroprotective effect of Rapamycin as a modulator of the mTOR-NF-κB axis during retinal inflammation
  5485. Cyclosporin a and Rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells
  5486. Synergy between Rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell–dependent induction of CD4+CD25+FoxP3+ Treg
  5487. inhibition of mammalian target of Rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling
  5488. TOR (target of Rapamycin) is a key regulator of triacylglycerol accumulation in microalgae
  5489. Effect of chronic administration of low dose Rapamycin on development and immunity in young rats
  5490. Effects of Rapamycin treatment on neurogenesis and synaptic reorganization in the dentate gyrus after controlled cortical impact injury in mice
  5491. Chronic mTOR inhibition in mice with Rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
  5492. … N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of Rapamycin
  5493. Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem …
  5494. Targeted inhibition of rictor/mTORC2 in cancer treatment: a new era after Rapamycin
  5495. Immune-stimulatory effects of Rapamycin are mediated by stimulation of antitumor γδ T cells
  5496. Immunosuppression with mammalian target of Rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients
  5497. … model of neuronopathic Gaucher disease demonstrates lysosomal-autophagic defects and altered mTOR signalling and is functionally rescued by Rapamycin
  5498. Histone modifications change with age, dietary restriction and Rapamycin treatment in mouse brain
  5499. Rapamycin improves palmitate-induced ER stress/NF κ B pathways associated with stimulating autophagy in adipocytes
  5500. Rapamycin reveals an mTOR-independent repression of Kv1. 1 expression during epileptogenesis
  5501. Intravitreal injection of Rapamycin-loaded polymeric micelles for inhibition of ocular inflammation in rat model
  5502. Effects of Rapamycin pretreatment on blood-brain barrier disruption in cerebral ischemia-reperfusion
  5503. Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis
  5504. The mammalian target of Rapamycin at the crossroad between cognitive aging and Alzheimer’s disease
  5505. Cystinosin is a component of the vacuolar H+-ATPase-ragulator-rag complex controlling mammalian target of Rapamycin complex 1 signaling
  5506. L-Tryptophan activates mammalian target of Rapamycin and enhances expression of tight junction proteins in intestinal porcine epithelial cells
  5507. Skin expression of mammalian target of Rapamycin and forkhead box transcription factor O1, and serum insulin‐like growth factor‐1 in patients with acne vulgaris and …
  5508. Rapamycin inhibits epithelial‐to‐mesenchymal transition of peritoneal mesothelium cells through regulation of Rho GTPases
  5509. Platelet-derived growth factor regulates vascular smooth muscle phenotype via mammalian target of Rapamycin complex 1
  5510. Phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer
  5511. Rapamycin protects against gentamicin-induced acute kidney injury via autophagy in mini-pig models
  5512. Layer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of Rapamycin
  5513. Mammalian target of Rapamycin controls glucose consumption and redox balance in human Sertoli cells
  5514. Yeast m6A Methylated mRNAs Are Enriched on Translating Ribosomes during Meiosis, and under Rapamycin Treatment
  5515. Repression of mammalian target of Rapamycin complex 1 inhibits intestinal regeneration in acute inflammatory bowel disease models
  5516. Epithelial to mesenchymal transition is associated with Rapamycin resistance
  5517. Anti-breast cancer potential of quercetin via the Akt/AMPK/mammalian target of Rapamycin (mTOR) signaling cascade
  5518. Metabolic consequences of long-term Rapamycin exposure on common marmoset monkeys (Callithrix jacchus)
  5519. Rapamycin loaded magnetic Fe3O4/carboxymethylchitosan nanoparticles as tumor-targeted drug delivery system: synthesis and in vitro characterization
  5520. Topical Rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind …
  5521. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by Rapamycin in nasopharyngeal carcinoma
  5522. Effect of low-dose Rapamycin on senescence markers and physical functioning in older adults with coronary artery disease: results of a pilot study
  5523. In vitro and in vivo sustained zero-order delivery of Rapamycin (sirolimus) from a biodegradable intraocular device
  5524. Rapamycin ameliorates cadmium-induced activation of MAPK pathway and neuronal apoptosis by preventing mitochondrial ROS inactivation of PP2A
  5525. Rapamycin/DiR loaded lipid-polyaniline nanoparticles for dual-modal imaging guided enhanced photothermal and antiangiogenic combination therapy
  5526. Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis
  5527. Imbalanced mechanistic target of Rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function
  5528. Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy
  5529. Rapamycin reverses age-related increases in mitochondrial ROS production at complex I, oxidative stress, accumulation of mtDNA fragments inside nuclear DNA, and …
  5530. The role of amino acid-induced mammalian target of Rapamycin complex 1 (mTORC1) signaling in insulin resistance
  5531. Olive oil‐derived oleocanthal as potent inhibitor of mammalian target of Rapamycin: biological evaluation and molecular modeling studies
  5532. Adaptations to chronic Rapamycin in mice
  5533. Optimal dietary alpha‐linolenic acid/linoleic acid ratio improved digestive and absorptive capacities and target of Rapamycin gene expression of juvenile grass carp (C …
  5534. The mammalian target of Rapamycin modulates the immunoproteasome system in the heart
  5535. Methylglyoxal activates the target of Rapamycin complex 2-protein kinase C signaling pathway in Saccharomyces cerevisiae
  5536. Inorganic polyphosphate elicits pro‐inflammatory responses through activation of the mammalian target of Rapamycin complexes 1 and 2 in vascular endothelial cells
  5537. inhibition of regulatory-associated protein of mechanistic target of Rapamycin prevents hyperoxia-induced lung injury by enhancing autophagy and reducing apoptosis …
  5538. Mammalian target of Rapamycin and tuberous sclerosis complex
  5539. Rapatar, a nanoformulation of Rapamycin, decreases chemically-induced benign prostate hyperplasia in rats
  5540. … reduces renal damage in ischemia/reperfusion injury: Unraveling antiapoptotic mechanisms and regulation of phosphorylated mammalian target of Rapamycin
  5541. Baicalein triggers autophagy and inhibits the protein kinase B/mammalian target of Rapamycin pathway in hepatocellular carcinoma HepG2 cells
  5542. Rapamycin-induced oligomer formation system of FRB–FKBP fusion proteins
  5543. Port wine stain treated with a combination of pulsed dye laser and topical Rapamycin ointment
  5544. SOX9-regulated cell plasticity in colorectal metastasis is attenuated by Rapamycin
  5545. Rapamycin-resistant mTOR activity is required for sensory axon regeneration induced by a conditioning lesion
  5546. Rapamycin reverses the senescent phenotype and improves immuno-regulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus …
  5547. inhibition of mTOR pathway by Rapamycin reduces brain damage in rats subjected to transient forebrain ischemia
  5548. … of autophagic flux against xenoestrogen bisphenol-A-induced hippocampal neurodegeneration via AMP kinase (AMPK)/mammalian target of Rapamycin …
  5549. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of Rapamycin
  5550. Differential effects of calcineurin and mammalian target of Rapamycin inhibitors on alloreactive Th1, Th17, and regulatory T cells
  5551. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a Rapamycin analog
  5552. Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of Rapamycin via selectively inhibiting mTORC1 in mice
  5553. Apoptotic effects of high-dose Rapamycin occur in S-phase of the cell cycle
  5554. Mechanistic target of Rapamycin complex 1 (mTORC1) and mTORC2 as key signaling intermediates in mesenchymal cell activation
  5555. Rapamycin-induced autophagy activity promotes bone fracture healing in rats
  5556. AKT inhibition overcomes Rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis
  5557. Rapamycin reduces motivated responding for cocaine and alters GluA1 expression in the ventral but not dorsal striatum
  5558. Complications of mammalian target of Rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life …
  5559. The effect of mammalian target of Rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients
  5560. Leucine and mammalian target of Rapamycin–dependent activation of muscle protein synthesis in aging
  5561. inhibition of mammalian target of Rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in …
  5562. Blocking mammalian target of Rapamycin (mTOR) attenuates HIF-1α pathways engaged-vascular endothelial growth factor (VEGF) in diabetic retinopathy
  5563. Effects of Rapamycin on cell apoptosis in MCF-7 human breast cancer cells
  5564. Dual-modal imaging-guided theranostic nanocarriers based on indocyanine green and mTOR inhibitor Rapamycin
  5565. Rapamycin attenuates cardiac fibrosis in experimental uremic cardiomyopathy by reducing marinobufagenin levels and inhibiting downstream pro‐fibrotic signaling
  5566. Increased mammalian target of Rapamycin signaling contributes to the accumulation of protein oxidative damage in a mouse model of Down’s syndrome
  5567. Transforming growth factor-β is an upstream regulator of mammalian target of Rapamycin complex 2–dependent bladder cancer cell migration and invasion
  5568. TORC1 inhibition by Rapamycin Promotes Antioxidant Defences in a Drosophila Model of Friedreich’s Ataxia
  5569. Effects of Rapamycin against paraquat-induced pulmonary fibrosis in mice
  5570. The Rapamycin-sensitive complex of mammalian target of Rapamycin is essential to maintain male fertility
  5571. Best: a randomized phase ii study of vascular endothelial growth factor, RAF kinase, and mammalian target of Rapamycin combination targeted therapy with …
  5572. Drug-related pneumonitis during mammalian target of Rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenström macroglobulinemia …
  5573. Drug-related pneumonitis during mammalian target of Rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based …
  5574. … regulates the apoptosis of bone marrow‐derived mesenchymal stem cells under hypoxic condition via AMP‐activated protein kinase/mammalian target of Rapamycin …
  5575. Fishmeal replacement by mixed plant proteins and maggot meal on growth performance, target of Rapamycin signalling and metabolism in juvenile turbot (S …
  5576. Quercetin inhibits fibroblast activation and kidney fibrosis involving the suppression of mammalian target of Rapamycin and β-catenin signaling
  5577. Rapamycin loaded solid lipid nanoparticles as a new tool to deliver mTOR inhibitors: formulation and in vitro characterization
  5578. Signaling through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by …
  5579. Mammalian target of Rapamycin mediates kidney injury molecule 1-dependent tubule injury in a surrogate model
  5580. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of Rapamycin (mTOR), in patients with advanced …
  5581. Rapamycin and dietary restriction induce metabolically distinctive changes in mouse liver
  5582. Blood–brain barrier leakage after status epilepticus in Rapamycin‐treated rats II: Potential mechanisms
  5583. Topical use of mammalian target of Rapamycin (mTOR) inhibitors in tuberous sclerosis complex—a comprehensive review of the literature
  5584. REDV/Rapamycin-loaded polymer combinations as a coordinated strategy to enhance endothelial cells selectivity for a stent system
  5585. On the discovery of TOR as the target of Rapamycin
  5586. Hepatitis B virus pre-S2 mutant induces aerobic glycolysis through mammalian target of Rapamycin signal cascade
  5587. Phase II study of dual phosphoinositol‐3‐kinase (PI 3K) and mammalian target of Rapamycin (mTOR) inhibitor BEZ 235 in patients with locally advanced or metastatic …
  5588. Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin
  5589. mTORC1 inhibitor Rapamycin and ER stressor tunicamycin induce differential patterns of ER-mitochondria coupling
  5590. Effect of dietary glutamine on growth performance, non-specific immunity, expression of cytokine genes, phosphorylation of target of Rapamycin (TOR), and anti …
  5591. Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice
  5592. Formulation development and toxicity assessment of triacetin mediated nanoemulsions as novel delivery systems for Rapamycin
  5593. Comparative metabolic profiling reveals the key role of amino acids metabolism in the Rapamycin overproduction by Streptomyces hygroscopicus
  5594. Rapamycin suppresses PTZ-induced seizures at different developmental stages of zebrafish
  5595. Glycine Regulates Protein Turnover by Activating Protein Kinase B/Mammalian Target of Rapamycin and by Inhibiting MuRF1 and Atrogin-1 Gene Expression in …
  5596. Rapamycin inhibition of mTOR reduces levels of the Na+/H+ exchanger 3 in intestines of mice and humans, leading to diarrhea
  5597. Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down’s syndrome
  5598. Discovery of mammalian target of Rapamycin (mTOR) kinase inhibitor CC-223
  5599. Conophylline protects cells in cellular models of neurodegenerative diseases by inducing mammalian target of Rapamycin (mTOR)-independent autophagy
  5600. Pharmaceutical inhibition of mTOR in the common marmoset: effect of Rapamycin on regulators of proteostasis in a non-human primate
  5601. Rapamycin suppresses tumor growth and alters the metabolic phenotype in T-cell lymphoma
  5602. The immunosuppressive drug–Rapamycin–electroanalytical sensing using boron-doped diamond electrode
  5603. A NIR fluorescent probe: imaging endogenous hydrogen peroxide during an autophagy process induced by Rapamycin
  5604. Rapamycin inhibits lipopolysaccharide-induced neuroinflammation in vitro and in vivo
  5605. Targeting the mammalian target of Rapamycin in lung cancer
  5606. Mammalian target of Rapamycin complex 2 regulates invariant NKT cell development and function independent of promyelocytic leukemia zinc-finger
  5607. Leucine does not affect mechanistic target of Rapamycin complex 1 assembly but is required for maximal ribosomal protein s6 kinase 1 activity in human skeletal …
  5608. Sex-specific Tradeoffs With Growth and Fitness Following Life-span Extension by Rapamycin in an Outcrossing Nematode, Caenorhabditis remanei
  5609. Rapamycin attenuates age-associated changes in tibialis anterior tendon viscoelastic properties
  5610. Effects of Rapamycin on cerebral oxygen supply and consumption during reperfusion after cerebral ischemia
  5611. Huaier aqueous extract sensitizes cells to Rapamycin and cisplatin through activating mTOR signaling
  5612. Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade
  5613. Target of Rapamycin activation predicts lifespan in fruit flies
  5614. Rapamycin prevents, but does not reverse, aberrant migration in Pten knockout neurons
  5615. Unleashing Rapamycin in fibrosis
  5616. Metformin attenuates graft-versus-host disease via restricting mammalian target of Rapamycin/signal transducer and activator of transcription 3 and promoting …
  5617. Mechanistic target of Rapamycin (mTOR) regulates trophoblast folate uptake by modulating the cell surface expression of FR-α and the RFC
  5618. Prevention of irradiation-induced salivary hypofunction by Rapamycin in swine parotid glands
  5619. Muscle wasting in fasting requires activation of NF-κB and inhibition of AKT/mechanistic target of Rapamycin (mTOR) by the protein acetylase, GCN5
  5620. Postdepletion lymphocyte reconstitution during belatacept and Rapamycin treatment in kidney transplant recipients
  5621. Prevention of carcinogen and inflammation-induced dermal cancer by oral Rapamycin includes reducing genetic damage
  5622. Placenta growth factor induces invasion and activates p70 during Rapamycin treatment in trophoblast cells
  5623. Effects of dietary leucine supplementation on the gene expression of mammalian target of Rapamycin signaling pathway and intestinal development of broilers
  5624. Rapamycin inhibits human laryngotracheal stenosis–derived fibroblast proliferation, metabolism, and function in vitro
  5625. Perspective: the potential role of essential amino acids and the mechanistic target of Rapamycin complex 1 (mTORC1) pathway in the pathogenesis of child stunting
  5626. Successful topical Rapamycin treatment for facial angiofibromata in two children
  5627. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
  5628. Rapamycin enhances the anti-cancer effect of dasatinib by suppressing Src/PI3K/mTOR pathway in NSCLC cells
  5629. Soy-dairy protein blend or whey protein isolate ingestion induces similar postexercise muscle mechanistic target of Rapamycin complex 1 signaling and protein …
  5630. Rapamycin attenuates mouse liver ischemia and reperfusion injury by inhibiting endoplasmic reticulum stress
  5631. Up‐regulation of the mammalian target of Rapamycin complex 1 subunit raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns …
  5632. Synergistic antitumor activity of the combination of salubrinal and Rapamycin against human cholangiocarcinoma cells
  5633. Effect of mammalian target of Rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a …
  5634. Rapamycin impairs endothelial cell function in human internal thoracic arteries
  5635. Addition of Rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic …
  5636. Combinatorial antitumor effect of Rapamycin and β-elemene in follicular thyroid cancer cells
  5637. Mammalian target of Rapamycin: a target for (lung) diseases and aging
  5638. Proximity-directed labeling reveals a new Rapamycin-induced heterodimer of FKBP25 and FRB in live cells
  5639. Development of a model describing regulation of casein synthesis by the mammalian target of Rapamycin (mTOR) signaling pathway in response to insulin …
  5640. Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms
  5641. … growth factor β1-induced apoptosis in podocytes via the extracellular signal-regulated kinase-mammalian target of Rapamycin complex 1-NADPH oxidase 4 …
  5642. Valacyclovir combined with artesunate or Rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone
  5643. Differential phosphorylation of a regulatory subunit of protein kinase CK2 by target of Rapamycin complex 1 signaling and the Cdc-like kinase Kns1
  5644. Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance
  5645. Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta …
  5646. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of Rapamycin kinase inhibitor, in patients with advanced solid tumors
  5647. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of Rapamycin signaling pathway in human bladder cancer …
  5648. Optimization of adipose tissue-derived mesenchymal stem cells by Rapamycin in a murine model of acute graft-versus-host disease
  5649. Blocking mammalian target of Rapamycin alleviates bone cancer pain and morphine tolerance via µ‐opioid receptor
  5650. The effect of Rapamycin on biodiesel-producing protist Euglena gracilis
  5651. Roles of mechanistic target of Rapamycin and transforming growth factor-β signaling in the molting gland (Y-organ) of the blackback land crab, Gecarcinus lateralis
  5652. Traumatic brain injury stimulates neural stem cell proliferation via mammalian target of Rapamycin signaling pathway activation
  5653. Blocking mammalian target of Rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury
  5654. Caloric restriction promotes the reserve of follicle pool in adult female rats by inhibiting the activation of mammalian target of Rapamycin signaling
  5655. Rapamycin inhibits oxidized low density lipoprotein uptake in human umbilical vein endothelial cells via mTOR/NF-κB/LOX-1 pathway
  5656. The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of Rapamycin complex 1/hypoxia-inducible factor-1α …
  5657. The transcription factor p8 regulates autophagy in response to palmitic acid stress via a mammalian target of Rapamycin (mTOR)-independent signaling …
  5658. Ubiquilin-mediated small molecule inhibition of mammalian target of Rapamycin complex 1 (mTORC1) signaling
  5659. Combination therapy using IL-2/IL-2 monoclonal antibody complexes, Rapamycin, and islet autoantigen peptides increases regulatory T cell frequency and protects …
  5660. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of Rapamycin pathway, versus everolimus in …
  5661. Chronic Rapamycin treatment on the nutrient utilization and metabolism of juvenile turbot (Psetta maxima)
  5662. Expression of mammalian target of Rapamycin and downstream targets in normal and gestational diabetic human term placenta
  5663. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival
  5664. Rapamycin protects from type-I peritoneal membrane failure inhibiting the angiogenesis, lymphangiogenesis, and Endo-MT
  5665. Regulation of the target of Rapamycin and other phosphatidylinositol 3-kinase-related kinases by membrane targeting
  5666. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+ PTEN− glioblastoma in vivo
  5667. Mammalian target of Rapamycin inhibitors and life-threatening conditions in tuberous sclerosis complex
  5668. Characterization of negative regulatory genes for the biosynthesis of Rapamycin in Streptomyces Rapamycinicus and its application for improved production
  5669. The pivotal role of mammalian target of Rapamycin inhibition in the treatment of patients with neuroendocrine tumors
  5670. Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice
  5671. Mammalian target of Rapamycin (mTOR) complex 2 regulates filamin A‐dependent focal adhesion dynamics and cell migration
  5672. Brain-expressed X-linked 2 is pivotal for hyperactive mechanistic target of Rapamycin (mTOR)-mediated tumorigenesis
  5673. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of Rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis …
  5674. Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of Rapamycin: potential drug to treat Alzheimer’s disease
  5675. Rapamycin increases length and mechanosensory function of primary cilia in renal epithelial and vascular endothelial cells
  5676. Analysis of proteins that rapidly change upon mechanistic/mammalian target of Rapamycin complex 1 (mTORC1) repression identifies Parkinson protein 7 …
  5677. Characterization of the Nocardiopsin Biosynthetic Gene Cluster Reveals Similarities to and Differences from the Rapamycin and FK‐506 Pathways
  5678. Rapamycin, a specific inhibitor of the target of Rapamycin complex 1, disrupts intestinal barrier integrity in broiler chicks
  5679. The mechanism of Rapamycin in the intervention of paraquat-induced acute lung injury in rats
  5680. Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+ CD25+ Foxp3 regulatory T cells
  5681. Rapamycin influences the efficiency of in vitro fertilization and development in the mouse: a role for autophagic activation
  5682. Profiling of the fetal and adult rat liver transcriptome and translatome reveals discordant regulation by the mechanistic target of Rapamycin (mTOR)
  5683. Mechanistic target of Rapamycin complex 1/S6 kinase 1 signals influence T cell activation independently of ribosomal protein S6 phosphorylation
  5684. Pharmacodynamic monitoring of mammalian target of Rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity
  5685. Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of Rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence …
  5686. Rapamycin reverses paraquat-induced acute lung injury in a rat model through inhibition of NFκB activation
  5687. Primary intestinal lymphangiectasia treated with Rapamycin in a child with tuberous sclerosis complex (TSC)
  5688. Interferon γ (IFNγ) signaling via mechanistic target of Rapamycin complex 2 (mTORC2) and regulatory effects in the generation of type II interferon biological …
  5689. Mammalian target of Rapamycin signaling pathway changes with intestinal epithelial cells renewal along crypt-villus axis
  5690. Efficacy of Rapamycin as inducer of Hb F in primary erythroid cultures from sickle cell disease and β-thalassemia patients
  5691. A central role for the mammalian target of Rapamycin in LPS-induced anorexia in mice
  5692. Intrathecal Rapamycin attenuates morphine-induced analgesic tolerance and hyperalgesia in rats with neuropathic pain
  5693. Phosphorylation of ribosomal protein S6 mediates mammalian target of Rapamycin complex 1–induced parathyroid cell proliferation in secondary hyperparathyroidism
  5694. Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase
  5695. Amino acid sensing and activation of mechanistic target of Rapamycin complex 1: implications for skeletal muscle
  5696. Rapamycin‐induced autophagy sensitizes A549 cells to radiation associated with DNA damage repair inhibition
  5697. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of Rapamycin complex 1 in mice
  5698. Rapamycin protects cardiomyocytes against anoxia/reoxygenation injury by inducing autophagy through the PI3k/Akt pathway
  5699. Paradoxical effect of Rapamycin on inflammatory stress-induced insulin resistance in vitro and in vivo
  5700. Effect of Rapamycin on endometriosis in mice
  5701. Mammalian target of Rapamycin (mTOR) tagging promotes dendritic branch variability through the capture of Ca2+/calmodulin-dependent protein kinase II α …
  5702. Combined treatment of Nimotuzumab and Rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
  5703. Effects of combining Rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors
  5704. Particulate matter 2.5 induces autophagy via inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin kinase signaling pathway in …
  5705. Th1, Th2 and Th17 cytokine profile in patients with multiple sclerosis following treatment with Rapamycin
  5706. Mechanistic target of Rapamycin (mTOR) inhibition synergizes with reduced internal ribosome entry site (IRES)-mediated translation of cyclin D1 and c-MYC …
  5707. A phase I–II study on the combination of Rapamycin and short course radiotherapy in rectal cancer
  5708. Mechanical stretch activates mammalian target of Rapamycin and AMP-activated protein kinase pathways in skeletal muscle cells
  5709. Safety considerations of mammalian target of Rapamycin inhibitors in tuberous sclerosis complex and renal transplantation
  5710. Self-assembled micelles of amphiphilic PEGylated Rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells
  5711. Defining the domain arrangement of the mammalian target of Rapamycin complex component Rictor protein
  5712. Target of Rapamycin signaling mediates vacuolar fission caused by endoplasmic reticulum stress in Saccharomyces cerevisiae
  5713. Ciliary transport regulates PDGF-AA/αα signaling via elevated mammalian target of Rapamycin signaling and diminished PP2A activity
  5714. Anorexic response to Rapamycin does not appear to involve a central mechanism
  5715. Rapamycin versus intermittent feeding: dissociable effects on physiological and behavioral outcomes when initiated early and late in life
  5716. Conversion from calcineurin to mammalian target of Rapamycin inhibitors in liver transplantation: a meta-analysis of randomized controlled trials
  5717. Rapamycin-Mediated mTOR inhibition Reverses Drug Resistance to Adriamycin in Colon Cancer Cells.
  5718. Rapamycin-loaded solid lipid nanoparticles: Morphology and impact of the drug loading on the phase transition between lipid polymorphs
  5719. 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of Rapamycin in human cancer cells
  5720. Cardiac energy dependence on glucose increases metabolites related to glutathione and activates metabolic genes controlled by mechanistic target of Rapamycin
  5721. Rapamycin protects neurons from brain contusion‑induced inflammatory reaction via modulation of microglial activation
  5722. Rapamycin inhibited the function of lung CSCs via SOX2
  5723. iPSC-MSCs combined with low-dose Rapamycin induced islet allograft tolerance through suppressing Th1 and enhancing regulatory T-cell differentiation
  5724. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [Rapamycin] inhibition in prostate cancer cell …
  5725. Encapsulation and controlled release of Rapamycin from polycaprolactone nanoparticles prepared by membrane micromixing combined with antisolvent precipitation
  5726. Active mechanistic target of Rapamycin plays an ancillary rather than essential role in zebrafish CNS axon regeneration
  5727. First-line and sequential use of pazopanib followed by mammalian target of Rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US …
  5728. Mammalian target of Rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy
  5729. Mechanistic target of Rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells
  5730. Rapamycin/GABA combination treatment ameliorates diabetes in NOD mice
  5731. Isoflurane promotes non-small cell lung cancer malignancy by activating the Akt-mammalian target of Rapamycin (mTOR) signaling pathway
  5732. Synergistic effect of JQ 1 and Rapamycin for treatment of human osteosarcoma
  5733. Local application of Rapamycin reduces epidural fibrosis after laminectomy via inhibiting fibroblast proliferation and prompting apoptosis
  5734. SR4 uncouples mitochondrial oxidative phosphorylation, modulates AMP-dependent kinase (AMPK)-mammalian target of Rapamycin (mTOR) signaling, and …
  5735. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1
  5736. Four-week Rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy
  5737. Rapamycin normalizes serum leptin by alleviating obesity and reducing leptin synthesis in aged rats
  5738. L-arginine upregulates the gene expression of target of Rapamycin signaling pathway and stimulates protein synthesis in chicken intestinal epithelial cells
  5739. Blockade of excitatory synaptogenesis with proximal dendrites of dentate granule cells following Rapamycin treatment in a mouse model of temporal lobe epilepsy
  5740. Rapamycin treatment during in vitro maturation of oocytes improves embryonic development after parthenogenesis and somatic cell nuclear transfer in pigs
  5741. Dual phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitor is an effective radiosensitizer for colorectal cancer
  5742. Intrathecal administration of Rapamycin inhibits the phosphorylation of DRG Nav1. 8 and attenuates STZ-induced painful diabetic neuropathy in rats
  5743. Chemical genomics approach to identify genes associated with sensitivity to Rapamycin in the fission yeast Schizosaccharomyces pombe
  5744. Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of Rapamycin complex 1 pathway by regulating amino …
  5745. Validation of mammalian target of Rapamycin biomarker panel in patients with clear cell renal cell carcinoma
  5746. The rodent malaria liver stage survives in the Rapamycin-induced autophagosome of infected Hepa1–6 cells
  5747. inhibition of MDM2 Re-sensitizes Rapamycin resistant renal cancer cells via the activation of p53
  5748. Expression of zTOR-associated microRNAs in zebrafish embryo treated with Rapamycin
  5749. Glucocorticoids inhibited hypothalamic target of Rapamycin in high fat diet-fed chicks
  5750. Diosmetin inhibits cell proliferation and induces apoptosis by regulating autophagy via the mammalian target of Rapamycin pathway in hepatocellular …
  5751. Outcome of Rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series
  5752. Therapeutic targeting of the IL-6 trans-signaling/mechanistic target of Rapamycin complex 1 axis in pulmonary emphysema
  5753. Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model
  5754. … of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of Rapamycin complex 1 (mTORC1) …
  5755. Suppression of the proliferation of hypoxia‐Induced retinal pigment epithelial cell by Rapamycin through the/mTOR/HIF‐1α/VEGF/signaling
  5756. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 against osteosarcoma
  5757. Preparation and preclinical evaluation of inhalable particles containing Rapamycin and anti-tuberculosis agents for induction of autophagy
  5758. Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate Rapamycin treatment
  5759. Efficacy and safety of a mammalian target of Rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis
  5760. Mammalian target of Rapamycin overexpression antagonizes chronic hypoxia-triggered pulmonary arterial hypertension via the autophagic pathway
  5761. Mammalian target of Rapamycin complex 2 (mTORC2) regulates LPS‐induced expression of IL‐12 and IL‐23 in human dendritic cells
  5762. Comparative analysis of Rapamycin biosynthesis clusters between Actinoplanes sp. N902-109 and Streptomyces hygroscopicus ATCC29253
  5763. … acid broadly suppresses cancer metabolism and synergistically induces strong anticancer activity in combination with etoposide, Rapamycin and UCN-01
  5764. inhibition of Akt enhances the chemopreventive effects of topical Rapamycin in mouse skin
  5765. Comparative analysis of protocols to induce human CD4+ Foxp3+ regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, Rapamycin and butyrate
  5766. Role of the mammalian target of Rapamycin pathway and Rapamycin in lentiviral vector gene transduction of hematopoietic stem cells
  5767. Dysregulation of anergy‐related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in …
  5768. Profibrotic up‐regulation of glucose transporter 1 by TGF‐β involves activation of MEK and mammalian target of Rapamycin complex 2 pathways
  5769. Screening of mammalian target of Rapamycin inhibitors in natural product extracts by capillary electrophoresis in combination with high performance liquid …
  5770. Mammalian target of Rapamycin complex (mTOR) pathway modulates blood-testis barrier (BTB) function through F-actin organization and gap junction
  5771. Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B …
  5772. Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell
  5773. Peroxisome proliferator‑activated receptor‑γ agonist inhibits the mammalian target of Rapamycin signaling pathway and has a protective effect in a rat model of …
  5774. Rapamycin interferes with postdepletion regulatory T cell homeostasis and enhances DSA formation corrected by CTLA4‐Ig
  5775. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression
  5776. … activating polypeptide II contributes to the inhibition of malignant biological behaviors by the combination of EMAP II with Rapamycin in human glioblastoma
  5777. Nephrin contributes to insulin secretion and affects mammalian target of Rapamycin signaling independently of insulin receptor
  5778. Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production
  5779. Renal tumours in a Tsc2+/− mouse model do not show feedback inhibition of Akt and are effectively prevented by Rapamycin
  5780. 17ss-Estradiol regulates mTORC2 sensitivity to Rapamycin in adaptive cardiac remodeling
  5781. Rapamycin and fructose-1, 6-bisphosphate reduce the HEPG2 cell proliferation via increase of free radicals and apoptosis
  5782. The mechanistic target of Rapamycin (mTOR) pathway and S6 Kinase mediate diazoxide preconditioning in primary rat cortical neurons
  5783. Different in vitro proliferation and cytokine‐production inhibition of memory T‐cell subsets after calcineurin and mammalian target of Rapamycin inhibitors treatment
  5784. Functional proteomics identifies acinus L as a direct insulin-and amino acid-dependent mammalian target of Rapamycin complex 1 (mTORC1) substrate
  5785. Phosphorylated mammalian target of Rapamycin p-mTOR is a favorable prognostic factor than mTOR in gastric cancer
  5786. Formaldehyde exposure inhibits the expression of mammalian target of Rapamycin in rat testis
  5787. Rapamycin attenuates splenomegaly in both intrahepatic and prehepatic portal hypertensive rats by blocking mTOR signaling pathway
  5788. Transforming somatic mutations of mammalian target of Rapamycin kinase in human cancer
  5789. Significance of mammalian target of Rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy …
  5790. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of Rapamycin-induced aerobic glycolysis and tumor growth
  5791. Local in vitro delivery of Rapamycin from electrospun PEO/PDLLA nanofibers for glioblastoma treatment
  5792. Target of Rapamycin Complex 2 regulates cell growth via Myc in Drosophila
  5793. Expression and clinical significance of mammalian target of Rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma …
  5794. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways
  5795. Differential effects of Rapamycin treatment on tonic and phasic GABAergic inhibition in dentate granule cells after focal brain injury in mice
  5796. The effect of Rapamycin on oxidative stress in MCF-7 and MDA MB-231 human breast cancer cell lines
  5797. Rapamycin inhibits Erk1/2-mediated neuronal apoptosis caused by cadmium
  5798. Discovery of leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of Rapamycin complex 1 (mTORC1) inhibitors
  5799. … and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer’s disease via mammalian target of Rapamycin-dependent and-independent …
  5800. Targeting Rapamycin to podocytes using a vascular cell adhesion molecule-1 (VCAM-1)-harnessed SAINT-based lipid carrier system
  5801. Rapamycin promotes the autophagic degradation of oxidized low-density lipoprotein in human umbilical vein endothelial cells
  5802. Effects of topically applied Rapamycin and mycophenolic acid on TNCB-induced atopic dermatitis-like skin lesions in NC/Nga mice
  5803. Rapamycin ameliorates brain metabolites alterations after transient focal ischemia in rats
  5804. Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine
  5805. Angiographic and volumetric effects of mammalian target of Rapamycin inhibitors on angiomyolipomas in tuberous sclerosis
  5806. Effects of metformin and a mammalian target of Rapamycin (mTOR) ATP-competitive inhibitor on targeted metabolomics in pancreatic cancer cell line
  5807. Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo
  5808. The mechanism of synergistic effects of arsenic trioxide and Rapamycin in acute myeloid leukemia cell lines lacking typical t (15; 17) translocation
  5809. Anti-tumor effect of the mammalian target of Rapamycin inhibitor everolimus in oral squamous cell carcinoma
  5810. Functionally conserved effects of Rapamycin exposure on zebrafish
  5811. Neuroendocrine tumors resistant to mammalian target of Rapamycin inhibitors: A difficult conversion from biology to the clinic
  5812. Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of Rapamycin …
  5813. Preventive effects of Rapamycin on inflammation and capillary degeneration in a rat model of NMDA-induced retinal injury
  5814. Profiling the role of mammalian target of Rapamycin in the vascular smooth muscle metabolome in pulmonary arterial hypertension
  5815. Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes
  5816. Relationship between mammalian target of Rapamycin and autophagy in lipopolysaccharide-induced lung injury
  5817. CX-5461 induces autophagy and inhibits tumor growth via mammalian target of Rapamycin-related signaling pathways in osteosarcoma
  5818. Rapamycin protects dopaminergic neurons against rotenone-induced cell death in primary mesencephalic cell culture
  5819. Downregulation of p70S6K enhances cell sensitivity to Rapamycin in esophageal squamous cell carcinoma
  5820. … and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitor: a phase 1 …
  5821. Combined image guided monitoring the pharmacokinetics of Rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter
  5822. Celecoxib sensitizes gastric cancer to Rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway
  5823. Effects of Rapamycin on reduction of peridural fibrosis: an experimental study
  5824. Long-term alcohol-induced activation of mammalian target of Rapamycin is a key risk factor of epilepsy
  5825. Time-dependent effects of Rapamycin on consolidation of predator stress-induced hyperarousal
  5826. Plum polyphenols inhibit colorectal aberrant crypt foci formation in rats: potential role of the miR-143/protein kinase B/mammalian target of Rapamycin axis
  5827. Tuberous Sclerosis Complex 1–Mechanistic Target of Rapamycin Complex 1 Signaling Determines Brown-to-White Adipocyte Phenotypic Switch
  5828. Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice
  5829. … inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235
  5830. Stents coated with mammalian target of Rapamycin inhibitors (mTOR) appear to be the best choice in patients with antiphospholipid syndrome and myocardial …
  5831. Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of Rapamycin
  5832. Microsphere-based Rapamycin delivery, systemic versus local administration in a rat model of renal ischemia/reperfusion injury
  5833. … sorting complex required for transport pathway mediates chemokine receptor CXCR4-promoted lysosomal degradation of the mammalian target of Rapamycin …
  5834. A comprehensive proteomic and phosphoproteomic analysis of yeast deletion mutants of 14‐3‐3 orthologs and associated effects of Rapamycin
  5835. Targeting the mammalian target of Rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer
  5836. Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas
  5837. … of long‐chain acyl‐CoA synthetase isoform 1 impairs cardiac autophagy and mitochondrial structure through mechanistic target of Rapamycin complex 1 activation
  5838. Glucocorticoids retard skeletal muscle development and myoblast protein synthesis through a mechanistic target of Rapamycin (mTOR)-signaling pathway in broilers …
  5839. … first‐line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of Rapamycin inhibitors: a single …
  5840. Evaluating the effect of 20-hydroxyecdysone (20HE) on mechanistic target of Rapamycin complex 1 (mTORC1) signaling in the skeletal muscle and liver of rats
  5841. Mammalian target of Rapamycin inhibitor–associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft …
  5842. Rapamycin (Sirolimus) alters mechanistic target of Rapamycin pathway regulation and microRNA expression in mouse meiotic spermatocytes
  5843. Rapamycin ameliorates chitosan nanoparticle-induced developmental defects of preimplantation embryos in mice
  5844. The Akt/mTOR/p70S6K pathway is activated in IgA nephropathy and Rapamycin may represent a viable treatment option
  5845. Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of Rapamycin regulated proteins following mithramycin …
  5846. Slow-releasing Rapamycin-coated bionic peripheral nerve scaffold promotes the regeneration of rat sciatic nerve after injury
  5847. Differential expression of GAS 5 in Rapamycin‐induced reversion of glucocorticoid resistance
  5848. Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells
  5849. Klotho upregulation by Rapamycin protects against vascular disease in CKD
  5850. Pharmacokinetics of orally administered low-dose Rapamycin in healthy dogs
  5851. Reduction of intraarticular adhesion of knee by local application of Rapamycin in rabbits via inhibition of fibroblast proliferation and collagen synthesis
  5852. … and cancer stem-like cell properties via the vascular endothelial growth factor (VEGF)/phosphatidylinositol 3-kinase (PI3K)/Akt/mechanistic target of Rapamycin …
  5853. Anticancer mammalian target of Rapamycin (mTOR) signaling pathway inhibitors: current status, challenges and future prospects in management of epilepsy
  5854. … contributes to early oligodendrocyte progenitor proliferation by activating phosphatidylinositol 3-kinase (PI3K)/AKT and the mammalian target of Rapamycin (mTOR) …
  5855. Curcumin attenuates Rapamycin-induced cell injury of vascular endothelial cells
  5856. Formulation and characterization of a 0.1% Rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas
  5857. Potential role for mammalian target of Rapamycin inhibitors as first-line therapy in hormone receptor–positive advanced breast cancer
  5858. Mammalian target of Rapamycin is required for phrenic long-term facilitation following severe but not moderate acute intermittent hypoxia
  5859. inhibition of insulin-like growth factor receptor/AKT/mammalian target of Rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate …
  5860. A treadmill exercise reactivates the signaling of the mammalian target of Rapamycin (mTOR) in the skeletal muscles of starved mice
  5861. The pan phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary …
  5862. … peptide-2 on the tight junction and barrier function in IPEC-J2 cells through phosphatidylinositol 3-kinase–protein kinase B–mammalian target of Rapamycin …
  5863. Protein kinase FgSch 9 serves as a mediator of the target of Rapamycin and high osmolarity glycerol pathways and regulates multiple stress responses and secondary …
  5864. Manganese-stimulated kisspeptin is mediated by the IGF-1/Akt/mammalian target of Rapamycin pathway in the prepubertal female rat
  5865. Anticancer effect of Rapamycin on MCF-7 via downregulation of VEGF expression
  5866. … -2-decenoic acid, the major lipid component of royal jelly, extends the lifespan of Caenorhabditis elegans through dietary restriction and target of Rapamycin …
  5867. Immunohistochemical analysis of phosphorylated mammalian target of Rapamycin and its downstream signaling components in invasive breast cancer
  5868. … factor induces autophagy to resist hypoxia/serum deprivation‑induced apoptosis via the AMP‑activated protein kinase/mammalian target of Rapamycin …
  5869. Rapamycin impairs HPD‐induced beneficial effects on glucose homeostasis
  5870. Effects of mammalian target of Rapamycin inhibitors on cytokine production and differentiation in keratinocytes
  5871. Factors influencing the central nervous system distribution of a novel phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitor GSK2126458: implications …
  5872. Regulation of cardiac miR‐208a, an inducer of obesity, by Rapamycin and nebivolol
  5873. A pilot, single arm, prospective trial using neoadjuvant Rapamycin prior to definitive therapy in head and neck squamous cell carcinoma.
  5874. inhibition of mTOR by Rapamycin results in auditory hair cell damage and decreased spiral ganglion neuron outgrowth and neurite formation in vitro
  5875. Target of Rapamycin (TOR) in Fenneropenaeus chinensis: cDNA cloning, characterization, tissue expression and response to amino acids
  5876. Targeted inhibition of phosphoinositide 3-kinase/mammalian target of Rapamycin sensitizes pancreatic cancer cells to doxorubicin without exacerbating cardiac toxicity
  5877. Rapamycin inhibits the proliferation of SW1990 pancreatic cancer cell
  5878. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells
  5879. Rapamycin release study of porous poly (L-lactic acid) scaffolds, prepared via coaxial electrospinning
  5880. Activation of autophagy by Rapamycin does not protect oligodendrocytes against protein aggregate formation and cell death induced by proteasomal inhibition
  5881. … inhibition of tumor necrosis factor-alpha-stimulated pro-inflammatory cytokine expression in HaCaT cells by a combination of Rapamycin and mycophenolic acid
  5882. Systemic Rapamycin to prevent in-stent stenosis in peripheral pulmonary arterial disease: early clinical experience
  5883. Characterization of the Rapamycin-inducible EBV LMP1 activation system
  5884. … antitumoral properties and renal-associated tissue damage induced by tacrolimus and mammalian target of Rapamycin inhibitors in hepatocarcinoma: in vitro …
  5885. Mammalian Target of Rapamycin Inhibitors and Nephrotoxicity: Fact or Fiction.
  5886. HIF-1α and Rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress
  5887. inhibition of the mammalian target of Rapamycin complex 1 signaling pathway reduces itch behaviour in mice
  5888. Rapamycin ameliorates the CTLA4‐Ig–mediated defect in CD8+ T cell immunity during gammaherpesvirus infection
  5889. inhibition of mammalian target of Rapamycin activation in the rostral anterior cingulate cortex attenuates pain-related aversion in rats
  5890. … Factor Beta 1 Induced Myofibroblast Differentiation via the Phosphorylated-Phosphatidylinositol 3-Kinase Mammalian Target of Rapamycin Signal Pathways in Nasal …
  5891. Aschantin targeting on the kinase domain of mammalian target of Rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation
  5892. Up-regulation of the excitatory amino acid transporters EAAT1 and EAAT2 by mammalian target of Rapamycin
  5893. Stereoselective synthesis of Rapamycin fragment to build a macrocyclic toolbox
  5894. Rapamycin increases grip strength and attenuates age-related decline in maximal running distance in old low capacity runner rats
  5895. Rapamycin up-regulates triglycerides in hepatocytes by down-regulating Prox1
  5896. The regulatory T cell effector molecule fibrinogen‐like protein 2 is necessary for the development of Rapamycin‐induced tolerance to fully MHC‐mismatched murine …
  5897. Importance of EEG in validating the chronic effects of drugs: Suggestions from animal models of epilepsy treated with Rapamycin
  5898. The effect of mammalian target of Rapamycin versus calcineurin inhibitor–based immunosuppression on measured versus estimated glomerular filtration rate after …
  5899. inhibition of wild‐type p53‐induced phosphatase 1 promotes liver regeneration in mice by direct activation of mammalian target of Rapamycin
  5900. MicroRNA-761 inhibits Angiotensin II-induced vascular smooth muscle cell proliferation and migration by targeting mammalian target of Rapamycin
  5901. Targeted therapy of colorectal neoplasia with Rapamycin in peptide-labeled pegylated octadecyl lithocholate micelles
  5902. Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells
  5903. Role of mechanistic target of Rapamycin (mTOR) in renal function and ischaemia–reperfusion induced kidney injury
  5904. Clinically-relevant cyclosporin and Rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: an in-vitro study in …
  5905. Effects of slow-release urea and rumen-protected methionine and histidine on mammalian target of Rapamycin (mTOR) signaling and ubiquitin proteasome …
  5906. Rapamycin‐induced hypoxia inducible factor 2A is essential for chondrogenic differentiation of amniotic fluid stem cells
  5907. Tumor Progression Locus 2 (Tpl2) activates the mammalian target of Rapamycin (mTOR) pathway, inhibits forkhead box P3 (FoxP3) Expression, and limits …
  5908. Pubertal development in pediatric kidney transplant patients receiving mammalian target of Rapamycin inhibitors or conventional immunosuppression
  5909. Rapamycin as novel treatment for refractory-to-standard-care slow-flow vascular malformations
  5910. Contribution of mammalian target of Rapamycin in the pathophysiology of cirrhotic cardiomyopathy
  5911. Possible activation by the green tea amino acid theanine of mammalian target of Rapamycin signaling in undifferentiated neural progenitor cells in vitro
  5912. inhibition of mammalian target of Rapamycin complex 1 (mTORC1) downregulates ELOVL1 gene expression and fatty acid synthesis in goat fetal fibroblasts
  5913. … and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of Rapamycin inhibitor temsirolimus and …
  5914. Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
  5915. Lack of benefits of mammalian target of Rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
  5916. The efficacy and safety of mammalian target of Rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy
  5917. In silico analysis of conformational changes induced by normal and mutation of macrophage infectivity potentiator catalytic residues and its interactions with Rapamycin
  5918. … of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of Rapamycin (mTOR) and impaired …
  5919. Synergism between the mTOR inhibitor Rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
  5920. inhibition of galectin-1 sensitizes HRAS-driven tumor growth to Rapamycin treatment
  5921. A signal-on fluorosensor based on quench-release principle for sensitive detection of antibiotic Rapamycin
  5922. Two crystal structures of the FK506-binding domain of Plasmodium falciparum FKBP35 in complex with Rapamycin at high resolution
  5923. Rapamycin inhibits expression of elongation of very-long-chain fatty acids 1 and synthesis of docosahexaenoic acid in bovine mammary epithelial cells
  5924. Rapamycin combined with immature dendritic cells attenuates obliterative bronchiolitis in trachea allograft rats by regulating the balance of regulatory and effector T …
  5925. An efficient method to generate gene deletion mutants of the Rapamycin-producing bacterium Streptomyces iranensis HM 35
  5926. Are invertebrates relevant models in ageing research? Focus on the effects of Rapamycin on TOR
  5927. Ileal neuroendocrine tumors show elevated activation of mammalian target of Rapamycin complex
  5928. Activation of extracellular regulated kinase and mechanistic target of Rapamycin pathway in focal cortical dysplasia
  5929. Use of mammalian target of Rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A …
  5930. Resveratrol Potentiates Growth Inhibitory Effects of Rapamycin in PTEN-deficient Lipoma Cells by Suppressing p70S6 Kinase Activity
  5931. Mechanistic target of Rapamycin is activated in bovine granulosa cells after LH surge but is not essential for ovulation
  5932. Insulin-like growth factor 1/mammalian target of Rapamycin and AMP-activated protein kinase signaling involved in the effects of metformin in the human endometrial …
  5933. Rapamycin-associated lymphoedema in an infant with Kasabach-Merritt phenomenon
  5934. Selective tuberous sclerosis complex 1 gene deletion in smooth muscle activates mammalian target of Rapamycin signaling and induces pulmonary hypertension
  5935. Effect of imatinib mesylate and Rapamycin on the preformed intimal hyperplasia in rat carotid injury model
  5936. Effect of the dual phosphatidylinositol 3‑kinase/mammalian target of Rapamycin inhibitor NVP‑BEZ235 against human Merkel cell carcinoma MKL‑1 cells
  5937. Effects of intrathecal injection of Rapamycin on pain threshold and spinal cord glial activation in rats with neuropathic pain
  5938. Phase 1b study of the mammalian target of Rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid …
  5939. Cell synchronization by Rapamycin improves the developmental competence of porcine SCNT embryos
  5940. Rapamycin-conditioned dendritic cells induced immune tolerance through the regulation of Treg/Th17 cells in mice
  5941. The regulation of autophagy in porcine blastocysts: Regulation of PARylation-mediated autophagy via mammalian target of Rapamycin complex 1 (mTORC1) signaling
  5942. The mammalian target of Rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways
  5943. Combination therapy of intraperitoneal Rapamycin and convection-enhanced delivery of nanoliposomal CPT-11 in rodent orthotopic brain tumor xenografts
  5944. Rapamycin protects against neuronal death and improves neurological function with modulation of microglia after experimental intracerebral hemorrhage in rats
  5945. Intracrine steroid production and mammalian target of Rapamycin pathways in pulmonary lymphangioleiomyomatosis
  5946. Torin2 potentiates anticancer effects on adult T-cell leukemia/lymphoma by inhibiting mammalian target of Rapamycin
  5947. Role of Ragulator in the regulation of mechanistic target of Rapamycin signaling in podocytes and glomerular function
  5948. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo
  5949. Corosolic acid enhances 5‑fluorouracil‑induced apoptosis against SNU‑620 human gastric carcinoma cells by inhibition of mammalian target of Rapamycin
  5950. Effectiveness of inhibitor Rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells
  5951. Dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal …
  5952. Mammalian target of Rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
  5953. Down‐regulation of mitogen‐activated protein kinases and nuclear factor‐κB signaling is involved in Rapamycin suppression of TLR2‐induced inflammatory response …
  5954. PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of Rapamycin complex 2/AKT1 signaling …
  5955. Enhanced antitumor activity of 3-bromopyruvate in combination with Rapamycin in vivo and in vitro
  5956. Preparation and experimental research into retrievable Rapamycin-and heparin-coated vena cava filters: a pilot study
  5957. Delayed reendothelialization with Rapamycin is rescued by the addition of nicorandil in balloon-injured rat carotid arteries
  5958. Mammalian target of Rapamycin/p70 ribosomal S6 protein kinase signaling is altered by sevoflurane and/or surgery in aged rats
  5959. Rapamycin attenuates palmitate-induced lipid aggregation by up-regulating sirt-1 signaling in AML12 hepatocytes
  5960. Direct implantation of Rapamycin-eluting stents with bioresorbable drug carrier technology utilising the Svelte coronary stent-on-a-wire: the DIRECT II study
  5961. Regulation of human trophoblast GLUT3 glucose transporter by mammalian target of Rapamycin signaling
  5962. … of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of Rapamycin and osteoblast differentiation …
  5963. The imidazo [1, 2-a] pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) inhibitors
  5964. Frameshift mutations in mammalian target of Rapamycin pathway genes and their regional heterogeneity in sporadic colorectal cancers
  5965. Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used as Potential mTOR‐Targeted Anticancer Agents
  5966. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of Rapamycin inhibitors in patients with renal cell carcinoma …
  5967. mTOR inhibition by Rapamycin increases ceramide synthesis by promoting transforming growth factor‐β1/Smad signaling in the skin
  5968. Effects of Rapamycin treatment on pancreatic fibrosis, cellular apoptosis and oxidative stress in experimental chronic pancreatitis model
  5969. PC-1/PrLZ confers resistance to Rapamycin in prostate cancer cells through increased 4E-BP1 stability
  5970. In vitro interactions between target of Rapamycin kinase inhibitor and antifungal agents against Aspergillus species
  5971. Topical mTOR (mechanistic target of Rapamycin) inhibitor therapy in facial angiofibroma
  5972. Design, synthesis and biological evaluation of novel Rapamycin benzothiazole hybrids as mTOR targeted anti-cancer agents
  5973. Extracellular signal–regulated kinase–mammalian target of Rapamycin signaling and forkhead-box transcription factor 3a phosphorylation are involved in …
  5974. Cell cycle status dictates effectiveness of Rapamycin
  5975. Recognition and management of oral mucosal injury caused by mammalian target of Rapamycin inhibitors: a case series
  5976. The 4E-BP1/eIF4E ratio is a determinant for Rapamycin response in esophageal cancer cells
  5977. Use of topical Rapamycin in facial angiofibromas in Indian skin type
  5978. Blocking mammalian target of Rapamycin alleviates bladder hyperactivity and pain in rats with cystitis
  5979. Rapamycin prevents acute dendritic injury following seizures
  5980. Oxaliplatin-Rapamycin combination was superior to mono-drug in treatment of hepatocellular carcinoma both in vitro and in vivo.
  5981. Rapamycin decreases the osteogenic response in aortic valve interstitial cells through the stat3 pathway
  5982. Pathological findings of a subependymal giant cell astrocytoma following treatment with Rapamycin
  5983. Restoration of normal cerebral oxygen consumption with Rapamycin treatment in a rat model of autism–tuberous sclerosis
  5984. Gene expression in the liver of female, but not male mice treated with Rapamycin resembles changes observed under dietary restriction
  5985. Protective effects of Rapamycin induced autophagy on acute kidney injury induced by sepsis
  5986. … receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin or mitogen-activated …
  5987. 4D MRI of polycystic kidneys from Rapamycin‐treated Glis3‐deficient mice
  5988. The mammalian target of Rapamycin signaling pathway regulates myocyte enhancer factor‐2C phosphorylation levels through integrin‐linked kinase in goat skeletal …
  5989. Mammalian‐target of Rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the …
  5990. Rapamycin decreases irradiation-induced hematopoietic system damage
  5991. Conversion from calcineurin inhibitors to mammalian target-of-Rapamycin inhibitors in heart transplant recipients: a meta-analysis of randomized controlled trials
  5992. Mechanistic target of Rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes
  5993. The dynamics of histone H2A ubiquitination in HeLa cells exposed to Rapamycin, ethanol, hydroxyurea, ER stress, heat shock and DNA damage
  5994. Intracellular release of Rapamycin from poly (lactic acid) nanospheres modifies autophagy
  5995. Chronic Rapamycin treatment exacerbates metabolism and does not down-regulate mTORC2/Akt signaling in diabetic mice induced by high-fat diet and streptozotocin
  5996. A case of esophageal adenocarcinoma on long‐term Rapamycin monotherapy
  5997. Early and delayed intervention with Rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice
  5998. The effect of Rapamycin on TGFβ1 and MMP1 expression in a rabbit model of urethral stricture
  5999. Effects of Rapamycin induced cellular autophagy in aging-related diseases
  6000. Rapamycin slows down gut aging
  6001. Rapamycin in the treatment of cardiac rhabdomyoma associated with tuberous sclerosis complex
  6002. miR-144 regulates BCG-and Rapamycin-induced autophagy by targeting Atg4a in RAW264. 7 cells
  6003. Joining forces: first application of a Rapamycin‐induced dimerizable Cre system for conditional null mutant analysis in Leishmania
  6004. Additive effects of Rapamycin and aspirin on dendritic cell allostimulatory capacity
  6005. Rapamycin-conditioned dendritic cells activated with monophosphoryl lipid-A promote allograft acceptance in vivo
  6006. The yeast ζ‐crystallin/NADPH: quinone oxidoreductase (Zta1p) is under nutritional control by the target of Rapamycin pathway and is involved in the regulation of …
  6007. Role of Mammalian Target of Rapamycin (mTOR) in Cardiac Homeostasis in Metabolic Disorders
  6008. Effect of nourishing “yin” removing “fire” Chinese herbal mixture on hypothalamic mammalian target of Rapamycin expression during onset of puberty in female …
  6009. Effect of Rapamycin (RAPA) on the growth of lung cancer and its mechanism in mice with A549
  6010. Mammalian target of Rapamycin (mTOR) activity promotes neuronal survival in stroke with or without ischemic postconditioning
  6011. Overexpression of TOR (target of Rapamycin) inhibits cell proliferation in Dictyostelium discoideum
  6012. … and activator of transcription 3 (JAK2/STAT3) signaling pathway in pancreatic acinar cells in rats, while AG490 and Rapamycin inhibit their activation
  6013. Protective effects of low-dose Rapamycin combined with valsartan on podocytes of diabetic rats
  6014. Mammalian target of Rapamycin inhibitor monotherapy: efficacy in renal transplantation
  6015. Activation of the mammalian target of Rapamycin in the rostral ventromedial medulla contributes to the maintenance of nerve injury-induced neuropathic pain …
  6016. Rapamycin improves mortality following intestinal ischemia-reperfusion via the inhibition of remote lung inflammation in mice
  6017. Effect of Rapamycin on the balance of T helper cell subsets in rats with pulmonary fibrosis
  6018. Protective effect of silymarin against Rapamycin-induced apoptosis and proliferation inhibition in endothelial progenitor cells
  6019. Efficacy and toxicity of mammalian target Rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency: the Korean Cancer …
  6020. Efficacy and mechanism of local delivery of Rapamycin and Rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles on coronary restenosis of injury-stenosis …
  6021. Topical Rapamycin combined with pulsed dye laser (PDL) in the treatment of capillary vascular malformations—Anatomical differences in response to PDL are relevant …
  6022. Serendipity in splendid isolation: Rapamycin
  6023. Brain size is controlled by the mammalian target of Rapamycin (mTOR) in mice
  6024. 4E-BP2 hardwires lymphocytes for Rapamycin sensitivity
  6025. Effects of mechanistic target of Rapamycin signaling pathway on the estrogen-mediated NaPi-IIb protein expression in pig small intestinal epithelial cells
  6026. Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of Rapamycin to alter murine effector CD8+ T‐cell differentiation
  6027. Activation of Mammalian target of Rapamycin in canine mammary carcinomas: an immunohistochemical study
  6028. Rapamycin as a Potential Treatment for Obesity
  6029. Rapamycin does not impede survival or induction of antibody responses to primary and Heterosubtypic influenza infections in mice
  6030. … -Kuey-Jian-Tang induces autophagy in HepG2 cells via regulation of the phosphoinositide-3 kinase/Akt/mammalian target of Rapamycin and p38 mitogen …
  6031. CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced …
  6032. Mammalian target of Rapamycin (mTOR), aging, neuroscience, and their association with aging-related diseases
  6033. Understanding the cellular impact of low dose Rapamycin treatment.
  6034. Tumor cell-derived secretory factor downregulates Semaphorin-3a in osteoblasts by activating mammalian target of Rapamycin pathway
  6035. Mammalian target of Rapamycin inhibitor induced complete remission of a recurrent subependymal giant cell astrocytoma in a patient without features of tuberous …
  6036. Rapamycin reverse lipopolysaccharide-induced acute lung injury through acti-vating autophagy flux
  6037. Regulation of hypoxia-inducible factor-1α, regulated in development and DNA damage response-1 and mammalian target of Rapamycin in human placental BeWo …
  6038. Phase II trial of gemcitabine plus Rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.
  6039. Combined antitumor gene therapy with herpes simplex virus-thymidine kinase and short hairpin RNA specific for mammalian target of Rapamycin
  6040. Preventive and therapeutic effects of Rapamycin against autoimmune hepatitis and liver fibrosis and possible mechanisms
  6041. Rapamycin enhances IFN-γ and IL-4 production in co-culture of gδ T and dendritic cells from mice with lipopolysaccharide-induced acute lung injury
  6042. Expression of Concern. A Central Role for Neuronal AMP-Activated Protein Kinase (AMPK) and Mammalian Target of Rapamycin (mTOR) in High-Protein Diet …
  6043. Topical Rapamycin for angiofibromas in patients with tuberous sclerosis: how does it work in clinical practice?
  6044. Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of Rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma
  6045. Effects of dietary soy protein concentrate on growth, digestive enzymes activities and target of Rapamycin signaling pathway regulation in juvenile soft-shelled …
  6046. Growth inhibitory effect of Rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation
  6047. Pharmacology of mammalian (mechanistic) target of Rapamycin (mTOR) inhibitors
  6048. Role of the phosphatidylinositol-3-kinase/Akt/target of Rapamycin pathway during ambidensovirus infection of insect cells
  6049. Mechanism of Polypeptide Extract from Scorpion Venom Combined Rapamycin in Enhancing Autophagy of H22 Hepatoma Cells: an Experimental Study
  6050. In vitro study of effects and mechanism of Rapamycin-induced autophagy in keloid fibroblasts
  6051. Using the mycelium-covered cereals as an efficient inoculation method for Rapamycin fermentation in a 15-L fermenter using Streptomyces hygroscopicus
  6052. Erratum to: Optimization of adipose tissue-derived mesenchymal stem cells by Rapamycin in a murine model of acute graft-versus-host disease
  6053. Rapamycin increases RSV RNA levels and survival of RSV-infected dendritic cell depending on T cell contact
  6054. Efficacy of Rapamycin therapy in the women with metastatic breast cancer in West Iran
  6055. Mechanisms for reversal of pulmonary hypertension by Rapamycin in rats
  6056. Roles of Mechanistic Target of Rapamycin in the Adaptive and Innate Immune Systems
  6057. An Analytical Approach for Insulin-like Growth Factor Receptor 1 and Mammalian Target of Rapamycin Blockades in Ewing Sarcoma
  6058. Potential future Indication of Rapamycin Analogs for the Treatment of solid Tumors
  6059. Abstract B59: Dual mTOR kinase inhibitor reverses Rapamycin resistance in prostate cancer cells
  6060. Effects of Ras homolog gene family, member C gene silencing combined with Rapamycin on hepatocellular carcinoma cell growth
  6061. A phase I/II multi-center study of intravesical nanoparticle albumin-bound Rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer.
  6062. Costimulatory blockade and use of mammalian target of Rapamycin inhibitors: avoiding injury part 1
  6063. Autologous Rapamycin-Resistant T Cell Therapy of Multiple Myeloma
  6064. Association of mammalian target of Rapamycin gene polymorphisms with the risk of pediatric epilepsy
  6065. Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor gd T Cells
  6066. The Effect of Rapamycin on Penicillin-Induced Epileptiform Activity in Rats: An Electrophysiological Study
  6067. PT684. Treatment with Rapamycin improves deficits of social interaction in the mice exposed in utero to valproic acid
  6068. Comparable neuroprotective effect of Rapamycin against low and high rotenone concentrations in primary dopaminergic cell culture
  6069. Enhanced antitumor activity of Rapamycin and genipin, a UCP-2 inhibitor, in lung cancer
  6070. … nephrectomy specimens as a predicting factor of progression-free survival in patients with metastatic renal cell carcinoma treated with mammalian target of Rapamycin …
  6071. Rapamycin results in Bim-mediated loss of thymic regulatory T cells during development in organ culture
  6072. Mammalian target of Rapamycin (mTOR) inhibition in advanced bronchial carcinoids
  6073. Sann-Joong-Kuey-Jian-Tang decreases the protein expression of mammalian target of Rapamycin but increases microtubule associated protein II light chain 3 …
  6074. Rapamycin protects ova induced asthma in mice through regulating autophagy
  6075. Oleuropein potently inhibits mammalian target of Rapamycin: possible involvement of tandem anomeric hyperconjugation–Michael reaction
  6076. Structural studies on the target of Rapamycin complex 1
  6077. Risk factors associated with mammalian target of Rapamycin inhibitor withdrawal in kidney transplant recipients
  6078. Rapamycin Enhances the Suppressive Capacity of Ex Vivo Expanded Regulatory T Cells (Tregs) Isolated From Pediatric Thymus
  6079. Activation of mTOR signaling pathway in cancer stem cells of nasopharyngeal carcinoma and inhibitive effect of Rapamycin against the cancer stem cells
  6080. Catalytic mammalian target of Rapamycin inhibitors as antineoplastic agents
  6081. Efficacy of Rapamycin in Tuberous Sclerosis–Associated Hypopigmented Macules: Back to the Future
  6082. Topical Rapamycin suppresses lacrimal gland inflammation in a mouse model of Sjögren’s Syndrome
  6083. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of Rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic …
  6084. Changes of Sexual Behaviors in Rapamycin-injected Cichlid Fish Astatotilapia burtoni Males
  6085. Down-regulation of MAPKs and NF-κB Signaling is Involved in Rapamycin Suppression of
  6086. Molecular characterization and expression analysis of target of Rapamycin (TmTOR) in coleopteran insect Tenebrio molitor
  6087. Comparative proteomic analysis of Rapamycin versus cyclosporine combination treatment in mouse podocytes
  6088. The role of Rapamycin-eluted stent in vascular endothelial injury
  6089. A phase I/II study of albumin-bound Rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer …
  6090. Rapamycin-topotecan combination exhibited enhanced antitumor efficacy compared to topotecan used alone in cisplatin-resistant ovarian cancer cells.
  6091. Probing mitosis by manipulating the interactions of mitotic regulator proteins using Rapamycin-inducible dimerization
  6092. Studies on the response to, and recovery from, Rapamycin in Saccharomyces cerevisiae
  6093. P-113 Mammilian target of Rapamycin (mTOR) and autophagy in hepatitis C virus-related hepatocellular carcinoma: relation to tumor progression
  6094. LB-S&T-03 A PHASE 1/2 STUDY OF ALBUMIN-BOUND Rapamycin NANOPARTICLES IN BACILLUS CALMETTE-GUERIN REFRACTORY NON-MUSCLE …
  6095. Novel insights into regulation of Target of Rapamycin Complex 2 by hyperosmotic stress.
  6096. Halofuginone synergistically enhances anti-proliferation of Rapamycin in T cells and reduces cytotoxicity of cyclosporine in cultured renal tubular epithelial …
  6097. Neuroprotective effect of Rapamycin in the retina
  6098. Rapamycin for vascular tumor/malformation
  6099. Identifying rational combination therapies with Rapamycin for the treatment of epithelial cancers
  6100. The pilot study on Rapamycin retarding the differentiation of RPE cells in vitro
  6101. … hematological disorders observed in Shwachman-Diamond syndrome: mTOR and STAT3 hyper-phosphorylation in CD4+ and CD8+ T cells and efficacy of Rapamycin …
  6102. In vivo Toll‐like receptor 5 (TLR5) imaging with radiolabeled anti‐TLR5 monoclonal antibody in Rapamycin‐treated mouse allogeneic skin transplantation model
  6103. Rapamycin and Chloroquine: The
  6104. The role of Rapamycin-eluted stent in vascular endothelial injury
  6105. Rapamycin Improves Vascular Remodeling in a Controlled Rat Model of Monocrotaline-induced Pulmonary Hypertension
  6106. Effects of leucine and histidine on milk protein synthesis via mammalian target of Rapamycin signaling pathway in the bovine mammary epithelial cells.
  6107. Effects of tetrandrine and caffeine on cell viability and expression of mammalian target of Rapamycin, phosphatase and tensin homolog, histone deacetylase 1 …
  6108. Neurotensin and Corticotropin‐releasing Hormone Synergistically Activate Human Microglia through Mammalian Target of Rapamycin Complex 1 (mTORC1)
  6109. Determination of GDC‐0980 (apitolisib), a small molecule dual phosphatidylinositide 3‐kinase/mammalian target of Rapamycin inhibitor in dog plasma by LC‐MS/MS …
  6110. Rapamycin POLYMER NANOTHERAPEUTICS FOR PULMONARY HYPERTENSION TREATMENT
  6111. FCT-14: Topical 0.2% Rapamycin for angiofibromas due to tuberous sclerosis complex (TSC)
  6112. Effect of Rapamycin on apoptosis of mouse astrocytes in vitro
  6113. Mammalian Target of Rapamycin Signaling Pathways and Depression
  6114. Serendipity in splendid isolation: Rapamycin
  6115. Regulation of Hepatic Metabolism by the Mechanistic Target of Rapamycin
  6116. Therapeutic effect of Rapamycin on the clinical and radiological aspects in patients with multiple sclerosis
  6117. Rapamycin inhibits the phosphorylation of mSin1 by targeting a new mTOR complex
  6118. Effect of Rapamycin on Proliferation and Cell Cycle of Human Bladder Carcinoma Cell Line 5637
  6119. FP471 EFFECT OF Rapamycin ON EXPRESSION OF IL17 AND TLR4 IN EARLY STAGE OF DN RATS
  6120. Structural and functional characterization of Rapamycin-resistant TORC2
  6121. Improvement of antitumor effect of ionizing radiation to treat nasopharyngeal carcinoma in combination with Rapamycin
  6122. Effects and mechanisms of Rapamycin on renal interstitial fibrosis in rats
  6123. Congenital Hyperinsulinism; Effects of Rapamycin on Min6 Pancreatic?-Cell Line
  6124. The Adjuvant Effect of Rapamycin for a New Multi-stage Subunit Vaccine Candidate LT69
  6125. Effect of Rapamycin on Expression of Survivin and Caspase-3 and Its Influence on K562 Cell Ultrastructure
  6126. Rapamycin regulates autophagy and cell adhesion in induced pluripotent stem cells
  6127. The Impact of Rapamycin and Metformin on Genome Organization and Function in Normal Human Fibroblasts
  6128. Alterations of the electrophysiological properties from cortical layer 5 pyramidal neurons in temporary Rapamycin-treated rodent brain slices
  6129. The Effects of Rapamycin on the Unfolded Protein Response in Relation to Healthy Aging
  6130. The Effect of Rapamycin on Mitochondrial Electron Transport Chain (ETC) Activity and Superoxide Production
  6131. Sensitivity of esophageal squamous cell carcinoma cells to Rapamycin can be improved by siRNA-interfered expression of p70S6K
  6132. Rapamycin Activates TGF Receptor Independently of Its Ligands: Implications for Endothelial Dysfunction
  6133. Effect of Rapamycin on the migration of human epidermal cell line HaCaT and its possible molecular mechanism
  6134. Anticancer effect of Rapamycin on MCF-7 via downregulation of VEGF expression Animal
  6135. Study on Effects and Mechanism of Rapamycin on Invasion and Metastasis of Cervical Cancer HeLa Cells
  6136. Is it necessary to investigate Rapamycin-modulated autophagy during the development of experimental osteoporosis in female rat?
  6137. Dual mTOR kinase inhibitor overcomes Rapamycin resistance in vitro
  6138. Anti-fibrotic effects of Rapamycin by activation of autophagy in scarforming fibroblasts
  6139. Host Ingestion of Rapamycin Increased Nematode and Cestode Reproduction
  6140. A Novel Multiple Sclerosis Model Utilizing Cuprizone and Rapamycin
  6141. CP-173 Topical 0.1% Rapamycin for angiofibromas in a paediatric patient with tuberous sclerosis
  6142. Identification of a natural compound as mammalian target of Rapamycin kinase inhibitor
  6143. Characterization and Rapamycin Treatment Of Laryngotracheal Stenosis, In Vitro and In Vivo
  6144. Chronic mTOR inhibition by Rapamycin and Diabetes: What is the Role of Mitochondria?
  6145. Mammalian target of Rapamycin inhibitors: A paradigm shift in current immunosuppression protocols
  6146. Augmentation of nonsense mediated decay by Rapamycin
  6147. Sphingolipids mediate the signals for all the essential functions of Target Of Rapamycin Complex 2
  6148. Effect of Rapamycin on proliferation of rat heart valve interstitial cells in vitro
  6149. Rapamycin adjuvant therapy did not improve the outcome of severe influenza virus infection in an experimental mouse model system
  6150. Advance in research on the relationship between mammalian target of Rapamycin signaling pathway and ophthalmic diseases
  6151. Rapamycin expands t-regulatory cells and improves implantation and live birth rates in a murine model
  6152. Outcome of Rapamycin Therapy for Post Transplant-Lymphoproliferative Disorder after Kidney Transplantation: Case Series
  6153. Effects of Rapamycin and 3-MA on motor behavior and autophagy related protein LC3 in PD model mice
  6154. The Breeding of High-yielding Actinoplanes of Rapamycin
  6155. Changes in expression of autophagy-related proteins, Beclin-1 and LC3, and effects of Rapamycin on their expression in hypoxic-ischemic hippocampus
  6156. Enhanced antitumor activity of Rapamycin and genipin, a UCP-2 inhibitor, in lung cancer.
  6157. Rapamycin rescues the innate immune/inflammatory response in the retina of the Ndufs4 mouse
  6158. In Vivo Sustained Release of Rapamycin (Sirolimus) from a Biodegradable Intravitreal Device
  6159. Combination therapy of FK228 with Rapamycin synergistically promotes human breast cancer cell apoptosis by DNA damage and cell cycle arrest
  6160. 4-(N-Phenyl-N′-substituted benzenesulfonyl)-6-(4-hydroxyphenyl) quinolines as inhibitors of mammalian target of Rapamycin
  6161. Rapamycin Induced Acute Myelogenous Leukemia U937 Cell Autophagy and Apoptosis
  6162. THE EFFECTS OF Rapamycin ON THE GLYCOLYSIS IN BREAST CANCER CELL LINES MCF-7 & MDAMB231
  6163. Sensitivity of esophageal squamous cell carcinoma cells to Rapamycin can be improved by si RNA-interfered expression of p70S6K
  6164. Efficacy of Rapamycin and paclitaxel eluting stent implantation in treatment of coronary artery disease
  6165. Investigating novel interaction partners of amyloid precursor protein: the mechanistic target of Rapamycin and pikyve complex
  6166. Small molecules as tool compounds to probe Target of Rapamycin (TOR) signaling
  6167. Effect and Mechanism of Rapamycin Inhibiting mTOR on Heart Valve Cell Calcification in Experimental Rats
  6168. Reperfusion Therapy With Rapamycin Prevents Myocardial Injury in Type 2 Diabetic Rabbits
  6169. Cardiac-specific Overactivation of the Mechanistic Target of Rapamycin Complex 1 Induces Metabolic, Structural and Functional Remodeling
  6170. Target of Rapamycin signaling mediates vacuolar fission caused by endoplasmic reticulum stress in S. cerevisiae.
  6171. Effect of Rapamycin on the Gene Expression Signature of Focal Lesions in a Model of Progenitor‐Derived HCC
  6172. Microinjection Technique to Relieve Neuropathic Pain by Infusion of Rapamycin into the Insular Cortex
  6173. Rapamycin-based macrocyclic library development and Equilibrative Nucleoside Transporter 1 (ENT1) inhibition
  6174. Abstract T P79: Rapamycin Improves Outcome Post Stroke Injury by Enhancing Autophagy in Neuronal Cells
  6175. Investigating efficacy of combinational use of Rapamycin and Valproic acid in treatment of triple negative breast cancer cells
  6176. Preparation of nearly monodispersed polycaprolactone nano-particles loaded with the immunosuppressive drug Rapamycin by membrane micromixing …
  6177. Rapamycin Treatment Regulates miRNAs Associated With Mitochodrial and Endoplasmic Reticulum Functions in a Pig Model of Miocardial Ischemia-reperfusion …
  6178. Rapamycin Regulates Autophagy and Cell Adhesion in Induced Pluripotent Stem Cells
  6179. Rapamycin in combination with gemcitabine reduced viability, growth and metastasis of the murine osteosarcoma cell line LM8 in vitro and in vivo
  6180. Characterizing the Mechanistic Target of Rapamycin Complex 2 Pathway in Glioblastoma Multiforme
  6181. Role of hippocampal mammalian target of Rapamycin signaling pathway in inflammatory pain in rats
  6182. Impact of autophagy on allorejection and underlying mechanisms in Rapamycin-treated allotransplantation model
  6183. Molecular mechanism of amino acids in regulation of mammalian target of Rapamycin complex 1 signaling pathway.
  6184. Research progress of mammalian target of Rapamycin and hypoxia-inducible factor-1 in malignant tumors
  6185. Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex
  6186. Inhibiting the mammalian target of Rapamycin as an adjunctive therapy for cerebral malaria (MPF7P. 714)
  6187. Effects of Rapamycin on expression of six kinds miRNAs in RAW264. 7 macrophages and research on miR-20a’s targeted regulation of ATG16L1 gene expression
  6188. Linking Metabolic and Structural Remodeling by Cardiac‐Specific Activation of the Mechanistic Target Of Rapamycin Complex 1
  6189. Microencapulated Rapamycin prevents carcinogen and inflammation driven colon cancer through immune mechanisms
  6190. Rapamycin-and paclitaxel-eluting stents for prevention of cardiovascular events: effectiveness and safety
  6191. Mammalian target of Rapamycin inhibition with enterically given Rapamycin alters immunity and gut flora in young and aged wild type mice and extends life of …
  6192. Evolution of disease activity and biomarkers on and off Rapamycin in 28 patients with autoimmune lymphoproliferative syndrome
  6193. Rapamycin-INDUCED RESCUE OF AUTOPHAGY DRIVES GLIOBLASTOMA STEM/PROGENITOR CELLS DIFFERENTIATION
  6194. Rapamycin Prevents Bronchiolitis Obliterans through Increasing Regulatory B Cells Infiltration in A Murine Tracheal Transplantation Model
  6195. Environmental Signaling through the Target of Rapamycin Complex 1 (TORC1) and the Regulation of Epigenetic Mechanisms
  6196. Rapamycin Blocks a Key Thermogenesis Pathway in White Adipose Tissue: Diabetes/Obesity Implications
  6197. Rapamycin Reverses Lymphatic Abnormalities In A Transgenic Mouse Model Of Pulmonary Lymphangiectasia
  6198. Immunofluorescent approaches to investigate the mammalian target of Rapamycin (mTOR) complex in human skeletal muscle
  6199. Rapamycin Is Highly Effective in a Mouse Model of Immune-Mediated Bone Marrow Failure By Mechanisms Distinct from Cyclosporine
  6200. Th1, Th2 and Th17 cytokine profile in patients with multiple sclerosis following treatment with Rapamycin
  6201. A Novel Compound Tanshinol Prolongs Cardiac Allograft Survival Induced by Rapamycin
  6202. Estimates in several industrial yeast strains ploidy by flow cytometer with Rapamycin.
  6203. Study of the effect of Rapamycin on mTOR complex using capillary isoelectric focusing coupled with laser induced fluorescence-detector
  6204. Drug Development against Rapamycin-resistant Cancers via Leucyl-tRNASynthetase
  6205. Assessing efficacy of combinational therapy of Rapamycin and Tamoxifen on estrogen receptor positive MCF7 breast cancer cells
  6206. Topical Rapamycin treatment is effective in hypopigmented macules of tuberous sclerosis
  6207. The influence of the Target of Rapamycin (TOR) on starch metabolism in Arabidopsis thaliana
  6208. Rapamycin treatment of normal human fibroblasts increases the transcriptional abundance of genes involved in cytokine-cytokine receptor signalling
  6209. D44 FIRST LINE OF DEFENSE: AIRWAY RESPONSE TO INFECTIONS AND IRRITANTS: Rapamycin Protects Ova Induced Asthma In Mice Through Regulating …
  6210. Anti‑migratory effect of Rapamycin impairs allograft imaging by 18F‑fluorodeoxyglucose‑labeled splenocytes
  6211. GW27-e0513 inhibition of mammalian target of Rapamycin complex 1 protects against reperfusion injury in heart through STAT3 signaling
  6212. Rapamycin Preferentially Inhibits IL5+ Th2 Cell Proliferation through the mTORC1/S6 Kinase Pathway
  6213. Abstract B055: The impact of Rapamycin and tacrolimus treatment on resident CD8+ T-cell populations in cutaneous squamous cell carcinoma
  6214. Abstract T P85: Mammalian Target of Rapamycin (mTOR) Signaling Pathway Mediates Cerebral Ischemic Brain Damage
  6215. GW27-e0035 Delayed reendothelialization with Rapamycin is rescued by the addition of nicorandil in balloon-injured rat carotid arteries
  6216. Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes Molecular and cell biology of lipids
  6217. Mammalian target of Rapamycin inhibitors are promising T cell lymphoma treatment agents that synergize with ERβ agonists in vitro but not in vivo (VAC3P. 1061)
  6218. Protective role and the mechanism of Rapamycin against concanavalin A (ConA) induced autoimmune hepatitis in mice
  6219. The Evolving Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma
  6220. Confirmation Of The Cellular Targets Of Benomyl And Rapamycin And Studies Into The Mode Of Action Of Cationic Amphiphilic Drugs (CADs)
  6221. Binge Drinking With Protein Kinase C Epsilon: A Role for Mammalian Target of Rapamycin Complex 2?
  6222. Rapamycin Treatment Inhibits the Progression of Optic Neuritis Mediated Visual Loss in Experimental Autoimmune Encephalomyelitis (EAE) Mice
  6223. The Role of Protein Kinase C in Mammalian Target of Rapamycin Signaling and its Therapeutic Implications in Non-Small Cell Lung Cancer
  6224. Cell synchronization by Rapamycin improves the developmental competence of porcine SCNT embryos
  6225. Mammalian target of Rapamycin inhibitors against hepatocellular carcinoma recurrence after liver transplantation
  6226. Reperfusion Therapy With Rapamycin Prevents Myocardial Injury by Induction of Cardiac MicroRNA-302a in Diabetic Rabbits
  6227. Effects of Rapamycin on amyloid β-protein induced impairments of working memory and synaptic plasticity in rats
  6228. Specificity to capture endothelial progenitor cells in the peripheral blood by CD34 antibody applied on a Rapamycin eluting stent
  6229. inhibition of glucose metabolism in neuroendocrine tumors by lanreotide, sunitinib, and Rapamycin
  6230. Effects of Rapamycin and Rapamycin-loaded Poly (lactic-co-glycolic) Acid Nanoparticles on Apoptosis and Expression of bcl-2 and p27 (kip1) Proteins of Human …
  6231. Differential Roles of Mammalian Target of Rapamycin (mTOR) in Phrenic Long‐Term Facilitation
  6232. Abstract B12: Rapamycin-induced miR-21 promotes the survival of mTORC1 hyperactivated cells in tuberous sclerosis complex models
  6233. Rapamycin Increases the Thrombogenic Potential of Neutrophil Extracellular Traps (NETs): Potential Mechanism of Prothrombotic Drug-Eluting Stents
  6234. Modulation of mTOR and p53 signaling using Rapamycin plus CP-31398 inhibits growth and progression of urothelial carcinoma in-vivo
  6235. Reperfusion Therapy with Rapamycin Prevents Myocardial Injury and restores Plasma Levels of Stress‐Sensitive microRNA‐191 in Conscious Diabetic Rabbits
  6236. Rapamycin, an evolving role in up-regulation of autophagy to improve stroke outcome and increase neuronal survival to stroke type injuries
  6237. Effect of Electro-acupuncture on Mammalian Target of Rapamycin Expression in Hypoxic-ischemic Encephalopathy Newborn Rats
  6238. Rapamycin enhances Sox9 expression during chondrogenic differentiation of amniotic fluid stem cells
  6239. Short-term prognostic implication for patients with ST-elevation myocardial infarction undergoing domestic Rapamycin drug-eluting stent implantation
  6240. The Role of Hypoxia on Pyruvate Kinase M2, mammalian Target of Rapamycin, Mitochondrial Function, and Cell Invasion in the Trophoblast
  6241. Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+ CD25+ Foxp3 regulatory T cells
  6242. Mammalian target of Rapamycin is required for axon growth of adult dorsal root ganglion neurons
  6243. Rrd1p, an RNA Polymerase II‐specific Prolyl Isomerase and Activator of Phosphoprotein Phosphatase, Promotes Transcription Independently of Rapamycin …
  6244. Rapamycin Protects Diabetic Heart Against Ischemia-reperfusion Injury by Inhibiting JNK and STAT4
  6245. Effects of Mammalian Target of Rapamycin inhibition on Circuitry Changes in the Dentate Gyrus of Mice after Focal Brain Injury
  6246. Rapamycin ameliorates ethambutol induced toxic optic neuropathy by facilitating mitophagy
  6247. Renal angiomyolipomas, Tuberous Sclerosis Complex and mammalian target of Rapamycin inhibitors
  6248. Insulin stimulates retinal ganglion cell dendrite regeneration through activation of the mammalian target of Rapamycin complex 1and complex 2
  6249. Reperfusion Therapy With Rapamycin Prevents Myocardial Ischemic Injury, Through Activation of AKT and ERK
  6250. Selective TSC1 deletion in smooth muscle results in mTOR signaling activation and development of pulmonary hypertension that can be reversed by Rapamycin
  6251. Alteration of mammalian target of Rapamycin signaling pathways in an In Vitro model of repetitive mild traumatic brain injury
  6252. DNA methyltransferase expression and proliferation status of metastatic breast cancer cell line after prolonged and repeated Rapamycin and melatonin application
  6253. Adopting the Rapamycin trapping assay to track the trafficking of murine MHC class I alleles, H-2K b
  6254. Positive expression of phosphorylated mammalian target of Rapamycin in gastric caner and its clinicopathological and prognostic significance: a meta analysis
  6255. Lipophilic bisphosphonates plus Rapamycin: a deadly combination for KRAS-mutated lung adenocarcinoma
  6256. Preparation of Rapamycin and methyl-β-cyclodextrin complexes using a single-step, organic solvent-free supercritical fluid process: An approach to enhance the …
  6257. Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down’s syndrome
  6258. Evaluation of Rapamycin for the Treatment of Autoimmune-Mediated Dry Eye in a Mouse Model of Sjögren’s Syndrome
  6259. The role of amino acid-induced mammalian target of Rapamycin complex 1 (mTORC1) signaling in insulin resistance
  6260. B62 THE BIOLOGY OF SCARRING. WHERE ARE WE NOW: Rapamycin Insensitive mTOR Signalling Promotes Tgf-[Beta] Induced Pro-Fibrotic Gene Expression In …
  6261. Diazoxide preconditioning is mediated by mechanistic target of Rapamycin (mTOR) and S6 Kinase (S6K)
  6262. Rapamycin Insensitive mTOR Signalling Promotes TGF-β Induced Pro-Fibrotic Gene Expression In Human Lung Fibroblasts
  6263. AME is a Mammalian Target of Rapamycin kinase inhibitor on EGF-induced neoplastic cell transformation
  6264. B52 NEONATAL LUNG DISEASE: FROM BENCH TO BABIES: Rapamycin Reverses Lymphatic Abnormalities In A Transgenic Mouse Model Of Pulmonary …
  6265. Comment on retinal ganglion cell electrical activity, mammalian target of Rapamycin signaling and optic nerve regeneration
  6266. Rapamycin directly inhibits T cell lymphoma proliferation at high doses and facilitates immune-independent toxin-mediated killing at a low dose in vivo.
  6267. In vivo Rapamycin-treated mouse allogeneic transplanted skin imaging with radiolabeled anti-Toll-like receptor 5 (TLR5) mAb
  6268. Role of Mammalian Target of Rapamycin (mTOR) Signalling in BeWo Trophoblast Differentiation and Fusion
  6269. AKT inhibition sensitizes tumor cells to Rapamycin by enhancing the repressive function of PRS40 on mTORC1/4E-BP1 axis
  6270. Expressions of the key proteins of the protein kinase B/mammalian target of Rapamycin signaling pathway in skin tissue and wound tissue of diabetic rats
  6271. Control of cell fate by the mammalian target of Rapamycin (mTOR) under stress depends on eIF2α serine 51 phosphorylation
  6272. Crucial Role of the Mammalian Target of Rapamycin (mTOR) in Activation of Human Microglia, Mast Cells and Keratinocytes, Inhibitable by Methoxyluteolin
  6273. Differentiation therapy of the neoplastic stromal cells in giant cell tumor of bone using the US Food and Drug Administration (FDA)-approved drugs, Rapamycin …
  6274. Effects of hydrogen-rich saline on hippocampal mammalian target of Rapamycin/tau pathway after operation in aged rats
  6275. A Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin, GSK2126458, Inhibits Laser-Induced Choroidal Neovascularization
  6276. Altered electrolyte homeostasis in mice with collecting‐duct‐principal‐cell select knockout of the mammalian‐target‐of‐Rapamycin (mTOR)
  6277. MP39-09 Rapamycin INHIBITS FLCN-DEFICIENT RENAL TUMOR GROWTH IN MICE
  6278. Haploidentical Peripheral Blood Stem Cell Transplantation after Treosulfan-Based Conditioning and Rapamycin GvHD Prophylaxis in Hodgkin Lymphoma
  6279. Rapamycin and retinoic acid downregulate the methylation of FoXP3 after restimulation in human treg derived from naive t cells
  6280. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of Rapamycin inhibitors in patients with malignancies: A meta …
  6281. The energy sensor AMP-activated protein kinase (AMPK) signals neuronal death in glaucoma through inhibition of the mammalian target of Rapamycin (mTOR).
  6282. Comparison of the effect of bone marrow cells infusion through the portal vein and inferior vena cava combined with short‐term Rapamycin on allogeneic islet grafts in …
  6283. Effect of Rapamycin as an Inhibitor of the mTOR Cell Cycle Entry Complex on the Selective Lysis of Human Leukemia Cells Lines in Vitro Using 20 kHz Pulsed Low …
  6284. Expression of phosphorylated mammalian target of Rapamycin (p-mTOR) and phosphorylated eukaryotic translation initiation factor 4E binding protein 1 in pathologic …
  6285. Knock-in of Dnmt3a R878H Recapitulates Human Acute Myeloid Leukemia Harboring DNMT3A Mutation and Is Highly Responsive to mTOR Inhibitor Rapamycin
  6286. Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of Rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.
  6287. TCT-456 Direct Implantation of Rapamycin-Eluting Stents with Bioresorbable Drug Carrier Technology Utilizing the Svelte Coronary Stent-on-a-Wire: 2-Year Follow …
  6288. Optimal dietary alphaâ linolenic acid/linoleic acid ratio improved digestive and absorptive capacities and target of Rapamycin gene expression of juvenile grass carp …
  6289. Rapamycin protects livers from ischemia and reperfusion Injury via both autophagy induction and mTORC2-Akt activation
  6290. Activation of mammalian target of Rapamycin complex 1 (mTORC1) and 2 (mTORC2) is required for retinal ganglion cell dendrite regeneration after axonal injury.
  6291. AB0061 mTOR inhibition by Rapamycin is Associated with Downregulation of Pro-Infammatory Cytokine TNFα, and Genes Involved in Bone Resoption (MMP-9 and …
  6292. … stretch promotes mesenchymal stem cell-osteoblast lineage migration through activation of mammalian target of Rapamycin/matrix metalloproteinases signaling …
  6293. … FOR PATIENTS WITH MULTIPLE VESSEL DISEASE AND UNPROTECTED LEFT MAIN WITH A COBALT-CHROMIUM Rapamycin ELUTING STENT: TWO YEARS …
  6294. … acid broadly suppresses cancer metabolism and synergistically induces strong anticancer activity in combination with Etoposide, Rapamycin and UCN-01
  6295. … Trial of Lymphocyte-Selective Pentostatin Plus Cyclophosphamide Conditioning, High Dose Sirolimus and Pre-Emptive DLI with Rapamycin-Resistant Donor CD4+ T …
  6296. Functional Proteomics Identifies Acinus L as a Direct Insulin-and Amino Acid-Dependent Mammalian Target of Rapamycin Complex 1 (mTORC1) Substrate* DS
  6297. Neuropeptides stimulate pro-inflammatory mediator secretion from human microglia through mammalian target of Rapamycin signaling, which is inhibited by the …
  6298. TCT-598 Revascularization strategies for patients with multiple vessel disease and unprotected left main with a cobalt-chromium Rapamycin eluting stent (ERACI IV …
  6299. REDOX SENSITIVE ACTIVATION OF MAMMALIAN TARGET OF Rapamycin SIGNALING COMPLEX-2 (mTORC2): ROLE OF SUPEROXIDE ANION IN ACTIVATION …
  6300. Lifespan extension in a semelparous chordate Oikopleura dioica via developmental growth arrest: Roles of Target of Rapamycin (TOR) signaling and D type cyclins
  6301. Rictor Oxidation and Disruption of the Mammalian Target of Rapamycin Complex 2 (mTORC2) Links Mitochondrial Oxidative Stress to Insulin Resistance in …
  6302. INSULINE LIKE GROWTH FACTOR-1 AND LEUCINE ACTIVATE PIG MYOGENIC SATELLITE CELLS THROUGH MAMMALIAN TARGET OF Rapamycin …
  6303. Phosphatidylinositol 3-kinase/protein kinase B/mammalian target of Rapamycin signaling pathway and epilepsy
  6304. … standard chemotherapy: Final results of a phase I study of infusional cyclophosphamide (cy), pulse dexamethasone (dex), Rapamycin (rapa) and hydroxychloroquine …
  6305. Combined Application of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Inhibitors Suppresses Cell Growth and Promotes Apoptosis in …
  6306. Clinical significance of the expression of eukaryotic initiation factor 4 E and mammalian target of Rapamycin in esophageal squamous carcinoma tissues
  6307. MP39-11 DECREASING SURVIVIN BY YM155 REVERSES Rapamycin RESISTANCE IN RENAL CANCER
  6308. Targeted inhibition of phosphoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) sensitizes pancreatic cancer cells to doxorubicin without …
  6309. ID: 21: ALTERNATIVE Rapamycin TREATMENT REGIMENS MITIGATE THE IMPACT OF Rapamycin ON GLUCOSE HOMEOSTASIS AND THE IMMUNE SYSTEM …
  6310. MP39-06 ENHANCED CELL PROLIFERATION AND INCREASED RESISTANCE TO MAMMALIAN TARGET OF Rapamycin INHIBITORS BY inhibition OF 4E …
  6311. MP65-08 A PHARMACODYNAMIC PHASE 0/I STUDY OF ORAL Rapamycin IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER
  6312. … of milk protein synthesis by energy and essential amino acids through adenosine 5′-monophosphate-activated protein kinase/mammalian target Rapamycin …
  6313. … on apoptosis of HL-60 leukemic cells via the regulation of the phosphatidylinositol 3-kinase/serine/threonine protein kinase/mammalian target of Rapamycin signaling …
  6314. inhibition of Galectin-1 sensitizes oncogenic H-Ras to Rapamycin treatment
  6315. FCT 1-1 Oral sirolimus (Rapamycin) on 22 patients with various types of vascular anomalies
  6316. 293. Optimal In Vivo Treg Induction and Suppression of Immune Responses By Synergistic Use of Rapamycin and FLT3 Ligand
  6317. Abstract LB-027: inhibition of mammalian target of Rapamycin by Torin2, an ATP-competitive inhibitor, induces growth inhibition in adult T cell leukemia
  6318. … of histidine on expressions of β-casein, and Janus kinases 2-signal transducer and activator of transcription 5/mammalian target Rapamycin signaling pathways related …
  6319. 5-Azacytidine and Rapamycin: different and synergistic effect on ex vivo expansion of natural human T Regulatory cells
  6320. Different and synergistic effect of 5-Azacytidine and Rapamycin on ex vivo expansion of natural human T Regulatory cells
  6321. FCT-05: Topical Rapamycin: The promising therapeutic agent for lymphangioma circumscriptum
  6322. Kinome Screen Reveals SGK1 as a Therapeutic Target for NF2: inhibition of mTORC1/2 is More Effective than Rapamycin
  6323. P075 Prospective pilot study on combined use of pulsed dye laser and 1% topical Rapamycin of cutaneous capillary malformation
  6324. Abstract# 1853 Behaviorally conditioning of anti-proliferative and immosuppressive effects with Rapamycin
  6325. Abstract P622: Regulation of Neuroprotective Myeloid Cell Leukemia 1 by Rapamycin and AT2R Agonists in Dopaminergic Neuronal Cell-line
  6326. Breast Cancer Development in Rats Under the Influence of Platelet Factor-4 (PF4) And/or Rapamycin
  6327. EPT-13 RAPIRI I–PHASE I STUDY OF DAILY ORAL Rapamycin AND INTRAVENOUS IRINOTECAN IN CHILDREN WITH A RECURRENT/REFRACTORY …
  6328. An overview of Rapamycin: from discovery to future perspectives
  6329. A randomized controlled trial to establish effects of short-term Rapamycin treatment in 24 middle-aged companion dogs
  6330. Towards natural mimetics of metformin and Rapamycin
  6331. The role of mammalian target of Rapamycin (mTOR) in insulin signaling
  6332. Rapamycin in mice
  6333. Cryo-EM structure of Saccharomyces cerevisiae target of Rapamycin complex 2
  6334. The complex roles of mechanistic target of Rapamycin in adipocytes and beyond
  6335. Game of TOR—the target of Rapamycin rules four kingdoms
  6336. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2‐independent mechanism
  6337. Rapamycin treatment attenuates age-associated periodontitis in mice
  6338. A functional mammalian target of Rapamycin complex 1 signaling is indispensable for c‐Myc‐driven hepatocarcinogenesis
  6339. Combination of Rapamycin and resveratrol for treatment of bladder cancer
  6340. Mammalian target of Rapamycin (mTOR) as a potential therapeutic target in various diseases
  6341. inhibition of mammalian target of Rapamycin signaling with Rapamycin prevents trauma-induced heterotopic ossification
  6342. Short‐term Rapamycin treatment increases ovarian lifespan in young and middle‐aged female mice
  6343. Low-dose Rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome
  6344. Reperfusion therapy with Rapamycin attenuates myocardial infarction through activation of AKT and ERK
  6345. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and Rapamycin for breast cancer therapy
  6346. Target of Rapamycin (TOR) regulates growth in response to nutritional signals
  6347. Epigenetic aging signatures in mice livers are slowed by dwarfism, calorie restriction and Rapamycin treatment
  6348. Rapamycin suppresses microglial activation and reduces the development of neuropathic pain after spinal cord injury
  6349. Emerging role for mammalian target of Rapamycin in male fertility
  6350. Anti‐aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and Rapamycin by local application
  6351. Rapamycin is highly effective in murine models of immune-mediated bone marrow failure
  6352. Rapamycin reversal of VEGF-C–driven lymphatic anomalies in the respiratory tract
  6353. Rapamycin and the inhibition of the secretory phenotype
  6354. Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity
  6355. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease
  6356. Mechanistic target of Rapamycin is necessary for changes in dendritic spine morphology associated with long-term potentiation
  6357. The crosstalk between Target of Rapamycin (TOR) and Jasmonic Acid (JA) signaling existing in Arabidopsis and cotton
  6358. Dietary Rapamycin supplementation reverses age‐related vascular dysfunction and oxidative stress, while modulating nutrient‐sensing, cell cycle, and senescence …
  6359. Resistance exercise initiates mechanistic target of Rapamycin (mTOR) translocation and protein complex co-localisation in human skeletal muscle
  6360. Ectopic expression of Arabidopsis Target of Rapamycin (AtTOR) improves water-use efficiency and yield potential in rice
  6361. Microcystic lymphatic malformation successfully treated with topical Rapamycin
  6362. Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson’s disease
  6363. Rapamycin effectively impedes melamine-induced impairments of cognition and synaptic plasticity in Wistar rats
  6364. Rapamycin protects sepsis-induced cognitive impairment in mouse hippocampus by enhancing autophagy
  6365. Rapamycin inhibits spermatogenesis by changing the autophagy status through suppressing mechanistic target of Rapamycin-p70S6 kinase in male rats
  6366. Rapamycin eye drops suppress lacrimal gland inflammation in a murine model of Sjögren’s syndrome
  6367. Mammalian target of Rapamycin complex 2 regulates muscle glucose uptake during exercise in mice
  6368. Evolution of disease activity and biomarkers on and off Rapamycin in 28 patients with autoimmune lymphoproliferative syndrome
  6369. Rapamycin prevents cyclophosphamide-induced over-activation of primordial follicle pool through PI3K/Akt/mTOR signaling pathway in vivo
  6370. Mammalian target of Rapamycin (mTOR) as a potential therapeutic target in pathological ocular angiogenesis
  6371. Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NFκB pathways in autophagy-and p62-dependent manners
  6372. GTP ase ROP 2 binds and promotes activation of target of Rapamycin, TOR, in response to auxin
  6373. Infantile Lhermitte-Duclos disease treated successfully with Rapamycin
  6374. Rapamycin suppresses Aβ25–35-or LPS-induced neuronal inflammation via modulation of NF-κB signaling
  6375. Post onset, oral Rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses
  6376. Mammalian target of Rapamycin (mTOR): a central regulator of male fertility?
  6377. The triangle of death in Alzheimer’s disease brain: the aberrant cross-talk among energy metabolism, mammalian target of Rapamycin signaling, and protein …
  6378. Differential regulation of cardiac function and intracardiac cytokines by Rapamycin in healthy and diabetic rats
  6379. Rapamycin ameliorates experimental autoimmune encephalomyelitis by suppressing the mTOR-STAT3 pathway
  6380. Brassinosteriod Insensitive 2 (BIN2) acts as a downstream effector of the Target of Rapamycin (TOR) signaling pathway to regulate photoautotrophic growth in …
  6381. Rapamycin prolongs the survival of corneal epithelial cells in culture
  6382. Blocking mTOR signalling with Rapamycin ameliorates imiquimod-induced psoriasis in mice
  6383. Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model
  6384. Efficacy of topical sirolimus (Rapamycin) for the treatment of microcystic lymphatic malformations
  6385. Rapamycin inhibits oxidative/nitrosative stress and enhances angiogenesis in high glucose-treated human umbilical vein endothelial cells: role of autophagy
  6386. Progressive slowdown/prevention of cellular senescence by CD9-targeted delivery of Rapamycin using lactose-wrapped calcium carbonate nanoparticles
  6387. Rapamycin treatment dose‐dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell‐cycle‐associated CDK1/cyclin axis
  6388. Fluoride-induced autophagy via the regulation of phosphorylation of mammalian targets of Rapamycin in mice leydig cells
  6389. Modulation of nonsense mediated decay by Rapamycin
  6390. Targeted co-delivery of polypyrrole and Rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy
  6391. mTORC1 inhibition with Rapamycin exacerbates adipose tissue inflammation in obese mice and dissociates macrophage phenotype from function
  6392. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of Rapamycin by inhibiting Rapamycin-induced feedback activation of Akt signaling in …
  6393. Mechanistic target of Rapamycin is a novel molecular mechanism linking folate availability and cell function
  6394. Rapamycin confers neuroprotection against colistin-induced oxidative stress, mitochondria dysfunction, and apoptosis through the activation of autophagy and mTOR …
  6395. Neuroprotection through Rapamycin-induced activation of autophagy and PI3K/Akt1/mTOR/CREB signaling against amyloid-β-induced oxidative stress, synaptic …
  6396. Rapamycin protects against paraquat-induced pulmonary fibrosis: Activation of Nrf2 signaling pathway
  6397. Cell-autonomous requirement for mammalian target of Rapamycin (mTOR) in spermatogonial proliferation and differentiation in the mouse
  6398. Mammalian target of Rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease
  6399. inhibition of mammalian target of Rapamycin (mTOR) signaling in the insular cortex alleviates neuropathic pain after peripheral nerve injury
  6400. Antifibrotic effect of Rapamycin containing polyethylene glycol‐coated alginate microcapsule in islet xenotransplantation
  6401. Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells
  6402. Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension
  6403. The post‐therapeutic effect of Rapamycin in mild traumatic brain‐injured rats ensuing in the upregulation of autophagy and mitophagy
  6404. Mammalian target of Rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death
  6405. In vitro and in vivo degradation of Rapamycin-eluting Mg-Nd-Zn-Zr alloy stents in porcine coronary arteries
  6406. Rapamycin maintains the chondrocytic phenotype and interferes with inflammatory cytokine induced processes
  6407. Bifunctional elastin-like polypeptide nanoparticles bind Rapamycin and integrins and suppress tumor growth in Vivo
  6408. Role for target of Rapamycin (mTOR) signal pathway in regulating neuronal injury after intracerebral hemorrhage
  6409. Inactivation of regulatory-associated protein of mTOR (Raptor)/mammalian target of Rapamycin complex 1 (mTORC1) signaling in osteoclasts increases bone …
  6410. m TOR inhibition by Rapamycin protects against deltamethrin‐induced apoptosis in PC 12 Cells
  6411. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated …
  6412. Rapamycin augments immunomodulatory properties of bone marrow-derived mesenchymal stem cells in experimental autoimmune encephalomyelitis
  6413. Effects of ketamine administration on mTOR and reticulum stress signaling pathways in the brain after the infusion of Rapamycin into prefrontal cortex
  6414. Placentome nutrient transporters and mammalian target of Rapamycin signaling proteins are altered by the methionine supply during late gestation in dairy cows and …
  6415. The molecular mechanism of glucagon-like peptide-1 therapy in Alzheimer’s disease, based on a mechanistic target of Rapamycin pathway
  6416. Synergistic effect of Rapamycin and metformin against age-dependent oxidative stress in rat erythrocytes
  6417. Thioredoxin-1 maintains mechanistic target of Rapamycin (mTOR) function during oxidative stress in cardiomyocytes
  6418. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
  6419. Rapamycin facilitates fracture healing through inducing cell autophagy and suppressing cell apoptosis in bone tissues
  6420. Single and combined effect of retinoic acid and Rapamycin modulate the generation, activity and homing potential of induced human regulatory T cells
  6421. Hyaluronic acid nanohydrogel loaded with quercetin alone or in combination to a macrolide derivative of Rapamycin RAD001 (Everolimus) as a new treatment for …
  6422. Combination of Rapamycin and garlic-derived S-allylmercaptocysteine induces colon cancer cell apoptosis and suppresses tumor growth in xenograft nude …
  6423. Rapamycin attenuates acute seizure-induced astrocyte injury in mice in vivo
  6424. Rapamycin-induced autophagy restricts porcine epidemic diarrhea virus infectivity in porcine intestinal epithelial cells
  6425. inhibition of Cyclosporine A or Rapamycin on T lymphocyte counts and the influence on the immune responses of B lymphocytes in flounder (Paralichthys olivaceus)
  6426. … acid transporter SLC 36A4 regulates the amino acid pool in retinal pigmented epithelial cells and mediates the mechanistic target of Rapamycin, complex 1 signaling
  6427. Pre-S2 mutant-induced mammalian target of Rapamycin signal pathways as potential therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma
  6428. Increased expression of (immuno) proteasome subunits during epileptogenesis is attenuated by inhibition of the mammalian target of Rapamycin pathway
  6429. Rapamycin modulated brain-derived neurotrophic factor and B-cell lymphoma 2 to mitigate autism spectrum disorder in rats
  6430. inhibition of mammalian target of Rapamycin complex 1 attenuates salt-induced hypertension and kidney injury in dahl salt-sensitive rats
  6431. Everolimus is better than Rapamycin in attenuating neuroinflammation in kainic acid-induced seizures
  6432. Cryptotanshinone inhibition of mammalian target of Rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer
  6433. Adrenoceptors promote glucose uptake into adipocytes and muscle by an insulin-independent signaling pathway involving mechanistic target of Rapamycin complex 2
  6434. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and Rapamycin
  6435. Berunda polypeptides: multi-headed fusion proteins promote subcutaneous administration of Rapamycin to breast cancer in vivo
  6436. Two mTOR inhibitors, Rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS
  6437. Combined targeting of mTOR and Akt using Rapamycin and MK-2206 in the treatment of tuberous sclerosis complex
  6438. Rapamycin and CHIR 99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
  6439. Choline kinase α mediates interactions between the epidermal growth factor receptor and mechanistic target of Rapamycin complex 2 in hepatocellular carcinoma cells …
  6440. Usnic acid benzylidene analogues as potent mechanistic target of Rapamycin inhibitors for the control of breast malignancies
  6441. PEGylated lipid bilayer-wrapped nano-graphene oxides for synergistic co-delivery of doxorubicin and Rapamycin to prevent drug resistance in cancers
  6442. A brain proteomic investigation of Rapamycin effects in the Tsc1+/− mouse model
  6443. Rapamycin promotes the survival and adipogenesis of ischemia-challenged adipose derived stem cells by improving autophagy
  6444. Rapamycin inhibits mTOR/p70S6K activation in CA3 region of the hippocampus of the rat and impairs long term memory
  6445. Chronic treatment with novel nanoformulated micelles of Rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury
  6446. … seizures and associated neurological conditions in lithium-pilocarpine rat model of temporal lobe epilepsy through inhibition of mammalian target of Rapamycin …
  6447. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of Rapamycin pathway dephosphorylation
  6448. … carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of Rapamycin …
  6449. Optimal ratios of essential amino acids stimulate β-casein synthesis via activation of the mammalian target of Rapamycin signaling pathway in MAC-T cells and …
  6450. mTOR (mechanistic target of Rapamycin) inhibition decreases mechanosignaling, collagen accumulation, and stiffening of the thoracic aorta in elastin-deficient mice
  6451. Brain injury-induced synaptic reorganization in hilar inhibitory neurons is differentially suppressed by Rapamycin
  6452. Rapamycin-loaded immunoliposomes functionalized with Trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells
  6453. Loss of cardiac carnitine palmitoyltransferase 2 results in Rapamycin-resistant, acetylation-independent hypertrophy
  6454. inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of Rapamycin kinase inhibitors in aggressive B-cell lymphomas
  6455. Prognostic significance and function of mammalian target of Rapamycin in tongue squamous cell carcinoma
  6456. Rictor/mammalian target of Rapamycin complex 2 promotes macrophage activation and kidney fibrosis
  6457. A pilot study on using Rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in …
  6458. Kinetic modeling and analysis of the akt/mechanistic target of Rapamycin complex 1 (mTORC1) signaling axis reveals cooperative, feedforward regulation
  6459. Neuroprotective effects of intrastriatal injection of Rapamycin in a mouse model of excitotoxicity induced by quinolinic acid
  6460. inhibition of p70S6K does not mimic the enhancement of Akt phosphorylation by Rapamycin
  6461. Modulation of the immune response in rheumatoid arthritis with strategically released Rapamycin
  6462. Target of Rapamycin signaling mediates vacuolar fragmentation
  6463. Chronic exposure to Rapamycin and episodic serum starvation modulate ageing of human fibroblasts in vitro
  6464. Topical Rapamycin for facial angiofibromas in a child with tuberous sclerosis complex (TSC): a case report and long-term follow-up
  6465. Mammalian target of Rapamycin (mTOR) regulates transforming growth factor-β1 (TGF-β1)-induced epithelial-mesenchymal transition via decreased pyruvate …
  6466. Rapamycin decreased blood-brain barrier permeability in control but not in diabetic rats in early cerebral ischemia
  6467. Enhancement of Rapamycin production by metabolic engineering in Streptomyces hygroscopicus based on genome-scale metabolic model
  6468. Celastrol prevents cadmium‐induced neuronal cell death by blocking reactive oxygen species‐mediated mammalian target of Rapamycin pathway
  6469. Identification of mechanically regulated phosphorylation sites on tuberin (TSC2) that control mechanistic target of Rapamycin (mTOR) signaling
  6470. … , dedifferentiation, and Rapamycin resistance of vascular smooth muscle cells by inhibiting insulin-like growth factor-1 receptor and mammalian target of Rapamycin
  6471. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature–Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide
  6472. Rapamycin inhibits the proliferation of endothelial cells in hemangioma by blocking the mTOR-FABP4 pathway
  6473. The downregulation of ATG4B mediated by microRNA-34a/34c-5p suppresses Rapamycin-induced autophagy
  6474. The effect of Rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS)
  6475. Treatment of port wine stains using pulsed dye laser, erbium YAG laser, and topical Rapamycin (sirolimus)—A randomized controlled trial
  6476. Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis
  6477. Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of Rapamycin inhibitor
  6478. Rapamycin promotes differentiation increasing βIII-tubulin, NeuN, and NeuroD while suppressing nestin expression in glioblastoma cells
  6479. Tanshinone IIA affects autophagy and apoptosis of glioma cells by inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling pathway
  6480. Antidepressant actions of ketamine mediated by the mechanistic target of Rapamycin, nitric oxide, and Rheb
  6481. Mesangial cell mammalian target of Rapamycin complex 1 activation results in mesangial expansion
  6482. Preservation of anticancer and immunosuppressive properties of Rapamycin achieved through controlled releasing particles
  6483. Improved antitumor effect of ionizing radiation in combination with Rapamycin for treating nasopharyngeal carcinoma
  6484. Combination of IL-2, Rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells
  6485. A mechanistic target of Rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin …
  6486. … eukaryotic initiation factor 3C (EIF3C) suppresses proliferation and stimulates apoptosis in breast cancer cell lines through mammalian target of Rapamycin …
  6487. The mammalian target of Rapamycin and DNA methyltransferase 1 axis mediates vascular endothelial dysfunction in response to disturbed flow
  6488. Approaches towards the enhanced production of Rapamycin by Streptomyces hygroscopicus MTCC 4003 through mutagenesis and optimization of process …
  6489. Triggering of eryptosis, the suicidal erythrocyte death by mammalian target of Rapamycin (mTOR) inhibitor temsirolimus
  6490. CD9 monoclonal antibody-conjugated PEGylated liposomes for targeted delivery of Rapamycin in the treatment of cellular senescence
  6491. Rapamycin promotes osteogenesis under inflammatory conditions
  6492. Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of Rapamycin inhibitor restrains hepatocellular carcinoma growth …
  6493. Suppression of Th17-polarized airway inflammation by Rapamycin
  6494. Impact on autophagy and ultraviolet B induced responses of treatment with the mTOR inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in human …
  6495. Overgrowth syndromes caused by somatic variants in the phosphatidylinositol 3-kinase/AKT/mammalian target of Rapamycin pathway
  6496. Ketamine exhibits different neuroanatomical profile after mammalian target of Rapamycin inhibition in the prefrontal cortex: the role of inflammation and oxidative stress
  6497. Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem‐cell like features by activating the mammalian target of Rapamycin pathway in oral …
  6498. Rapamycin/sodium hyaluronate binding on nano-hydroxyapatite coated titanium surface improves MC3T3-E1 osteogenesis
  6499. Biphasic Rapamycin effects in lymphoma and carcinoma treatment
  6500. CENPH inhibits Rapamycin sensitivity by regulating GOLPH3-dependent mTOR signaling pathway in colorectal cancer
  6501. Reciprocal regulation of target of Rapamycin complex 1 and potassium accumulation
  6502. Rapamycin-loaded nanoporous α-Fe 2 O 3 as an endothelial favorable and thromboresistant coating for biodegradable drug-eluting Fe stent applications
  6503. Programmed Death-1 inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4+ T Cell Proliferation
  6504. Rapamycin enhances repressed autophagy and attenuates aggressive progression in a rat model of IgA nephropathy
  6505. Intrauterine growth retardation promotes fetal intestinal autophagy in rats via the mechanistic target of Rapamycin pathway
  6506. Construction of a Rapamycin-susceptible strain of the unicellular red alga Cyanidioschyzon merolae for analysis of the target of Rapamycin (TOR) function
  6507. While reinforcing cell cycle arrest, Rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts
  6508. Expression of (pro) renin receptor during Rapamycin-induced erythropoiesis in K562 erythroleukemia cells and its possible dual actions on erythropoiesis
  6509. Isoimperatorin ameliorates osteoarthritis by downregulating the mammalian target of Rapamycin C1 signaling pathway
  6510. Folic acid orchestrates root development linking cell elongation with auxin response and acts independently of the TARGET OF Rapamycin signaling in Arabidopsis …
  6511. inhibition of mTOR pathway by Rapamycin decreases P-glycoprotein expression and spontaneous seizures in pharmacoresistant epilepsy
  6512. Mammalian target of Rapamycin signaling is a mechanistic link between increased endoplasmic reticulum stress and autophagy in the placentas of pregnancies …
  6513. Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of Rapamycin complex 1 (mTORC1) inhibitors
  6514. General control nonderepressible 2 (GCN2) kinase inhibits target of Rapamycin complex 1 in response to amino acid starvation in Saccharomyces cerevisiae
  6515. Renal function in heart transplant patients after switch to combined mammalian target of Rapamycin inhibitor and calcineurin inhibitor therapy
  6516. Delayed and short course of Rapamycin prevents organ rejection after allogeneic liver transplantation in rats
  6517. Rapamycin and bafilomycin A1 alter autophagy and megakaryopoiesis
  6518. … protein 1 activity by way of the calcium/calmodulin‐dependent kinase kinase–AMP‐activated protein kinase–mechanistic target of Rapamycin–p70 ribosomal S6 …
  6519. Covalent modification of pericardial patches for sustained Rapamycin delivery inhibits venous neointimal hyperplasia
  6520. Dynamin-dependent amino acid endocytosis activates mechanistic target of Rapamycin complex 1 (mTORC1)
  6521. Naringin in Ganshuang Granule suppresses activation of hepatic stellate cells for anti‐fibrosis effect by inhibition of mammalian target of Rapamycin
  6522. Rapamycin protects testes against germ cell apoptosis and oxidative stress induced by testicular ischemia-reperfusion
  6523. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of Rapamycin
  6524. Combination of histidine, lysine, methionine, and leucine promotes β-casein synthesis via the mechanistic target of Rapamycin signaling pathway in bovine …
  6525. Temporal changes in mammalian target of Rapamycin (mTOR) and phosphorylated-mTOR expressions in the hippocampal CA1 region of rat with vascular …
  6526. Rapamycin treatment for benign multicystic peritoneal mesothelioma: a rare disease with a difficult management
  6527. Rapamycin preferentially inhibits human IL-5+ TH2-cell proliferation via an mTORC1/S6 kinase-1–dependent pathway
  6528. Effect of Rapamycin treatment during post‐activation and/or in vitro culture on embryonic development after parthenogenesis and in vitro fertilization in pigs
  6529. Glucose adsorption to chitosan membranes increases proliferation of human chondrocyte via mammalian target of Rapamycin complex 1 and sterol regulatory element …
  6530. Use of Rapamycin in a patient with juvenile myelomonocytic leukemia: a case report
  6531. Role of mammalian target of Rapamycin signaling in autophagy and the neurodegenerative process using a senescence accelerated mouse‑prone 8 model
  6532. Effects of cyclosporine, tacrolimus, and Rapamycin on osteoblasts
  6533. Neonatal mouse hippocampus: phlebotomy-induced anemia diminishes and treatment with erythropoietin partially rescues mammalian target of Rapamycin …
  6534. Activation of the unfolded protein response in sarcoma cells treated with Rapamycin or temsirolimus
  6535. Prenatal mechanistic target of Rapamycin complex 1 (m TORC1) inhibition by Rapamycin treatment of pregnant mice causes intrauterine growth restriction and alters …
  6536. Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with Rapamycin and dimethylsulfoxide
  6537. Therapeutic effects of Rapamycin on alcoholic cardiomyopathy
  6538. Lycorine induces apoptosis of A549 cells via AMPK-mammalian target of Rapamycin (mTOR)-S6K signaling pathway
  6539. … cells from reactive oxygen species through changes in autophagy and activation of phosphatidylinositol 3-kinase, protein kinas B, and mechanistic target of Rapamycin …
  6540. … through CC Motif Chemokine Receptor 2–Dependent Phosphatidylinositol 3-Kinase-AKT–Mechanistic Target of Rapamycin Signaling and Hypoxia-Inducible …
  6541. Autophagy activation by Rapamycin before hypoxia-reoxygenation reduces endoplasmic reticulum stress in alveolar epithelial cells
  6542. Determination of mammalian target of Rapamycin hyperactivation as prognostic factor in well-differentiated neuroendocrine tumors
  6543. Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis
  6544. Rapamycin efficiently promotes cardiac differentiation of mouse embryonic stem cells
  6545. mTORC1 inhibitors Rapamycin and metformin affect cardiovascular markers differentially in ZDF rats
  6546. Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery–jugular vein …
  6547. Rapamycin induces autophagy and reduces the apoptosis of podocytes under a stimulated condition of immunoglobulin a nephropathy
  6548. inhibition of hemangioma growth using polymer–lipid hybrid nanoparticles for delivery of Rapamycin
  6549. Phosphorylated Mechanistic target of Rapamycin (p-mTOR) and Noncoding RNA expression in follicular and Hürthle cell thyroid neoplasm
  6550. Rapamycin suppresses hypoxia/reoxygenation‐induced islet injury by up‐regulation of miR‐21 via PI3K/Akt signalling pathway
  6551. Evaluating the effectiveness of GTM-1, Rapamycin, and carbamazepine on autophagy and Alzheimer disease
  6552. Probing the phosphatidylinositol 3‐kinase/mammalian target of Rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low‐grade gliomas
  6553. IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of Rapamycin pathways
  6554. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
  6555. Mammalian target of Rapamycin signaling and ubiquitin proteasome–related gene expression in 3 different skeletal muscles of colostrum-versus formula-fed …
  6556. … mediates the effect of micro RNA‐26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B/mammalian target of Rapamycin …
  6557. Short-course Rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term …
  6558. Meta-analysis of 29 experiments evaluating the effects of Rapamycin on life span in the laboratory mouse
  6559. Hyperactivation of mammalian target of Rapamycin complex 1 by HIV‐1 is necessary for virion production and latent viral reactivation
  6560. Migratory properties of ex vivo expanded regulatory T cells: influence of all-trans retinoic acid and Rapamycin
  6561. Differential role of Rapamycin in epidermis-induced IL-15-IGF-1 secretion via activation of Akt/mTORC2
  6562. Target of Rapamycin complex 1 and Tap42‐associated phosphatases are required for sensing changes in nitrogen conditions in the yeast Saccharomyces cerevisiae
  6563. Co‐Delivery of Disease Associated Peptide and Rapamycin via Acetalated Dextran Microparticles for Treatment of Multiple Sclerosis
  6564. A single Rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite …
  6565. Attenuation of pentylenetrazole-induced acute status epilepticus in rats by adenosine involves inhibition of the mammalian target of Rapamycin pathway
  6566. A new treatment for vascular anomalies: Six cases treated with Rapamycin
  6567. Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of Rapamycin inhibitors in kidney transplant
  6568. Association between high expression of phosphorylated Akt and mammalian target of Rapamycin and improved survival in salivary gland adenoid cystic carcinoma
  6569. Mycophenolate mofetil and Rapamycin induce apoptosis in the human monocytic U937 cell line through two different pathways
  6570. Rapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 in oral squamous cell carcinoma
  6571. 2,5-Dimethyl-Celecoxib Extends Drosophila Life Span via a Mechanism That Requires Insulin and Target of Rapamycin Signaling
  6572. Rapamycin targets several pathophysiological features of immune-mediated bone marrow failure in murine models
  6573. Rapid Rapamycin-only induced osteogenic differentiation of blood-derived stem cells and their adhesion to natural and artificial scaffolds
  6574. Biodegradable cable-tie Rapamycin-eluting stents
  6575. Use of sirolimus (Rapamycin) for treatment of cytopenias and lymphoproliferation linked to autoimmune lymphoproliferative syndrome (ALPS). Two case reports
  6576. Triolimus: A multi‐drug loaded polymeric micelle containing paclitaxel, 17‐AAG, and Rapamycin as a novel radiosensitizer
  6577. Immunosuppression With CD 40 Costimulatory Blockade Plus Rapamycin for Simultaneous Islet–Kidney Transplantation in Nonhuman Primates
  6578. Role of triggering receptor expressed on myeloid cell-1 expression in mammalian target of Rapamycin modulation of CD8+ T-cell differentiation during the …
  6579. Expression of miRNA-155 in carotid atherosclerotic plaques of apolipoprotein E knockout (ApoE−/−) mice and the interventional effect of Rapamycin
  6580. Beneficial effects of Rapamycin in a Drosophila model for hereditary spastic paraplegia
  6581. Mammalian target of Rapamycin complex 1 signalling is essential for germinal centre reaction
  6582. MicroRNA-185-5p restores glucocorticoid sensitivity by suppressing the mammalian target of Rapamycin complex (mTORC) signaling pathway to enhance …
  6583. Rapamycin inhibits expansion of cord blood derived NK and T cell
  6584. Rapamycin induces human acute promyelocytic leukemia cell HL-60 autophagic apoptosis
  6585. Mammalian target of Rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by …
  6586. Rapamycin inhibits CaCl2-induced thoracic aortic aneurysm formation in rats through mTOR-mediated suppression of proinflammatory mediators
  6587. Rapamycin-ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high-fat diet
  6588. Rapamycin-sensitive late-LTP is enhanced in the hippocampus of IL-6 transgenic mice
  6589. Effects of the mammalian target of Rapamycin inhibitor everolimus on hepatitis C virus replication in vitro and in vivo
  6590. Conversion to mammalian target of Rapamycin inhibitors in kidney transplant recipients with de novo cancers
  6591. The antimalarial action of FK506 and Rapamycin: evidence for a direct effect on FK506-binding protein PfFKBP35
  6592. Down regulation of Peroxiredoxin-3 in 3T3-L1 adipocytes leads to oxidation of Rictor in the mammalian-target of Rapamycin complex 2 (mTORC2)
  6593. Rapamycin keeps the reproductive clock ticking
  6594. Prospective pilot study on combined use of pulsed dye laser and 1% topical Rapamycin for treatment of nonfacial cutaneous capillary malformation
  6595. Whey protein concentrate renders MDA-MB-231 cells sensitive to Rapamycin by altering cellular redox state and activating GSK3β/mTOR signaling
  6596. Insights into the metabolic mechanism of Rapamycin overproduction in the shikimate-resistant Streptomyces hygroscopicus strain UV-II using comparative …
  6597. Mammalian target of Rapamycin (mTOR)/nitric oxide system possibly modulate antidepressant-like effect of 17α-ethinyl estradiol in ovariectomized mice
  6598. Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the Rapamycin pathway in spheroid cancer stem …
  6599. An insight of Rapamycin against cadmium’s neurotoxicity
  6600. Mechanistic target of Rapamycin (mTOR): A mediator of social development
  6601. Prognostic Significance of periostin and mammalian target of Rapamycin (mTOR) in locally advanced esophageal squamous cell carcinoma
  6602. Rapamycin additively extends lifespan in short-and long-lived lines of the nematode Caenorhabditis remanei
  6603. Chronic Rapamycin treatment improved metabolic phenotype but inhibited adipose tissue browning in high-fat diet-fed C57BL/6J mice
  6604. Effects of mTOR Inhibitor Rapamycin on Burkitt’s Lymphoma Cells
  6605. Metabolic impact of Rapamycin (sirolimus) and B-estradiol using mouse embryonic fibroblasts as a model for lymphangioleiomyomatosis
  6606. Effects of Rapamycin on life span and on expression of TOR and S6K in Brachionus calyciflorus (Rotifera)
  6607. Mammalian target of Rapamycin complex 1 and FoxO1 in the transcriptional control of lipolysis and de novo lipogenesis
  6608. Nudix-type motif 2 contributes to cancer proliferation through the regulation of Rag GTPase-mediated mammalian target of Rapamycin complex 1 localization
  6609. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
  6610. PPAR gamma coactivator 1 beta (PGC-1β) reduces mammalian target of Rapamycin (mTOR) expression via a SIRT1-dependent mechanism in neurons
  6611. Effects of Rapamycin on clinical manifestations and blood lipid parameters in different preeclampsia-like mouse models
  6612. IL-21 augments Rapamycin in expansion of alpha fetoprotein antigen specific stem-cell-like memory t cells in vitro
  6613. The relationship between preptin, Forkhead box protein O1 and mechanistic target of Rapamycin levels in prediabetic patients.
  6614. Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/− Mice
  6615. Comparison of tyrosine kinase inhibitor versus mammalian target of Rapamycin inhibitor as second-line molecular-targeted therapy for patients with poor-risk …
  6616. Mammalian target of Rapamycin/eukaryotic initiation factor 4F pathway regulates follicle growth and development of theca cells in mice
  6617. Invariant natural killer T cells treated with Rapamycin or transforming growth factor-β acquire a regulatory function and suppress T effector lymphocytes
  6618. Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of Rapamycin
  6619. Topical Rapamycin for facial angiofibromas in tuberous sclerosis complex
  6620. Moderate mammalian target of Rapamycin inhibition induces autophagy in HTR8/SVneo cells via O‐linked β‐N‐acetylglucosamine signaling
  6621. Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: Response to mammalian target of Rapamycin inhibitor therapy
  6622. The influence of Rapamycin on the early cardioprotective effect of hypoxic preconditioning on cardiomyocytes
  6623. THU0245 Mammalian target of Rapamycin pathway might contribute the minor salivary gland changes in both sjogren’s syndrome and systemic sclerosis patients
  6624. Targeted dendritic cell therapy utilising antibody-displaying porous silicon nanoparticles loaded with Rapamycin
  6625. THU0176 Efficiency and safety of Rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis
  6626. Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002
  6627. Nutrient medium optimization for Streptomyces hygroscopicus, a producer of Rapamycin pharmaceutical substance
  6628. Autophagy plays an important role in Rapamycin-mediated primary cultured neonatal rat cardiac myocytes death
  6629. Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
  6630. Extraction of Rapamycin (sirolimus) from Streptomyces Rapamycinicus using ultrasound
  6631. Effects of small rna interference targeting mammalian target of Rapamycin on paraquat-induced pulmonary fibrosis in rats
  6632. Rapamycin enhances the antiproliferative effect of transforming growth factor‑β on MCF‑7 human breast cancer cells
  6633. … domain 2-mediated signaling pathway in human dendritic cells in an X-linked inhibitor of apoptosis protein and mammalian target of Rapamycin-dependent …
  6634. Extending Lifespan by Inhibiting the Mechanistic Target of Rapamycin (mTOR)
  6635. Expression profile of mammalian target of Rapamycin‐related proteins in graft biopsy specimens: Significance for predicting interstitial fibrosis after kidney …
  6636. Surendra Nath Sehgal: A pioneer in Rapamycin discovery
  6637. Rapamycin attenuates atrial fibrosis in 5/6 nephrectomized rats by inhibiting mammalian target of Rapamycin and profibrotic signaling
  6638. Nitrogen starvation and Rapamycin both induce autophagic degradation of proteasome complexes
  6639. BRAF gene alterations and enhanced mammalian target of Rapamycin signaling in gangliogliomas
  6640. Monitoring Rapamycin treatment response in lymphangioleiomyomatosis with [18F] fluoroethylcholine PET
  6641. Corrigendum: Ectopic expression of Arabidopsis Target of Rapamycin (AtTOR) improves water-use efficiency and yield potential in rice
  6642. Historical story on natural medicinal chemistry: Rapamycin
  6643. Effect of immobilisation on production of Rapamycin by Streptomyces hygroscopicus
  6644. Themes: Title: Investigating Protein Binding Intractions of Rapamycin: pH variations
  6645. Effect of Rapamycin on early stage apoptosis of neutrophils in Sprague‑Dawley rats with acute lung injury
  6646. Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic …
  6647. Profile of Michael N. Hall, 2017 Albert Lasker Basic Medical Research Awardee: Target of Rapamycin, cell growth, and translational control
  6648. Lipid Sensing by Mammalian Target of Rapamycin
  6649. The Pharmacodynamic Functions of Low-Dose Rapamycin as a Model for Universal Influenza Protection
  6650. PERAN MAMMALIAN TARGET OF Rapamycin DALAM EPILEPSI
  6651. The efficacy of Rapamycin against the neuropathic pain for Fabry disease
  6652. Preoperative application of combination of portal venous injection of donor spleen cells and intraperitoneal injection of Rapamycin prolongs the survival of …
  6653. Anti-angiogenic effect of Rapamycin in mouse oxygen-induced retinopathy is mediated through suppression of HIF-1alpha/VEGF pathway
  6654. Effects of Rapamycin on blood lipid metabolism in renal transplant recipients
  6655. Short-term use of Rapamycin combined with Tregs prolongs mouse cardiac graft survival but attenuates recipient’s anti-tumor immunity
  6656. Allogeneic Hair Transplantation with Enhanced Survival by Anti-ICAM-1 Antibody with Short-Term Rapamycin Treatment in Nonhuman Primates
  6657. Important role for the mammalian‐target‐of‐Rapamycin (mTOR) in the collecting duct as a determinant of transporter/channel profile and function
  6658. Insulinoma and Tuberous Sclerosis: A possible mechanistic target of Rapamycin (mTOR) pathway abnormality?
  6659. Diagnostic significance of phosphoinositide 3-kinase and mammalian target of Rapamycin complex 1 in preeclampsia
  6660. Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to Rapamycin through regulating phosphorylation of Akt in …
  6661. Rapamycin Alleviated the Symptoms of Fat Embolism Syndrome by Modulating Autophagy in a Rat Model
  6662. The Role of Mammalian Target of Rapamycin (mTOR) in a Mouse Model of Cerebral Palsy
  6663. Effects of Rapamycin and deferoxamin on wound healing after ischemia and hypoxia
  6664. Effect of Rapamycin and chloroquine on osteosarcoma
  6665. Rapamycin prevents apoptosis of myocardial cells in heart failure rats through up-regulating Akt.
  6666. Neurotoxicity of Paclitaxel and Rapamycin in Rat Model with Transient Blood-Brain Barrier Disruption
  6667. The influence and significance of Rapamycin on cardiomyocyte autophagy level of early heart failure rat
  6668. The effect of Rapamycin on autophagy in human corneal epithelial cells
  6669. AB0421 Rapamycin reduces disease activity through restoring regulatory t cell numbers in patients with active refractory rheumatoid arthritis
  6670. Mechanisms of Rapamycin inhibition on mTOR and Drug Design
  6671. Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus
  6672. The role of Nrf2 in the anti-cell senescence effect of Rapamycin
  6673. Rapamycin preserves the chondrogenic phenotype and suppresses cartilage degrading and inflammatory processes in osteoarthritis
  6674. Rapamycin reduced inhibition of Vγ1 γδ T cells towards Vγ4 γδ T cells through down-regulating IL-4
  6675. Immunomodulatory Effects of Rapamycin in Xenogeneic Graft Versus Host Disease
  6676. Congenital Hyperinsulinism; Effects of Rapamycin on Min6 Pancreatic β-Cell Line
  6677. EFFECTS OF Rapamycin ON AIRWAY INFLAMMATION IN A MOUSE MODEL OF ASTHMA IN REMISSION
  6678. Rule-Based Modeling Project of Insulin-Like Growth Factor and Mechanistic Target of Rapamycin Signaling Network with Site-Specific Interactions
  6679. Rapamycin as a Novel Therapeutic for Alzheimer’s Disease: Prevention Assessed Through Neuroimaging
  6680. Adsorption of a tumor-associated antigen onto crystalized Rapamycin nanoparticles for combined immuno-and antitumor therapy
  6681. S23 Evaluation of phosphorylated protein kinase b (akt) and mammalian target of Rapamycin (mTOR) expression in malignant pleural mesothelioma (mpm) and their …
  6682. FK506 and Rapamycin Bioconjugation: A Proposal to Increase the Viability of Transplanted Pancreatic Islets
  6683. Role of mammalian target of Rapamycin protein in oxidative stress-induced lung injury and pulmonary fibrosis in immature rats
  6684. The Role of Rapamycin‐Insensitive mTOR Signaling in the Regulation of Muscle Protein Synthesis in a Rat Model of Resistance Exercise
  6685. Protective Effect of Rapamycin against Mitochondrial Injury in an Aging Parkinson’s Disease Mouse Model
  6686. Investigation of the clinical predictors of in-stent restenosis after Rapamycin-eluting coronary stent implantation
  6687. Activation of phosphoinositide 3-kinase/Akt/mechanistic target of Rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic …
  6688. CIP2A can be a therapeutic target of Rapamycin in radioresistant head and neck cancer with P53 mutation
  6689. Effect of Rapamycin on proliferation, apoptosis and cell cycles of high glucose-cultured rat glomerular mesangial cell
  6690. Rapamycin Interacts with Nutrition to Decrease Basal Metabolic Rate of Drosophila melanogaster
  6691. Regulatory effect of Rapamycin on key genes of circadian rhythm in senescent cells
  6692. Antifibrotic effect of Rapamycin, an inhibitor of mTOR pathway, on the TGF-β2 induced proliferation of human tenon fibroblasts
  6693. NBR1 and KIF14 Downstream of the Mammarian Target of Rapamycin Pathway Predict Recurrence in Nonmuscle Invasive Low Grade Urothelial Carcinoma …
  6694. Expression of signaling pathway of mammalian target of Rapamycin in articular cartilage cell induced by interleukin 1β
  6695. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor
  6696. Abstract P340: Immunomodulatory Effect of Rapamycin on the Expression of Anti-inflammatory Cytokines in Npr1 Gene-deleted Mice
  6697. Age-Specific Prolongation of Graft Survival in Recipients Treated With Rapamycin is Linked to CD4+ IFN-g+ IL-10+ Cells
  6698. Establishment and Application of HPLC Method for Content Determination of Rapamycin in Human Monocyte THP-1 Derived Foam Cells
  6699. Effects of Rapamycin preconditioning on lung injury induced by limb ischemia-reperfusion in rats
  6700. The protective effect of Rapamycin on beta-amyloid protein 25-35-induced PC12 cells death
  6701. Effect of Rapamycin treatment during postâ activation and/or in vitro culture on embryonic development after parthenogenesis and in vitro fertilization in pigs
  6702. Therapeutic effect of edaravone combined with Rapamycin on neural injury in rats with subarachnoid hem-orrhage
  6703. Rapamycin-Fortified Diet Delays Wound Repair, Alters CD4+ & γδ+ Splenocyte, CD3+ Thymocyte Distributions in Mice
  6704. Toxic effect of Rapamycin in a young rat model of pentylenetetrazole-induced Kindling epilepsy
  6705. Cell-intrinsic PD-L1 directs tumor initiating cell fate and Rapamycin and interferon-γ response
  6706. Short-term Rapamycin persistently improves cardiac function after cessation of treatment in aged male and female mice.
  6707. Combination of Rapamycin and crizotinib induces partial remission of pleural mesothelioma in a patient-derived xenograft model
  6708. Mammalian Target Of Rapamycin Is A Key Molecule For Eosinophil Differentiation In Bone Marrow
  6709. … communities of developing countries. In the national project entitled: TREATMENT OF BETA-THALASSEMIA PATIENTS WITH Rapamycin (SIROLIMUS): FROM PRE …
  6710. Rapamycin suppresses ErbB2-overexpressing mammary tumors through selective inhibition of luminal progenitor cells and tumor-initiating cells
  6711. 361 Focal adhesion kinase–mammalian target of Rapamycin pathway–mediated different proliferation, migration, and differentiation abilities of satellite cells in Lantang …
  6712. Is phosphatidylinositol 3-kinase/AKT/mammalian target of Rapamycin pathway therapeutic target for esophageal adenocarcinoma
  6713. Rapamycin-loaded nanoporous α-Fe₂O₃ as an endothelial favorable and thromboresistant coating for biodegradable drug-eluting Fe stent applications
  6714. Identification of the mechanistic target of Rapamycin complex 2-associated interactome involved in brain cancer cell motility by affinity purification-mass spectrometry
  6715. Advances in lack of amino acid-mediated autophagy via mammalian target of Rapamycin complex 1 signal pathway.
  6716. Nicotine inhibits Rapamycin-induced hyperalgesia in na? ve mice via activating mTORC1/S6K/IRS-1-related feedback inhibition loop
  6717. Autophagy-inducer Rapamycin alleviates malnutrition-associated liver steatosis: The role of autophagy in malnutrition induced liver damage
  6718. The Analyses Of Alveolar Epithelial Injury Through The Lipid Metabolic Stress In The Mammalian Target Of Rapamycin Inhibitor Induced Lung Disease
  6719. Abstract P209: Mechanistic Target of Rapamycin Complex 1 (mTORC1) Signaling Generates Reactive Oxygen Species in Mouse Endothelial Cells via NFkB …
  6720. Study on the regulation of mammalian target of Rapamycin complex 1 (mTORC1) by nudix-type motif 2 (NUDT2) in cancer cells
  6721. The Mammalian Target of Rapamycin and DNA methyltransferase 1 axis mediates vascular endothelial dysfunction in response to disturbed flow
  6722. … Control Conventional T-Cells While Supporting Treg Reconstitution Post-Transplant: Long-Term GVHD-Free Survival by Combining OX40L Blockade with Rapamycin
  6723. Induction of miR-302a by Rapamycin Protects Human Pluripotent Stem Cells Derived Cardiomyocytes Against Simulated Ischemia/Reoxygenation Injury Under …
  6724. CALCINEURIN INHIBITOR WITHDRAWAL AND CONVERSION TO MAMMALIAN TARGET OF Rapamycin INHIBITOR (EVEROLIMUS) IN PEDIATRIC …
  6725. … acid (M4N) broadly suppresses cancer metabolism and synergistically induces strong anticancer activity in combination with etoposide, Rapamycin and UCN-01
  6726. … DRIVING FIBROSIS: The Analyses Of Alveolar Epithelial Injury Through The Lipid Metabolic Stress In The Mammalian Target Of Rapamycin Inhibitor Induced Lung …
  6727. Statement of Retraction. A Central Role for Neuronal AMP-Activated Protein Kinase (AMPK) and Mammalian Target of Rapamycin (mTOR) in High-Protein Diet …
  6728. Down‐Regulation of OATP1B1‐Mediated Transport by Mammalian Target of Rapamycin (mTOR) Inhibitors Everolimus and Sirolimus: Potential Mechanism and …
  6729. B-cell activating factor involved in the pathogenesis of lupus nephritis through regulating phosphoino-sitide 3-kinase/protein kinase B/mammalian target of Rapamycin …
  6730. … systemic lupus erythematosus is mainly associated with the decreased number of regulatory t cells and low-dose il-2 combined with Rapamycin can efficiently recovery …
  6731. Correlation of metastasis associated gene-1 and mammalian target of Rapamycin expression with clinical pathology in rectal cancer
  6732. Microrna-25 Binds To Tuberous Sclerosis Complex 1 To Modulate Airway Smooth Muscle Proliferation Via Mammalian Target Of Rapamycin Signaling Pathway
  6733. MP06-07 CD4+IFN-γ+IL-10+ CELLS FACILITATE A PROLONGATION OF GRAFT SURVIVAL IN OLD RECIPIENT MICE TREATED WITH Rapamycin
  6734. LSC-2017-RNA-Seq analysis reveals major differences between the effects of Rapamycin and dual mTORC1/2 inhibition during TGFß1-induced myofibroblast …
  6735. P01. 31 Mammalian target of Rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death
  6736. Expression of Phosphatidylinositol 3-Kinase, Protein Kinase B and Mammalian Target of Rapamycin in Substan-tia Nigra in Rats with Parkinson’s Disease
  6737. The effects and regulation of the Wnt inhibitor Dickkopf-1 and the mechanistic target of Rapamycin in osteotropic cancers
  6738. … Kinase Kinase Kinase Kinase-3 (MAP4K3) in Preterm Skeletal Muscle Satellite Cell Myogenesis and Mammalian Target of Rapamycin Complex 1 (mTORC1) …
  6739. Immune tolerance to recombinant immunotoxin LMB-100 using synthetic vaccine particles encapsulating Rapamycin
  6740. Induction of immune tolerance to recombinant immunotoxin LMB-100 using synthetic vaccine particles encapsulating Rapamycin
  6741. The target of Rapamycin and mechanisms of cell growth
  6742. Rapamycin and Alzheimer’s disease: time for a clinical trial?
  6743. Rapamycin for longevity: opinion article
  6744. Rapamycin activates mammalian microautophagy
  6745. Rapamycin and Alzheimer disease: a double-edged sword?
  6746. Rapamycin, proliferation and geroconversion to senescence
  6747. Rapamycin-inspired macrocycles with new target specificity
  6748. Recent discoveries on the role of TOR (Target of Rapamycin) signaling in translation in plants
  6749. Rapamycin and treatment of venous malformations
  6750. Mechanistic target of Rapamycin complex 1 and 2 in human temporal lobe epilepsy
  6751. Cell cycle control by the target of Rapamycin signalling pathway in plants
  6752. Rapamycin improves healthspan but not inflammaging in nfκb1−/− mice
  6753. Rapamycin: a bacteria-derived immunosuppressant that has anti-atherosclerotic effects and its clinical application
  6754. ETV7 is an essential component of a Rapamycin-insensitive mTOR complex in cancer
  6755. The role of the mammalian target of Rapamycin (mTOR) in pulmonary fibrosis
  6756. Target of Rapamycin signaling orchestrates growth–defense trade‐offs in plants
  6757. Rapamycin for the aging skin
  6758. Promising effect of Rapamycin on multiple sclerosis
  6759. Rapamycin in ischemic stroke: Old drug, new tricks?
  6760. Rapamycin‐insensitive mechanistic target of Rapamycin regulates basal and resistance exercise‐induced muscle protein synthesis
  6761. Effect of caloric restriction and Rapamycin on ovarian aging in mice
  6762. Mechanistic target of Rapamycin–independent antidepressant effects of (R)-ketamine in a social defeat stress model
  6763. Rapamycin administration is not a valid therapeutic strategy for every case of mitochondrial disease
  6764. A novel Rapamycin analog is highly selective for mTORC1 in vivo
  6765. Effects of Rapamycin on growth hormone receptor knockout mice
  6766. Rapamycin improves the neuroprotection effect of inhibition of NLRP3 inflammasome activation after TBI
  6767. Comparison of folate-conjugated Rapamycin versus unconjugated Rapamycin in an orthologous mouse model of polycystic kidney disease
  6768. Mechanistic target of Rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy
  6769. Target of Rapamycin kinase: Central regulatory hub for plant growth and metabolism
  6770. A Rapamycin-activated caspase 9-based suicide gene
  6771. Fasting and Rapamycin: diabetes versus benevolent glucose intolerance
  6772. Lung function response and side effects to Rapamycin for lymphangioleiomyomatosis: a prospective national cohort study
  6773. A randomized control trial to establish the feasibility and safety of Rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive …
  6774. Rapamycin protects against peritendinous fibrosis through activation of autophagy
  6775. Rapamycin enhances mitophagy and attenuates apoptosis after spinal ischemia-reperfusion injury
  6776. Protective effects of the mechanistic target of Rapamycin against excess iron and ferroptosis in cardiomyocytes
  6777. Rapamycin inhibits proliferation and induces autophagy in human neuroblastoma cells
  6778. Resistance exercise-induced hypertrophy: a potential role for Rapamycin-insensitive mTOR
  6779. Rapamycin modulates tissue aging and lifespan independently of the gut microbiota in Drosophila
  6780. Efficacy and safety of topical Rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial
  6781. Antigen-selective modulation of AAV immunogenicity with tolerogenic Rapamycin nanoparticles enables successful vector re-administration
  6782. A Rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials
  6783. Rapamycin increases oxidative metabolism and enhances metabolic flexibility in human cardiac fibroblasts
  6784. Novel roles of mechanistic target of Rapamycin signaling in regulating fetal growth
  6785. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP …
  6786. Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis
  6787. Topical Rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial
  6788. Combination of melatonin and Rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis …
  6789. Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis
  6790. Rapamycin protects aging muscle
  6791. Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy
  6792. inhibition of mTOR signaling and clinical activity of Rapamycin in head and neck cancer in a window of opportunity trial
  6793. Multiple critical periods for Rapamycin treatment to correct structural defects in Tsc-1-suppressed brain
  6794. Mammalian target of Rapamycin as a therapeutic target in osteoporosis
  6795. Transcriptional and epigenetic regulation by the mechanistic target of Rapamycin complex 1 pathway
  6796. Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1β and IL-18 production
  6797. Efficacy of Rapamycin in modulating autophagic activity of Botrytis cinerea for controlling gray mold
  6798. Target of Rapamycin inhibition in Chlamydomonas reinhardtii triggers de novo amino acid synthesis by enhancing nitrogen assimilation
  6799. Intranasal Rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome
  6800. Mutations in PI3K110δ cause impaired natural killer cell function partially rescued by Rapamycin treatment
  6801. Target of Rapamycin, a master regulator of multiple signalling pathways and a potential candidate gene for crop improvement
  6802. Effects of Rapamycin and curcumin on inflammation and oxidative stress in vitro and in vivo—in search of potential anti-epileptogenic strategies for temporal …
  6803. Oncogenic signalling through mechanistic target of Rapamycin (mTOR): A driver of metabolic transformation and cancer progression
  6804. Effects of Rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero
  6805. Negative effects of chronic Rapamycin treatment on behavior in a mouse model of fragile X syndrome
  6806. Long term Rapamycin treatment improves mitochondrial DNA quality in aging mice
  6807. Mechanistic target of Rapamycin (mTOR) signaling in status epilepticus
  6808. Functional characterization of target of Rapamycin signaling in Verticillium dahliae
  6809. Targeting mTOR with MLN0128 overcomes Rapamycin and chemoresistant primary effusion lymphoma
  6810. Does Rapamycin slow down time?
  6811. Mechanistic/mammalian target of Rapamycin: recent pathological aspects and inhibitors
  6812. Mechanistic target of Rapamycin complex 1 signaling modulates vascular endothelial function through reactive oxygen species
  6813. E-selectin targeted immunoliposomes for Rapamycin delivery to activated endothelial cells
  6814. Metformin reduces glucose intolerance caused by Rapamycin treatment in genetically heterogeneous female mice
  6815. Topical use of mammalian target of Rapamycin inhibitors in dermatology: A systematic review with meta-analysis
  6816. Therapeutic control of leishmaniasis by inhibitors of the mammalian target of Rapamycin
  6817. Multifunctional platinum@ BSA–Rapamycin nanocarriers for the combinatorial therapy of cerebral cavernous malformation
  6818. Rapamycin directly activates lysosomal mucolipin TRP channels independent of mTOR
  6819. Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation
  6820. Effect of mycophenolate and Rapamycin on renal fibrosis in lupus nephritis
  6821. Rapamycin and fasting sustain autophagy response activated by ischemia/reperfusion injury and promote retinal ganglion cell survival
  6822. Neuroprotective effects of Rapamycin on spinal cord injury in rats by increasing autophagy and Akt signaling
  6823. Therapeutic activation of autophagy by combined treatment with Rapamycin and trehalose in a mouse MPTP-induced model of Parkinson’s disease
  6824. Rapalogs potential as practical alternatives to Rapamycin
  6825. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by Rapamycin
  6826. Nanoparticle ferritin-bound erastin and Rapamycin: a nanodrug combining autophagy and ferroptosis for anticancer therapy
  6827. Repeated systemic treatment with Rapamycin affects behavior and amygdala protein expression in rats
  6828. Sleep-deprived cognitive impairment in aging mice is alleviated by Rapamycin
  6829. Rapamycin attenuates mitochondrial injury and renal tubular cell apoptosis in experimental contrast-induced acute kidney injury in rats
  6830. Metformin synergizes with Rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo
  6831. Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of Rapamycin and berberine to lung carcinoma
  6832. Rapamycin prevents cerebral stroke by modulating apoptosis and autophagy in penumbra in rats
  6833. Target of Rapamycin (TOR) regulates the expression of lncRNAs in response to abiotic stresses in cotton
  6834. Rapamycin increases collateral circulation in rodent brain after focal ischemia as detected by multiple modality dynamic imaging
  6835. Rapamycin is not protective against ischemic and cisplatin-induced kidney injury
  6836. Target of Rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
  6837. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of Rapamycin cross‐talk in hepatocellular carcinoma
  6838. Regulation of dendritic cell immune function and metabolism by cellular nutrient sensor mammalian target of Rapamycin (mTOR)
  6839. The target of Rapamycin kinase affects biomass accumulation and cell cycle progression by altering carbon/nitrogen balance in synchronized Chlamydomonas …
  6840. Disease evolution and response to Rapamycin in activated phosphoinositide 3-kinase δ syndrome: the european society for immunodeficiencies-activated …
  6841. Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome
  6842. Rapamycin prevents thoracic aortic aneurysm and dissection in mice
  6843. Caloric restriction and Rapamycin differentially alter energy metabolism in yeast
  6844. Investigating the effect of target of Rapamycin kinase inhibition on the Chlamydomonas reinhardtii phosphoproteome: from known homologs to new targets
  6845. Outcomes associated with mammalian target of Rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis
  6846. The use of Rapamycin in patients with tuberous sclerosis complex: Long-term results
  6847. Discovery of novel dual histone deacetylase and mammalian target of Rapamycin target inhibitors as a promising strategy for cancer therapy
  6848. Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of Rapamycin and wogonin to breast cancer
  6849. Advanced glycation end‐products suppress autophagic flux in podocytes by activating mammalian target of Rapamycin and inhibiting nuclear translocation of …
  6850. Rapamycin rescues age-related changes in muscle-derived stem/progenitor cells from progeroid mice
  6851. Farnesyltransferase inhibitor and Rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria …
  6852. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein …
  6853. Combined treatment with doxorubicin and Rapamycin is effective against in vitro and in vivo models of human glioblastoma
  6854. Mammalian target of Rapamycin inhibition attenuates myocardial ischaemia–reperfusion injury in hypertrophic heart
  6855. Rapamycin for refractory discoid lupus erythematosus
  6856. Anti-fibrotic effects of pirfenidone and Rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
  6857. Use of topical Rapamycin in the treatment of superficial lymphatic malformations
  6858. Hybrid electrospun Rapamycin-loaded small-diameter decellularized vascular grafts effectively inhibit intimal hyperplasia
  6859. Efficacy and safety of mTOR inhibitors (Rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
  6860. Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer
  6861. Rapamycin-induced autophagy protects proximal tubular renal cells against proteinuric damage through the transcriptional activation of the nerve growth factor …
  6862. Synthesis and application of light-switchable arylazopyrazole Rapamycin analogs
  6863. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
  6864. Mood-stabilizing effects of Rapamycin and its analog temsirolimus: relevance to autophagy
  6865. Target of Rapamycin complex 2–dependent phosphorylation of the coat protein Pan1 by Akl1 controls endocytosis dynamics in Saccharomyces cerevisiae
  6866. Investigation of novel regulation of N-myristoyltransferase by mammalian target of Rapamycin in breast cancer cells
  6867. Regulation of GSK3 cellular location by FRAT modulates mTORC1-dependent cell growth and sensitivity to Rapamycin
  6868. Mechanistic target of Rapamycin inhibitors: successes and challenges as cancer therapeutics
  6869. Dual roles of mammalian target of Rapamycin in regulating liver injury and tumorigenesis in autophagy‐defective mouse liver
  6870. Rapamycin protects skin fibroblasts from ultraviolet B-induced photoaging by suppressing the production of reactive oxygen species
  6871. Effects of Rapamycin on the mechanistic target of Rapamycin (mTOR) pathway and telomerase in breast cancer cells
  6872. Ponatinib combined with Rapamycin causes regression of murine venous malformation
  6873. Restoration of aberrant mTOR signaling by intranasal Rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down …
  6874. Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage
  6875. Rapamycin removes damaged mitochondria and protects human trabecular meshwork (TM-1) cells from chronic oxidative stress
  6876. Rapamycin mitigates erythrocyte membrane transport functions and oxidative stress during aging in rats
  6877. Estimating the concentration of therapeutic range using disease-specific iPS cells: low-dose Rapamycin therapy for Pendred syndrome
  6878. Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and Rapamycin
  6879. A binding site hotspot map of the fkbp12–Rapamycin–frb ternary complex by photoaffinity labeling and mass spectrometry-based proteomics
  6880. Protective effect of Rapamycin on endothelial-to-mesenchymal transition in HUVECs through the Notch signaling pathway
  6881. Mammalian target of Rapamycin at the crossroad between Alzheimer’s disease and diabetes
  6882. … stem cells protect against hypoxia‐ischemia brain damage by enhancing autophagy through brain derived neurotrophic factor/mammalin target of Rapamycin …
  6883. Mammalian target of Rapamycin inhibition in Trypanosoma cruzi-infected macrophages leads to an intracellular profile that is detrimental for infection
  6884. Saccharomyces cerevisiae adapted to grow in the presence of low-dose Rapamycin exhibit altered amino acid metabolism
  6885. Rapamycin attenuates high glucose-induced inflammation through modulation of mTOR/NF-κB pathways in macrophages
  6886. The mechanistic target of Rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders
  6887. Rapamycin reduces podocyte apoptosis and is involved in autophagy and mTOR/P70S6K/4EBP1 signaling
  6888. inhibition of mTOR by Rapamycin Aggravates Corneal Epithelial Stem Cell Deficiency by Upregulating Inflammatory Response
  6889. Rapamycin‑induced miR‑30a downregulation inhibits senescence of VSMCs by targeting Beclin1
  6890. The impairments of α-synuclein and mechanistic target of Rapamycin in rotenone-induced SH-SY5Y cells and mice model of Parkinson’s disease
  6891. Berunda polypeptides: biheaded Rapamycin carriers for subcutaneous treatment of autoimmune dry eye disease
  6892. Rapamycin confers neuroprotection against aging-induced oxidative stress, mitochondrial dysfunction, and neurodegeneration in old rats through activation of …
  6893. Antileishmanial effect of Rapamycin as an alternative approach to control Leishmania tropica infection
  6894. Reduced menin expression impairs Rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration
  6895. Rapamycin modulates glucocorticoid receptor function, blocks atrophogene REDD1, and protects skin from steroid atrophy
  6896. Depletion of NBR1 in urothelial carcinoma cells enhances Rapamycin‐induced apoptosis through impaired autophagy and mitochondrial dysfunction
  6897. The effect of Rapamycin treatment on cerebral ischemia: A systematic review and meta-analysis of animal model studies
  6898. Endoplasmic reticulum stress-induced apoptosis in intestinal epithelial cells: a feed-back regulation by mechanistic target of Rapamycin complex 1 (mTORC1)
  6899. Intravesical delivery of Rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel
  6900. A Perfect sTORm: the role of the mammalian target of Rapamycin (mTOR) in cerebrovascular dysfunction of alzheimer’s disease: a mini-review
  6901. Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg/Th17 in a mouse model
  6902. … of cardiac miRNA Transcriptomes induced by diabetes and Rapamycin treatment and identification of a Rapamycin-associated cardiac MicroRNA signature
  6903. Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor Rapamycin
  6904. Therapeutic suppression of mTOR (mammalian target of Rapamycin) signaling prevents and reverses salt-induced hypertension and kidney injury in dahl salt-sensitive …
  6905. Enhanced supply of methionine or arginine alters mechanistic target of Rapamycin signaling proteins, messenger RNA, and microRNA abundance in heat …
  6906. New mammalian target of Rapamycin (mTOR) modulators derived from natural product databases and marine extracts by using molecular docking techniques
  6907. Hypervascularization in mTOR‐dependent focal and global cortical malformations displays differential Rapamycin sensitivity
  6908. Acute and chronic Rapamycin use in patients with fibrodysplasia ossificans progressiva: a report of two cases
  6909. Melatonin and Rapamycin attenuate isoflurane-induced cognitive impairment through inhibition of neuroinflammation by suppressing the mTOR signaling in …
  6910. Intracellular delivery of Rapamycin from FKBP elastin-like polypeptides is consistent with macropinocytosis
  6911. The regulation of Rapamycin in planarian Dugesia japonica Ichikawa & Kawakatsu, 1964 regeneration according to TOR signaling pathway
  6912. Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of Rapamycin pathway in a streptozotocin …
  6913. Rapamycin, an immunosuppressant and mTORC1 inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment: a double-blind …
  6914. Combined ischemic and Rapamycin preconditioning alleviated liver ischemia and reperfusion injury by restoring autophagy in aged mice
  6915. … maintaining the ratios of Thr: Phe, Lys: Thr, Lys: His, and Lys: Val alters mammary cellular metabolites, mammalian target of Rapamycin signaling, and gene …
  6916. Target of Rapamycin‐signaling modulates starch accumulation via glycogenin phosphorylation status in the unicellular red alga Cyanidioschyzon merolae
  6917. Metformin ameliorates experimental diabetic periodontitis independently of mammalian target of Rapamycin (mTOR) inhibition by reducing NIMA‐related kinase 7 …
  6918. Rapamycin Induced Autophagy Inhibits Inflammation‐Mediated Endplate Degeneration by Enhancing Nrf2/Keap1 Signaling of Cartilage Endplate Stem Cells
  6919. Local release of Rapamycin by microparticles delays islet rejection within the anterior chamber of the eye
  6920. High glucose-induced podocyte injury involves activation of mammalian target of Rapamycin (mTOR)-induced endoplasmic reticulum (ER) stress
  6921. Hippocampal mammalian target of Rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test
  6922. Label-free single-molecule quantification of Rapamycin-induced FKBP–FRB dimerization for direct control of cellular mechanotransduction
  6923. Rapamycin-loaded polysorbate 80-coated PLGA nanoparticles: Optimization of formulation variables and in vitro anti-glioma assessment
  6924. Synergistic clearance of intracellular pathogens by hyaluronan-streptomycin micelles encapsulated with Rapamycin
  6925. Protective effect of a mechanistic target of Rapamycin inhibitor on an in vivo model of cisplatin-induced ovarian gonadotoxicity
  6926. Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined Rapamycin/celecoxib delivery and cancer imaging
  6927. Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms
  6928. Role of mammalian target of Rapamycin in atherosclerosis
  6929. Rapamycin mediates mTOR signaling in reactive astrocytes and reduces retinal ganglion cell loss
  6930. Cardioprotective effects of dietary Rapamycin on adult female C57BLKS/J-Leprdb mice
  6931. Blockade of Treg cell differentiation and function by the interleukin‐21–mechanistic target of Rapamycin axis via suppression of autophagy in patients with systemic …
  6932. Rapamycin attenuates Tc1 and Tc17 cell responses in cigarette smoke-induced emphysema in mice
  6933. Mammalian target of Rapamycin inhibitors combined with calcineurin inhibitors as initial immunosuppression in renal transplantation: a meta-analysis
  6934. Differential effects of Rapamycin on Bursaphelenchus xylophilus with different virulence and differential expression of autophagy genes under stresses in nematodes
  6935. Impacting dementia and cognitive loss with innovative strategies: mechanistic target of Rapamycin, clock genes, circular non-coding ribonucleic acids, and …
  6936. Rapamycin Supplementation May Ameliorate Erectile Function in Rats With Streptozotocin–Induced Type 1 Diabetes by Inducing Autophagy and Inhibiting Apoptosis …
  6937. Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer
  6938. Alteration of the Wnt/GSK3β/β‑catenin signalling pathway by Rapamycin ameliorates pathology in an Alzheimer’s disease model
  6939. Preconditioning of umbilical cord‐derived mesenchymal stem cells by Rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice …
  6940. Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways
  6941. Rapamycin loaded TPGS-Lecithins-Zein nanoparticles based on core-shell structure for oral drug administration
  6942. A study on the mechanism of Rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway
  6943. Transcriptome of white shrimp Litopenaeus vannamei induced with Rapamycin reveals the role of autophagy in shrimp immunity
  6944. … supply during the periparturient period enhances insulin signaling, amino acid transporters, and mechanistic target of Rapamycin pathway proteins in adipose …
  6945. Rapamycin synergizes with cisplatin in antiendometrial cancer activation by improving il-27–stimulated cytotoxicity of nk cells
  6946. Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of Rapamycin/hypoxia‐inducible factor 1α axis
  6947. Rapamycin upregulates connective tissue growth factor expression in hepatic progenitor cells through TGF-β-Smad2 dependent signaling
  6948. Rapamycin induces autophagy to alleviate acute kidney injury following cerebral ischemia and reperfusion via the mTORC1/ATG13/ULK1 signaling pathway
  6949. Metabolic shift induced by ω-3 PUFAs and Rapamycin lead to cancer cell death
  6950. Mammalian target of Rapamycin complex 2 (mTORC2) controls glycolytic gene expression by regulating Histone H3 Lysine 56 acetylation
  6951. Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency‐mediated mitochondrial dysregulation
  6952. Mechanistic target of Rapamycin complex 1 promotes the expression of genes encoding electron transport chain proteins and stimulates oxidative …
  6953. … stress affects muscle hypertrophy, muscle protein synthesis and uptake of amino acid in broilers via insulin like growth factor-mammalian target of Rapamycin …
  6954. Mammalian target of Rapamycin complex 1 signaling is required for the dedifferentiation from biliary cell to bipotential progenitor cell in zebrafish liver regeneration
  6955. Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of Rapamycin (mTOR) signaling pathway
  6956. Self-assembled amphiphilic-dextran nanomicelles for delivery of Rapamycin
  6957. Controversies on the potential therapeutic use of Rapamycin for treating a lysosomal cholesterol storage disease
  6958. Involvement of pro-inflammation signal pathway in inhibitory effects of Rapamycin on oxaliplatin-induced neuropathic pain
  6959. Direct targeting of the mTOR (mammalian target of Rapamycin) kinase improves endothelial permeability in drug-eluting stents—brief report
  6960. … , a novel nerve poison, triggers neuronal autophagic death via reactive oxygen species-mediated inhibition of the protein kinase B/mammalian target of Rapamycin …
  6961. Oligo (lactic acid) 8-Rapamycin prodrug-loaded poly (ethylene glycol)-block-poly (lactic acid) micelles for injection
  6962. New metformin derivative HL 156A prevents oral cancer progression by inhibiting the insulin‐like growth factor/AKT/mammalian target of Rapamycin pathways
  6963. Mammalian target of Rapamycin complex 1 and its downstream effector collapsin response mediator protein‐2 drive reinstatement of alcohol reward seeking
  6964. Lysosome membrane permeabilization and disruption of the molecular target of Rapamycin (mTOR)-lysosome interaction are associated with the inhibition of lung …
  6965. Effects of mammalian target of Rapamycin on proliferation, apoptosis and differentiation of myoblasts undergoing mechanical stress
  6966. Low dose of IL-2 combined with Rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients
  6967. Amino acids stimulate glycyl‐tRNA synthetase nuclear localization for mammalian target of Rapamycin expression in bovine mammary epithelial cells
  6968. Sodium fluoride induces splenocyte autophagy via the mammalian targets of Rapamycin (mTOR) signaling pathway in growing mice
  6969. Role of mammalian target of Rapamycin in regulating HIF-1α and vascular endothelial growth factor signals in glaucoma
  6970. Glucosamine promotes osteoblast proliferation by modulating autophagy via the mammalian target of Rapamycin pathway
  6971. Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway
  6972. Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
  6973. … acids affect jejunal cell proliferation and functions by affecting antioxidant capacity, Wnt/β-catenin, and the mechanistic target of Rapamycin signaling pathways in …
  6974. Mammalian target of Rapamycin 2 (mTOR2) and C-MYC modulate glucosamine-6-phosphate synthesis in glioblastoma (GBM) cells through glutamine: fructose-6 …
  6975. Rapamycin inhibits activation of AMPK-mTOR signaling pathway-induced Alzheimer’s disease lesion in hippocampus of rats with type 2 diabetes mellitus
  6976. The protective effects of Rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway
  6977. Rapamycin alleviates proinflammatory cytokines and nociceptive behavior induced by chemotherapeutic paclitaxel
  6978. … neonatal hypoxic brain injury by reducing oxidative stress and activation of phosphatidylinositol-3-kinase/Akt/mammalian target of Rapamycin (PI3K/Akt/mTOR …
  6979. Synthesis and biological evaluation of Rapamycin-derived, next generation small molecules
  6980. Rapamycin relieves anxious emotion and synaptic plasticity deficits induced by hindlimb unloading in mice
  6981. Rapamycin inhibits peritoneal fibrosis by modifying lipid homeostasis in the peritoneum
  6982. Rapamycin prevents the intervertebral disc degeneration via inhibiting differentiation and senescence of annulus fibrosus cells
  6983. Rapamycin combined with α-Cyanoacrylate contributes to inhibiting intimal hyperplasia in rat models
  6984. Crocin induces anti-ischemia in middle cerebral artery occlusion rats and inhibits autophagy by regulating the mammalian target of Rapamycin
  6985. Haploinsufficiency of mechanistic target of Rapamycin ameliorates bag3 cardiomyopathy in adult zebrafish
  6986. … -mediated apoptosis in renal cell carcinoma via the p53/AMP‑activated protein kinase/mammalian target of Rapamycin autophagy signaling pathway
  6987. Mammalian target of Rapamycin signaling and ubiquitin-proteasome–related gene expression in skeletal muscle of dairy cows with high or normal body …
  6988. p53 induces miR‐199a‐3p to suppress mechanistic target of Rapamycin activation in cisplatin‐induced acute kidney injury
  6989. … -protective role of metformin in patients with acute stroke and type 2 diabetes mellitus via AMPK/mammalian target of Rapamycin (mTOR) signaling pathway …
  6990. Rapamycin modulate Treg/Th17 balance via regulating metabolic pathways: a study in mice
  6991. Stomatitis associated with mammalian target of Rapamycin inhibition: a review of pathogenesis, prevention, treatment, and clinical implications for oral practice in …
  6992. Proteomic mapping by Rapamycin-dependent targeting of APEX2 identifies binding partners of VAPB at the inner nuclear membrane
  6993. Feedback activation of SGK3 and AKT contributes to Rapamycin resistance by reactivating mTORC1/4EBP1 axis via TSC2 in breast cancer
  6994. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of Rapamycin (mTOR) inhibitors and its effect on malignancy following …
  6995. Rapamycin attenuates BAFF‐extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B‐lymphoid cells
  6996. mTOR inhibitor Rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease …
  6997. Effect of Rapamycin on bone mass and strength in the α2 (I)‐G610C mouse model of osteogenesis imperfecta
  6998. A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and Rapamycin
  6999. Mammalian target of Rapamycin (mTOR) and the proteasome attenuates IL-1β expression in primary mouse cardiac fibroblasts
  7000. A Rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells
  7001. Investigating effect of Rapamycin and metformin on angiogenesis in hepatocellular carcinoma cell line
  7002. Sirolimus (Rapamycin) for the targeted treatment of the fibrotic sequelae of Graves’ orbitopathy
  7003. Rapamycin nano-micelle ophthalmic solution reduces corneal allograft rejection by potentiating myeloid-derived suppressor cells’ function
  7004. Targeting the phosphatidylinositol 3‐kinase/Akt/mechanistic target of Rapamycin signaling pathway in B‐lineage acute lymphoblastic leukemia: An update
  7005. Comprehensive analysis of lysine acetylome reveals a site-specific pattern in Rapamycin-induced autophagy
  7006. Rapamycin suppresses postnatal muscle hypertrophy induced by myostatin-inhibition accompanied by transcriptional suppression of the Akt/mTOR pathway
  7007. Targeting delivery of Rapamycin with anti-collagen IV peptide conjugated Fe3O4@ nanogels system for vascular restenosis therapy
  7008. Involvement of phosphatidylinositol-3 kinase/Akt/mammalian target of Rapamycin/peroxisome proliferator-activated receptor γ pathway for induction and maintenance …
  7009. MiR‐99a‐5p inhibits bladder cancer cell proliferation by directly targeting mammalian target of Rapamycin and predicts patient survival
  7010. T-2 Toxin Exposure Induces Apoptosis in TM3 Cells by Inhibiting Mammalian Target of Rapamycin/Serine/Threonine Protein Kinase (mTORC2/AKT) to Promote Ca2+ …
  7011. Targeting the mammalian target of Rapamycin for epileptic encephalopathies and malformations of cortical development
  7012. … the levels of autophagy-related genes via adenosine 5′-monophosphate-activated protein kinase/mammalian target of Rapamycin signaling pathway in …
  7013. Chronic oral Rapamycin decreases adiposity, hepatic triglycerides and insulin resistance in male mice fed a diet high in sucrose and saturated fat
  7014. The sources of essential fatty acids for allergic and cancer patients; a connection with insight into mammalian target of Rapamycin: A narrative review
  7015. Challenging the CNS targeting potential of systemically administered nanoemulsion delivery systems: a case study with Rapamycin-containing fish oil nanoemulsions …
  7016. Rapamycin inhibited photoreceptor necroptosis and protected the retina by activation of autophagy in experimental retinal detachment
  7017. Renal toxicity with mammalian target of Rapamycin inhibitors: A meta-analysis of randomized clinical trials
  7018. Organ preservation with targeted Rapamycin nanoparticles: a pre-treatment strategy preventing chronic rejection in vivo
  7019. Effect of Rapamycin microspheres in Sjögren syndrome dry eye: preparation and outcomes
  7020. Blocking mammalian target of Rapamycin (mTOR) alleviates neuropathic pain induced by chemotherapeutic bortezomib
  7021. Rapamycin-mediated mTOR inhibition impairs silencing of sex chromosomes and the pachytene piRNA pathway in the mouse testis
  7022. … oxygen species (ROS) production, and inhibition of cell migration and nuclear factor kappa B (Nf-κB)/mammalian target of Rapamycin (m-TOR) signalling …
  7023. Rapamycin corrects T regulatory cell depletion and improves embryo implantation and live birth rates in a murine model
  7024. The effect of the mTOR inhibitor Rapamycin on glucoCEST signal in a preclinical model of glioblastoma
  7025. Neolymphostin A is a covalent phosphoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) dual inhibitor that employs an unusual electrophilic …
  7026. Nicotine inhibits Rapamycin-induced pain through activating mTORC1/S6K/IRS-1-related feedback inhibition loop
  7027. The local mammalian target of Rapamycin (mTOR) modulation: a promising strategy to counteract neurodegeneration
  7028. Regulation of YAP by Mammalian Target of Rapamycin Complex 1 in Endothelial Cells Controls Blood Pressure Through COX-2/mPGES-1/PGE2 Cascade
  7029. Long‐term treatment with the mTOR inhibitor Rapamycin has minor effect on clinical laboratory markers in middle‐aged marmosets
  7030. Androgens induce growth of the limb skeletal muscles in a Rapamycin-insensitive manner
  7031. Rapamycin improves bone mass in high-turnover osteoporosis with iron accumulation through positive effects on osteogenesis and angiogenesis
  7032. Synergistic effect of Rapamycin and metformin against germ cell apoptosis and oxidative stress after testicular torsion/detorsion-induced ischemia/reperfusion …
  7033. Effect and molecular mechanism of mTOR inhibitor Rapamycin on temozolomide‑induced autophagic death of U251 glioma cells
  7034. Clinical significance of chemokine receptor CXCR4 and mammalian target of Rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma
  7035. Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of Rapamycin signaling …
  7036. Delivery of Rapamycin using in situ forming implants promotes immunoregulation and vascularized composite allograft survival
  7037. Rapamycin protects spiral ganglion neurons from gentamicin-induced degeneration in vitro
  7038. Rapamycin may inhibit murine S180 sarcoma growth by regulating the pathways associated with autophagy and cancer stem cells
  7039. Rapamycin ameliorates immune-mediated aplastic anemia by inhibiting the proliferation and metabolism of T cells
  7040. Rapamycin attenuates liver injury caused by vinyl chloride metabolite chloroethanol and lipopolysaccharide in mice
  7041. Plk1-mediated phosphorylation of TSC1 enhances the efficacy of Rapamycin
  7042. Characterization of female germline stem cells from adult mouse ovaries and the role of Rapamycin on them
  7043. Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
  7044. Antitumor effect of sorafenib and mammalian target of Rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence
  7045. The Slt2-MAPK pathway is involved in the mechanism by which target of Rapamycin regulates cell wall components in Ganoderma lucidum
  7046. … to lysine while maintaining an ideal ratio of lysine: methionine alters mammary cellular metabolites, mammalian target of Rapamycin signaling, and gene …
  7047. Dissecting the Biological Effects of Isoflurane through the Mechanistic Target of Rapamycin (mTOR) and microRNAs (miRNAs)
  7048. Is Rapamycin a rapalog?
  7049. Global gene expression of histologically normal primary skin cells from BCNS subjects reveals “single-hit” effects that are influenced by Rapamycin
  7050. The checkpoint kinase TOR (target of Rapamycin) regulates expression of a nuclear‐encoded chloroplast RelA‐SpoT homolog (RSH) and modulates chloroplast …
  7051. Multifarious biologic loaded liposomes that stimulate the mammalian target of Rapamycin signaling pathway show retina neuroprotection after retina damage
  7052. … Carcinoma Tumorigenesis Through Regulating Adenosine‐Monophosphate–Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice
  7053. Rapamycin attenuates articular cartilage degeneration by inhibiting β-catenin in a murine model of osteoarthritis
  7054. Mechanistic target of Rapamycin inhibition with Rapamycin induces autophagy and correlative regulation in white shrimp (Litopenaeus vannamei)
  7055. Targeting cellular metabolism using Rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells
  7056. Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction
  7057. Rapamycin improves sevoflurane‑induced cognitive dysfunction in aged rats by mediating autophagy through the TLR4/MyD88/NF‑κB signaling pathway
  7058. Methionine and valine activate the mammalian target of Rapamycin complex 1 pathway through heterodimeric amino acid taste receptor (TAS1R1/TAS1R3) …
  7059. Response to Rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
  7060. Aldosterone modulates the mechanistic target of Rapamycin signaling in male mice
  7061. Mammalian target of Rapamycin: is it relevant to COPD pathogenesis or treatment?
  7062. Testicular injury attenuated by Rapamycin through induction of autophagy and inhibition of endoplasmic reticulum stress in streptozotocin-induced diabetic rats
  7063. Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to Rapamycin
  7064. … carcinoma cell proliferation and migration by inactivating phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of Rapamycin (mTOR) signaling pathway
  7065. Akt Serine/Threonine Kinase 1 Regulates de Novo Fatty Acid Synthesis through the Mammalian Target of Rapamycin/Sterol Regulatory Element Binding Protein 1 …
  7066. … the synthesis of pancreatic enzymes via the activation of mRNA expression and phosphorylation in the mammalian target of Rapamycin signalling pathways in …
  7067. Rapamycin as a potential treatment for succinate dehydrogenase deficiency
  7068. Rapamycin treatment increases hippocampal cell viability in an mTOR-independent manner during exposure to hypoxia mimetic, cobalt chloride
  7069. Effect of acute aerobic exercise and Rapamycin treatment on autophagy in peripheral blood mononuclear cells of adults with prediabetes
  7070. Everolimus, a mammalian target of Rapamycin inhibitor, ameliorated streptozotocin-induced learning and memory deficits via neurochemical alterations in …
  7071. Use of mammalian target of Rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis
  7072. Curcumin‑induced promoter hypermethylation of the mammalian target of Rapamycin gene in multiple myeloma cells
  7073. A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined Rapamycin and crizotinib therapy
  7074. Rapamycin treatment attenuates angiotensin II-induced abdominal aortic aneurysm formation via VSMC phenotypic modulation and down-regulation of ERK1/2 …
  7075. Addition of the mammalian target of Rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 …
  7076. Critical role of mammalian target of Rapamycin for IL-10 dendritic cell induction by a flagellin A conjugate in preventing allergic sensitization
  7077. Synergistic antitumour effects of Rapamycin and oncolytic reovirus
  7078. The contribution of non-essential Schizosaccharomyces pombe genes to fitness in response to altered nutrient supply and target of Rapamycin activity
  7079. The plant target of Rapamycin kinase: a connecTOR between sulfur and growth
  7080. Graded replacing fishmeal with canola meal in diets affects growth and target of Rapamycin pathway gene expression of juvenile blunt snout bream, Megalobrama …
  7081. Mechanistic target of Rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy
  7082. “Tandem” Nanomedicine Approach against Osteoclastogenesis: Polysulfide Micelles Synergically Scavenge ROS and Release Rapamycin
  7083. … effects on human pancreatic cancer cells by triggering cell cycle arrest, apoptosis, and modulation of AKT/mammalian target of Rapamycin (mTOR) and signal …
  7084. Negative feedback loop of autophagy and endoplasmic reticulum stress in Rapamycin protection against renal ischemia‐reperfusion injury during initial reperfusion …
  7085. Functional effects of cuprizone-induced demyelination in the presence of the mTOR-inhibitor Rapamycin
  7086. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β …
  7087. … cell activation and liver fibrosis through modulation of intracellular ATP levels and the liver kinase B1/AMP-activated protein kinase/mammalian target of Rapamycin …
  7088. Fluorofenidone inhibits UV‐A induced senescence in human dermal fibroblasts via the mammalian target of Rapamycin‐dependent SIRT1 pathway
  7089. Rapamycin-and starvation-induced autophagy are associated with miRNA dysregulation in A549 cells
  7090. The antidiabetic drug lobeglitazone protects mice from lipogenesis-induced liver injury via mechanistic target of Rapamycin complex 1 inhibition
  7091. Protective effects of Rapamycin induced autophagy on CLP septic mice
  7092. Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of Rapamycin binding site
  7093. Preclinical evidence of the enhanced effectiveness of combined Rapamycin and AICAR in reducing kidney cancer
  7094. Chloroquine Enhances Rapamycin-induced Apoptosis in MG63 Cells
  7095. Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK
  7096. Takeda G protein-coupled receptor 5-mechanistic target of Rapamycin complex 1 signaling contributes to the increment of glucagon-like peptide-1 production …
  7097. Eriocalyxin B induces apoptosis and autophagy involving Akt/mammalian target of Rapamycin (mTOR) pathway in prostate cancer cells
  7098. Rapamycin treatment ameliorates age-related accumulation of toxic metabolic intermediates in brains of the Ts65Dn mouse model of Down syndrome and …
  7099. Interplay of autophagy inducer Rapamycin and proteasome inhibitor mg132 in reduction of foam cell formation and inflammatory cytokine expression
  7100. Gymnemic acid I triggers mechanistic target of Rapamycin‐mediated β cells cytoprotection through the promotion of autophagy under high glucose stress
  7101. Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK 1/2 and mTOR pathways in vitro and in vivo
  7102. l-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of Rapamycin complex 1 signaling
  7103. Target of Rapamycin (TOR) determines appendage size during pupa formation of the red flour beetle Tribolium castaneum
  7104. Rapamycin-induced autophagy decreases Myf5 and MyoD proteins in C2C12 myoblast cells
  7105. Heterogeneity of phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of Rapamycin activation in cancer: Is PI3K isoform specificity important?
  7106. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression
  7107. inhibition of mammalian target of Rapamycin complex 1 signaling by n-3 polyunsaturated fatty acids promotes locomotor recovery after spinal cord injury
  7108. … and new bone formation by cultured adipose tissue-derived stem cells through the IGF-1R/AKT/mammalian target of Rapamycin complex 1 (mTORC1) …
  7109. Dysregulated expression of the key effectors of the mammalian target of Rapamycin signalling pathway in cutaneous papillomas of dogs
  7110. Rapamycin-Loaded, CapryolTM 90 and Oleic Acid Mediated Nanoemulsions: Formulation Development, Characterization and Toxicity Assessment
  7111. Compound C enhances tau phosphorylation at Serine396 via PI3K activation in an AMPK and Rapamycin independent way in differentiated SH-SY5Y cells
  7112. The potential effects of hemp seed/evening primrose oils on the mammalian target of Rapamycin complex 1 and interferon-gamma genes expression in …
  7113. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells
  7114. Identification of novel components of target-of-Rapamycin signaling pathway by network-based multi-omics integrative analysis
  7115. Fructose and glucose can regulate mammalian target of Rapamycin complex 1 and lipogenic gene expression via distinct pathways
  7116. Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of Rapamycin
  7117. … mesenchymal stem cells promote head and neck cancer progression through Periostin‐mediated phosphoinositide 3‐kinase/Akt/mammalian target of Rapamycin
  7118. Long non‑coding RNA SENCR alleviates the inhibitory effects of Rapamycin on human umbilical vein endothelial cells
  7119. Enhanced Rapamycin production through kinetic and purification studies by mutant strain of Streptomyces hygroscopicus NTG-30-27
  7120. Prevention of post-ischemic seizure by Rapamycin is associated with deactivation of mTOR and ERK1/2 pathways in hyperglycemic rats
  7121. Topical Rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature
  7122. Inhibitory effect of Rapamycin on proliferation of human umbilical arterial smooth muscle cells
  7123. Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8+ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous …
  7124. Mechanistic target of Rapamycin pathway in epileptic disorders
  7125. inhibition of the mammalian target of Rapamycin may augment the increase in soluble klotho levels in renal transplantation recipients
  7126. … induces apoptosis of estrogen receptor-positive MG-63 osteosarcoma cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian target of Rapamycin …
  7127. Circadian rhythms, metabolic oscillators, and the target of Rapamycin (TOR) pathway: the Neurospora connection
  7128. Leucine regulates α-amylase and trypsin synthesis in dairy calf pancreatic tissue in vitro via the mammalian target of Rapamycin signalling pathway
  7129. Adrenoceptor regulation of the mechanistic target of Rapamycin in muscle and adipose tissue
  7130. Accelerated autophagy of cecal ligation and puncture-induced myocardial dysfunction and its correlation with mammalian target of Rapamycin pathway in rats
  7131. A selective CD28 antagonist and Rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice
  7132. A component of the TOR (Target of Rapamycin) nutrient-sensing pathway plays a role in circadian rhythmicity in Neurospora crassa
  7133. … reverses palbociclib resistance in ER+ human breast cancer cells by inhibiting phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of Rapamycin …
  7134. … attenuates high glucose-mediated mesangial cell injury by inhibiting the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin (PI3K/Akt/mTOR) …
  7135. Comparing the effects of the mTOR inhibitors azithromycin and Rapamycin on in vitro expanded regulatory T cells
  7136. Development and characterisation of a panel of phosphatidylinositide 3-kinase–mammalian target of Rapamycin inhibitor resistant lung cancer cell lines
  7137. Rapamycin rescues BMP mediated midline craniosynostosis phenotype through reduction of mTOR signaling in a mouse model
  7138. … inhibitor, TUPS, attenuates isoproterenol/angiotensin II‐induced cardiac hypertrophy through mammalian target of Rapamycin‐mediated autophagy inhibition
  7139. Pathology of calcineurin and mammalian target of Rapamycin inhibitors in kidney transplantation
  7140. Calorie restriction and Rapamycin administration induce stem cell self-renewal and consequent development and production in the mammary gland
  7141. Rapamycin exacerbates cardiovascular dysfunction after complete high-thoracic spinal cord injury
  7142. Mechanistic target of Rapamycin (mTOR) in the cancer setting
  7143. … multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (Rapamycin target-eluting) system for …
  7144. Dynamic regulation of caveolin-1 phosphorylation and caveolae formation by mammalian target of Rapamycin complex 2 in bladder cancer cells
  7145. Concentration‑dependent effects of Rapamycin on proliferation, migration and apoptosis of endothelial cells in human venous malformation
  7146. Effects of long-term Rapamycin treatment on glial scar formation after cryogenic traumatic brain injury in mice
  7147. Rapamycin liposome gutta inhibiting fungal keratitis of rats
  7148. Successful reversal of ovarian hyperstimulation syndrome in a mouse model by Rapamycin, an mTOR pathway inhibitor
  7149. Rapamycin alleviates hormone imbalance-induced chronic nonbacterial inflammation in rat prostate through activating autophagy via the mTOR/ULK1/ATG13 …
  7150. The mTOR kinase inhibitor Rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human …
  7151. … ‐1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin‐1/Mechanistic Target of Rapamycin Complex 2 and 5 …
  7152. Ethanol-induced cognitive dysfunction is associated with alterations in the mammalian target of Rapamycin signalling pathway in the hippocampus of male mice
  7153. Mammalian target of Rapamycin regulates a hyperresponsive state in pulmonary neutrophils late after burn injury
  7154. Effect of silencing lncRNATUG1 on Rapamycin‑induced inhibition of endothelial cell proliferation and migration
  7155. Mesenchymal stem cells in combination with low-dose Rapamycin significantly prolong islet allograft survival through induction of regulatory T cells
  7156. MicroRNA-495 confers increased sensitivity to chemotherapeutic agents in gastric cancer via the mammalian target of Rapamycin (mTOR) signaling pathway …
  7157. HPV-16 E7 expression up-regulates phospholipase D activity and promotes Rapamycin resistance in a pRB-dependent manner
  7158. Integrin alpha V beta 3 targeted dendrimer‐Rapamycin conjugate reduces fibroblast‐mediated prostate tumor progression and metastasis
  7159. Rapamycin provides anti‑epileptogenic effect in a rat model of post‑traumatic epilepsy via deactivation of mTOR signaling pathway
  7160. Rapamycin− mTOR+ BRAF=? Using relational similarity to find therapeutically relevant drug-gene relationships in unstructured text
  7161. Mammalian target of Rapamycin: A metabolic rheostat for regulating adipose tissue function and cardiovascular health
  7162. Efficacy and Tolerance of Sirolimus (Rapamycin) for Extracranial Arteriovenous Malformations in Children and Adults
  7163. In vitro evaluation of effects of metformin on morphine and methadone tolerance through mammalian target of Rapamycin signaling pathway
  7164. High Glucose Affects the Cytotoxic Potential of Rapamycin, Metformin and Hydrogen Peroxide in Cultured Human Mesenchymal Stem Cells
  7165. Amino acid starvation promotes podocyte autophagy through mammalian target of Rapamycin inhibition and transcription factor EB activation
  7166. Rapamycin rescues endoplasmic reticulum stress–induced dry eye syndrome in mice
  7167. Activation of the mammalian target of Rapamycin signaling pathway underlies a novel inhibitory role of ring finger protein 182 in ventricular remodeling after myocardial …
  7168. Rapamycin–“One size does not fit all”
  7169. Cross talk networks of mammalian target of Rapamycin signaling with the ubiquitin proteasome system and their clinical implications in multiple myeloma
  7170. Rapamycin attenuates Th2-driven experimental allergic conjunctivitis
  7171. A combined N-terminomics and shotgun proteomics approach to investigate the responses of human cells to Rapamycin and zinc at the mitochondrial level
  7172. Lactobacillus casei protects dextran sodium sulfate-or Rapamycin-induced colonic inflammation in the mouse
  7173. … synthetase-mediated essential amino acids regulate β-casein synthesis via cell proliferation and mammalian target of Rapamycin (mTOR) signaling pathway …
  7174. MicroRNA-496 and mechanistic target of Rapamycin expression are associated with type 2 diabetes mellitus and obesity in elderly people
  7175. … , leucine, methionine, threonine, and other amino acids on insulin and glucagon concentrations, mammalian target of Rapamycin (mTOR) signaling, and …
  7176. Retraction: A005, a novel inhibitor of phosphatidylinositol 3-kinase/mammalian target of Rapamycin, prevents osteosarcoma-induced osteolysis.
  7177. Rapamycin regulates cholesterol biosynthesis and cytoplasmic ribosomal proteins in hippocampus and temporal lobe of APP/PS1 mouse
  7178. Rapamycin attenuates a murine model of thoracic aortic aneurysm by downregulating the miR-126–3p mediated activation of MAPK/ERK signalling pathway
  7179. Use of mammalian target of Rapamycin inhibitors for pancreas transplant immunosuppression is associated with improved allograft survival and improved early patient …
  7180. Effect of topical Rapamycin 1% on multiple trichoepitheliomas
  7181. Activation of mechanistic target of Rapamycin complex 1: the common link between rheumatoid arthritis and diabetes mellitus
  7182. Dysplasia and overgrowth: magnetic resonance imaging of pediatric brain abnormalities secondary to alterations in the mechanistic target of Rapamycin pathway
  7183. Rapamycin combi with TAE on the growth, metastasis, and prognosis of hepatocellular carcinoma in rat models
  7184. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated …
  7185. Favorable response to mammalian target of Rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver
  7186. … inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of Rapamycin …
  7187. … inhibits reactive oxygen species production and apoptosis in primary spinal cord neurons by activating autophagy via the mechanistic target of Rapamycin …
  7188. Distinct patterns of gene expression in human cardiac fibroblasts exposed to Rapamycin treatment or methionine restriction
  7189. … factor 1α (HIF-1α) promotes autophagy and inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian target of Rapamycin (mTOR) signaling pathway in …
  7190. NR6A1 regulates lipid metabolism through mammalian target of Rapamycin complex 1 in HepG2 cells
  7191. … relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of Rapamycin complex 1 (mTORC1)
  7192. Effects of early exposure of isoflurane on chronic pain via the mammalian target of Rapamycin signal pathway
  7193. Analyses of alveolar epithelial injury via lipid-related stress in mammalian target of Rapamycin inhibitor-induced lung disease
  7194. The role of CIP2A as a therapeutic target of Rapamycin in radioresistant head and neck cancer with TP53 mutation
  7195. Effects of NVP‑BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor, on HTLV-1-infected T-cell lines
  7196. … an antidiabetic drug, against ovarian cancer cells involves inhibition of cysteine-rich 61 (Cyr61)/Akt/Mammalian target of Rapamycin (mTOR) signaling pathway
  7197. Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of Rapamycin complex 1 (mTORC1) inhibitors
  7198. Mechanistic target of Rapamycin: integrating growth factor and nutrient signaling in the collecting duct
  7199. … Restriction Was Attenuated by Oxidative-Stress-Induced inhibition of Vacuolar H+-Adenosine Triphosphatase/Mechanistic Target of Rapamycin Complex 1 Signaling
  7200. Rapamycin and FK506 derivative TH2849 could ameliorate neurodegenerative diseases through autophagy with low immunosuppressive effect
  7201. … Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 …
  7202. Prevention of type 1 diabetes with acetalated dextran microparticles containing Rapamycin and pancreatic peptide P31
  7203. Rapamycin attenuates pathological hypertrophy caused by an absence of trabecular formation
  7204. Rapamycin prolongs graft survival and induces CD4+ IFN-γ+ IL-10+ regulatory type 1 cells in old recipient mice
  7205. Hollow Fe3O4/graphene oxide nanocomposites as novel Rapamycin carrier: formulation optimization and in vitro characterization
  7206. … GTPase-activating protein 1 regulates cytoskeletal reorganization and facilitates NKG2D-mediated mechanistic target of Rapamycin complex 1 activation and …
  7207. Production, characterization, and cross-reactivity of a polyclonal antibody against Arabidopsis TARGET OF Rapamycin
  7208. Differential effects of various genetic mouse models of the mechanistic target of Rapamycin complex I inhibition on heart failure
  7209. Different roles of Akt and mechanistic target of Rapamycin in serum‑dependent chondroprotection of human osteoarthritic chondrocytes
  7210. Glaucocalyxin A as a natural product increases amyloid β clearance and decreases tau phosphorylation involving the mammalian target of Rapamycin signaling …
  7211. in vitro determination of Rapamycin-triggered FKBP–FRB interactions using a molecular tension probe
  7212. … of the roles of phosphatidylinositol-4,5-bisphosphate and individual subunits in assembly, localization, and function of Saccharomyces cerevisiae target of Rapamycin …
  7213. Derivation of Rapamycin: adventures in natural product chemistry
  7214. Performance, diameter of muscle fibers, and gene expression of mechanistic target of Rapamycin in pectoralis major muscle of broilers supplemented with leucine and …
  7215. Biogenesis of Autophagosome in Trichomonas vaginalis during Macroautophagy Induced by Rapamycin‐treatment and Iron or Glucose Starvation Conditions
  7216. Regulation of protein kinase cδ nuclear import and Apoptosis by Mechanistic target of Rapamycin Complex-1
  7217. … and hydrodynamic injection and sequential stacking featuring sweeping for signal amplification following MEKC during the analysis of Rapamycin (sirolimus) in serum …
  7218. Restoring T-helper 17 cell/regulatory T-cell balance and decreasing disease activity by Rapamycin and all-trans retinoic acid in patients with systemic lupus …
  7219. Rapamycin and FTY720 alleviate atherosclerosis by cross talk of macrophage polarization and autophagy
  7220. CLOVES syndrome: treatment with oral Rapamycin. Report of two cases
  7221. Enhanced Rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody
  7222. Insulin-mimetic effects of short-term Rapamycin in type 1 diabetic patients prior to islet transplantation
  7223. Clinical monitoring challenges in the pharmacological treatment and management of lymphatic anomalies with mammalian target of Rapamycin inhibition
  7224. Rapamycin inhibits the growth and collagen production of fibroblasts derived from human urethral scar tissue
  7225. Osteopontin counters human immunodeficiency virus type 1–induced impairment of neurite growth through mammalian target of Rapamycin and beta-integrin …
  7226. … effects of hemp seed/evening primrose oil supplement in comparison with Rapamycin on the expression of the mammalian target of Rapamycin-complex 2 and …
  7227. Concomitant use of Rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han: SPRD rats: A study of the mechanism of action
  7228. Poly (ADP‐ribose) polymerase 1 induces cardiac fibrosis by mediating mammalian target of Rapamycin activity
  7229. Premature recruitment of oocyte pool and increased mTOR activity in Fmr1 knockout mice and reversal of phenotype with Rapamycin
  7230. A unified mitochondria mechanistic target of Rapamycin acyl‐coenzyme A dehydrogenase 10 signal relay modulation for metformin growth inhibition in human …
  7231. Epimagnolin targeting on an active pocket of mammalian target of Rapamycin suppressed cell transformation and colony growth of lung cancer cells
  7232. Single injection of Rapamycin blocks post–food restriction hyperphagia and body-weight regain in rats.
  7233. Hypertrophied myocardium is vulnerable to ischemia/reperfusion injury and refractory to Rapamycin-induced protection due to increased oxidative/nitrative stress
  7234. Effects of minocycline and Rapamycin in gamma-irradiated human embryonic stem cells-derived cerebral organoids
  7235. Hepatic phosphorylation status of serine/threonine kinase 1, mammalian target of Rapamycin signaling proteins, and growth rate in Holstein heifer calves in …
  7236. Overexpression of Biglycan is Associated with Resistance to Rapamycin in Human WERI-Rb-1 Retinoblastoma Cells by Inducing the Activation of the …
  7237. Effect of Rapamycin on the level of autophagy in rats with early heart failure
  7238. Protein kinase C is a key target for attenuation of Leigh syndrome by Rapamycin
  7239. Mammalian target of Rapamycin complex 1 activation disrupts the Low-Density lipoprotein receptor pathway: a novel mechanism for extracellular matrix accumulation …
  7240. … by lowering drug resistance through inhibition of far-upstream element-binding protein 2-mediated phosphoinositide 3-Kinase/Akt/mammalian target of Rapamycin …
  7241. Effects of inhibiting mTOR with Rapamycin on behavior, development, neuromuscular physiology and cardiac function in larval Drosophila
  7242. … promotes the proliferation and migration of human glioma cancer cells through the protein kinase B/mechanistic target of Rapamycin pathway by phosphatase …
  7243. Combining the mammalian target of Rapamycin inhibitor, Rapamycin, with resveratrol has a synergistic effect in multiple myeloma
  7244. … protects the myocardium in sepsis by activating the phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of Rapamycin (mTOR) pathway and inhibiting …
  7245. Nanostructured lipid carriers containing Rapamycin for prevention of corneal fibroblasts proliferation and haze propagation after burn injuries: In vitro and in vivo
  7246. … of cell migration and invasion, and suppression of phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of Rapamycin (mTOR) signaling pathway
  7247. … of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of Rapamycin inhibitors and programmed death …
  7248. Insulin-like growth factor 1 inhibits autophagy of human colorectal carcinoma drug-resistant cells via the protein kinase B/mammalian target of Rapamycin …
  7249. Simultaneous activation of impaired autophagy and the mammalian target of Rapamycin pathway in oral squamous cell carcinoma
  7250. Correction: Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of akt/mammalian target of Rapamycin pathway
  7251. Rapamycin enhances lytic replication of Epstein-Barr virus in gastric carcinoma cells by increasing the transcriptional activities of immediate-early lytic promoters
  7252. Mammalian target of Rapamycin complex 2 signaling in obese women changes after bariatric surgery
  7253. Activity dependent mammalian target of Rapamycin pathway and brain derived neurotrophic factor release is required for the rapid antidepressant effects of puerarin
  7254. Rapamycin protects against early brain injury independent of cerebral blood flow changes in a mouse model of subarachnoid haemorrhage
  7255. Expression of the miR-150 tumor suppressor is restored by and synergizes with Rapamycin in a human leukemia T-cell line
  7256. Locomotor treadmill training promotes soleus trophism by mammalian target of Rapamycin pathway in paraplegic rats
  7257. A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
  7258. Discovery of the actinoplanic acid pathway in Streptomyces Rapamycinicus reveals a genetically conserved synergism with Rapamycin
  7259. Molecular interplay between hyperactive mammalian target of Rapamycin signaling and Alzheimer’s disease neuropathology in the NS-Pten knockout mouse model
  7260. … against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of Rapamycin complex 1 pathways
  7261. The putative transcription factor CaMaf1 controls the sensitivity to lithium and Rapamycin and represses RNA polymerase III transcription in Candida albicans
  7262. Myeloid-derived suppressor cells (MDSCs) and mechanistic target of Rapamycin (mTOR) signaling pathway interact through inducible nitric oxide synthase …
  7263. Rapamycin exposure to host and to adult worms affects life history traits of Heligmosomoides bakeri
  7264. Rapamycin‑induced autophagy attenuates hormone‑imbalance‑induced chronic non‑bacterial prostatitis in rats via the inhibition of NLRP3 inflammasome …
  7265. Genetic defects in SAPK signalling, chromatin regulation, vesicle transport and CoA-related lipid metabolism are rescued by Rapamycin in fission yeast
  7266. Effects and Mechanisms of Rapamycin Action on Experimental Neurodegeneration
  7267. Mechanistic target of Rapamycin (mTOR) implicated in plasticity of the reproductive axis during social status transitions
  7268. … attenuates airway inflammation by suppressing autophagy via phosphatidylinositol 3‐kinase/protein kinase B/mammalian target of Rapamycin signaling pathway in rat …
  7269. CLAPO syndrome: Effective response to treatment with oral Rapamycin
  7270. Ketamine effects on mammalian target of Rapamycin signaling in the mouse limbic system depend on functional dopamine D3 receptors
  7271. Novel function of cyclooxygenase-2: suppressing mycobacteria by promoting autophagy via the protein kinase B/mammalian target of Rapamycin pathway
  7272. … Epithelial-to-Mesenchymal Transition (EMT) progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin …
  7273. … proliferation of human ovarian cancer cells in vitro via the phosphatidylinositol-3-kinase (PI3K)/akt and the mammalian target of Rapamycin (mTOR) and Wnt/β …
  7274. Role of mammalian target of Rapamycin signaling pathway in regulation of fatty acid oxidation in a preeclampsia-like mouse model treated with pravastatin
  7275. Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a …
  7276. PPP2R2D, a regulatory subunit of protein phosphatase 2A, promotes gastric cancer growth and metastasis via mechanistic target of Rapamycin activation
  7277. Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of Rapamycin signaling
  7278. Rapamycin reduces mortality in acute-stage paraquat-induced toxicity in zebrafish
  7279. Cloning and characterization of the target protein subunit lst8 of Rapamycin in Apostichopus japonicus
  7280. Target of Rapamycin FATC domain as a general membrane anchor: The FKBP‐12 like domain of FKBP38 as a case study
  7281. Stable isotope labeling reveals novel insights into ubiquitin-mediated protein aggregation with age, calorie restriction, and Rapamycin treatment
  7282. The correlation between mammalian target of Rapamycin (mTOR) gene expression and sperm DNA damage among infertile patients with and without varicocele
  7283. CC-115, a Dual mammalian target of Rapamycin/DNA-dependent protein kinase inhibitor in clinical trial, is a substrate of ATP-binding cassette G2, a risk factOR for …
  7284. Facial angiofibromas treated by Rapamycin 0.05% ointment and a combined laser therapy
  7285. … are mediated via mitochondrial-mediated apoptosis, inhibition of cell migration, invasion suppression, and mammalian target of Rapamycin (mTOR)-TOR/PI3K …
  7286. The Continuous Story of the Miraculous Drug, Rapamycin
  7287. … lysine/methionine ratios and glucose levels and their effects on casein synthesis via activation of the mechanistic target of Rapamycin signaling pathway in …
  7288. The combination of NVP‑BEZ235 and Rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway
  7289. CD8+ T cells: mechanistic target of Rapamycin and eukaryotic initiation factor 2 in elite HIV-1 control
  7290. Rapamycin blocks the neuroprotective effects of sex steroids in the adult birdsong system
  7291. Orexin-A Stimulates Insulin Secretion Through the Activation of the OX1 Receptor and Mammalian Target of Rapamycin in Rat Insulinoma Cells
  7292. Rapamycin but not acarbose decreases age-related loss of outer hair cells in the mouse Cochlea
  7293. Sepsis-induced myocardial dysfunction and mammalian target of Rapamycin signalling pathways
  7294. Rapamycin induces an eNOS dependent increase in brain collateral perfusion after acute experimental stroke in rats
  7295. Polycystin-2 is required for starvation-and Rapamycin-induced atrophy in myotubes
  7296. Current Update on Rapamycin Production and its Potential Clinical Implications
  7297. The effects of AICAR and Rapamycin on mitochondrial function in immortalized mitochondrial DNA mutator murine embryonic fibroblasts
  7298. Tivantinib hampers the proliferation of glioblastoma cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) signaling
  7299. … lignocaine exhibits potent antilung cancer cell activity by inhibiting the phosphoinositide 3-kinases/mammalian target of Rapamycin/mammalian target of Rapamycin …
  7300. Systemic Rapamycin Attenuates Morphine-Induced Analgesic Tolerance and Hyperalgesia in Mice
  7301. Integrating microRNA and mRNA expression in Rapamycin-treated T-cell acute lymphoblastic leukemia
  7302. Gastric Mammalian Target of Rapamycin Signaling Contributes to inhibition of Ghrelin Expression Induced by Roux-En-Y Gastric Bypass
  7303. Neuroprotective effect of Rapamycin against Parkinson’s disease in mice
  7304. Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of Rapamycin inhibitors
  7305. Effects of Rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells
  7306. Rapamycin affect the apoptosis of splenic CD4+ CD25+ regulatory T cells of mouse severe aplastic anemia model
  7307. Role of mammalian target of Rapamycin activation in menthol-induced expressions of airway inflammation-related factors in human bronchial epithelial cells in vitro
  7308. Local intra-articular injection of Rapamycin inhibits NLRP3 activity and prevents osteoarthritis in mouse DMM models
  7309. Rapamycin increases breast tumor burden in young wheel-running mice
  7310. Decreased Expression of Urinary Mammalian Target of Rapamycin mRNA Is Related to Chronic Renal Fibrosis in IgAN
  7311. Rapamycin induces the expression of heme oxygenase-1 and peroxyredoxin-1 in normal hepatocytes but not in tumorigenic liver cells
  7312. Activation of mammalian terget of Rapamycin kinase and glycogen synthase kinase‐3β accompanies abnormal accumulation of cholesterol in fibroblasts from …
  7313. … expression of muscle RING‐finger protein‐1 and muscle atrophy F‐box proteins and proteins involved in the mechanistic target of Rapamycin pathway and autophagy …
  7314. Rapamycin protects against paraquat‑induced pulmonary epithelial‑mesenchymal transition via the Wnt/β‑catenin signaling pathway
  7315. … (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of Rapamycin inhibitors (mTORI) after …
  7316. Rapamycin administration during normal and diabetic pregnancy effects the mTOR and angiogenesis signaling in the rat placenta
  7317. … neointima hyperplasia after vascular injury via p-adenosine 5′-monophosphate-activated protein kinase/mammalian target of Rapamycin complex 1 pathway
  7318. inhibition of mammalian target of Rapamycin decreases intrarenal oxygen availability and alters glomerular permeability
  7319. Chromosomal Instability and Evolution of Transformed Phenotype in Cell Lines Selected from Senescent Rat Embryonic Fibroblasts with Rapamycin
  7320. Renal Cell Carcinoma Associated With Xp11. 2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of Rapamycin (mTOR) Inhibitors
  7321. A combination regimen of low-dose bortezomib and Rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model
  7322. Synthesis and anticancer activity of novel Rapamycin C‐28 containing triazole moiety compounds
  7323. Correction to: The mTOR inhibitor Rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
  7324. Co-localization of insulin-like growth factor binding protein-1, casein kinase-2β, and mechanistic target of Rapamycin in human hepatocellular carcinoma cells …
  7325. Oral Preconditioning of Donors After Brain Death With Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation.
  7326. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use—Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With …
  7327. Cysteine‐rich protein 61 regulates adipocyte differentiation from mesenchymal stem cells through mammalian target of Rapamycin complex 1 and canonical Wnt …
  7328. Retrospective study of Rapamycin or rapalog 0· 1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost
  7329. … Flux in Human Bone Mesenchymal Stromal Cells via NMDA Receptor–Ca2+–Extracellular Signal-Regulated Kinase–Mammalian Target of Rapamycin …
  7330. Variability of the mammalian target of Rapamycin inhibitors is correlated with long-term renal graft survival
  7331. inhibition of 5‐Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β‐Arrestin2–Mammalian Target of Rapamycin/p70S6K Pathway
  7332. Assessing the mechanistic target of Rapamycin complex-1 pathway in response to resistance exercise and feeding in human skeletal muscle by multiplex assay
  7333. Rapamycin Rescues Age-Related Changes in Muscle-Derived Stem/Progenitor Cells from Progeroid Mice
  7334. A Photo‐Stable Indocyanine Green and Rapamycin Co‐Delivery System Based on Poly (Glutamic Acid)‐Modified Manganese Phosphate for Synergetic Tumor …
  7335. Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year Results
  7336. Captopril suppresses hepatic mammalian target of Rapamycin cell signaling and biomarkers of inflammation and oxidative stress in thioacetamide-induced …
  7337. Rapamycin-induced Protein Dimerization as a Tool for C. elegans research​
  7338. … and inflammatory response by Rapamycin in target and distant organs in rats exposed to hindlimb ischemia–reperfusion: the role of mammalian target of Rapamycin
  7339. FRI0063 Rapamycin induces remission in patients with refractory rheumatoid arthritis
  7340. Laser-Assisted Delivery of Topical Rapamycin: mTOR inhibition for Birt–Hogg–Dube Syndrome
  7341. Influence of phosphatidylinositol-3-kinase/protein kinase b-mammalian target of Rapamycin signaling pathway on the neuropathic pain complicated by …
  7342. Rapamycin and ZSTK474 can have differential effects at different post‑infection time‑points regarding CVB3 replication and CVB3‑induced autophagy
  7343. … in vitro and in mouse tumor xenografts and activates autophagy and apoptosis by downregulation of the mammalian target of Rapamycin (mTOR)/PI3K/AKT …
  7344. AB0536 Rapamycin attenuates symptom and restores the balance of th17/treg in refractory primary sjogren’s syndrome
  7345. Suren Sehgal & The Story of Rapamycin
  7346. Molecular Mechanisms in Signaling by Target of Rapamycin Complex 2 in Saccharomyces cerevisiae
  7347. Analysis of the inhibitory effect of Rapamycin on Fusarium asiaticum by next generation RNA sequencing
  7348. Bioinformatics analysis of gefitinib or Rapamycin on inhibiting the survival of hela in the low glucose and high lactic acid environment
  7349. Semisynthesis of 3‐Hydroxyoxindole Rapamycin Analogues Through Site‐ and Stereoselective Trapping of Oxonium Ylides in RhII‐Catalyzed Three‐Component …
  7350. Rapamycin alleviated pulmonary injury induced by fat embolism syndrome in rats
  7351. AB0376 Rapamycin induces remission in patients with newly diagnosed rheumatoid arthritis
  7352. Effect of mechanistic target of Rapamycin inhibitors on postrenal transplantation malignancy: A nationwide cohort study
  7353. Central action of Rapamycin on early ischemic injury and related cardiac depression following experimental subarachnoid hemorrhage
  7354. … electromagnetic fields inhibit osteoclast differentiation in RAW264. 7 macrophages via suppression of the protein kinase B/mammalian target of Rapamycin …
  7355. Assessing the efficacy of mammalian target of Rapamycin inhibitors by phosphorylation of p70S6K in CD4-positive cells of liver transplant patients
  7356. CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR …
  7357. The role of mammalian target of Rapamycin pathway in the pathogenesis of pauci-immune glomerulonephritis
  7358. Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm …
  7359. Redox-proteomes of human NOS1-transduced versus MOCK SH-SY5Y neuroblastoma cells under full nutrition, serum-free starvation, and Rapamycin …
  7360. Activation of mammalian target of Rapamycin induces lipid accumulation in the diaphragm of ventilated rats and hypoxia-treated C2C12 cells
  7361. Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency
  7362. Construction of a mutant of Actinoplanes sp. N902-109 that produces a new Rapamycin analog
  7363. The protective effect and mechanism of Rapamycin in the rat model of IgA nephropathy
  7364. Silent information regulator 1 negatively regulates atherosclerotic angiogenesis via mammalian target of Rapamycin complex 1 signaling pathway
  7365. Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex
  7366. P. 255Possible efficacy of Rapamycin on myodegeneration in VCPDM mouse model
  7367. A NOVEL APPROACH IN COLORECTAL CANCER AND DIABETES MANAGEMENT: ROLE OF METFORMIN AND Rapamycin
  7368. B-cell-specific mammalian target of Rapamycin complex 1 activation results in severe osteoarthritis in mice
  7369. A novel diazoresin/Rapamycin covalent capillary coating for the separation of biomacromolecules by capillary electrophoresis
  7370. Role of LncRNA MALAT-1 and MicroRNA-199 in Rapamycin induced cardioprotection against reperfusion injury in diabetic rabbits
  7371. Treatment of benign cephalic histiocytosis with topical 1% Rapamycin ointment
  7372. inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway, Reactive …
  7373. Does mammalian target of Rapamycin or sestrin 1 protein signaling have a role in bone fracture healing?
  7374. Deregulated phospholipase D2/mammalian target of Rapamycin/hypoxia-inducible factor 1 alpha in peripheral T lymphocytes of oral lichen planus correlated with …
  7375. Synergistic cytoprotection by co-treatment with dexamethasone and Rapamycin against proinflammatory cytokine-induced alveolar epithelial cell injury
  7376. Evidence that decreased expression of sinusoidal bile acid transporters accounts for the inhibition by Rapamycin of bile flow recovery following liver ischemia
  7377. SP772 Rapamycin PROMOTES CELLULAR DEATH THROUGH THE ACTIVATION OF AUTOPHAGY VIA P75NTR IN KAPOSI SARCOMA CELLS
  7378. Rapamycin Suppresses TGF-β1-Induced Nasopharyngeal Cancer Stem Cell Metastasis by Inhibiting Mitochondrial Metabolism
  7379. Research advances in the mammalian target of Rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma
  7380. The impact of mammalian target of Rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer …
  7381. Mammalian target of Rapamycin inhibitors in a patient with polycystic kidney disease-1-tuberous sclerosis-2 contiguous gene syndrome
  7382. siRNA blocking of mammalian target of Rapamycin (mTOR) attenuates pathology in annonacin-induced tauopathy in mice
  7383. Effect of Rapamycin on mesenchymal stem cells treatment for swine myocardial infarction
  7384. Amino Acid-and Insulin-Induced Activation of Mechanistic Target of Rapamycin Complex 1 in Neonatal Piglet Skeletal Muscle Involves Sestin2-GATOR2, Rag A/C …
  7385. Enhanced Production of Anti-PD1 Antibody in CHO Cells through Transient Co-Transfection with Anti-Apoptotic Gene Bcl-xL Combined with Rapamycin
  7386. Metformin: Antineoplastic Activity through the Mammalian Target of Rapamycin Pathway
  7387. 4-Phenylbutyric acid and Rapamycin improved diabetic status in high fat diet/streptozotocin-induced type 2 diabetes through activation of autophagy
  7388. … Papillomavirus of High Oncogenic Potential in Immunosuppressed Women on Renal Replacement Therapy With and Without Mammalian Target of Rapamycin …
  7389. The Mammalian Target of Rapamycin–70-kDa Ribosomal Protein S6 Kinase Axis Inhibits the Biological Function of Tongue Squamous Cell Carcinoma
  7390. Assessment of drug–drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of Rapamycin kinase
  7391. Regression of renal angiomyolipomas with oral Rapamycin therapy in a patient with tuberous sclerosis complex disease
  7392. Combined treatment with simvastatin and Rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells
  7393. Differential expression of phospho‐S6 in hair follicle tumors: Evidence of mammalian target of Rapamycin pathway activation
  7394. Impact of Rapamycin on Genome Organization
  7395. Srategies for enhanced production of Rapamycin
  7396. Targeting Cancer cell metabolism via Target of Rapamycin
  7397. INTERVENTION WITH Rapamycin TO IMPROVE HEALTHY AGING AND LONGEVITY IN A NON-HUMAN PRIMATE
  7398. Kaposi Sarcoma in the Era of Rapamycin Remains a Therapeutic Challenge in Organ Transplant Recipients.
  7399. Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
  7400. The mammalian target of Rapamycin protein expression in human granulosa cell tumors
  7401. Effects of Rapamycin on chromatin–implications for ageing and tumour suppression
  7402. Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage?
  7403. Reply: Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage?
  7404. Differential Roles of Mammalian Target of Rapamycin Complexes 1 and 2 in Migration of Prostate Cancer Cells
  7405. Mitigation of Inflammation Induced By Monosodium Urate Crystals in Mice By Treatment with SVP-Rapamycin
  7406. Arterial infusion of Rapamycin in the treatment of rabbit hepatocellular carcinoma to improve the effect of TACE
  7407. … 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of …
  7408. Treatment with Rapamycin or Rapamycin in combination with metformin contributes to mechanisms of mitochondrial proteostasis in vivo and in vitro
  7409. GW29-e1749 Delayed reendothelialization with Rapamycin is rescued by the addition of nicorandil in balloon-injured rat carotid arteries
  7410. The effects of Rapamycin on the symptoms of cerebral ischemia due to changing the expression of miR-1 and its target genes, Bad and Bcl-w
  7411. Correction: Rapamycin Is Neuroprotective in a Rat Chronic Hypertensive Glaucoma Model
  7412. Successful transcatheter aortic valve replacement in a kidney allograft patient on Rapamycin
  7413. Pre-treatment with Rapamycin protects hematopoiesis against radiation injury
  7414. Role of Mammalian Target of Rapamycin in Muscle Growth
  7415. Anti-scarring effect of Rapamycin in rabbits following glaucoma filtering surgery
  7416. Target Of Rapamycin pathway in the white-rot fungus Phanerochaete chrysosporium
  7417. Synergy of Rapamycin and Cyanoacrylate in Reducing Intimal Hyperplasia
  7418. 067 Rapamycin Suppresses NADPH Oxidase-mediated Reactive Oxygen Species Production and Reverses Erectile Dysfunction in Western Diet-fed Mice
  7419. Viability, Growth and Reproduction of Heligmosomoides bakeri During a Secondary Infection of a Host Treated with Rapamycin
  7420. Use of Topical Rapamycin as Maintenance Treatment after a Single Session of Fractionated CO 2 Laser Ablation: A Method to Enhance Percutaneous Drug …
  7421. Discovery of potential mammalian target of Rapamycin inhibitors: A combination of virtual screening and molecular docking studies.
  7422. Mathematical modelling of mammalian target of Rapamycin following leucine ingestion
  7423. Wound Repair and the Immune System in the Presence of Rapamycin
  7424. SAT0280 Rapamycin restores the balance between th17 and regulatory t cells in uspa patients
  7425. Synergistic antifibrotic effect of Rapamycin and Zoledronic acid in advanced murine biliary fibrosis
  7426. Production of interleukin-1β related to mammalian target of Rapamycin/Toll-like receptor 4 signaling pathway during Aspergillus fumigatus infection of the …
  7427. AB0382 Rapamycin selectively increases circulating tregcellsand maintain remission of patients with rheumatoid arthritis
  7428. Local release of Rapamycin by microparticles delays islet rejection within the anterior chamber of the eye
  7429. Regarding “Rapamycin prevents thoracic aortic aneurysm and dissection in mice”
  7430. Rapamycin Promote the inhibition Rate of Proliferation on SHI-1 Cells and Enhance the Efficacy of Chemotherapy in Npg Leukemia Mice
  7431. ANTI-CELL SENESCENT EFFECTS OF Rapamycin AND THEIR ROLE IN DISEASES, INCLUDING ALZHEIMER’S
  7432. Different expression patterns of exosomal miRNAs under Cyclosporin A and Rapamycin treatment in distinct aggressiveness colorectal carcinomas
  7433. Targeting Delivery of Rapamycin With Anti-Collagen IV Peptide Conjugated Fe₃O₄@ Nanogels System for Vascular Restenosis Therapy
  7434. Rapamycin alleviates inflammation by up-regulating TGF-β/Smad signaling in a mouse model of autoimmune encephalomyelitis
  7435. Intranasal Rapamycin protects against cognitive decline in a mouse model of Down syndrome
  7436. Farnesyltransferase inhibitor and Rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome …
  7437. Evaluation of the Effects of Nicotine on Mammalian Target of Rapamycin Complex 2 and Signal Transducer and Activator of Transcription 3 Genes Expression in a …
  7438. Efficacy of brain-targeted Rapamycin for treatment of epilepsy in rats
  7439. AN EXPERIMENTAL RESEARCH OF THE EFFECTS OF Rapamycin ON THE IN VITRO PROLIFERATION AND GROWTH OF TREGS IN MICE BY …
  7440. Rapamycin-Based Expansion of Natural CD8+ Tregs for Cell Therapy
  7441. Metabolic regulation of insulin secretion: the link between excess glucose, mechanistic target of Rapamycin complex 1 & hyperinsulinemia
  7442. Autophagy in Hepatocellular Carcinoma-29 after Single or Combined Administration of Lithium Carbonate and Rapamycin
  7443. Belatacept and Rapamycin with Short-Term Use of Tacrolimus Delay Allograft Rejection in a Novel, Large Animal Vascularized Composite Allotransplantation Model
  7444. The Effect of Acute Aerobic Exercise and Rapamycin Treatment on Autophagy and the Heat Shock Response in Peripheral Blood Mononuclear Cells of Prediabetics
  7445. A Randomized Trial of Rapamycin to Increase Longevity and Healthspan in Companion Animals: Navigating the Boundary Between Protections for Animal Research …
  7446. Use of TGF-beta plus Rapamycin to Induce Foxp3, promote iTreg Development and Suppressive Function, and Induce Long-Term Allograft Survival
  7447. Rapamycin decreases presenilin-1 in SK-N-SH cells
  7448. Deep proteome of human nNOS/NOS1-positive versus MOCK SH-SY5Y neuroblastoma cells under full nutrition, serum free starvation and Rapamycin …
  7449. Immunohistochemical study of folate receptor-α and mammalian target of Rapamycin in endometrial hyperplasia and endometrioid endometrial carcinoma
  7450. Advance of Mechanisms and Clinical Applications about Rapamycin for Treating Immune Mediated Hemocytopenia–Review
  7451. Mammalian target of Rapamycin inhibitor and transarterial embolization for treatment of tuberous sclerosis complex patients with renal angiomyolipoma
  7452. P126/O29 mTOR blockade by Rapamycin decreases arthritis and spondylitis development and severity in HLA-B27 transgenic rats
  7453. Efficacy and Safety of Early Mammalian Target of Rapamycin Inhibitors with Minimization of Calcineurin Inhibitors in Kidney Transplant Recipients
  7454. … kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of Rapamycin (mTOR) in patients …
  7455. New Use of Rapamycin Stent in Non-Responding Facial Lymphatic Malformation
  7456. Roles of Mammalian Target of Rapamycin Signaling and Autophagy Pathway in Alzheimer’s Disease
  7457. Erratum: Rapamycin-induced protein dimerization as a tool for C. elegans research. microPublication Biology
  7458. FRI0150 mTOR blockade by Rapamycin decreases arthritis and spondylitis development and severity in hla-b27 transgenic rats
  7459. Lung Function Response and Changes of Lung Cysts to Rapamycin for Lymphangioleiomyomatosis: Long-Term Follow-Up Observational Study
  7460. Rapamycin Induces Apoptosis of K562 Cells through EZH2/Hedgehog Signaling Pathway
  7461. Rapamycin prevents surgery-induced T cell exhaustion in patients with bladder cancer
  7462. Safety and Effectiveness of FlexyRap® Cobalt-Chromium Rapamycin-Eluting Stents with Biodegradable Polymer in Coronary Artery Disease: Results from a 2 …
  7463. Clinical importance of microtubule-associated protein 1 light chain 3 and mammalian target of Rapamycin expression in oral leukoplakia and oral squamous cell …
  7464. Evaluation of the interaction between melatonin and Rapamycin for head and neck cancer therapy
  7465. A new mTOR-independent effect of Rapamycin: Transcriptional regulation of TRIB3
  7466. INTERACTION OF ALPHA SYNUCLEIN WITH TARGET OF Rapamycin (TOR): A REVIEW
  7467. Evaluation of the Effects of Nicotine on Mammalian Target of Rapamycin Complex 2 and Signal Transducer and Activator of Transcription 3 Genes Expression in a …
  7468. Mammalian target of Rapamycin: biological functions and mechanisms.
  7469. Rapamycin attenuates Th2-driven experimental allergic conjunctivitis
  7470. Rapamycin partially rescues oocyte dysfunction in mice deficient for mitochondrial stress response protein CLPP
  7471. Impaired follicular development and ovulation in PCOS mouse model can rescued by Rapamycin treatment
  7472. The activity of S. pombe LTR retrotransposons is activated in response to Rapamycin
  7473. Combination of Rapamycin with immune checkpoint blockade in a syngeneic breast carcinoma model
  7474. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.
  7475. Overexpression of regulatory gene rapG enhances the yield of Rapamycin.
  7476. THU0098 Combination therapy of Rapamycin and a glutamine antagonist facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in skg …
  7477. Toward Novel Therapeutics for TSC and LAM: Using Mechanisms of a Bacterial Protein to Sensitize Cells to Rapamycin
  7478. Neuroprotective Effects of the Small-Molecule Enhancer of Rapamycin in the Cellular Model of Parkinson’s Disease
  7479. Rapamycin treatment starting at 24 h after cerebral ischemia/reperfusion exhibits protective effect on brain injury in rats
  7480. Resistance Reversion of Rapamycin on Ovarian Cancer Cell Line SKOV3/DDP and Its Molecular Mechanisms
  7481. Discovery of Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors
  7482. The mammalian target of Rapamycin complex 1 (mTORC1) and the regulation of opioid efficacy
  7483. Consensus Statement: sirolimus (Rapamycin) as therapy for lymphangioleiomyomatosis (2018)
  7484. Evaluation of the Effects of Nicotine on Mammalian Target of Rapamycin Complex 2 and Signal Transducer and Activator of Transcription 3 Genes Expression …
  7485. Expression of autophagy level in the aorta of diabetic rats and the intervention effect of Rapamycin
  7486. Sugar and spice in epilepsy: Modulation of epilepsy and epileptogenesis by Rapamycin and curcumin in experimental models of temporal lobe epilepsy
  7487. Retracted: Rapamycin prevents apoptosis of myocardial cells in heart failure rats through up-regulating Akt
  7488. Effect of Rapamycin on gene expression of nuclear factor-? B p65 and STAT-1 in sprague-dawley rats with acute lung injury
  7489. Expression and Clinical Significance of Late Endosomal/Lysosomal Adaptor, Mitogen-activated Protein Kinase and Mammalian Target of Rapamycin Activator 3 in …
  7490. Autophagy and Expression of UCH-L3 Induced by Rapamycin in HL-60 Cells
  7491. MON-LB054 Activity of Prolactin Receptor Antagonist-Rapamycin Conjugate in Glioblastoma Multiform
  7492. siRNA Blocking of Mammalian Target of Rapamycin (mTOR) Attenuates Toxicity in Annonacin Induced Tauopathy in Mice
  7493. Effect of Rapamycin on expression of Caspase-9 and Ki-67 in neuroendocrine tumor tissues
  7494. IGF2 as a Potential Novel Therapeutic Target for Rapamycin-Insensitive LAM Patients
  7495. TCT-624 A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET …
  7496. Rapamycin suppresses T cell responses in recoverin-induced autoimmune retinopathy and prevents disease progression in the eyes
  7497. Rapamycin-eluting stents for unprotected left main coronary artery stenosis in older adult patients with coronary atherosclerosis: study protocol for a …
  7498. Rapamycin Treatment Promotes Myofibril Relaxation Kinetics and Reduces Myocardial Stiffness to Improve Diastolic Function in Old Murine Hearts
  7499. Disruption of Mammalian Target of Rapamycin Complex 1 in Myeloid cells Promotes Lung Cancer Metastasis
  7500. Abstract# 3183 Treatment with Rapamycin affects behavioral and brain protein expression in rats with experimentally induced glioblastoma
  7501. Effect of Rapamycin on the biological behaviors of human non-Hodgkin lymphoma Raji cells and its mechanism
  7502. Immunohistochemical evaluation of p-mTOR (Phosphorylated Mammalian Target of Rapamycin) in oral squamous cell carcinoma
  7503. Rapamycin-induced autophagy of Ana-1 cells play the lethality to melanized Penicillium marneffei
  7504. THE EFFECTS OF 4 WEEKS HIGH INTENSITY INTERVAL TRAINING ON MAMMALIAN Rapamycin TARGET PROTEIN (mTOR) AND STEROL TRANSCRIPTION …
  7505. Rapamycin Protects Against Paraquat-induced Pulmonary Epithelial Mesenchymal Transition through Wnt/β-catenin Pathway
  7506. Rapamycin promotes trans-differentiation while inhibiting mTOR activity in glioblastoma cells
  7507. Efficacy of self-made Gengnian decoction on phosphatidylinositol 3-kinases/protein kinase B/mammalian target of Rapamycin signaling pathway in perimenopausal …
  7508. TREATMENT OF BETA-THALASSEMIA PATIENTS WITH Rapamycin (SIROLIMUS): FROM PRE-CLINICAL RESERCH TO A CLINICAL TRIAL
  7509. Cuprizone model of demyelination in the presence of mTOR inhibitor Rapamycin
  7510. BD-02 Blockade of the mechanistic target of Rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell …
  7511. Rapamycin protects human lens epithelial cells against oxidative stress induced by high glucose
  7512. IGF-Ⅱrestores Rapamycin-induced suppression of β-cell differentiation and expansion of adult pancreas stem cells
  7513. Roles of Mechanistic Target of Rapamycin Complexes in Retinal Development and Visual Function
  7514. Investigation of Functionally Important Residues in Histone Variant H2A. Z and the Effect of Rapamycin on Saccharomyces Cerevisiae
  7515. Mechanistic target of Rapamycin enhances fibrosis in lung by promoting epithelial mesenchymal transition
  7516. MP38-06 Rapamycin REGULATION OF CORE CLOCK GENES IS ASSOCIATED WITH ALTERED DE-OBSTRUCTION SIGNATURES COORDINATE WITH …
  7517. Case Report: Surgical trauma induces overgrowth in lower limb gigantism: regulation with use of Rapamycin is promising
  7518. Delivery of Rapamycin-enriched Nanoparticles to Atherosclerotic Plaques Provides Targeted Regulation of the Macrophage mTORc1-autophagy Signaling Axis
  7519. PD-L1 as a Notential Therapeutic Target for Patients with Advanced or Refractory-to-Rapamycin Pulmonary Lymphangioleiomyomatosis (LAM)
  7520. The Mammalian Target of Rapamycin (mTOR)/Peroxisome Proliferator-Activated Receptor γ (PPARγ) axis drives immune dysfunction and outcome after burn injury.
  7521. Regulation of central carbon and nitrogen metabolism by Target of Rapamycin (TOR) kinase in Chlamydomonas reinhardtii
  7522. Effects of Rapamycin and mammalian target of Rapamycin-small interfering RNA (mTOR siRNA) on proli-feration, apoptosis and extracellular matrix in premature rats …
  7523. Original Investigation The mammalian target of Rapamycin protein expression in human granulosa cell tumors Güralp et al. mTOR protein expression in …
  7524. Effect of Rapamycin on the expression of autophagy-related proteins Unc-51 like autophagy activating kinase 1 and microtubule-associated protein 1 light chain 3 in …
  7525. Rapamycin protect puromycin amino nucleoside induced podocyte injury by up-regulating autophagy
  7526. Rapamycin Alters MicroRNA Signature Profile in Diabetic Rabbit following Myocardial Ischemia Reperfusion Injury: A Preclinical Approach for Cardioprotection.
  7527. Effects of postruminal amino acid supplementation on protein deposition and the mammalian target of Rapamycin signaling pathway in growing steers
  7528. Elastin-like polypeptide mediate subcutaneous delivery of Rapamycin in a murine model of Sjögren’s Syndrome
  7529. Rapamycin and Zoledronic Acid strongly retard growth of advanced murine hepatocellular carcinoma via skewing and activation of innate and adaptive immunity
  7530. Rapamycin-eluting stents for unprotected left main coronary artery stenosis in coronary atherosclerosis in the older adults: study protocol for a prospective, non …
  7531. Rapamycin and Zoledronic acid exert a potent antifibrotic effect in murine biliary fibrosis
  7532. Proteomics study of Rapamycin-injured human coronary artery endothelial cells based on two dimension fluorescence differential gel electrophoresis
  7533. Rapamycin promotes the survival and angiogenesis of high glucose-exposed human umbilical vein endothelial cells by improving autophagy
  7534. Rapamycin Can Ameliorate Antiretroviral Drug Mediated Cardiotoxicity
  7535. Correction to: Mammalian Target of Rapamycin 2 (mTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through …
  7536. Rapamycin Treatment Reduces Myocardial Stiffness and Promotes Cardiomyocyte Relaxation to Restore Diastolic Function in Old Murine Hearts
  7537. Dissecting Rapamycin resistance in a Tsc2-null rat leiomyoma cell line developed in a murine xenograft
  7538. The role of mechanistic target of Rapamycin complex 2-component RICTOR in hepatocellular carcinoma progression and sorafenib-resistance
  7539. Tuberin S1365 Phosphorylation Regulates Mechanistic Target of Rapamycin Complex 1 (mTORC1) Pathological Signaling While Sustaining Metabolic Sensor …
  7540. Discovery and evaluation of WX047, a potent and oral active phosphoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) dual inhibitor
  7541. FDG-PET of mouse breast cancers on ketogenic vs. standard chow diets, with or without added Rapamycin.
  7542. Rapamycin enhanced autophagy favors tolerance induction in allotransplantation model through mTORC1/ULK1 pathway
  7543. Collecting‐duct‐principal‐cell‐select knockout (KO) of the mechanistic‐target‐of‐Rapamycin (mTOR) alters sodium and acid/base homeostasis
  7544. The Mammalian Target of Rapamycin Regulates Platelet Integrin Activation, Aggregation, and Ischemic Stroke
  7545. Mammalian Target of Rapamycin (mTOR) Inhibitor Induced Pulmonary Alveolar Proteinosis
  7546. Rapamycin affect the apoptosis of splenic CD4~+ CD25~+ regulatory T cells of mouse severe aplastic anemia model
  7547. Safety and efficacy of conversion from calcineurin inhibitors to mammalian-target-of-Rapamycin inhibitors in liver transplant recipients: a meta-analysis of randomized …
  7548. Promoter hypermethylation of Mammalian Target of Rapamycin Gene in Multiple Myeloma cells induced by curcumin
  7549. Rapamycin Protects Against Myocardial Ischemia/Reperfusion Injury in Diabetic Mice Through Stat3-mir17/92 Signaling and Suppression of Prolyl Hydroxylase
  7550. Rapamycin upregulates autophagy by inhibiting mTOR/P70S6K/4EBP1 signaling and reducing podocyte apoptosis
  7551. The Mechanistic Target of Rapamycin (mTOR) and Its Complex 1 Associated Protein RPTOR are Germ Cell-autonomously Required for Spermatogonial Development …
  7552. Mammalian target of Rapamycin (mTOR) and autophagy in hepatitis c virus-related hepatocellular carcinoma: relation to tumor progression
  7553. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of Rapamycin (PI3K/Akt/mTOR) signaling pathway in B-lineage acute lymphoblastic leukemia
  7554. … , Sirtuin1 and peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha, overactive mammalian target of Rapamycin, and dysregulated metabolites …
  7555. MicroRNA-25 Modulates Proliferative Signaling Via the Mammalian Target of Rapamycin Pathway in Asthmatic Airway Smooth Muscle Cells In Vitro
  7556. D-1: The TOR (Target of Rapamycin) pathway governs growth and stress response in C. neoformans
  7557. The level of microRNA 21 is upregulated by Rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA) …
  7558. … : Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) is a negative regulator of the mammalian target of Rapamycin complex 1 (mTORC1).
  7559. Abstract P6-07-04: Rapamycin inhibits the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
  7560. Dysregulation of microRNA-25 Modulates Airway Smooth Muscle Cell Proliferation via the Mammalian Target of Rapamycin Pathway by Targeting Tuberous Sclerosis …
  7561. Deficiency of Myocardial miR-17-92 Cluster Exacerbates Ischemic Injury and Abrogates Rapamycin-Induced Protection in Diabetic Mice
  7562. HGG-16. SUSTAINED RESPONSE TO ERLOTINIB AND Rapamycin IN A PATIENT WITH PEDIATRIC ANAPLASTIC OLIGODENDROGLIOMA
  7563. Clinical significance of microtubule-associated protein 1 light chain 3 and mammalian target of Rapamycin expression in oral leukoplakia in smokers and never …
  7564. Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-Rapamycin) in patients with advanced malignant perivascular …
  7565. Abstract P1-07-27: Prognostic value of programmed death 1/Programmed death ligand 1/mammalian target of Rapamycin/Rictor/Tuberin in human breast cancer
  7566. … with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinaseM2 and mechanistic target of Rapamycin complex 1 pathways
  7567. Low Dose IL-2 and Rapamycin Leads to Prolongation of Human Islet Allograft Survival by inhibition of IFN-gamma+ T cells and Expansion of FOXP3+ CD25+ Tregs in …
  7568. … for optimal inhibition of colon cancer stem cells: Simultaneous inhibition of Insulin-like growth factor-1 receptor-AKT-mammalian target of Rapamycin axis and the …
  7569. Antitumor activity of ABI-009 (nab-Rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
  7570. 4CPS-143 Topical application of Rapamycin 0.4% for treatment of facial angiokeratomas in a paediatric patient
  7571. Defining the Properties of the OS-33 Osteosarcoma Cell Line and Effects of mTORC1 inhibition by Rapamycin
  7572. A phase 1b investigation of safety/efficacy of nivolumab and ABI-009 (nab-Rapamycin) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS) …
  7573. … IN HEPATOCELLULAR CARCINOMA-29 CELLS AFTER SEPARATE AND COMBINED ADMINISTRATION OF LITHIUM CARBONATE AND Rapamycin
  7574. … Is Dentin Sensitivity: Effect of an Experimental Desensitizing Agent on Stomatitis: Stomatitis Associated With Mammalian Target of Rapamycin inhibition: A Review of …
  7575. Target of Rapamycin signaling in plant stress responses
  7576. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor Rapamycin
  7577. The mechanistic target of Rapamycin (mTOR): novel considerations as an antiviral treatment
  7578. Rapamycin rejuvenates oral health in aging mice
  7579. Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation
  7580. Effect of Rapamycin on aging and age-related diseases—past and future
  7581. Brain protein synthesis rates in the UM-HET3 mouse following treatment with Rapamycin or Rapamycin with metformin
  7582. Is Rapamycin a dietary restriction mimetic?
  7583. Exaptive evolution of target of Rapamycin signaling in multicellular eukaryotes
  7584. Targeting T-cell senescence and cytokine storm with Rapamycin to prevent severe progression in COVID-19
  7585. The target of Rapamycin signalling pathway in ageing and lifespan regulation
  7586. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment
  7587. Commentary: Rapamycin for the aging skin
  7588. Differential effects of Rapamycin and metformin in combination with Rapamycin on mechanisms of proteostasis in cultured skeletal myotubes
  7589. Mechanism of Activation of Mechanistic Target of Rapamycin Complex 1 by Methionine
  7590. Rationally designed Rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance
  7591. Mechanistic target of Rapamycin regulates the oligodendrocyte cytoskeleton during myelination
  7592. Mechanistic target of Rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer
  7593. The regulation of Rapamycin on nutrient metabolism in Nile tilapia fed with high-energy diet
  7594. Mechanistic target of Rapamycin signaling in mouse models of accelerated aging
  7595. Cannabidiol elevates mechanistic target of Rapamycin inhibitor levels in patients with tuberous sclerosis complex
  7596. Rapamycin protects chondrocytes against IL-18-induced apoptosis and ameliorates rat osteoarthritis
  7597. Rapamycin induces morphological and physiological changes without increase in lipid content in Ustilago maydis
  7598. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19
  7599. APOE genotype-dependent pharmacogenetic responses to Rapamycin for preventing Alzheimer’s disease
  7600. Luteolin suppresses bladder cancer growth via regulation of mechanistic target of Rapamycin pathway
  7601. Targeting mammalian target of Rapamycin: prospects for the treatment of inflammatory bowel diseases
  7602. Treatment with Rapamycin can restore regulatory T-cell function in IPEX patients
  7603. Rapamycin maintains NAD+/NADH redox homeostasis in muscle cells
  7604. TARGET OF Rapamycin signaling plays a role in Arabidopsis growth promotion by Azospirillum brasilense Sp245
  7605. Rapamycin promotes endothelial–mesenchymal transition during stress-induced premature senescence through the activation of autophagy
  7606. Rapamycin treatment correlates changes in primary cilia expression with cell cycle regulation in epithelial cells
  7607. The anticancer effects of curcumin via targeting the mammalian target of Rapamycin complex 1 (mTORC1) signaling pathway
  7608. Enhanced skeletal muscle insulin sensitivity after acute resistance-type exercise is upregulated by Rapamycin-sensitive mTOR complex 1 inhibition
  7609. Lowe syndrome patient cells display mTOR-and RhoGTPase-dependent phenotypes alleviated by Rapamycin and statins
  7610. Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of Rapamycin and circadian clock gene pathways
  7611. Targeted pathological collagen delivery of sustained-release Rapamycin to prevent heterotopic ossification
  7612. The plant target of Rapamycin: a conduc TOR of nutrition and metabolism in photosynthetic organisms
  7613. The effect of Rapamycin on bovine oocyte maturation success and metaphase telomere length maintenance
  7614. Rapamycin regulates the balance between cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mTOR signaling
  7615. Rapamycin affects palmitate-induced lipotoxicity in osteoblasts by modulating apoptosis and autophagy
  7616. Effects of Rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer
  7617. Rapamycin attenuates the paraquat‐induced pulmonary fibrosis through activating Nrf2 pathway
  7618. Metformin rescues Rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome
  7619. Discovery of a brain-penetrant ATP-competitive inhibitor of the mechanistic target of Rapamycin (mTOR) for CNS disorders
  7620. Rapamycin preserves the primordial follicle pool during cisplatin treatment in vitro and in vivo
  7621. Wide electrochemical window of screen-printed electrode for determination of Rapamycin using ionic liquid/graphene composites
  7622. The mechanistic target of Rapamycin pathway downregulates bone morphogenetic protein signaling to promote oligodendrocyte differentiation
  7623. Target of Rapamycin regulates potassium uptake in Arabidopsis and potato
  7624. Steady Augmentation of Anti-Osteoarthritic Actions of Rapamycin by Liposome-Encapsulation in Collaboration with Low-Intensity Pulsed Ultrasound
  7625. Rapidly dissolving microneedles for the delivery of cubosome-like liquid crystalline nanoparticles with sustained release of Rapamycin
  7626. Target of Rapamycin signaling is tightly and differently regulated in the plant response under distinct abiotic stresses
  7627. Metabolite regulatory interactions control plant respiratory metabolism via Target of Rapamycin (TOR) kinase activation
  7628. Target of Rapamycin regulates genome methylation reprogramming to control plant growth in Arabidopsis
  7629. Linc‐ROR promotes the progression of breast cancer and decreases the sensitivity to Rapamycin through miR‐194‐3p targeting MECP2
  7630. Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer
  7631. Transdermal delivery of Rapamycin with poor water-solubility by dissolving polymeric microneedles for anti-angiogenesis
  7632. Rapamycin relieves the cataract caused by ablation of Gja8b through stimulating autophagy in zebrafish
  7633. Functional analysis target of Rapamycin (TOR) on the Penaeus vannamei in response to acute low temperature stress
  7634. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors
  7635. Deregulated mTOR (mechanistic target of Rapamycin kinase) is responsible for autophagy defects exacerbating kidney stone development
  7636. Radiosensitising cancer using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or mammalian target of Rapamycin (mTOR) Inhibitors
  7637. Rapamycin inhibits pathogen transmission in mosquitoes by promoting immune activation
  7638. Inflammation‐induced mammalian target of Rapamycin signaling is essential for retina regeneration
  7639. Targeting mechanistic target of Rapamycin complex 1 restricts proinflammatory T cell differentiation and ameliorates Takayasu arteritis
  7640. Unlike dietary restriction, Rapamycin fails to extend lifespan and reduce transcription stress in progeroid DNA repair‐deficient mice
  7641. Target Of Rapamycin pathway in the white-rot fungus Phanerochaete chrysosporium
  7642. Rapamycin and mTORC2 inhibition synergistically reduce contraction‐stimulated muscle protein synthesis
  7643. Upregulation of Akt/Raptor signaling is associated with Rapamycin resistance of breast cancer cells
  7644. PKC downregulation upon Rapamycin treatment attenuates mitochondrial disease
  7645. Microalgal Target of Rapamycin (TOR): A Central Regulatory Hub for Growth, Stress Response and Biomass Production
  7646. Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or Rapamycin
  7647. Rapamycin treatment maintains developmental potential of oocytes in mice and follicle reserve in human cortical fragments grafted into immune-deficient mice
  7648. Fpr1, a primary target of Rapamycin, functions as a transcription factor for ribosomal protein genes cooperatively with Hmo1 in Saccharomyces cerevisiae
  7649. Inhaled Rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis
  7650. Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis
  7651. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and Rapamycin-induced MNK-eIF4E signaling
  7652. Mechanistic Target of Rapamycin Signaling Activation Antagonizes Autophagy To Facilitate Zika Virus Replication
  7653. The efficacy and safety of topical Rapamycin–calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double‐blind, randomized …
  7654. Rapamycin–PLGA microparticles prevent senescence, sustain cartilage matrix production under stress and exhibit prolonged retention in mouse joints
  7655. Sirolimus and other mechanistic target of Rapamycin inhibitors directly activate latent pathogenic human polyomavirus replication
  7656. Angiotensin-converting enzyme inhibitor rapidly ameliorates depressive-type behaviors via bradykinin-dependent activation of mammalian target of Rapamycin …
  7657. Nanoporous Gold Monolith for High Loading of Unmodified Doxorubicin and Sustained Co-Release of Doxorubicin-Rapamycin
  7658. An exploratory study of metformin with or without Rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic …
  7659. Low‐dose Rapamycin‐induced autophagy in cochlear outer sulcus cells
  7660. Mammalian Target of Rapamycin Complex 2 Signaling Is Required for Liver Regeneration in a Cholestatic Liver Injury Murine Model
  7661. mTOR Mysteries: Nuances and Questions About the Mechanistic Target of Rapamycin in Neurodegeneration
  7662. Supply of methionine and arginine alters phosphorylation of mechanistic target of Rapamycin (mTOR), circadian clock proteins, and α-s1-casein abundance in …
  7663. The mammalian target of Rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior
  7664. Rapamycin extends life span in ApcMin/+ colon cancer FAP model
  7665. Advances in mammalian target of Rapamycin kinase inhibitors: application to devices used in the treatment of coronary artery disease
  7666. Effects of glycosylation on the bioactivity of Rapamycin
  7667. Rapamycin inhibits Nf-ΚB activation by autophagy to reduce catabolism in human chondrocytes
  7668. Mitochondrial spongiotic brain disease: astrocytic stress and harmful Rapamycin and ketosis effect
  7669. Target of Rapamycin signaling inhibits autophagy in sea cucumber Apostichopus japonicus
  7670. Bioproperties, Nanostructured System and Analytical and Bioanalytical Methods for Determination of Rapamycin: A Review
  7671. Short-and long-term effects of Rapamycin on ischemic damage and apoptotic changes in torsion of rat testes
  7672. Therapeutic effects of Rapamycin and surgical decompression in a rabbit spinal cord injury model
  7673. Effects of Rapamycin Combined with Cisplatin on Tumor Necrosis Factor TNF-α in MG-63 Cells
  7674. Sex differences in changes of protein synthesis with Rapamycin treatment are minimized when metformin is added to Rapamycin
  7675. Inhibitory efficacy of Rapamycin against potato white mold
  7676. Gene transfer in adeno-associated virus seropositive rhesus macaques following Rapamycin treatment and subcutaneous delivery of AAV6, but not retargeted AAV6 …
  7677. Wheat Germination Is Dependent on Plant Target of Rapamycin Signaling
  7678. Differential roles and activation of mammalian target of Rapamycin complexes 1 and 2 during cell migration in prostate cancer cells
  7679. Dietary and Pharmacological Interventions That Inhibit Mammalian Target of Rapamycin Activity Alter the Brain Expression Levels of Neurogenic and Glial Markers in …
  7680. Rapamycin increases the incidence of neuropsychiatric illness in kidney transplant patients through the suppression of neural stem cells
  7681. Roles of the mammalian target of Rapamycin (mTOR) signaling pathway in the repair of hyperoxia-induced acute lung injury.
  7682. Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects
  7683. Mammalian target of Rapamycin-RhoA signaling impairments in direct striatal projection neurons induce altered behaviors and striatal physiology in mice
  7684. The mTOR inhibitor Rapamycin prevents general anesthesia-induced changes in synaptic transmission and mitochondrial respiration in late postnatal mice
  7685. Low nitrogen induces root elongation via auxin-induced acid growth and auxin-regulated target of Rapamycin (TOR) pathway in maize
  7686. Resveratrol potentiates the anti-tumor effects of Rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved
  7687. … analysis of neonatal regenerative myocardium revealed important roles of checkpoint kinase 1 via activating mammalian target of Rapamycin C1/Ribosomal protein …
  7688. Epidermal mammalian target of Rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formation
  7689. Lithium chloride combination with Rapamycin for the treatment of COVID-19 pneumonia
  7690. Dendrimer-Mediated Targeted Delivery of Rapamycin to Tumor-Associated Macrophages Improves Systemic Treatment of Glioblastoma
  7691. PD-L1 cellular nanovesicles carrying Rapamycin inhibit alloimmune responses in transplantation
  7692. Melatonin regulates the ovarian function and enhances follicle growth in aging laying hens via activating the mammalian target of Rapamycin pathway
  7693. Acetate regulates milk fat synthesis through the mammalian target of Rapamycin/eukaryotic initiation factor 4E signaling pathway in bovine mammary epithelial cells
  7694. Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor Rapamycin
  7695. Short-Term Rapamycin Preconditioning Diminishes Therapeutic Efficacy of Human Adipose-Derived Stem Cells in a Murine Model of Multiple Sclerosis
  7696. Intralacrimal Sustained Delivery of Rapamycin Shows Therapeutic Effects without Systemic Toxicity in a Mouse Model of Autoimmune Dacryoadenitis Characteristic of …
  7697. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of Rapamycin (mTOR) pathway
  7698. DNA-and telomere-damage does not limit lifespan: evidence from Rapamycin
  7699. Spermidine and Rapamycin Reveal Distinct Autophagy Flux Response and Cargo Receptor Clearance Profile
  7700. Properties of Rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size
  7701. Transient and late-life Rapamycin for healthspan extension
  7702. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies
  7703. Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, Rapamycin
  7704. Rapamycin restrains platelet procoagulant responses via FKBP-mediated protection of mitochondrial integrity
  7705. Hypothalamic orexin and mechanistic target of Rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex
  7706. Rapamycin Plus Vildagliptin to Recover β-Cell Function in Long-Standing Type 1 Diabetes: A Double-Blind, Randomized Trial
  7707. Differential Effects of Rapamycin on Glucose Metabolism in Nine Inbred Strains
  7708. The effect of a ketogenic diet and synergy with Rapamycin in a mouse model of breast cancer
  7709. inhibition of mechanistic target of Rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta
  7710. Implications of maraviroc and/or Rapamycin in a mouse model of fragility
  7711. Properties of Rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge
  7712. Potential new therapy of Rapalink‐1, a new generation mammalian target of Rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
  7713. Visualizing protein-protein interactions in plants by Rapamycin-dependent delocalization
  7714. Mmi1, the yeast ortholog of mammalian translationally controlled tumor protein (TCTP), negatively affects Rapamycin-induced autophagy in post-diauxic growth phase
  7715. Efficacy of AAV8-hUGT1A1 with Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients
  7716. … expression of activator proteins that control follicle reserve after ovarian tissue cryopreservation/transplantation and primordial follicle loss prevention by Rapamycin
  7717. Pharmacophore-guided fragment-based design of novel mammalian target of Rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D …
  7718. The Release of cyclophilin a from Rapamycin-stimulated vascular smooth muscle cells mediated by myosin ii activation: involvement of apoptosis but not autophagy
  7719. Mechanistic target of Rapamycin kinase (mTOR) is required for spermatogonial proliferation and differentiation in mice
  7720. A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of …
  7721. Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of Rapamycin …
  7722. Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling …
  7723. Thioredoxin-1 maintains mitochondrial function via mechanistic target of Rapamycin signalling in the heart
  7724. Azospirillum brasilense Sp245 lipopolysaccharides induce target of Rapamycin signaling and growth in Arabidopsis thaliana
  7725. Rapamycin Treatment of Tendon Stem/Progenitor Cells Reduces Cellular Senescence by Upregulating Autophagy
  7726. … of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors
  7727. Mammalian target of Rapamycin and p70S6K mediate thrombin-induced nuclear factor-κB activation and IL-8/CXCL8 release in human lung epithelial cells
  7728. Resveratrol, Rapamycin and Metformin as Modulators of Antiviral Pathways
  7729. Effects of Rapamycin on osteosarcoma cell proliferation and apoptosis by inducing autophagy
  7730. Rapamycin for aging stem cells
  7731. Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
  7732. Efficacy of AAV8-hUGT1A1 with Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients
  7733. Target of Rapamycin (TOR) negatively regulates ethylene signals in Arabidopsis
  7734. inhibition of the mechanistic target of Rapamycin induces cell survival via MAPK in tuberous sclerosis complex
  7735. Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTOR Signalling in the Liver
  7736. Structural insights into CYP107G1 from Rapamycin-producing Streptomyces Rapamycinicus
  7737. Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence
  7738. Genetically encoded biosensors for the detection of Rapamycin: toward the screening of agonists and antagonists
  7739. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin
  7740. Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia
  7741. Rapamycin Induces an eNOS (Endothelial Nitric Oxide Synthase) Dependent Increase in Brain Collateral Perfusion in Wistar and Spontaneously Hypertensive Rats
  7742. mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo
  7743. Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells-A synergistic effect with Temozolomide
  7744. Rapamycin Promotes Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells in a Stage-Dependent Manner
  7745. Rapamycin and abundant TCR stimulation are required for the generation of stable human induced regulatory T cells
  7746. Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling
  7747. Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease
  7748. Interactions of FK506 and Rapamycin With FK506 Binding Protein 12 in Opportunistic Human Fungal Pathogens
  7749. Rapamycin-loaded lipid nanocapsules induce selective inhibition of the mTORC1-signaling pathway in glioblastoma cells
  7750. Cytotoxicity of nonylphenol on spermatogonial stem cells via phosphatidylinositol-3-kinase/protein kinase B/mammalian target of Rapamycin pathway
  7751. Copper induces hepatocyte autophagy via the mammalian targets of the Rapamycin signaling pathway in mice
  7752. Rapamycin and dexamethasone during pregnancy prevent tuberous sclerosis complex–associated cystic kidney disease
  7753. Effects of mammalian target of Rapamycin inhibitors on fibrosis after trabeculectomy
  7754. Phase I Trial of Encapsulated Rapamycin in Prostate Cancer Patients Under Active Surveillance to Prevent Progression
  7755. SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers
  7756. Effect of Rapamycin on repeated immobilization stress-induced immune alterations in the rat spleen
  7757. Reduction of FoxP3+ Tregs by an immunosuppressive protocol of Rapamycin plus Thymalfasin and Huaier extract predicts positive survival benefits in a rat …
  7758. The Rapamycin analog Everolimus reversibly impairs male germ cell differentiation and fertility in the mouse
  7759. Protective Effects of Rapamycin on Trabecular Meshwork Cells in Glucocorticoid-Induced Glaucoma Mice
  7760. Insulin potentiates essential amino acids effects on mechanistic target of Rapamycin complex 1 signaling in MAC-T cells
  7761. Mechanistic target of Rapamycin-mediated autophagy is involved in the alleviation of lipopolysaccharide-induced acute lung injury in rats
  7762. Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function
  7763. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy
  7764. Mammalian target of Rapamycin (mTOR) inhibitors and skin cancer risk in nonrenal solid organ transplant recipients: systematic review and meta‐analysis
  7765. Effect of mechanistic/mammalian target of Rapamycin complex 1 on mitochondrial dynamics during skeletal muscle hypertrophy
  7766. Rictor promotes tumor progression of Rapamycin-insensitive triple-negative breast cancer cells
  7767. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells
  7768. Novel brain permeant mTORC1/2 inhibitors are as efficacious as Rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis …
  7769. Topical administration of Rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model
  7770. MYC‐binding lncRNA EPIC1 promotes AKT‐mTORC1 signaling and Rapamycin resistance in breast and ovarian cancer
  7771. Human monocyte-derived macrophage responses to M. tuberculosis differ by the host’s tuberculosis, diabetes or obesity status, and are enhanced by Rapamycin
  7772. … RNA 0152 promotes hepatocellular carcinoma progression by regulating phosphatidylinositol 3-Kinase/Akt/mammalian target of Rapamycin signaling pathway through …
  7773. Optimized Rapamycin-loaded PEGylated PLGA nanoparticles: Preparation, characterization and pharmacokinetics study
  7774. Modulatory effect of Rapamycin and tacrolimus on monocyte-derived dendritic cells phenotype and function
  7775. Rapamycin improves renal injury induced by Iodixanol in diabetic rats by deactivating the mTOR/p70S6K signaling pathway
  7776. Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51
  7777. … angiogenic function of human lung microvascular endothelial cells via LAT1 (L-type amino acid transporter 1)-mediated mTOR (Mammalian Target of Rapamycin) …
  7778. Rapamycin Reduces Cervical Cancer Cells Viability in Hypoxic Condition: Investigation of the Role of Autophagy and Apoptosis
  7779. Proteasome activity and expression of mammalian target of Rapamycin signaling factors in skeletal muscle of dairy cows supplemented with conjugated linoleic acids …
  7780. In Silico Strategy for Targeting the mTOR Kinase at Rapamycin Binding Site by Small Molecules
  7781. Metastatic role of mammalian target of Rapamycin signaling activation by chemoradiotherapy in advanced rectal cancer
  7782. Chloroquine and Rapamycin Augment Interleukin-37 Expression via the LC3, ERK, and AP-1 Axis in the Presence of Lipopolysaccharides
  7783. Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis
  7784. … Study of Immunomodulatory Agents to Induce Human T Regulatory (Treg) Cells: Preferential Treg-Stimulatory Effect of Prednisolone and Rapamycin
  7785. Rapamycin Inhibitors for Eye Squamous Cell Carcinoma after Renal Transplantation: A Case Report
  7786. Autophagy induction by Rapamycin ameliorates experimental colitis and improves intestinal epithelial barrier function in IL-10 knockout mice
  7787. A high-dose Rapamycin treatment alleviates hepatopulmonary syndrome in cirrhotic rats
  7788. Antifungal activity of Rapamycin on Botryosphaeria dothidea and its effect against Chinese hickory canker
  7789. Protective effects of glucagon‐like peptide‐1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of Rapamycin complex 1/p70 ribosomal …
  7790. Toxicity Evaluation of a Novel Rapamycin Liposomal Formulation After Subconjunctival and Intravitreal Injection
  7791. Results of a phase Ib trial of encapsulated Rapamycin in prostate cancer patients under active surveillance to prevent progression.
  7792. Limited efficacy of Rapamycin monotherapy in vascularized composite allotransplantation
  7793. inhibition of the mammalian target or Rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy
  7794. HIF-1α-Mediated Telomerase Reverse Transcriptase Activation Inducing Autophagy Through Mammalian Target of Rapamycin Promotes Papillary Thyroid Carcinoma …
  7795. Rapamycin Ameliorates Cognitive Impairments and Alzheimer’s Disease-Like Pathology with Restoring Mitochondrial Abnormality in the Hippocampus of …
  7796. Rapamycin-Induced Autophagy Promotes the Chondrogenic Differentiation of Synovium-Derived Mesenchymal Stem Cells in the Temporomandibular Joint in …
  7797. Tacrolimus, a Rapamycin target protein inhibitor, exerts anti-cystic echinococcosis effects both in vitro and in vivo
  7798. Mammalian target of Rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
  7799. Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
  7800. Rapamycin Improves Recognition Memory and Normalizes Amino-Acids and Amines Levels in the Hippocampal Dentate Gyrus in Adult Rats Exposed to Ethanol …
  7801. Exosomes secreted from mesenchymal stem cells mediate the regeneration of endothelial cells treated with Rapamycin by delivering pro-angiogenic microRNAs
  7802. Rapamycin is Effective for Upper but not for Lower Gastrointestinal Crohn’s Disease-Related Stricture: A Pilot Study
  7803. Upregulation of 6‐phosphofructo‐2‐kinase (PFKFB3) by hyperactivated mammalian target of Rapamycin complex 1 is critical for tumor growth in tuberous sclerosis …
  7804. mTORC1 (Mechanistic Target of Rapamycin Complex 1) Signaling in Endothelial and Smooth Muscle Cells Is Required for Vascular Function
  7805. The mTORC1 inhibitor Rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory
  7806. Rapamycin could increase the effects of melatonin against age-dependent bone loss
  7807. Chronic low-dose Rapamycin treatment fine tunes cardioprotective signalling in ischaemia-reperfused diabetic hearts
  7808. Low-Dose Interleukin-2 Combined With Rapamycin Led to an Expansion of CD4+ CD25+ FOXP3+ Regulatory T Cells and Prolonged Human Islet Allograft Survival in …
  7809. Rapamycin alleviates cognitive impairment in murine vascular dementia: The enhancement of mitophagy by PI3K/AKT/mTOR axis
  7810. … sensors and reproductive hypothalamo-pituitary ovarian axis (HPO) in female mammals: role of mTOR (mammalian target of Rapamycin), AMPK (AMP-activated …
  7811. Rapamycin ameliorates corneal injury after alkali burn through methylation modification in mouse TSC1 and mTOR genes
  7812. Blockade of the mTOR signaling pathway with Rapamycin ameliorates aristolochic acid nephropathy
  7813. STAT3-miR-17/20 signalling axis plays a critical role in attenuating myocardial infarction following Rapamycin treatment in diabetic mice
  7814. Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by Rapamycin
  7815. Activation of the Akt/mammalian target of Rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E …
  7816. Topical Rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, double‐blind, controlled study
  7817. Rapamycin Alleviates the Symptoms of Multiple Sclerosis in Experimental Autoimmune Encephalomyelitis (EAE) Through Mediating the TAM-TLRs-SOCS …
  7818. Rapamycin‐based graft‐versus‐host disease prophylaxis increases the immunosuppressivity of myeloid‐derived suppressor cells without affecting T cells and anti …
  7819. Rapamycin Protects Skin Fibroblasts From UVA-Induced Photoaging by inhibition of p53 and Phosphorylated HSP27
  7820. Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro
  7821. Effects of co-administration of Rapamycin and evening primrose/hemp seed oil supplement on immunologic factors and cell membrane fatty acids in experimental …
  7822. Sirt4 Modulates Oxidative Metabolism and Sensitivity to Rapamycin Through Species-Dependent Phenotypes in Drosophila mtDNA Haplotypes
  7823. NEAT1/hsa-miR-372-3p axis participates in Rapamycin-induced lipid metabolic disorder
  7824. Comparison of Two Strategies Based On Mammalian Target of Rapamycin Inhibitors In Secondary Prevention of Non‐Melanoma Skin Cancer After Kidney …
  7825. Correction: An ATP-competitive mammalian target of Rapamycin inhibitor reveals Rapamycin-resistant functions of mTORC1.
  7826. … replacement with composite mixture of shrimp hydrolysate and plant proteins on growth performance, feed utilization, and target of Rapamycin pathway in largemouth …
  7827. … amino acid transporter: Sodium-coupled neutral amino acid transporter 2 inhibits cell growth and mammalian target of Rapamycin complex 1 pathway in …
  7828. Metformin and Rapamycin protect cells from vital dye–induced damage in retinal pigment epithelial cells and in vivo
  7829. Rapamycin Preserves Neural Tissue, Promotes Schwann Cell Myelination and Reduces Glial Scar Formation After Hemi-Contusion Spinal Cord Injury in Mice
  7830. Persistent myopathy despite release of partial obstruction: in vivo reversal of dysfunction and transcriptional responses using Rapamycin
  7831. Exercise intervention attenuates neuropathic pain in diabetes via mechanisms of mammalian target of Rapamycin (mTOR)
  7832. Role of exercise and Rapamycin on the expression of energy metabolism genes in liver tissues of rats fed a high‑fat diet
  7833. The protective effects of Rapamycin pretreatment on ovarian damage during ovarian tissue cryopreservation and transplantation
  7834. Characteristics of Lymphedema in Patients Treated with Mammalian Target of Rapamycin Inhibitors
  7835. Protective effects of Rapamycin on the retinal vascular bed during the vaso‐obliteration phase in mouse oxygen‐induced retinopathy model
  7836. Rapamycin Alleviates Hypertriglyceridemia-Related Acute Pancreatitis via Restoring Autophagy Flux and Inhibiting Endoplasmic Reticulum Stress
  7837. Microvessel density and vascular endothelial growth factor receptors in breast carcinoma under the influence of Rapamycin and platelet factor 4
  7838. Mitochondrial General Control of Amino Acid Synthesis 5 Like 1 Regulates Glutaminolysis, Mammalian Target of Rapamycin Complex 1 Activity, and Murine Liver …
  7839. Matrix-assisted pulsed laser evaporation-deposited Rapamycin thin films maintain antiproliferative activity
  7840. The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure
  7841. Rapamycin induces megakaryocytic differentiation through increasing autophagy in Dami cells
  7842. Comprehensive Analysis of the Immunomodulatory Effects of Rapamycin on Human T Cells in Graft‐versus‐Host Disease Prophylaxis
  7843. Tumor Susceptibility Gene 101 facilitates Rapamycin-induced autophagic flux in neuron cells
  7844. FTY720 Suppresses Liver Tumor Growth and Metastasis by Reducing Circulating Regulating T Cells and Enhancing the Anti-Tumor Effect of Rapamycin
  7845. Oral Preconditioning of Donors After Brain Death With Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation
  7846. Polymeric nanoparticles containing Rapamycin and autoantigen induce antigen-specific immunological tolerance for preventing vitiligo in mice
  7847. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
  7848. Ultrasound Stimulation Increases Neurite Regeneration in Injured Dorsal Root Ganglion Neurons through Mammalian Target of Rapamycin Activation
  7849. Target of Rapamycin in Control of Autophagy: Puppet Master and Signal Integrator
  7850. Synergistic Effect of 3-Bromopyruvate in Combination with Rapamycin Impacted Neuroblastoma Metabolism by Inhibiting Autophagy
  7851. Role of mechanistic target of Rapamycin and autophagy in alcohol-induced adipose atrophy and liver injury
  7852. Targeted inhibition of the epidermal growth factor receptor and mammalian target of Rapamycin signaling pathways in olmsted syndrome
  7853. … by chemokine (cc motif) ligand 3 promote the progression of breast cancer via phosphoinositide 3-kinase-protein kinase b-mammalian target of Rapamycin …
  7854. Retraction: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF
  7855. … sensor based on carbon paste electrode modified with polypyrrole/multi‐walled carbon nanotubes for the electrochemical detection of cytostatic drug Rapamycin
  7856. Comparison of Rapamycin and methylprednisolone for treating inflammatory muscle disease in a murine model of experimental autoimmune myositis
  7857. Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+ CD25+ FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice
  7858. Rapamycin Inhibited Pyroptosis and Reduced the Release of IL-1β and IL-18 in the Septic Response
  7859. Methionine controls insulin/mammalian target of Rapamycin complex 1 activity by modulating tuberous sclerosis complex 2 stability
  7860. Reactive Oxygen Species‐Scavenging Scaffold with Rapamycin for Treatment of Intervertebral Disk Degeneration
  7861. Cell synchronization by Rapamycin improves the developmental competence of buffalos (Bubalus bubalis) somatic cell nuclear transfer embryos
  7862. Therapeutic Effect of Rapamycin on Aortic Dissection in Mice
  7863. Rapamycin inhibits proliferation and apoptosis of retinoblastoma cells through PI3K/AKT signaling pathway
  7864. Rapamycin-dependent delocalization as a novel tool to reveal protein-protein interactions in plants
  7865. … Membrane Cassette Transport Protein A1 via Adenosine Monophosphate-Activated Protein Kinase/Mammalian Target of Rapamycin Signaling in Macrophages
  7866. Protective effect of Rapamycin against acrylamide‐induced hepatotoxicity: The associations between autophagy, apoptosis, and necroptosis
  7867. Physiological function of FKBP12, a primary target of Rapamycin/FK506: a newly identified role in transcription of ribosomal protein genes in yeast
  7868. Sustained response to erlotinib and Rapamycin in a patient with pediatric anaplastic oligodendroglioma
  7869. Dermatological adverse events associated with use of oral mechanistic target of Rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex
  7870. Porcine circovirus 3 capsid protein induces autophagy in HEK293T cells by inhibiting phosphorylation of the mammalian target of Rapamycin
  7871. Use of topical Rapamycin in acral pseudolymphomatous angiokeratoma of children (APACHE): A report of two cases and review of the literature
  7872. Rapamycin (sirolimus) in treatment of recurrent intravenous leiomyomatosis: a case report
  7873. Genes responsive to Rapamycin and serum deprivation are clustered on chromosomes and undergo reorganization within local chromatin environments
  7874. Short-term oral Rapamycin prevents age-related learning impairment in mice
  7875. … in plant‐rich diets affects growth, feed utilization, body composition, blood biochemical indices and gene expressions of the target of Rapamycin signaling pathway in …
  7876. Investigation of the effects of Rapamycin on the mTOR pathway and apoptosis in metastatic and non-metastatic human breast cancer cell lines
  7877. Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer
  7878. Rapamycin and 3-Methyladenine Influence the Apoptosis, Senescence, and Adipogenesis of Human Adipose-Derived Stem Cells by Promoting and Inhibiting …
  7879. Rapamycin-Preactivated Autophagy Enhances Survival and Differentiation of Mesenchymal Stem Cells After Transplantation into Infarcted Myocardium
  7880. S100A8 and S100A9 promote endothelial cell activation through the RAGE‑mediated mammalian target of Rapamycin complex 2 pathway
  7881. Rapamycin Pretreatment Alleviates Cerebral Ischemia/Reperfusion Injury in Dose-Response Manner Through inhibition of the Autophagy and NFκB Pathways in Rats
  7882. Metabolic and Renal Effects of Mammalian Target of Rapamycin Inhibitors Treatment After Liver Transplantation: Real-Life Single-Center Experience
  7883. Use of Topical Sirolimus (Rapamycin) for Treating Confluent and Reticulated Papillomatosis
  7884. The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer
  7885. Effect and mechanism of Rapamycin on proliferation and apoptosis of human lung cancer cells
  7886. Iron Overload Impairs Autophagy: Effects of Rapamycin in Ameliorating Iron-Related Memory Deficits
  7887. Scopoletin Activates Adenosine Monophosphate-Activated Protein Kinase/Mammalian Target of Rapamycin Signaling Pathway and Improves Functional Recovery …
  7888. … Cancer Progression Through Directly Targeting Phosphatidylinositol 5‐Phosphate 4‐Kinase Type‐2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling …
  7889. Role of Akt and mammalian target of Rapamycin signalling in insulin-like growth factor 1-mediated cell proliferation in porcine Sertoli cells
  7890. Rapamycin prevents retinal neovascularization by downregulation of cyclin D1 in a mouse model of oxygen-induced retinopathy
  7891. … -like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of Rapamycin pathway
  7892. … Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin …
  7893. Growth inhibition and suppression of the mTOR and Wnt/β‐catenin pathways in T‐acute lymphoblastic leukemia by Rapamycin and MYCN depletion
  7894. Effect of Rapamycin on the Radio-Sensitivity of Cultured Tumor Cells Following Boron Neutron Capture Reaction
  7895. Target of Rapamycin: function in abiotic stress tolerance in Arabidopsis and its involvement in a possible cross-talk with ribosomal proteins
  7896. … /reperfusion injury by targeting connective tissue growth factor through the adenosine 5′-monophosphate-activated protein kinase/mammalian target of Rapamycin …
  7897. Topical Rapamycin for acanthosis nigricans in the Fitzpatrick IV/V adolescent population
  7898. Balancing Growth and Defense: Role of Target of Rapamycin and SNF1‐Related Protein Kinase 1 in Stress Signaling in Plants
  7899. … Disease by Inhibiting Apoptosis and Promoting Autophagy via Reactive Oxygen Species/Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin …
  7900. … to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin …
  7901. … Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin …
  7902. Rapamycin Overproduction by Combined Mutational Study
  7903. A systematic review and meta-analysis protocol of clinical characteristics and prognostic significance of mammalian target of Rapamycin for gastric cancer …
  7904. Rapamycin Treatment Reduces Acute Myocarditis Induced by Trypanosoma cruzi Infection
  7905. CLINICAL-EXPERIMENTAL EXPERIENCE WITH Rapamycin IN VISCERAL TRANSPLANTATION
  7906. Rapamycin Eyedrops Increased CD4+ Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface
  7907. Chronic Mechanistic Target of Rapamycin inhibition: Preventing Cancer to Delay Aging or Vice Versa?
  7908. Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum (II) Complex in Human Thyroid …
  7909. Mammalian Target of Rapamycin Signaling Enhances Ovalbumin-Induced Neutrophilic Airway Inflammation By Promoting Th17 Cell Polarization in Murine …
  7910. Arenobufagin Inhibits the Phosphatidylinositol 3-kinase/Protein Kinase B/Mammalian Target of Rapamycin Pathway and Induces Apoptosis and Autophagy in …
  7911. CARDIOVASCULAR OUTCOMES OF Rapamycin-BASED IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT RECIPIENTS: A SINGLE CENTER …
  7912. Stomach-specific c-Myc overexpression drives gastric adenoma in mice through AKT/mammalian target of Rapamycin signaling
  7913. Protein blend and casein supplementations before inactive phase similarly activate mechanistic target of Rapamycin signaling in rat skeletal muscle
  7914. Gene expression and regulatory factors of the mechanistic target of Rapamycin (mTOR) complex 1 predict mammalian longevity
  7915. Effectiveness of low dose of Rapamycin in preventing seizure-induced anxiety-like behaviour, cognitive impairment, and defects in neurogenesis in developing rats
  7916. Regulatory effect of apoptosis on morphological changes in cell mass of porcine blastocyst through supplementation of Rapamycin during in vitro culture
  7917. Identification of 3′, 4′, 5′-trihydroxyflavone as an mammalian target of Rapamycin inhibitor and its suppressive effects on dextran sulfate sodium-induced ulcerative …
  7918. Living Donor Preemptive Kidney Transplantation in Tuberous Sclerosis Complex Patient and the Role of Mammalian Target of Rapamycin Inhibitor: A Case Report
  7919. Rapamycin and Rapalogs
  7920. miR-331-3p is involved in glucocorticoid resistance reversion by Rapamycin through suppression of the MAPK signaling pathway
  7921. Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated …
  7922. Recent advances in the role of mammalian target of Rapamycin inhibitors on cardiac allograft vasculopathy
  7923. Activation of Mechanistic Target of Rapamycin (mTOR) in Human Endothelial Cells Infected with Pathogenic Spotted Fever Group Rickettsiae
  7924. Identification of a Novel Oxadiazole Inhibitor of Mammalian Target of Rapamycin
  7925. An inducible system for in vitro and in vivo Fas activation using FKBP-FRB-Rapamycin complex
  7926. Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy …
  7927. Prediction of Solanum lycopersicum Target of Rapamycin (SlTOR) Protein
  7928. Effect of In Vivo Expansion of Regulatory T Cells with IL-2/anti-IL-2 Antibody Complex Plus Rapamycin on Experimental Autoimmune Uveoretinitis
  7929. Therapy options after CDK4/6 inhibitors for HR+, HER2-postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of Rapamycin …
  7930. Combination of Rapamycin and MK-2206 induced cell death via autophagy and necroptosis in MYCN-amplified neuroblastoma cell lines
  7931. Refractory systemic juvenile idiopathic arthritis successfully treated with Rapamycin
  7932. … Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK …
  7933. Long-term stability of 0.1% Rapamycin hydrophilic gel in the treatment of facial angiofibromas
  7934. Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
  7935. Gambogic acid affects ribosomal occurrence in glioma cells by downregulating the phosphoinositide kinase-3/protein kinase b/mammalian target of Rapamycin …
  7936. … Conductance Ca2+-Activated K+ Channels in C2C12 Skeletal Muscle Cells Increases the Myotube Diameter via the Akt/Mammalian Target of Rapamycin Pathway
  7937. Pharmacokinetics of long-term low-dose oral Rapamycin in four healthy middle-aged companion dogs
  7938. Rapamycin Re-Directs Lysosome Network, Stimulates ER-Remodeling, Involving Membrane CD317 and Affecting Exocytosis, in Campylobacter Jejuni-Lysate …
  7939. The Mammalian Target of Rapamycin Complex 1 (mTORC1): An Ally of M. tuberculosis in Host Cells
  7940. … promotes gallbladder cancer proliferation and metastasis through activating phosphatidylinositol 3-kinase/protein kinase B/mammalian target of Rapamycin …
  7941. The long-term effects of Rapamycin-based immunosuppressive protocols on the expression of renal aquaporins 1, 2, 3 and 4 water channels in rats
  7942. Efficient Treatment of Atherosclerosis by Dexamethasone Acetate and Rapamycin Co-Loaded mPEG-DSPE Calcium Phosphate Nanoparticles
  7943. Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947
  7944. Amino acids regulate energy utilization through mammalian target of Rapamycin complex 1 and adenosine monophosphate activated protein kinase pathway …
  7945. Mammalian target of Rapamycin is activated in the kidneys of patients with scleroderma renal crisis
  7946. Abstract B08: Improved tumor penetration, antitumor activity, and survival of ABI-009 (nab-sirolimus) versus oral Rapamycin and everolimus and investigation of mTOR …
  7947. High-dose Rapamycin excerts a temporary impact on T. reesei through gene trFKBP12
  7948. Effective and safe treatment of a novel IL2RA deficiency with Rapamycin
  7949. DNA methylation age analysis of Rapamycin in common marmosets
  7950. The use of Rapamycin to treat vascular tumours and malformations: A single-centre experience
  7951. Treatment of angiokeratomas of Fordyce with topical Rapamycin 0.25% cream
  7952. SUBCUTANEOUS IMPLANTATION OF Rapamycin IMPREGNATED SCAFFOLDS DEMONSTRATE THE POTENTIAL FOR LOCALISED ISLET GRAFT …
  7953. GENERATION OF STABLE HUMAN INDUCED REGULATORY T-CELLS REQUIRES OPTIMAL Rapamycin CONCENTRATION AND TCR STIMULATION
  7954. Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients
  7955. The Effects of Evening Primrose/Hemp Seed Oil Compared to Rapamycin on the Gene Expression of Immunological Parameters in Experimental Autoimmune …
  7956. Inhibitor for protein disulfide‑isomerase family A member 3 enhances the antiproliferative effect of inhibitor for mechanistic target of Rapamycin in liver cancer: An in …
  7957. Corrigendum to: Differential Effects of Rapamycin and Metformin in Combination With Rapamycin on Mechanisms of Proteostasis in Cultured Skeletal Myotubes
  7958. Treatment of port wine stain with Tixel‐induced Rapamycin delivery following pulsed dye laser application
  7959. Effects and potential mechanisms of Rapamycin on MPTP-induced acute Parkinson’s disease in mice.
  7960. In silico-based approach to investigate the ability of PEGylated Rapamycin to inhibit Galectin-3.
  7961. Metabolic control of lupus pathogenesis: central role for activation of the mechanistic target of Rapamycin
  7962. Can mammalian target of Rapamycin inhibitors replace mycophenolate in hypersensitized kidney transplant recipients?
  7963. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of Rapamycin mutation: A novel finding for targeted treatment
  7964. Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, Rapamycin
  7965. Gene Expression Regulation in the Mouse Liver by Mechanistic Target Of Rapamycin Complexes I and II
  7966. Effects of Glycerol and Shikimic Acid on Rapamycin Production in Streptomyces Rapamycinicus
  7967. … and Platelet-derived Growth Factor-stimulated Vascular Smooth Muscle Cell Proliferation via Inhibiting the Mammalian Target of Rapamycin/p70 S6 Kinase …
  7968. Spermidine and Rapamycin Reveal Distinct Autophagy Flux Response and Cargo Receptor Clearance Profile. Cells 2021, 10, 95
  7969. Anti-scarring effect of Rapamycin following filtering surgery in rabbit eyes
  7970. Correction for: Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance
  7971. Rapamycin PREVENTS INTERSTITIAL FIBROSIS THROUGH DECREASING PERITUBULAR CAPILLARY (PTC) VEGF EXPRESSION AND ANGIOGENESIS WHILE …
  7972. Characteristics of Rapamycin-treated T cell products for advanced adoptive T cell therapy and evaluation of clinical feasibility
  7973. Effects of Different Exercise Modes and Intensities on Skeletal Muscle Mammalian Target of Rapamycin Signaling in Strepto-zotocin and High-Fat-Diet Induced …
  7974. Correction: Therapeutic effects of Rapamycin and surgical decompression in a rabbit spinal cord injury model
  7975. Mammalian target of Rapamycin complexes: regulation and Alzheimer’s
  7976. Modulation of the Antidepressant Effects of Ketamine by the mTORC1 Inhibitor Rapamycin
  7977. Maternal diabetes induces senescence and neural tube defects sensitive to the senomorphic Rapamycin
  7978. Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of Rapamycin to enhance allogeneic islet graft viability
  7979. The effect of Rapamycin on secretory activity of the rabbit ovarian fragments
  7980. Microspheres scar formation glaucoma filtration surgery area therapeutic effect—Based on Rapamycin-chitosan-calcium alginate sustained-release
  7981. Prenatal treatment with Rapamycin restores enhanced hippocampal mGluR-LTD and mushroom spine size in a Down’s syndrome mouse model
  7982. Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for …
  7983. Effect of Rapamycin on Canine Mast Cell Cancer Cells Following Radiation
  7984. Rapamycin-eluting Single and Double Stenting on Serum Markers in Coronary Bifurcation Lesions
  7985. Rapamycin Improves Recognition Memory and Normalizes Amino-Acids and Amines Levels in the Hippocampal Dentate Gyrus in Adult Rats Exposed to Ethanol …
  7986. The independent and combined effects of Rapamycin and metformin on naturally occurring osteoarthritis
  7987. … de la Lesión Hepática Inducida por Tioacetamida en ratas tratadas con Resveratrol: Rol de la vía de Señalización mTOR (mammalian Target of Rapamycin)
  7988. Autism spectrum disorder and mammalian target of Rapamycin system
  7989. Curcumin Promotes Recovery of Motor Function After Spinal Cord Injury in Rats Through Mammalian Target of Rapamycin (mTOR)-Signal Transducer and Activator of …
  7990. Study on the Treatment of Tuberous Sclerosis with Rapamycin Nanomicelles Based on Abdominal Ultrasound.
  7991. … Apoptosis of Gastric Cancer Cells via Phosphatidylinositol-3-Kinase (PI3K)/Protein Kinase B (Akt)/The Mammalian Target of Rapamycin (mTOR) Signaling Pathway
  7992. Mammalian Target of Rapamycin (mTOR) Inhibitors Induce Stomatitis in Patients with Metastatic Breast Cancer
  7993. Effect of adsorbing resins on the Rapamycin biosynthesis by Streptomyces hygroscopicus VKM Ac-2737D
  7994. The Effect of Forkhead Box Class O1, Mammalian Target of Rapamycin Complex 1, Survivin, and Interleukin-17 on the Degree of Acne Vulgaris Based on Serum …
  7995. Rapamycin as a potent and selective inhibitor of vascular endothelial growth factor receptor in breast carcinoma
  7996. Pharmacological treatment of Autoimmune Polyendocrine Syndrome type I with Rapamycin, a mTOR inhibitor
  7997. The role of salt inducible kinases in the regulation of the mammalian target of Rapamycin pathway in adipocytes
  7998. Rapamycin repairs damaged nerve cells and neurological function in rats with spinal cord injury through ERK signaling pathway.
  7999. Influence of an Early Application of Mammalian Target of Rapamycin Inhibitors Everolimus and Sirolimus on Acute Vascular Inflammatory Responses After Ischemia …
  8000. miR-34 Promotes Autophagy and Apoptosis of Spinal Chondrocytes by Mammalian Target of Rapamycin/Phosphatidylinositol-3-Kinase/Protein Kinase B Signaling
  8001. [Corrigendum] Rapamycin-induced autophagy activity promotes bone fracture healing in rats
  8002. The Interactions Between the Mechanistic Target of Rapamycin (mTOR) and the Microbiome
  8003. Sirtuins in mechanistic target of Rapamycin complex 1 signaling
  8004. Rapamycin-PLGA microspheres induce autophagy and prevent senescence in chondrocytes and exhibit long in vivo residence
  8005. Rapamycin alleviates experimental autoimmune hepatitis by immunoregulation of Th1 and Th17 cells
  8006. Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum (II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) …
  8007. Polyisoprenoids from Avicennia marina induces on P13k, Akt1, Mammalian target of Rapamycin, Egfr, and P53 Gene Expression Using Reverse Transcription …
  8008. Rapamycin proves both good and bad for aging in human cells
  8009. Repurposing metformin and Rapamycin to target age-related diseases
  8010. The new target of Rapamycin: lysosomal calcium channel TRPML1
  8011. THE EFFECT OF ENDURANCE TRAINING ON PROTEIN KINASE-B AND MECHANICAL TARGET OF Rapamycin IN THE LEFT VENTRICLE OF THE HEART OF …
  8012. inhibition of mammalian target of Rapamycin (mTOR) improves neurobehavioral deficit and modulates inflammatory response after traumatic brain injury
  8013. Targeting oxidative stress, transforming growth factor beta-1, and the mammalian target of Rapamycin by valproic acid to ameliorate bleomycin-induced …
  8014. … Inhibits Proliferation and Promotes Apoptosis of Ovarian Cancer Cells by Inactivating Phosphoinositide-3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin …
  8015. Is Rapamycin an Effective Anti-aging Drug?
  8016. inhibition of the Mammalian Target of Rapamycin Pathway Stimulates Osteoblast Proliferation and Differentiation Through Autophagy in MC3T3-E1 Cells
  8017. Abstract WP151: Rapamycin Improves Post-Recanalization Blood Flow After Acute Experimental Stroke in Rats
  8018. Combination Therapy with Rapamycin and Imatinib in Pulmonary Arterial Hypertension
  8019. The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A …
  8020. Evaluation of the Effects of Rapamycin Treatment on Antioxidant Enzyme Changes and AgNOR in Testicular Torsion
  8021. … Spinal Cord Repair and Nerve Regeneration Through Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling and Oxidative …
  8022. Effect of Rapamycin combined with nedaplatin in the treatment of bladder cancer and its influence on angiogenesis and invasion
  8023. Effect of glucose, soya oil and glutamine on protein expression and mammalian target of Rapamycin complex 1 pathway of jejunal crypt enterocytes in weaned piglets
  8024. The Effect of Rapamycin and Metformin Treatment on Primary OA Pathology
  8025. Mammalian target of Rapamycin complexes: protein synthesis and autophagy, Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia
  8026. The effect of mTOR inhibitor Rapamycin on a dietary Drosophila melanogaster model of calcium oxalate nephrolithiasis
  8027. Abstract A28: Rapamycin-upregulated miR-29b promotes mTORC1-hyperactivative cell growth by downregulating retinoic acid receptor β (RARβ)
  8028. Mammalian target of Rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
  8029. Interleukin-27 decreases ghrelin production through signal transducer and activator of transcription 3—mechanistic target of Rapamycin signaling
  8030. Combined application of Rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease.
  8031. Effect of mammalian target of Rapamycin on cognitive dysfunction of Alzheimer’s Disease via regulating Homer3
  8032. Impact of Rapamycin on Secondary Infection of Laboratory Mice (Mus musculus) with the Intestinal Nematode Heligmosomoides bakeri
  8033. Evaluation of TGF-beta, Rapamycin, and IL-2 microparticle (TRI MP) treatment for disease prevention in models of type 1 diabetes and arthritis
  8034. Cell Synchronization by Rapamycin Improves the Developmental Competence of Buffalos (Bubalus bubalis) SCNT Embryos.
  8035. Corrigendum to” Rapamycin Reverses TLR4 Signaling-Triggered Tumor Apoptosis Resistance by Disrupting Akt-mediated Bcl-xL Upregulation”[Int …
  8036. publisher correction: Regulation of protein kinase cδ nuclear import and Apoptosis by Mechanistic Target of Rapamycin Complex-1
  8037. … the Proliferation of Human Ovarian Cancer Cells In Vitro via the Phosphatidylinositol-3-Kinase (PI3K)/Akt and the Mammalian Target of Rapamycin (mTOR) and Wnt/β …
  8038. Correction: Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase
  8039. Rapamycin prevents the impairments of social recognition induced by anti-P antibody in a murine model
  8040. Supporting Data for” Identification of Novel Components of Target-of-Rapamycin Signaling Pathway by Network-Based Multi-Omics Integrative Analysis”
  8041. Rapamycin eluting stent implantation in the treatment of total coronary artery occlusion in a case of Kawasaki disease
  8042. Investigation of the Effects of mTOR Inhibitors Rapamycin and Everolimus in Combination with Carboplatin on Canine Malignant Melanoma Cells.
  8043. Rapamycin alleviates the symptoms of experimental autoimmune myasthenia gravis rats by down-regulating Th17 cell/regulatory T cell ratio
  8044. 235 Effects of Rapamycin during an acute heat stress exposure in growing pigs
  8045. Rapamycin and Rapalogs for Tuberous Sclerosis Complex: Updates on Studies’ and Outcomes’ Characteristics of a Cochrane Systematic Review
  8046. … : Activation of autophagic flux against xenoestrogen bisphenol-A-Induced hippocampal neurodegeneration via AMP kinase (AMPK)/mammalian target of Rapamycin …
  8047. inhibition of mammalian target of Rapamycin (mTOR) improves neurobehavioral deficit and modulates inflammatory response after traumatic brain injury
  8048. Combination Therapy of Sildenafil and Rapamycin Alleviates Doxorubicin Induced Cardiotoxicity With Improvement of Skeletal Muscle Function
  8049. Rapamycin ON THE TREATMENT OF MUCOEPIDERMOID CARCINOMAS AND SQUAMOUS CELL CARCINOMAS
  8050. Amino Acid Sensing Ability by the Mechanistic Target of Rapamycin in Oligodendrocytes
  8051. Rescue of Lipid-Induced Autophagy inhibition by Rapamycin Treatment
  8052. Rapamycin‐Dependent Gln3 Transcription Factor Dephosphorylation and Nuclear Localization Depend On Distinct Regions of the Gln3 Protein
  8053. Evaluation of S100A9 targeted nanoparticles containing Rapamycin to treat pancreatic adenocarcinoma
  8054. … Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT …
  8055. … Shenzhu Tiaopi granule on hepatic insulin resistance in diabetic Goto-Kakizakirats via liver kinase B1/adenosine 5′-monophosphate/mammalian target of Rapamycin …
  8056. Retracted: inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway …
  8057. Correction: Alternative mammalian target of Rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based …
  8058. Mechanistic Target of Rapamycin, but Not the Integrated Stress Response, Promotes ATF4-Dependent Metabolic Reprogramming in TGF-β-Treated Lung Fibroblasts
  8059. … Protein of Mammalian Target or Rapamycin mRNA (RPTOR) and Rapamycin‐insensitive Companion of Mammalian Target of Rapamycin (RICTR) messenger RNA
  8060. Rapamycin inhibits colorectal cancer progression through down-regulating mTOR-GP73 pathway
  8061. Abstract PS14-17: Rapamycin inhibits stem cell function and diminishes inflammation and senescence markers in human mammary gland
  8062. Intermittent Fasting (IF) Promotes Longevity through Alterations of the Mammalian Target of Rapamycin (mTOR) and the Epigenome
  8063. Rapamycin-based GVHD prophylaxis increases the immunosuppressivity of MDSCs without affecting T cells and anti-tumor cytotoxicity.
  8064. Effects of Quercetin on Autophagy and Phosphatidylinositol 3-kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway in Human Prostate Cancer …
  8065. The effect of high intensity interval training on complex mammalian target of Rapamycin 1 (mTORC1) pathway in Flexor hallucis longus muscle (FHL) of …
  8066. Six-year angiographic follow-up of a chronic total coronary occlusion successfully treated with BMS implantation followed by oral Rapamycin
  8067. Maf1 suppression of ATF5-dependent mitochondrial unfolded protein response contributes to Rapamycin-induced radio-sensitivity in lung cancer cell line A549.
  8068. COMPARISON OF Rapamycin WITH CYCLOSPORIN, AND TACROLIMUS IN REGARDS TO THE DEVELOPMENT OF EPITHELIAL-TO-MESENCHYMAL …
  8069. Abstract PS16-18: inhibition of mTOR signaling by Rapamycin abrogates mammary stem/progenitor cell activity in aged mice
  8070. Rapamycin does not reproduce the alterations to Caco‐2 transepithelial electrical resistance caused by the knockdown of Raptor
  8071. Oral preconditioning of donors after brain death with calcineurin inhibitors vs. inhibitors of mammalian target for Rapamycin in pig kidney transplantation
  8072. Rapamycin immune tolerization enables gene transfer following subcutaneous delivery of AAV6 but not CD4-retargeted AAV6 vectors in AAV-seropositive …
  8073. mTOR Inhibitor Rapamycin can reverses the combination antiretroviral therapy induced central nervous system disorder
  8074. Corrigendum to” Rapamycin suppresses TLR4-triggered IL-6 and PGE 2 production of colon cancer cells by inhibiting TLR4 expression and NF-κB activation”[Mol …
  8075. Rapamycin and chloroquine insensitivity reveal mTORC1‐independent regulation of epithelial permeability in differentiated intestinal Caco‐2 cells
  8076. … -4-one (PP-4-one) Exhibits Anti-Epileptogenic Effect in Rat Model of Traumatic Epilepsy by Mammalian Target of Rapamycin (mTOR) Signaling Pathway …
  8077. Mammalian Target of Rapamycin Mediates Expression and Activity of ADAM 17 in Diabetic Kidney Disease
  8078. Gattino, F; Biolatti, B; Sasaki, N; Nakagawa, T; Di Renzo, Mf; de Las Mulas, Jm; De Maria, R.. Activation of mammalian target of Rapamycin (mTOR) in triple …
  8079. Gorham-Stout disease successfully treated with sirolimus (Rapamycin): a case report and review of the literature
  8080. Age-dependent effects of short-term intermittent fasting and Rapamycin treatment in Zebrafish (Danio Rerio) brain
  8081. Molecular Dynamic Simulations for Mammalian Target of Rapamycin (mTOR) Variants to Characterize Potential Disruption of Porphyromonas gingivalis Induced …
  8082. Defining the properties of the OS-33 osteosarcoma cell line and the effects of mTORC1 inhibition by Rapamycin treatment
  8083. Deletion of the mechanistic‐target‐of‐Rapamycin (mTOR) from collecting duct principal associated with increased ubiquitinylation of epithelial sodium channel (ENaC)
  8084. Construction of lentiviral vector for late endosomal/lysosomal adaptor, mitogen-activated protein kinase and mammalian target of Rapamycin activator 2 interference …
  8085. 85 Regulation of mammalian target of Rapamycin signaling post-fertilisation is essential for efficient development of bovine pre-implantation embryos
  8086. … SUPPRESSES SQUAMOUS DIFFERENTIATION OF BLADDER CANCER AND CANCER GROWTH VIA REGULATION OF MAMMALIAN TARGET OF Rapamycin …
  8087. Abstract A16: Suppressor of morphogenesis in genitalia 1 (SMG1) is a novel negative regulator of mammalian target of Rapamycin complex 2 (mTORC2)
  8088. … by Chemokine (CC Motif) Ligand 3 Promote the Progression of Breast Cancer via Phosphoinositide 3-Kinase-Protein Kinase B-Mammalian Target of Rapamycin …
  8089. … Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin …
  8090. 69 Phosphorylation of mechanistic target of Rapamycin in porcine blastocyst-stage embryos is dependent on the concentration of glutamine in the medium

 

Related Posts

Shopping Cart
Scroll to Top